<SEC-DOCUMENT>0001280776-23-000013.txt : 20230803
<SEC-HEADER>0001280776-23-000013.hdr.sgml : 20230803
<ACCEPTANCE-DATETIME>20230803064816
ACCESSION NUMBER:		0001280776-23-000013
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		65
CONFORMED PERIOD OF REPORT:	20230630
FILED AS OF DATE:		20230803
DATE AS OF CHANGE:		20230803

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUNIC, INC.
		CENTRAL INDEX KEY:			0001280776
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				562358443
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36201
		FILM NUMBER:		231137956

	BUSINESS ADDRESS:	
		STREET 1:		1200 AVENUE OF THE AMERICAS
		STREET 2:		SUITE 200
		CITY:			NEW YORK
		STATE:			X1
		ZIP:			10036
		BUSINESS PHONE:		(332) 255-9818

	MAIL ADDRESS:	
		STREET 1:		1200 AVENUE OF THE AMERICAS
		STREET 2:		SUITE 200
		CITY:			NEW YORK
		STATE:			X1
		ZIP:			10036

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	VITAL THERAPIES INC
		DATE OF NAME CHANGE:	20040219
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>vtl-20230630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:c5b7d08b-4d18-4b53-b740-daba2f6d29fd,g:398611d2-4d63-409b-b481-5daa2ae6bce9,d:c553ef50e5794a188740fd92ee6a6b79--><html xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2023" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:vtl="http://vitaltherapies.com/20230630" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>vtl-20230630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-26">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-27">Q2</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-28">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" id="f-29">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-30">0001280776</ix:nonNumeric><ix:nonNumeric contextRef="c-63" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-303">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-5" name="us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-322">http://fasb.org/us-gaap/2023#NonoperatingIncomeExpense</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-323">http://fasb.org/us-gaap/2023#NonoperatingIncomeExpense</ix:nonNumeric><ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-372">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-373">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-375">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="f-376">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="c-121" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="f-481">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-559" escape="true">Subsequent Events TBD</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="vtl-20230630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>vtl:employee</xbrli:measure></xbrli:unit><xbrli:unit id="lease"><xbrli:measure>vtl:lease</xbrli:measure></xbrli:unit><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2014-04-17</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="financialinstitution"><xbrli:measure>vtl:financialInstitution</xbrli:measure></xbrli:unit><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:AustraliaAndGermanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:AustraliaAndGermanyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:GrafelfingGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:NewYorkCityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:NewYorkCityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:PlaneggGermanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-01</xbrli:startDate><xbrli:endDate>2023-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="d"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:May2022ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:May2022ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:May2022ATMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-10</xbrli:startDate><xbrli:endDate>2022-10-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-10</xbrli:startDate><xbrli:endDate>2022-10-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>vtl:vote</xbrli:measure></xbrli:unit><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-25</xbrli:startDate><xbrli:endDate>2021-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-28</xbrli:startDate><xbrli:endDate>2023-06-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:IncentiveEmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:NonStatutoryEmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:NonStatutoryEmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001280776</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtl:ExecutiveChairmanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtl:DuaneNashMDJDMBAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-28</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ic553ef50e5794a188740fd92ee6a6b79_1"></div><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the quarterly period ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">June 30, 2023</ix:nonNumeric> </span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">For the transition period from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commission File Number:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-36201</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">Immunic, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.444%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:53.654%"><tr><td style="width:1.0%"></td><td style="width:46.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.406%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">56-2358443</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">1200 Avenue of the Americas</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-10">Suite 200</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">New York,</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-12">NY</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">10036</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">332</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">255-9818</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.976%"><tr><td style="width:1.0%"></td><td style="width:35.856%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">IMUX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-19">Yes</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-20">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large&#160;accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-21">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="f-22">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-23">&#9744;</ix:nonNumeric></span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.       </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-24">&#9746;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">On July 28, 2023, <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-25">44,595,383</ix:nonFraction> shares of common stock, $0.0001 par value, were outstanding.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic553ef50e5794a188740fd92ee6a6b79_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMMUNIC, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INDEX</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.672%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page&#160;No.</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_10">PART I - FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_10">Condensed Consolidated Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_10">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_10">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_13">Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_13">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_16">Condensed Consolidated Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_16">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_19">Condensed Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_19">6</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_25">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_25">8</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_28">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_28">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_61">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_61">22</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_73">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_73">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_76">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_76">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_79">PART II - OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_82">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_82">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_85">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_85">34</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_88">Unregistered Sales of Equity Securities</a> and Use of Proceeds</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_88">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_91">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_88">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_94">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_94">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_97">Other Information </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_97">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_100">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic553ef50e5794a188740fd92ee6a6b79_100">35</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ic553ef50e5794a188740fd92ee6a6b79_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:73.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-31">77,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-32">106,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments - other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherShortTermInvestments" format="ixt:fixed-zero" scale="3" id="f-33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-34">9,629</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets and prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">9,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">9,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">86,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">125,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-39">290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-40">294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-41">1,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-42">1,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-43">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-44">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-45">88,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-46">127,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-47">4,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-48">4,281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">12,613</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-50">7,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-51">928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-52">810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">18,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-54">13,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long term liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-55">1,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="f-56">992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-57">1,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="f-58">992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-59">19,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-60">14,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 4)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-61"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-62"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-63"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-64">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-65"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-66">20,000,000</ix:nonFraction></ix:nonFraction> authorized and <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-67"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-68"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-69"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-70">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding as of June 30, 2023 and December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-73"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-74">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-75"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-76">130,000,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-77"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-78">44,488,371</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-79"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="f-80">39,307,286</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of June 30, 2023 and December&#160;31, 2022, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-81">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-82">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-83">431,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="f-84">427,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-85">3,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-86">3,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-87">366,551</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-88">317,280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-89">69,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-90">113,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-91">88,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-92">127,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ic553ef50e5794a188740fd92ee6a6b79_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands,&#160;except&#160;share&#160;and&#160;per&#160;share&#160;amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.812%"><tr><td style="width:1.0%"></td><td style="width:49.696%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.914%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.205%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.210%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>&#160;Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months<br/>&#160;Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-93">21,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-94">16,538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-95">44,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-96">33,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-97">3,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-98">4,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-99">8,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-100">8,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-101">25,021</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-102">20,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-103">52,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-104">42,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-105">25,021</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-106">20,610</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-107">52,272</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-108">42,045</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="f-109">968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="f-110">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="f-111">1,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="f-112">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other  income (expense), net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-113">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-114">1,397</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-115">1,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-116">777</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-117">1,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-118">1,291</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-119">3,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="f-120">664</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-121">23,999</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-122">21,901</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-123">49,271</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-124">42,709</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-125"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-126">0.54</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-127"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-128">0.72</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-129"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-130">1.12</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-131"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-132">1.49</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic and diluted</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-133"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-134">44,432,955</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-135"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-136">30,248,767</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-137"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-138">44,036,352</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="f-139"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-140">28,686,910</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ic553ef50e5794a188740fd92ee6a6b79_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Loss</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.543%"><tr><td style="width:1.0%"></td><td style="width:55.298%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.852%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.589%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.174%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>&#160;Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months<br/>&#160;Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-141">23,999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-142">21,901</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-143">49,271</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-144">42,709</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-145">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-146">350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-147">947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-148">408</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-149">23,828</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-150">22,251</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-151">48,324</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-152">43,117</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ic553ef50e5794a188740fd92ee6a6b79_19"></div><hr style="page-break-after:always"/><div style="min-height:36.72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:232%">IMMUNIC, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:232%">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands,&#160;except&#160;share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.920%"><tr><td style="width:1.0%"></td><td style="width:43.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.815%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.398%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.366%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.819%"></td><td style="width:0.1%"></td></tr><tr><td colspan="36" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2023</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income </span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-153">39,307,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-154">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-155">427,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-156">3,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-157">317,280</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-158">113,684</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-159">25,272</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-160">25,272</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-161">1,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-162">1,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-163">776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-164">776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued from exercise of pre-funded warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-165">5,096,552</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-166">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-167">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-168">44,403,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-169">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-170">429,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-171">3,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-172">342,552</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-173">91,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-174">23,999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-175">23,999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-176">1,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-177">1,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-178">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-179">171</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued in connection with the Company's Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-180">84,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-181">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-182">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-183">44,488,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-184">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-185">431,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-186">3,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-187">366,551</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-188">69,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:36.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36.72pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.920%"><tr><td style="width:1.0%"></td><td style="width:42.950%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.407%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.956%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.540%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.102%"></td><td style="width:0.1%"></td></tr><tr><td colspan="36" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Six Months Ended June 30, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at January 1, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-189">26,335,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-190">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-191">324,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-192">252</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-193">196,873</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-194">127,115</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-195">20,808</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-196">20,808</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-197">2,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-198">2,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-199">58</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-200">58</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued in connection with the Company's stock option plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="f-201">852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-202">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-203">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock - at the market Sales Agreement net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-204">918</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-205">2,904,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-206">29,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-207">29,638</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-208">29,240,383</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-209">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-210">355,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-211">310</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-212">217,681</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-213">137,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-214">21,901</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-215">21,901</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-216">2,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-217">2,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-218">350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-219">350</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares issued in connection with the Company's Employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-48" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-220">24,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-221">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-222">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock - at the market Sales Agreement net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-223">308</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-48" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="f-224">1,300,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-225">9,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-226">9,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-49" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-227">30,564,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-228">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-229">368,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-230">660</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-231">239,582</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-232">127,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center;text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:36.72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="ic553ef50e5794a188740fd92ee6a6b79_25"></div><hr style="page-break-after:always"/><div style="min-height:27.36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In&#160;thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.622%"><tr><td style="width:1.0%"></td><td style="width:79.521%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.219%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.221%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months<br/>&#160;Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-233">49,271</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-234">42,709</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-235">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="f-236">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized foreign currency  loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" scale="3" id="f-237">665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" format="ixt:num-dot-decimal" scale="3" id="f-238">2,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-239">3,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-240">4,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets and prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-241">312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-242">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-243">449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="f-244">826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-245">4,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="f-246">861</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="f-247">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="f-248">114</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-249">39,489</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-250">36,444</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sale of investments - other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfOtherInvestments" format="ixt:num-dot-decimal" scale="3" id="f-251">9,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromSaleOfOtherInvestments" format="ixt:fixed-zero" scale="3" id="f-252">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-253">125</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-254">40</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-255">9,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="f-256">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from public offering of common stock through At The Market Sales Agreement, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-257">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-258">39,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="f-259">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="f-260">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from shares issued in connection with the Company's employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="f-261">96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" scale="3" id="f-262">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from the exercise of pre-funded warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="f-263">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:fixed-zero" scale="3" id="f-264">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-265">147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-266">39,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-267">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-268">2,020</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-269">29,451</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-270">1,215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-271">106,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-272">86,863</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-273">77,294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-274">88,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplemental disclosure of noncash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of use asset obtained in exchange for lease obligation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="f-275">544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-276">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></div><div style="height:27.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="ic553ef50e5794a188740fd92ee6a6b79_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="ic553ef50e5794a188740fd92ee6a6b79_31"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="f-277" continuedAt="ia53a20c412f34cc398870fc96d52b439" escape="true">Description of Business and Basis of Financial Statements</ix:nonNumeric></span></div><ix:continuation id="ia53a20c412f34cc398870fc96d52b439" continuedAt="ie006174bf96e412c95dc854c9298bba3"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunic, Inc. ("Immunic" or the "Company") is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is headquartered in New York City with its main operations in Gr&#228;felfing near Munich, Germany. The Company currently has approximately <ix:nonFraction unitRef="employee" contextRef="c-3" decimals="INF" name="dei:EntityNumberOfEmployees" scale="0" id="f-278">75</ix:nonFraction> employees.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic is pursuing clinical development of orally administered, small molecule programs, each of which has unique features intended to directly address the unmet needs of patients with serious chronic inflammatory and autoimmune diseases. These include the vidofludimus calcium (IMU-838) program, which is in Phase 3 clinical development for patients with multiple sclerosis (&#8220;MS&#8221;) and which has shown therapeutic activity in Phase 2 clinical trials in patients suffering from relapsing-remitting MS and moderate-to-severe ulcerative colitis (&#8220;UC&#8221;); the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, UC, Crohn&#8217;s disease or irritable bowel syndrome with diarrhea; and the IMU-381 program, which is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of its clinical trials to meet their endpoints, failure to obtain regulatory approval and needing additional funding to complete the development and commercialization of the Company's <ix:nonFraction unitRef="lease" contextRef="c-3" decimals="INF" name="vtl:NumberOfDevelopmentPrograms" format="ixt-sec:numwordsen" id="f-279">three</ix:nonFraction> development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Financial Condition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic has no products approved for commercial sale and has not generated any revenue from product sales. It has never been profitable and has incurred operating losses in each year since inception in 2016. The Company has an accumulated deficit of approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-280">366.6</ix:nonFraction> million as of June 30, 2023 and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-281">317.3</ix:nonFraction> million as of December 31, 2022. Substantially all of Immunic's operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic expects to incur significant expenses and increasing operating losses for the foreseeable future as it initiates and continues the development of its product candidates and adds personnel necessary to advance its pipeline of product candidates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic expects that its operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through June 30, 2023, Immunic has raised net cash of approximately $<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" format="ixt:num-dot-decimal" scale="6" id="f-282">355.6</ix:nonFraction> million from private and public offerings of preferred and common stock. As of June 30, 2023, the Company had cash and cash equivalents of approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-283">77.3</ix:nonFraction> million.  With these funds, Immunic expects to be able to fund its operations beyond twelve months from the date of the issuance of the accompanying condensed consolidated financial statements.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-284" continuedAt="i9331fb27d3ab483e8d82e540a8141bbb" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles, ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG and Immunic Australia Pty Ltd.  All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions. </span></div><div style="padding-left:24.75pt"><span><br/></span></div><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic has prepared the accompanying interim unaudited condensed consolidated financial statements in accordance with United States generally accepted accounting principles, (&#8220;US GAAP&#8221;), for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie006174bf96e412c95dc854c9298bba3"><ix:continuation id="i9331fb27d3ab483e8d82e540a8141bbb">present fairly Immunic&#8217;s consolidated financial position, consolidated results of operations, consolidated statement of stockholders&#8217; equity and consolidated cash flows for the periods and as of the dates presented. The Company&#8217;s fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2022 was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto included on the Company's Annual Report on Form 10-K filed on February 23, 2023. The nature of Immunic&#8217;s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.</ix:continuation></ix:continuation> </span></div><div id="ic553ef50e5794a188740fd92ee6a6b79_34"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-285" continuedAt="i3a1c8a4911c046cc8f5150d35e138187" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i3a1c8a4911c046cc8f5150d35e138187" continuedAt="i1e567b1833754f3bbce593d987c35799"><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-286" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements. The most significant estimates in the Company&#8217;s financial statements and accompanying notes relate to recoverability of goodwill, clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-287" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is United States (&#8220;U.S.&#8221;) dollars. Immunic AG is located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.&#8217;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; assets and liabilities at reporting period-end rates;</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; income statement accounts at average exchange rates for the reporting period; and</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; components of equity at historical rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#8217; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="vtl:CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" id="f-288" continuedAt="i29623cdf65b34282a984b9509aaece98" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents and Investments - other</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  Time Deposits with an original maturity greater than three months are classified as Investments - other.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents and investments - other consist of cash on hand and deposits in banks located in the U.S. of approximately $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-289">62.7</ix:nonFraction>&#160;million, Germany of approximately $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-290">14.4</ix:nonFraction>&#160;million and Australia of approximately $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-291">0.2</ix:nonFraction>&#160;million as of June 30, 2023. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions. The Company currently deposits its cash and cash equivalents with <ix:nonFraction unitRef="financialinstitution" contextRef="c-3" decimals="INF" name="vtl:NumberOfFinancialInstitutionsUsedForCashDeposit" format="ixt-sec:numwordsen" scale="0" id="f-292">two</ix:nonFraction> large financial institutions. Cash and Cash equivalents in the U.S. are held at J.P. Morgan and as of June 30, 2023 are primarily held in a U.S. Government money market fund account earning interest at a rate of <ix:nonFraction unitRef="number" contextRef="c-58" decimals="3" name="us-gaap:InvestmentInterestRate" scale="-2" id="f-293">5.0</ix:nonFraction>%. Cash and cash equivalents in Germany are earning interest at a rate of <ix:nonFraction unitRef="number" contextRef="c-59" decimals="4" name="us-gaap:InvestmentInterestRate" scale="-2" id="f-294">1.75</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-60" decimals="4" name="us-gaap:InvestmentInterestRate" scale="-2" id="f-295">2.75</ix:nonFraction>% during the period ended June 30, 2023.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1e567b1833754f3bbce593d987c35799" continuedAt="iee203c8c050246d5b8efcb0da9b08e4c"><ix:continuation id="i29623cdf65b34282a984b9509aaece98" continuedAt="i4da778fd42d1496593ba80d5328e4594"><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentTableTextBlock" id="f-296" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments - other consists of the following as of (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"></td><td style="width:22.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time Deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:OtherShortTermInvestments" scale="3" id="f-297">0</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:OtherShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-298">9,629</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherShortTermInvestments" scale="3" id="f-299">0</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-300">9,629</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4da778fd42d1496593ba80d5328e4594">The time deposit accounts in our bank in Germany matured in January and April, 2023, respectively.</ix:continuation>   </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-301" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212;Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.</span></div></ix:nonNumeric><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-302" continuedAt="ic567143879f149d697377a9f2652c5f2" escape="true">Property and Equipment</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic567143879f149d697377a9f2652c5f2">Property and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets, which range from <span style="-sec-ix-hidden:f-303">three</span> to <ix:nonNumeric contextRef="c-64" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-304">thirteen years</ix:nonNumeric>.</ix:continuation> Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="f-305">22,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="f-306">20,000</ix:nonFraction> for the three months ended June 30, 2023 and 2022, respectively. Depreciation expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="f-307">54,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="0" id="f-308">41,000</ix:nonFraction> for the six months ended June 30, 2023 and 2022, respectively</span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-309" continuedAt="i7c488a64b1b1414ea03f69e9a1772bc3" escape="true">Impairment of Long-Lived Assets</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7c488a64b1b1414ea03f69e9a1772bc3">The Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#8217; carrying amount. Impaired assets are then recorded at their estimated fair value.</ix:continuation> There were <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt-sec:numwordsen" scale="0" id="f-310"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt-sec:numwordsen" scale="0" id="f-311"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt-sec:numwordsen" scale="0" id="f-312"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="INF" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt-sec:numwordsen" scale="0" id="f-313">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment losses during the three and six months ended June 30, 2023 and 2022.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="f-314" continuedAt="i125e07e640684911be1d0c6d1d6445ab" escape="true"><div style="margin-top:12pt;padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Goodwill</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#8217;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i125e07e640684911be1d0c6d1d6445ab">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, an unfavorable clinical trial result, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="iee203c8c050246d5b8efcb0da9b08e4c" continuedAt="i483c7a5fb4f04ebfac0e494e1b3d21e7"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 20, 2022, the Company announced the outcome of a  significant interim analysis of its Phase 1b clinical trial of izumerogant (IMU-935) in patients with moderate-to-severe psoriasis that were not deemed positive progress. On October 21, 2022, the Company experienced a significant decrease in the Company's market capitalization.  The Company considered this to be a triggering event indicating that it is more likely than not that goodwill was impaired.  The Company performed an analysis of the fair value compared to the Company's book value, utilizing the Company's traded stock price (a level 1 fair value input). As a result of that analysis, the Company recorded an approximately $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-5" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="f-315">33.0</ix:nonFraction>&#160;million non-cash goodwill impairment charge in the fourth quarter of 2022, which represents a full write down of its previous goodwill balance.  </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-316" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These costs primarily include external development expenses and internal personnel expenses for its development programs, vidofludimus calcium, izumerogant and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program for clinical trials in MS, UC and COVID-19.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements with contract research organizations (&#8220;CROs&#8221;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#8220;MSA&#8221;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="f-317" continuedAt="ided266d718d14d678fef01d2a01a96ae" escape="true"><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and ASU No. 2018-18, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ided266d718d14d678fef01d2a01a96ae">On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856, for which the Company received a notice of allowance from the U.S. Patent &amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GovernmentAssistancePolicyTextBlock" id="f-318" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Government assistance</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government assistance relating to research and development performed by Immunic Australia is recorded as a component of other (income) expense. This government assistance is recognized at a rate of <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="vtl:GovernmentAssistanceRate" scale="-2" id="f-319">43.5</ix:nonFraction>% of the qualified research and development expenditures which are incurred. We also receive government assistance from the German Government for reimbursement of research and development expenses up to one million Euros per year. We recognized $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:GovernmentAssistanceAmount" format="ixt:num-dot-decimal" scale="6" id="f-320">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GovernmentAssistanceAmount" format="ixt:num-dot-decimal" scale="6" id="f-321">2.1</ix:nonFraction>&#160;million of <span style="-sec-ix-hidden:f-322"><span style="-sec-ix-hidden:f-323">other income</span></span> related to research activities performed during the three and six months ended June 30, 2023, respectively and  $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:GovernmentAssistanceAmount" format="ixt:num-dot-decimal" scale="6" id="f-324">0.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:GovernmentAssistanceAmount" format="ixt:num-dot-decimal" scale="6" id="f-325">1.4</ix:nonFraction>&#160;million  related to research activities performed during the three and six months ended June 30, 2022, respectively.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i483c7a5fb4f04ebfac0e494e1b3d21e7" continuedAt="i96a1ff37b60040b4b2196db8b9574ff0"><ix:nonNumeric contextRef="c-1" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="f-326" escape="true"><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-327" escape="true"><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#8217;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#8217;s common stock, the expected volatility of the price of the Company&#8217;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#8217;s judgment. If factors change and different assumptions are used, the Company&#8217;s stock-based compensation expense could be materially different in the future.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-328" escape="true"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than <ix:nonNumeric contextRef="c-63" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="f-329">12</ix:nonNumeric> months and up to <ix:nonNumeric contextRef="c-64" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durmonth" id="f-330">60</ix:nonNumeric> months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="lease" contextRef="c-3" decimals="INF" name="vtl:LesseeOperatingLeasesNumberOfExistingLeases" format="ixt-sec:numwordsen" id="f-331">three</ix:nonFraction> existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#8217;s balance sheet. A right-of-use lease asset represents the Company&#8217;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="f-332" escape="true"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#8217; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-333" continuedAt="i87f3872a53a84182bcb90b44458835fc" escape="true"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i96a1ff37b60040b4b2196db8b9574ff0"><ix:continuation id="i87f3872a53a84182bcb90b44458835fc"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized.  As of June 30, 2023 and 2022, respectively, the Company maintained a full valuation allowance against the balance of deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the Company&#8217;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#8217;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2022 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityPolicyTextBlock" id="f-334" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#8220;ASC 480-10&#8221;) or ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock (&#8220;ASC 815-40&#8221;). Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable U.S. GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.  All of the Company's <ix:nonFraction unitRef="shares" contextRef="c-66" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-335">5,096,552</ix:nonFraction> pre-funded warrants were exercised in January 2023.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-336" continuedAt="ib73bb7ae1e8b4ec687c4f226bbcd4b27" escape="true">Net Loss Per Share</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib73bb7ae1e8b4ec687c4f226bbcd4b27">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.</ix:continuation> </span></div><div style="margin-top:12pt;text-indent:22.5pt"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-337" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:73.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-67" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-338">5,770,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-68" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-339">3,713,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-340" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued and/or Adopted Accounting Standards</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recently issued accounting standards that would have a significant impact on the company's consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="ic553ef50e5794a188740fd92ee6a6b79_37"></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="f-341" continuedAt="i4e647cb9a2484c66acf70d92e8e75e95" escape="true">Balance Sheet Details</ix:nonNumeric></span></div><ix:continuation id="i4e647cb9a2484c66acf70d92e8e75e95"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Assets and Prepaid Expenses</span></div><div style="margin-top:12pt;text-indent:22.5pt"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="f-342" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Assets and Prepaid Expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:74.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.255%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vtl:PrepaidClinicalAndRelatedCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-343">3,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vtl:PrepaidClinicalAndRelatedCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-344">5,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ValueAddedTaxReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-345">1,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ValueAddedTaxReceivableCurrent" scale="3" id="f-346">296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian research and development tax incentive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vtl:ResearchAndDevelopmentTaxIncentiveCurrent" format="ixt:num-dot-decimal" scale="3" id="f-347">2,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vtl:ResearchAndDevelopmentTaxIncentiveCurrent" format="ixt:num-dot-decimal" scale="3" id="f-348">2,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-349">1,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-350">1,225</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-351">9,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-352">9,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Payable</span></div><div style="margin-top:12pt;text-indent:22.5pt"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="f-353" continuedAt="ibb306c8c6f8641babcfad5f1effd5ae3" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts Payable consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.474%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vtl:ClinicalCostsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-354">4,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vtl:ClinicalCostsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-355">3,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vtl:LegalAndAuditCostsPayableCurrent" scale="3" id="f-356">128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vtl:LegalAndAuditCostsPayableCurrent" scale="3" id="f-357">288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="f-358">224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableOtherCurrent" scale="3" id="f-359">244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-360">4,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-361">4,281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-top:12pt;text-indent:22.5pt"><ix:continuation id="ibb306c8c6f8641babcfad5f1effd5ae3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vtl:AccruedClinicalCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-362">11,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vtl:AccruedClinicalCostsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-363">6,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vtl:AccruedLegalAndAuditCostsCurrent" scale="3" id="f-364">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vtl:AccruedLegalAndAuditCostsCurrent" scale="3" id="f-365">169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vtl:AccruedCompensationCurrent" scale="3" id="f-366">716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="vtl:AccruedCompensationCurrent" scale="3" id="f-367">890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-368">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="f-369">120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-370">12,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-371">7,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><span style="-sec-ix-hidden:f-372"><span style="-sec-ix-hidden:f-373">Other Current Liabilities</span></span></span></div><div style="margin-top:12pt;text-indent:22.5pt"><ix:nonNumeric contextRef="c-1" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="f-374" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Liabilities consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.740%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-375"><span style="-sec-ix-hidden:f-376">Lease liabilities</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-377">671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-378">571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="3" id="f-379">257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="3" id="f-380">239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-381">928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-382">810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="ic553ef50e5794a188740fd92ee6a6b79_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-383" continuedAt="i488f09c5537649c0bbfdf0a863f792e3" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i488f09c5537649c0bbfdf0a863f792e3" continuedAt="i3575d46aef564c9881f8045f7f9c25c2"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain office space under non-cancelable operating leases. The leases terminate on July 31, 2025 for the New York City office, June 30, 2025 for the Gr&#228;felfing, Germany office and November 30, 2028 related to the new lease of a research laboratory in Planegg, Germany. The Company formerly leased office space in Planegg-Martinsried, Germany pursuant to a modified lease that terminated on August 31, 2020. These agreements include both lease (e.g., fixed rent) and non-lease components (e.g., common-area and other maintenance costs). The non-lease components are deemed to be executory costs and are therefore excluded from the minimum lease payments used to determine the present value of the operating lease obligation and related right-of-use asset. The New York City lease was extended on December 22, 2022 for an additional 27 months resulting in the new lease termination date of July 31, 2025. The New York City lease has a renewal option, but this was not included in calculating the right of use asset and liabilities. On April 7, 2020, the Company signed a <ix:nonNumeric contextRef="c-69" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="f-384">five year</ix:nonNumeric> lease for its facility in Gr&#228;felfing, Germany. On March 1, 2021 and August 1, 2022 the Company added additional lease space at the Gr&#228;felfing, Germany office.  Renewal options were not included in calculating the right of use asset and liabilities for this facility. In February 2023, the Company leased space in Germany for a research laboratory. The leases do not have concessions, leasehold improvement incentives or other build-out clauses. Further, the leases do not contain contingent rent provisions. The New York City lease had a <ix:nonNumeric contextRef="c-70" name="vtl:LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" format="ixt-sec:durwordsen" id="f-385">six month</ix:nonNumeric> rent holiday at the beginning of the lease as well as a <ix:nonNumeric contextRef="c-1" name="vtl:LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" format="ixt-sec:durwordsen" id="f-386">three month</ix:nonNumeric> rent holiday upon the <ix:nonNumeric contextRef="c-71" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durmonth" id="f-387">27</ix:nonNumeric> month extension starting May 2023. There were net additions of $<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="vtl:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="f-388">544,000</ix:nonFraction> related to the addition of new laboratory space in Planegg, Germany in February 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The leases do not provide an implicit rate and, due to the lack of a commercially salable product, the Company is generally considered unable to obtain commercial credit. Therefore, the Company estimated its incremental interest rate to be <ix:nonFraction unitRef="number" contextRef="c-3" decimals="2" name="vtl:OperatingLeaseIncrementalBorrowingRate" scale="-2" id="f-389">6</ix:nonFraction>% for the original leases and <ix:nonFraction unitRef="number" contextRef="c-71" decimals="2" name="vtl:OperatingLeaseIncrementalBorrowingRate" scale="-2" id="f-390">8</ix:nonFraction>% for the New York City extension and German laboratory, considering the quoted rates for the lowest investment-grade debt and the interest rates implicit in recent financing leases. Immunic used its estimated incremental borrowing rate and other information available at the lease commencement date in determining the present value of the lease payments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Immunic&#8217;s operating lease costs and variable lease costs were $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="vtl:OperatingAndVariableLeasesCost" format="ixt:num-dot-decimal" id="f-391">238,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="vtl:OperatingAndVariableLeasesCost" format="ixt:num-dot-decimal" id="f-392">136,000</ix:nonFraction>  for the three months ended June 30, 2023 and 2022, respectively and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="vtl:OperatingAndVariableLeasesCost" format="ixt:num-dot-decimal" id="f-393">433,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="vtl:OperatingAndVariableLeasesCost" format="ixt:num-dot-decimal" scale="0" id="f-394">266,000</ix:nonFraction> for the six months ended June 30, 2023 and 2022, respectively. Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-395" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the operating lease obligation are as follows as of June 30, 2023 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:85.106%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.945%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="f-396">362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="f-397">820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="f-398">495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="f-399">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="f-400">144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="vtl:LesseeOperatingLeaseLiabilityPaymentsAfterDueYearFour" scale="3" id="f-401">136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-402">2,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-403">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PV of obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-404">1,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2023, the Company has non-cancelable contractual obligations under certain agreements related to its development programs for vidofludimus calcium and IMU-856 totaling approximately $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:ContractualObligation" format="ixt:num-dot-decimal" scale="6" id="f-405">3.4</ix:nonFraction>&#160;million, all of which is expected to be paid in the next twelve months.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><ix:continuation id="i3575d46aef564c9881f8045f7f9c25c2"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments and Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Daiichi Sankyo Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856, for which the Company received a notice of allowance from the U.S. Patent &amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not currently a party to any litigation, nor is it aware of any pending or threatened litigation, that it believes would materially affect its business, operating results, financial condition or cash flows. However, its industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, the Company may be involved in various legal proceedings from time to time.</span></div></ix:continuation><div id="ic553ef50e5794a188740fd92ee6a6b79_43"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-406" continuedAt="i45d4d377fea546be89e1456b2a0c26c4" escape="true">Fair Value</ix:nonNumeric></span></div><ix:continuation id="i45d4d377fea546be89e1456b2a0c26c4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-407" escape="true"><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy tables present information about each major category of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:50.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-408">62,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-409">62,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-410">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-411">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-412">62,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-413">62,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-414">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-415">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:50.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at Fair&#160;Value&#160;Measurement&#160;at&#160;December&#160;31,&#160;2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-416">85,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-417">85,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-418">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-419">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-420">85,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-421">85,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-422">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-423">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level&#160;1, Level&#160;2 or Level&#160;3 assets during the periods presented.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Company&#8217;s money market funds which are included as a component of cash and cash equivalents on the consolidated balance sheet, realized gains and losses are included in interest income (expense) on the consolidated statements of operations. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our money market fund account is held in our bank in the U.S. and was earning interest at a rate of <ix:nonFraction unitRef="number" contextRef="c-58" decimals="3" name="us-gaap:InvestmentInterestRate" scale="-2" id="f-424">5.0</ix:nonFraction>% in a U.S. Government money market fund.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has cash balances in banks in excess of the maximum amount insured by the FDIC and other international agencies as of June 30, 2023. The Company has not historically experienced any credit losses with balances in excess of FDIC limits.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximate their fair values due to their short-term nature. The fair value and book value of the money market funds presented in the table above are the same.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="ic553ef50e5794a188740fd92ee6a6b79_46"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-425" continuedAt="ifba6aba027154e8bbefabb54c3b5a588" escape="true">Common Stock</ix:nonNumeric></span></div><ix:continuation id="ifba6aba027154e8bbefabb54c3b5a588" continuedAt="if03c774f43b14669a115cba8dd54bb9e"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shelf Registration Statement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Immunic filed a shelf registration statement on Form S-3. The 2020 Shelf Registration Statement permits the offering, issuance and sale of up to $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" format="ixt:num-dot-decimal" scale="6" id="f-426">250.0</ix:nonFraction>&#160;million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing.  As of July 28, 2023, there is $<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="vtl:ShelfRegistrationStatementAmountRemaining" format="ixt:num-dot-decimal" scale="6" id="f-427">75.0</ix:nonFraction>&#160;million remaining on this shelf registration statement.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" format="ixt:num-dot-decimal" scale="6" id="f-428">50.0</ix:nonFraction>&#160;million of common stock that may be issued and sold under an at-the-market sales agreement ("December 2020 ATM") with SVB Leerink LLC (now Leerink Partners) as agent. The Company has used, and intends to continue to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink LLC on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon <ix:nonFraction unitRef="d" contextRef="c-92" decimals="INF" name="vtl:ShelfRegistrationTerminationPriorWrittenNotice" format="ixt-sec:numwordsen" scale="0" id="f-429">ten</ix:nonFraction> days&#8217; prior notice, or by SVB Leerink LLC at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of July 28, 2023, $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="vtl:SaleOfStockRemainingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-430">8.1</ix:nonFraction>&#160;million in capacity remains under the December 2020 ATM.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" format="ixt:num-dot-decimal" scale="6" id="f-431">80.0</ix:nonFraction>&#160;million of common stock that may be issued and sold under another at-the-market sales agreement ("May 2022 ATM") with SVB Leerink LLC as agent. The Company intends to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The May 2022 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Securities LLC on the terms and subject to the conditions set forth in the May 2022 ATM or (ii) termination of the May 2022 ATM as otherwise permitted thereby. The May 2022 ATM may be terminated at any time by either party upon <ix:nonFraction unitRef="d" contextRef="c-95" decimals="INF" name="vtl:ShelfRegistrationTerminationPriorWrittenNotice" format="ixt-sec:numwordsen" scale="0" id="f-432">ten</ix:nonFraction> days&#8217; prior notice, or by SVB Securities LLC at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.  As of July 28, 2023, $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="vtl:SaleOfStockRemainingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-433">80.0</ix:nonFraction>&#160;million in capacity remains under the May 2022 ATM.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company has agreed to pay SVB Securities LLC a commission equal to <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="vtl:ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" scale="-2" id="f-434">3.0</ix:nonFraction>% of the gross proceeds from the sales of common shares pursuant to both ATM's and has agreed to provide SVB Securities LLC with customary indemnification and contribution rights.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any ATM activity during the three or six months ended June 30, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended June 30, 2022, the Company raised gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-435">10.3</ix:nonFraction>&#160;million pursuant to the December 2020 ATM through the sale of <ix:nonFraction unitRef="shares" contextRef="c-97" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-436">1,300,000</ix:nonFraction> shares of common stock at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-97" decimals="2" name="vtl:SharesIssuedWeightedAverageSharePricePerShare" scale="0" id="f-437">7.90</ix:nonFraction> per share. The net proceeds from the December 2020 ATM were $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-438">10.0</ix:nonFraction>&#160;million after deducting underwriter commissions of $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="us-gaap:PaymentsForCommissions" format="ixt:num-dot-decimal" scale="6" id="f-439">0.3</ix:nonFraction>&#160;million.  In the six months ended June 30, 2022, the Company raised gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="6" id="f-440">40.9</ix:nonFraction>&#160;million pursuant to the December 2020 ATM through the sale of <ix:nonFraction unitRef="shares" contextRef="c-98" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-441">4,204,113</ix:nonFraction> shares of common stock at a weighted average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-98" decimals="2" name="vtl:SharesIssuedWeightedAverageSharePricePerShare" scale="0" id="f-442">9.72</ix:nonFraction> per share. The net proceeds from the December 2020 ATM were $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-443">39.6</ix:nonFraction>&#160;million after deducting underwriter commissions of $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="us-gaap:PaymentsForCommissions" format="ixt:num-dot-decimal" scale="6" id="f-444">1.2</ix:nonFraction>&#160;million. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Offerings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">$60 Million Private Placement Equity Financing</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 10, 2022, Immunic entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) for a private placement (the &#8220;Private Placement&#8221;) with select accredited investors and certain existing investors (each, a &#8220;Purchaser&#8221; and collectively, the &#8220;Purchasers&#8221;). Pursuant to the Purchase Agreement, the Company agreed to sell to the Purchasers (i) <ix:nonFraction unitRef="shares" contextRef="c-99" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-445">8,696,552</ix:nonFraction> shares of the Company&#8217;s common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-100" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-446">0.0001</ix:nonFraction> per share (the &#8220;Shares&#8221;), at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-100" decimals="INF" name="us-gaap:SharePrice" scale="0" id="f-447">4.35</ix:nonFraction> per Share, and (ii) <ix:nonFraction unitRef="shares" contextRef="c-101" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-448">5,096,552</ix:nonFraction> pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase Common Stock (the &#8220;Warrant Shares&#8221; and together with the Shares and the Pre-Funded Warrants, the &#8220;Securities&#8221;), at a purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-102" decimals="INF" name="us-gaap:SharePrice" scale="0" id="f-449">4.34</ix:nonFraction> per Pre-Funded Warrant.  The Pre-Funded Warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if03c774f43b14669a115cba8dd54bb9e"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">holders to receive a fixed number of shares of common stock upon exercise. In addition, the Pre-Funded Warrants do not provide any guarantee of value or return.  All of the pre-funded warrants were exercised in January of 2023.</span></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Common Stock</span></div><div style="margin-top:12pt;padding-right:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2023, the Company&#8217;s certificate of incorporation, as amended and restated, authorized the Company to issue <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-450">130,000,000</ix:nonFraction> shares of common stock, par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-451">0.0001</ix:nonFraction> per share. The voting, dividend and liquidation rights of the holders of the Company&#8217;s common stock are subject to and qualified by the rights, powers and preferences of any holders of preferred stock.</span></div><div style="margin-top:12pt;padding-right:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of common stock entitles the holder to <ix:nonFraction unitRef="vote" contextRef="c-3" decimals="INF" name="vtl:NumberOfVotesPerEachShareOfCommonStock" format="ixt-sec:numwordsen" id="f-452">one</ix:nonFraction> vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any. Through June 30, 2023, <ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" format="ixt:fixed-zero" scale="0" id="f-453"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" format="ixt:fixed-zero" scale="0" id="f-454">no</ix:nonFraction></ix:nonFraction> cash dividends had been declared or paid.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s certificate of incorporation, as amended and restated, authorizes the Company to issue <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="f-455">20</ix:nonFraction> million shares of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-456">0.0001</ix:nonFraction> par value preferred stock, having rights and preferences to be set by the Board of Directors. <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-457">No</ix:nonFraction> preferred shares were outstanding as of June 30, 2023.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Reserved for Future Issuance</span></div><div style="margin-top:12pt;text-indent:22.5pt"><ix:nonNumeric contextRef="c-1" name="vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" id="f-458" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares reserved for future issuance at June 30, 2023 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;2021 Employee Stock Purchase Plan    </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-103" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-459">32,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-104" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-460">5,770,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options available for future grant:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-105" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-461">43,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Inducement Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-106" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-462">46,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 Omnibus Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-107" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-463">4,579,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common shares reserved for future issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-464">10,471,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div id="ic553ef50e5794a188740fd92ee6a6b79_49"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-465" continuedAt="i26264433965e40c9b520c3b64c37466c" escape="true">Stock-Based Compensation Plans</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i26264433965e40c9b520c3b64c37466c" continuedAt="ib02f92d6f3f34739a864716f64887711"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Employee Stock Purchase Plan</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2021, the Company adopted the 2021 Employee Stock Purchase Plan ("ESPP"), which was approved by stockholder vote at the 2021 Annual Meeting of Stockholders held on June 10, 2021. The ESPP provides eligible employees of the Company with an opportunity to purchase common stock of the Company through accumulated payroll deductions, which are included in other current liabilities until they are used to purchase Company shares. Eligible employees participating in the bi-annual offering period can choose to have up to the lesser of <ix:nonFraction unitRef="number" contextRef="c-108" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="f-466">15</ix:nonFraction>% of their annual base earnings or the IRS annual share purchase limit of $25,000 in aggregate market value to purchase shares of the Company&#8217;s common stock. The purchase price of the stock is the lesser of (i) <ix:nonFraction unitRef="number" contextRef="c-108" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="f-467">85</ix:nonFraction>% of the closing market price on the date of purchase and (ii) the closing market price at the beginning of the bi-annual offering period. The maximum number of shares reserved for delivery under the plan is <ix:nonFraction unitRef="shares" contextRef="c-109" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-468">200,000</ix:nonFraction> shares.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">       </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first enrollment period under the plan commenced on August 1, 2021 and the Company has issued <ix:nonFraction unitRef="shares" contextRef="c-110" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-469">167,642</ix:nonFraction>  shares life-to-date under the ESPP.  The Company recognized  $<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-470">37,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-471">83,000</ix:nonFraction> of expense related to the plan during the three and six months ended June 30, 2023, respectively.  The Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-472">25,000</ix:nonFraction> and  $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="f-473">53,000</ix:nonFraction> of expense related to the plan during the three and six months ended June 30, 2022, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:22.5pt"><span><br/></span></div><ix:continuation id="ib02f92d6f3f34739a864716f64887711" continuedAt="i5adff4b4df6443e885250772a32f5931"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Programs</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company&#8217;s stockholders approved the 2019 Omnibus Equity Incentive Plan (the &#8220;2019 Plan&#8221;) which was adopted by the Board of Directors (the "Board") with an effective date of June 14, 2019. The 2019 Plan allows for the grant of equity awards to employees, consultants and non-employee directors. An initial maximum of <ix:nonFraction unitRef="shares" contextRef="c-115" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-474">1,500,000</ix:nonFraction> shares of the Company&#8217;s common stock were available for grant under the 2019 Plan. The 2019 Plan included an evergreen provision that allowed for the annual addition of up to <ix:nonFraction unitRef="number" contextRef="c-116" decimals="INF" name="vtl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" scale="-2" id="f-475">4</ix:nonFraction>% of the Company&#8217;s fully-diluted outstanding stock, with a maximum allowable increase of <ix:nonFraction unitRef="shares" contextRef="c-116" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-476">4,900,000</ix:nonFraction> shares over the term of the 2019 Plan. In accordance with this provision, the shares available for grant were increased in 2020 through 2023 by a total of <ix:nonFraction unitRef="shares" contextRef="c-117" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-477">4,408,871</ix:nonFraction> shares. At the Company's Annual Shareholders meeting on June 28, 2023, shareholders voted to increase the allowable shares under the 2019 plan by <ix:nonFraction unitRef="shares" contextRef="c-118" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" format="ixt:num-dot-decimal" scale="0" id="f-478">4,440,000</ix:nonFraction> shares as well as to eliminate the evergreen provision.  The 2019 Plan is currently administered by the Board, or, at the discretion of the Board, by a committee of the Board, which determines the exercise prices, vesting schedules and other restrictions of awards under the 2019 Plan at its discretion. Options to purchase stock may not have an exercise price that is less than the fair market value of underlying shares on the date of grant, and may not have a term greater than <ix:nonNumeric contextRef="c-119" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:durwordsen" id="f-479">ten years</ix:nonNumeric>. Incentive stock options granted to employees typically vest over <ix:nonNumeric contextRef="c-120" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-480">four years</ix:nonNumeric>. Non-statutory options granted to employees, officers, members of the Board, advisors, and consultants of the Company typically vest over <span style="-sec-ix-hidden:f-481">three</span> or <ix:nonNumeric contextRef="c-122" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-482">four years</ix:nonNumeric>. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares that are expired, terminated, surrendered or canceled under the 2019 Plan without having been fully exercised will be available for future awards. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Movements during the year </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-483" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the six months ended June 30, 2023 and 2022, respectively, for the 2019 Plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:52.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.421%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-123" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-484">3,791,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-123" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-485">11.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-124" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-486">2,059,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-124" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-487">1.45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-124" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="f-488">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-124" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-489">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-124" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-490">80,926</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-124" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-491">8.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-125" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-492">5,770,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-125" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-493">7.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-124" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-494">8.42</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="f-495">2,170,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-125" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-496">5,770,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-125" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-497">7.85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-124" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-498">8.42</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="f-499">2,170,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-125" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-500">2,184,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-125" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-501">12.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-124" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-502">7.43</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="0" id="f-503">62,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:52.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.858%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-126" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-504">2,157,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-126" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-505">13.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-127" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-506">1,702,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-127" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-507">9.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-127" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="f-508">852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-127" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-509">5.67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-127" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-510">145,873</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-127" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-511">11.88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-128" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-512">3,713,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-128" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-513">11.66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-127" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-514">8.86</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="f-515">23,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-128" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-516">3,713,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-128" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-517">11.66</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-127" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-518">8.86</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="f-519">23,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-128" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-520">1,127,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-128" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-521">13.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-127" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-522">8.00</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:fixed-zero" scale="0" id="f-523">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5adff4b4df6443e885250772a32f5931" continuedAt="i21a5d8aca50141a19994f1480a1ff5c8"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the BSM option pricing model to determine the fair value of the employee and non-employee stock option grants relating to the 2019 Plan were as follows:</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free rate assumption is based on U.S. Treasury instruments with maturities similar to the expected term of the stock options.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend Yield</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="f-524">zero</ix:nonFraction>.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company&#8217;s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of its own stock combined with a group of comparable companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the stock-based awards.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of stock options granted under the 2019 Plan during the six months ended June 30, 2023 and 2022 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-129" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-525">1.17</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-130" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-526">7.25</ix:nonFraction>, respectively. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-527" continuedAt="i9f1d5e45a27849a9b658a88a741304c3" escape="true">The following are the underlying assumptions used in the Black-Scholes option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:</ix:nonNumeric></span><ix:continuation id="i9f1d5e45a27849a9b658a88a741304c3"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six  Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-129" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-528">3.93</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-130" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-529">1.95</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-129" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-530">0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-130" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-531">0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-129" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-532">101.6</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-130" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-533">97.9</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-129" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-534">5.99</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-130" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-535">6.00</ix:nonNumeric></span></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-536" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense for all stock awards recognized in the accompanying unaudited condensed consolidated statements of operations is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.391%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>&#160;Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months<br/>&#160;Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-537">889,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-538">765,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-539">1,792,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-540">1,561,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-541">909,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-542">1,297,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-543">1,985,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-544">2,570,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-545">1,798,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-546">2,062,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-547">3,777,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-548">4,131,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="f-549">13.9</ix:nonFraction> million in total unrecognized compensation expense relating to the 2019 Plan to be recognized over a weighted average period of <ix:nonNumeric contextRef="c-1" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-550">2.88</ix:nonNumeric> years.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Equity Incentive Plans Assumed from Vital Therapies</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon completion of the Transaction with Vital Therapies, Inc. ("Vital") on April 12, 2019, Vital&#8217;s 2012 Stock Option </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i21a5d8aca50141a19994f1480a1ff5c8"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plan (the &#8220;2012 Plan&#8221;), Vital&#8217;s 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;) and Vital&#8217;s 2017 Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;), were assumed by the Company. All awards granted under these plans have either been forfeited or expired.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There remain <ix:nonFraction unitRef="shares" contextRef="c-143" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-551">43,311</ix:nonFraction> shares available for grant under the 2014 Plan as of June 30, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, Vital&#8217;s board of directors approved the Inducement Plan, which was amended and restated in November 2017. Under the Inducement Plan <ix:nonFraction unitRef="shares" contextRef="c-144" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-552">46,250</ix:nonFraction> shares of Vital&#8217;s common stock were reserved to be used exclusively for non-qualified grants to individuals who were not previously employees or directors as an inducement material to a grantee's entry into employment within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="f-553"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="f-554"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="f-555"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="f-556">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> expense was recorded for the plans assumed from Vital during the three and six months ended June 30, 2023 and 2022, respectively.</span></div></ix:continuation><div style="margin-top:17.6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div id="ic553ef50e5794a188740fd92ee6a6b79_55"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="f-557" continuedAt="i320048bde97e4ecc88d48f8d613f6daa" escape="true">Related Party Transactions</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i320048bde97e4ecc88d48f8d613f6daa"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Chairman Agreement with Duane Nash</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 15, 2020, the compensation committee of the Board of Directors of the Company independently reviewed and approved entering into an employment agreement with the Executive Chairman of the Board, Duane Nash, MD, JD, MBA (the &#8220;Executive Chairman Agreement&#8221;) and pursuant to such approval, on April 17, 2020, the Company and Dr. Nash entered into the Executive Chairman Agreement. The Executive Chairman Agreement establishes an &#8220;at will&#8221; employment relationship. On December 28, 2022, the Company and Dr. Nash entered into Addendum No. Four, which extended the term of employment from December 31, 2022 to December 31, 2023 with a base salary of $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="0" name="vtl:SalaryCostsMonthlyBaseSalary" format="ixt:num-dot-decimal" scale="0" id="f-558">30,250</ix:nonFraction> per month (which includes the cash retainer payable for serving on the Company&#8217;s Board or for acting as the Chairman of the Board). All other terms of the Executive Chairman Agreement remain the same.</span></div></ix:continuation><div id="ic553ef50e5794a188740fd92ee6a6b79_61"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of financial condition and results of operations should be read in conjunction with our unaudited interim condensed consolidated financial statements and notes thereto included in Item 1 &#8220;Financial Statements&#8221; in this Quarterly Report and audited Consolidated Financial Statements for the years ended December 31, 2022 and 2021 of Immunic, Inc. filed with the Securities and Exchange Commission ("SEC"), in our Annual Report on Form 10-K on February 23, 2023. As used in this report, unless the context suggests otherwise, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the Company&#8221; or &#8220;Immunic&#8221; refer to Immunic, Inc. and its subsidiaries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to historical information, this Quarterly Report includes forward-looking statements within the meaning of federal securities laws. Forward-looking statements are subject to certain risks and uncertainties, many of which are beyond our control. Such statements include, but are not limited to, statements preceded by, followed by or that otherwise include the words, &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;can,&#8221; &#8220;could,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;seek,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;expect,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; or similar expressions and the negatives of those terms.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements discuss matters that are not historical facts. Our forward-looking statements involve assumptions that, if they ever materialize or prove correct, could cause our results to differ materially from those expressed or implied by such forward-looking statements. In this Quarterly Report, for example, we make forward-looking statements, among others, regarding potential strategic options; financial estimates and projections; and the sufficiency of our capital resources to fund our operations.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The inclusion of any forward-looking statements in this Quarterly Report should not be regarded as a representation that any of our plans will be achieved. Our actual results may differ from those anticipated in our forward-looking statements as a result of various factors, including those noted below under the caption &#8220;Part II, Item 1A-Risk Factors&#8221; and in the section headed &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K filed with the SEC on February 23, 2023, and the differences may be material. These risk factors include, but are not limited to statements relating to our three development programs and the targeted diseases; the potential for vidofludimus calcium, IMU-856 and IMU-381 to safely and effectively target diseases; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">preclinical and clinical data for the Company&#8217;s development programs; the timing of current and future clinical trials and anticipated clinical milestones; the nature, strategy and focus of the Company; expectations regarding our capitalization and financial resources; the development and commercial potential of any product candidates of the Company; the Company&#8217;s expected cash runway; and our ability to retain certain personnel important to our ongoing operations and to maintain effective internal control over financial reporting.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our forward-looking statements reflect the good faith judgment of our management, these statements are based only on facts and factors currently known by us. As a result, investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update such statements to reflect events or circumstances after the date hereof, except as required by law.</span></div><div id="ic553ef50e5794a188740fd92ee6a6b79_64"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic, Inc. ("Immunic," &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; or the "Company") is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. We are headquartered in New York City with our main operations in Gr&#228;felfing near Munich, Germany. We currently have approximately 75 employees.</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are pursuing clinical development of orally administered, small molecule programs, each of which has unique features intended to directly address the unmet needs of patients with serious chronic inflammatory and autoimmune diseases. These include the vidofludimus calcium (IMU-838) program, which is in Phase 3 clinical development for patients with multiple sclerosis (&#8220;MS&#8221;) and which has shown therapeutic activity in Phase 2 clinical trials in patients suffering from relapsing-remitting MS and moderate-to-severe ulcerative colitis (&#8220;UC&#8221;); the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, UC, Crohn&#8217;s disease or irritable bowel syndrome with diarrhea; and the IMU-381 program, which is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the potential indications, clinical targets and clinical development status of our three product candidates:</span></div><div style="margin-top:12pt;text-align:justify"><img src="vtl-20230630_g1.jpg" alt="pipeline_20230719_2000px.jpg" style="height:264px;margin-bottom:5pt;vertical-align:text-bottom;width:654px"/></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our most advanced drug candidate, vidofludimus calcium (IMU-838), is being tested in several ongoing MS trials as part of its overall clinical program in order to support a potential approval for patients with MS in major markets. The Phase 3 ENSURE program of vidofludimus calcium in relapsing multiple sclerosis (&#8220;RMS&#8221;), comprising twin studies evaluating efficacy, safety, and tolerability of vidofludimus calcium versus placebo, and the supportive Phase 2 CALLIPER trial of vidofludimus calcium in progressive multiple sclerosis (&#8220;PMS&#8221;) are ongoing and actively enrolling patients. Our current expectation is to report data from the interim analysis of the CALLIPER trial in fall of 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and to read-out top-line data at the end of 2024. Moreover, we currently expect to report data from the interim analysis of the ENSURE program in late 2024 and to read-out the first of the ENSURE trials at the end of 2025. Although we currently believe that each of these goals is achievable, they are each dependent on numerous factors, most of which are not under our direct control and can be difficult to predict. We plan to periodically review this assessment and provide updates of material changes as appropriate.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If approved, we believe that vidofludimus calcium, with combined anti-inflammatory, anti-viral, and neuroprotective effects, has the potential to be a unique treatment option targeted to the complex pathophysiology of MS. Recently published preclinical data showed that vidofludimus calcium activates the neuroprotective transcription factor nuclear receptor related 1 (&#8220;Nurr1&#8221;), which is associated with direct neuroprotective properties and may enhance the potential benefit for patients. Additionally, vidofludimus calcium is a known inhibitor of the enzyme dihydroorotate dehydrogenase (&#8220;DHODH&#8221;), which is a key enzyme in the metabolism of overactive immune cells and virus-infected cells. This mechanism is associated with the anti-inflammatory and anti-viral effects of vidofludimus calcium. We believe that the combined mechanisms of vidofludimus calcium are unique in the MS space and support the therapeutic performance shown in our Phase 2 EMPhASIS trial in relapsing-remitting MS patients, in particular, via data illustrating the potential to reduce magnetic resonance imaging lesions, prevent relapses, reduce the rate of disability progression, and reduce levels of serum neurofilament light chain (&#8220;NfL&#8221;), an important biomarker of neuronal death. Vidofludimus calcium has shown a consistent pharmacokinetic, safety and tolerability profile and has already been exposed to more than 1,400 human subjects and patients in either of the drug&#8217;s formulations.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">IMU-856 is an orally available and systemically acting small molecule modulator that targets Sirtuin 6 (&#8220;SIRT6&#8221;), a protein which serves as a transcriptional regulator of intestinal barrier function and regeneration of bowel epithelium. Based on preclinical data, we believe this compound may represent a unique treatment approach, as the mechanism of action targets the restoration of the intestinal barrier function and bowel wall architecture in patients suffering from gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other intestinal barrier function associated diseases. We believe that, because IMU-856 has been shown in preclinical investigations to avoid suppression of immune cells, it may therefore have the potential to maintain immune surveillance for patients during therapy, which would be an important advantage versus immunosuppressive medications and may allow the potential for combination treatments with available treatments in gastroenterological diseases..</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Data from the final portion of a Phase 1 clinical trial in celiac disease patients during periods of gluten-free diet and gluten challenge demonstrated positive effects for IMU-856 over placebo in four key dimensions of celiac disease pathophysiology: protection of the gut architecture, improvement of patients&#8217; symptoms, biomarker response, and enhancement of nutrient absorption. IMU-856 was also observed to be safe and well-tolerated in this trial. We are currently preparing clinical Phase 2 testing of IMU-856 in ongoing active celiac disease, while also considering further potential clinical applications in other gastrointestinal disorders.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic has selected IMU-381 as a development candidate to specifically address the needs of gastrointestinal diseases. IMU-381 is a next generation molecule with improved overall properties, supported by a series of chemical derivatives. IMU-381 is currently in preclinical testing.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additional antiviral-directed development activities remain ongoing through preclinical research examining the potential to treat a broad set of viral indications with new antiviral molecules. We are exploring several options to possibly support further development of our antiviral portfolio, including a potential spin-off into a new or existing company and potential licensing transactions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">   </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect to continue to lead most of our research and development activities from our Gr&#228;felfing, Germany location, where dedicated scientific, regulatory, clinical and medical teams conduct their activities. Due to these teams' key relationships with local and international service providers, we anticipate that this will result in more timely and cost-effective execution of our development programs. In addition, we are using our subsidiary in Melbourne, Australia to expedite the early clinical trials for  IMU-856. We also conduct preclinical work in Halle/Saale, Germany through a collaboration with the Fraunhofer Institute.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of our clinical trials to meet their endpoints, failure to obtain regulatory approval and failure to obtain needed additional funding on acceptable terms, if at all, to complete the development and commercialization of our three development programs.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Strategy </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are focused on the development of new molecules that maximize the therapeutic benefits for patients by uniquely addressing biologically relevant immunological targets. We take advantage of our established research and development infrastructure and operations in Germany and Australia to more efficiently develop our product candidates in indications of high unmet need and where the product candidates have the potential to elevate the standard of care for the benefit of patients. Given the mechanisms of action and the data generated for our product candidates, to date, we continue to execute on the clinical development of our programs for established indications as well as explore additional indications where patients could potentially benefit from the unique profiles of each product candidate.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are currently focused on maximizing the potential of our development programs through the following strategic initiatives:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Executing the ongoing Phase 3 ENSURE and Phase 2 CALLIPER clinical trial programs of vidofludimus calcium in MS.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Exploring potential next steps for vidofludimus calcium in UC and other inflammatory bowel disease indications.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Executing the IMU-856 development program, including preparation of a Phase 2 clinical trial in patients with ongoing active celiac disease.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Continued preclinical research to complement the existing clinical activities, explore additional indications for future development, and where appropriate, generate additional molecules for future development.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Facilitating readiness for potential commercial launch of our product candidates through targeted and stage-appropriate pre-commercial activities.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Evaluating potential strategic collaborations for each product candidate in order to complement our existing research and development capabilities and to facilitate potential commercialization of these product candidates by taking advantage of the resources and capabilities of strategic collaborators in order to enhance the potential and value of each product candidate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Events</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in MS</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 17, 2023, we announced the publication of preclinical data showing that vidofludimus calcium acts as a potent Nurr1 activator, in addition to its known mode of action as a DHODH inhibitor. Activation of Nurr1 could be responsible for the drug&#8217;s postulated neuroprotective effects and may contribute to the previously reported reduction of confirmed disability worsening events in MS patients. Specifically, preclinical data shows potent Nurr1 activation by vidofludimus calcium at low concentrations in several test systems. The data was published in the peer-reviewed, high impact Journal of Medicinal Chemistry, in a paper entitled, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Development of a potent Nurr1 agonist tool for in vivo applications.&#8221;</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Presentation of Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 6, 2023, we announced the presentation of clinical and preclinical data for IMU-856 as a virtual e-poster at Digestive Disease Week 2023. Included in this presentation were new data on IMU-856&#8217;s mode of action as a potent modulator of SIRT6, a protein which serves as a transcriptional regulator of intestinal barrier function and regeneration of bowel epithelium.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 4, 2023, we announced positive results from the part C portion of our Phase 1 clinical trial of IMU-856 in patients with celiac disease. The data demonstrated positive effects for IMU-856 over placebo in four key dimensions of celiac disease pathophysiology: protection of the gut architecture, improvement of patients&#8217; symptoms, biomarker response, and enhancement of nutrient absorption. IMU-856 was also observed to be safe and well-tolerated in this trial.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that this data set provides initial clinical proof-of-concept for an entirely new therapeutic approach to gastrointestinal disorders by promoting regeneration of bowel architecture. The data provides first clinical evidence that IMU-856&#8217;s ability, observed in preclinical studies, to re-establish proper gut cell renewal translates into clinical benefits for patients with celiac disease. Most importantly, the observed protection of intestinal villi from gluten-induced destruction, independent of targeting immune mechanisms involved specifically in celiac disease, appears to be unique among proposed therapeutic approaches and may be applicable to other gastrointestinal diseases such as UC, Crohn&#8217;s disease or irritable bowel syndrome with diarrhea.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Appointment of Richard Rudick, M.D. to Board of Directors</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 27, 2023, we announced the appointment of Dr. Richard Rudick as a member of our Board of Directors, effective as of April 26, 2023. As a Class III director, Dr. Rudick&#8217;s initial term lasted until our 2023 Annual Meeting of Stockholders </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">held on June 28, 2023, at which meeting he was elected to a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three year term expiring at the 2026 Annual Meeting of Stockholders. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Richard Rudick, age 72, has over 35 years of experience in the biopharmaceutical industry and academic medicine. Since January 2023, Dr. Rudick has been the President and CEO of Astoria Biologic, a private biotechnology company developing novel therapies for MS. Previously, Dr. Rudick served as the Vice President of Development Science at Biogen, Inc., a biotechnology company which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases, from May 2014 until September 2020. Dr. Rudick also served as a staff neurologist and director of the Mellen Center for the Cleveland Clinic from January 1987 until May 2014. Dr. Rudick holds an M.D. from Case Western Reserve University School of Medicine. The Nominating and Corporate Governance Committee and the Board believe that Dr. Rudick&#8216;s extensive leadership in clinical research and development of MS treatments provides valuable clinical, strategy and management skills to the Board.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Director Not Standing for Re-Election at the 2023 Annual Meeting</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on April 26, 2023, Dr. Vincent Ossipow notified our Board that he plans to retire from the Board at the end of his current term and will not stand for re-election at the 2023 Annual Meeting. Dr. Ossipow continued to serve as a member of the Board until the date of the Annual Meeting, and as a member of the Nominating and Corporate Governance Committee until the date of the Annual Meeting, June 28, 2023. Dr. Ossipow&#8217;s decision not to stand for re-election was not the result of any disagreement with the Company or its management on any matter relating to the Company&#8217;s operations, policies or practices.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe UC</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 5, 2023, we reported positive data from the maintenance phase of our Phase 2b CALDOSE-1 trial of vidofludimus calcium in patients with moderate-to-severe UC. The data showed a dose-linear increase in clinical remission as compared to placebo at week 50. Moreover, an exploratory statistical analysis confirmed the 30 mg dose of vidofludimus calcium to be statistically superior (p=0.0358) in achieving clinical remission at week 50, with a 33.7% absolute improvement over placebo. A similar effect on clinical remission rates at week 50 was also found among those patients who received corticosteroids during the induction phase. Finally, a dose-linear increase in endoscopic healing was observed, with the 30 mg dose of vidofludimus calcium being associated with a 37.8% absolute improvement over placebo and also achieving statistical significance in an exploratory statistical analysis (p=0.0259).</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the maintenance phase data of CALDOSE-1 confirms vidofludimus calcium's activity in the absence of chronic corticosteroid co-administration. Consistent with prior data sets in other patient populations, administration of vidofludimus calcium in the maintenance phase of this trial was observed to be safe and well-tolerated.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deprioritization of Izumerogant (IMU-935) Development Program</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to focus on the rapidly advancing vidofludimus calcium and IMU-856 programs, and considering the totality of available data for izumerogant, including changes in expected time to market and increased complexity of potential further development in this competitive field, we announced on April 5, 2023 to focus our resources and, therefore, deprioritized the clinical portion of our izumerogant development program in psoriasis and castration-resistant prostate cancer.</span></div><div><span><br/></span></div><div id="ic553ef50e5794a188740fd92ee6a6b79_67"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Results of Operations </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, we may generate revenue in the future from product sales. We cannot predict if, when, or to what extent we will generate revenue from the commercialization and sale of our product candidates. We may never succeed in obtaining regulatory </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">approval for any of our product candidates or achieving market acceptance and commercial success for any product that does receive regulatory approval.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of costs associated with our research activities, including our product discovery efforts and the development of our product candidates. Our research and development expenses include: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">external research and development expenses and milestone payments incurred under arrangements with third parties, such as CROs, contract manufacturing organizations, collaborations with partners, consultants, and our scientific advisors; and</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">internal personnel expenses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. Non-refundable advance payments for goods and services that will be used in future research and development activities are capitalized as prepaid expenses and expensed when the service has been performed or when the goods have been received.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in March 2016, we have spent a total of approximately $259.0 million in research and development expenses through June 30, 2023. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These costs primarily include external development expenses and internal personnel expenses for the three development programs, vidofludimus calcium, izumerogant and IMU-856. We have spent the majority of our research and development resources on vidofludimus calcium, our lead development program, for clinical trials in MS, UC and COVID-19.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, Immunic AG received a grant of up to approximately $730,000 from the German Federal Ministry of Education and Research, in support of the InnoMuNiCH (Innovations through Munich-Nippon Cooperation in Healthcare) project.  The grant funds have been used to fund a three-year research project relating to autoimmune diseases by us and our three project partners.  Since the inception of the grant, we have recorded $611,000 of income in total of which $0 and $100,000 were recorded in the six months ended June 30,  2023 and 2022, respectively, and were classified in Other Income in the accompanying consolidated statement of operations. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our research and development expenses are expected to increase in the foreseeable future as we continue to conduct ongoing research and development activities, initiate new preclinical and clinical trials and build our pipeline of product candidates.   Our research and development expenses may also increase in the foreseeable future due to the current inflationary environment as well as supply chain shortages, which result in increased costs. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The process of conducting clinical trials and preclinical studies necessary to obtain regulatory approval is costly and time consuming. We may never succeed in achieving regulatory approval for any of our product candidates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Successful development of product candidates is highly uncertain and may not result in approved products. Completion dates and completion costs can vary significantly for each product candidate and are difficult to predict. We anticipate that we will make determinations as to which programs to pursue and how much funding to direct to each program on an ongoing basis in response to the development and regulatory success of each product candidate, and ongoing assessments as to each product candidate&#8217;s commercial potential.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of personnel expenses, professional fees for legal, accounting, tax and business consulting services, insurance premiums and stock-based compensation. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income consists of interest earned on our money market funds and bank accounts which are a portion of our cash and cash equivalents balance. Our interest income has been increasing throughout 2022 and 2023 as global interest rates have been increasing.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense), Net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense) consists primarily of a research and development tax incentive related to clinical trials performed in Australia, a German Government research and development grant and foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future. The intercompany loan between Immunic, Inc. and Immunic AG was settled on September 28, 2022 through an equity infusion from Immunic, Inc. to Immunic AG. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended June 30, 2023 and 2022 </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our operating expenses for the three months ended June 30, 2023 and 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.954%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(223)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,021&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,610&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,411&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,021)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,610)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,411)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,022&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,291)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,313&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,999)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,901)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,098)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development expenses increased by $4.6 million during the three months ended June 30, 2023, as compared to the three months ended June 30, 2022. The increase reflects (i) a $3.3 million increase in external development costs related to the Phase 3 program of vidofludimus calcium in relapsing multiple sclerosis, (ii) a $1.0 million increase in external development costs related to the Phase 1 clinical trial of IMU-856, (iii) a $1.0 million increase in external development costs related to the Phase 2 trial of vidofludimus calcium in progressive multiple sclerosis, (iv) a $0.7 million increase in drug supply for vidofludimus calcium to support our ongoing trials, (v) a $0.6 million increase in personnel expense in research and development related to an increase in headcount, $0.1 million of which was due to non-cash stock based compensation and (vi) a $0.7 million increase related costs across numerous categories. The increases were partially offset by (i) a decrease of $1.4 million in external development costs related to the Phase 2 clinical trial of vidofludimus calcium in ulcerative colitis and (ii) a decrease of $1.3 million related to the IMU-935 psoriasis program. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">General and administrative expenses decreased by $0.2 million during the three months ended June 30, 2023, as compared to the three months ended June 30, 2022. The decrease was primarily due to a $0.4 million decrease for non-cash stock based compensation. The decrease was offset by an increase of $0.2 million related costs across numerous categories.  </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other income increased by $2.3 million during the three months ended June 30, 2023, as compared to the three months ended June 30, 2022. The increase was primarily attributable to (i) a $1.7 million decrease in foreign exchange losses, (ii) a $0.9 million increase in interest income as a result of higher interest rates and (iii) a $0.1 million increase for grants received. The increase was partially offset by a $0.4 million decrease in research and development tax incentives for clinical trials in Australia as a result of decreased spending on clinical trials in Australia. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Comparison of the Six Months Ended June 30, 2023 and 2022 </span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our operating expenses for the six months ended June 30, 2023 and 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.954%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(dollars in thousands)</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,152&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,062&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,272&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,045&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,227&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,272)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,045)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,227)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,001&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(664)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,665&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(552)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,271)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,709)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,562)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Research and development expenses increased by $10.2 million during the six months ended June 30, 2023, as compared to the six months ended June 30, 2022. The increase reflects (i) a $7.2 million increase in external development costs related to the Phase 3 program of vidofludimus calcium in relapsing multiple sclerosis, (ii) a $2.0 million increase in external development costs related to the Phase 1 clinical trial of IMU-856, (iii) a $1.9 million increase in external development costs related to the Phase 2 trial of vidofludimus calcium in progressive multiple sclerosis, (iv) a $1.1 million increase in personnel expense in research and development related to an increase in headcount, $0.2 million of which was due to non-cash stock based compensation, (v) a $1.1 million increase in drug supply for vidofludimus calcium to support our ongoing trials and (vi) a $0.5 million increase related costs across numerous categories. The increases were partially offset by (i) a decrease of $2.0 million in external development costs related to the Phase 2 clinical trial of vidofludimus calcium in ulcerative colitis and (ii) a decrease of $1.6 million related to the IMU-935 psoriasis program.  </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">General and administrative expenses increased by $0.1 million during the six months ended June 30, 2023, as compared to the six months ended June 30, 2022. The increase was primarily due to (i) a $0.2 million increase in travel expense and (ii) a $0.4 million increase across numerous categories. The increases were partially offset by a decrease of $0.5 million in personnel expense in general and administrative which was primarily due to non-cash stock based compensation decrease.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other income increased by $3.7 million during the six months ended June 30, 2023, as compared to the six months ended June 30, 2022. The increase was primarily attributable to (i) a $1.7 million increase in interest income as a result of higher interest rates, (ii) a $1.4 million decrease in foreign exchange losses and (iii) a $1.1 million research allowance attributable to tax year 2021 from the German Federal Ministry of Finance. The increase was partially offset by a $0.5 million decrease in research and development tax incentives for clinical trials in Australia as a result of decreased spending on clinical trials in Australia.</span></div><div><span><br/></span></div><div id="ic553ef50e5794a188740fd92ee6a6b79_70"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Condition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no products approved for commercial sale and have not generated any revenue from product sales. We have never been profitable and have incurred operating losses in each year since our inception in 2016. We have an accumulated deficit of approximately $366.6 million at June 30, 2023 and $317.3 million as of December 31, 2022. Substantially all of our operating losses resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future as we initiate and continue the preclinical and clinical development of our product candidates and add personnel necessary to operate as a company with an advanced clinical pipeline of product candidates. To the extent additional funds are necessary to meet long-term liquidity needs as we continue to execute our business strategy, we anticipate that they will be obtained through the incurrence of indebtedness, additional equity financings or a combination of these potential sources of funds, although we can provide no assurance that these sources of funding will be available on reasonable terms.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through June 30, 2023, we have raised net cash of approximately $355.6 million from private and public offerings of preferred and common stock. As of June 30, 2023, we had cash and cash equivalents of approximately $77.3 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million.  With these funds, we expect to be able to fund our operations beyond twelve months from the date of the issuance of the accompanying condensed consolidated financial statements. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, we filed a shelf registration statement on Form S-3 (the "2020 Shelf Registration Statement").   The 2020 Shelf Registration Statement permits the offering, issuance and sale of up to $250.0&#160;million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing. As of July 28, 2023, there is $75.0&#160;million remaining on this shelf registration statement. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $50.0 million of common stock that may be issued and sold under an at-the-market sales agreement with SVB Leerink LLC (now Leerink Partners)as agent ("December 2020 ATM"). We have used and intend to continue to use the net proceeds from the December 2020 ATM to continue to fund the ongoing clinical development of our product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink LLC on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon ten days&#8217; prior notice, or by SVB Leerink LLC at any time in certain circumstances, including the occurrence of a material adverse effect on us.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of July 28, 2023, $8.1 million in capacity remains under the December 2020 ATM.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, we filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $80.0 million of common stock that may be issued and sold under another at-the-market sales agreement ("May 2022 ATM") with SVB Securities LLC (now Leerink Partners) as agent. We intend to use the net proceeds from the offering to continue to fund the ongoing clinical development of our product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The May 2022 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Securities LLC on the terms and subject to the conditions set forth in the May 2022 ATM or (ii) termination of the May 2022 ATM as otherwise permitted thereby. The May 2022 ATM may be terminated at any time by either party upon ten days&#8217; prior notice, or by SVB Securities LLC at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of July 28, 2023, $80.0 million in capacity remains under the May 2022 ATM.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have any ATM activity during the six months ended June 30, 2023.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended June 30, 2022, we raised gross proceeds of $10.3 million pursuant to the December 2020 ATM through the sale of 1,300,000 shares of common stock at a weighted average price of $7.90 per share. The net proceeds from the December 2020 ATM were $10.0 million after deducting underwriter commissions of $0.3 million. In the six months ended June 30, 2022, we raised gross proceeds of $40.9 million pursuant to the December 2020 ATM through the sale of 4,204,113 shares of common stock at a weighted average price of $9.72 per share. The net proceeds from the December 2020 ATM were $39.6 million after deducting underwriter commissions of $1.2 million</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Future Capital Requirements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, we have not generated any revenue from product sales and we do not know when, or if, we will generate any revenue from product sales. We do not expect to generate any revenue from product sales unless and until we obtain regulatory approval for and commercialize any of our product candidates. At the same time, we expect our expenses to increase as we continue the ongoing research, development, manufacture and clinical trials of, and seek regulatory approval for, our product candidates. We also incur additional costs associated with operating as a public company. In addition, subject to obtaining regulatory approval of any of our product candidates, we anticipate that we will need substantial additional funding in connection with our continuing operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future expenses and capital requirements are difficult to forecast and will depend on many factors, including, but not limited to:</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and structure of any strategic options and transactions, if any;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost, timing and outcome of any future litigation;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">personnel-related expenses, including salaries, benefits, stock-based compensation expense and other compensation expenses related to retention and termination of personnel;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, progress, duration, results and costs of research and development and ongoing clinical trials;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of future regulatory submissions;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of developing and validating the manufacturing processes for any potential product candidates;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of any commercialization activities, including reimbursement, marketing, sales and distribution costs;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish new collaborations, licensing or other arrangements and the financial terms of such agreements;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and characteristics of any future product candidates we pursue;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved with being a public company;</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patents, including litigation costs and the outcome of such litigation; and</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt and amount from the sales of, or royalties on, any future products.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of stock offerings, debt financings, strategic alliances, collaborations and licensing arrangements. Recent developments, however, will make it more difficult and costly for us to obtain funding for our cash needs. We do not expect to achieve revenue from product sales prior to the use of all the net proceeds from our public and private offerings to date. We do not have any committed external source of funds. Additional funds may not be available on acceptable terms, if at all. To the extent that we raise additional capital through the sale of equity securities, the ownership interest of our stockholders will be diluted and it may be on terms that are not favorable to us or our stockholders.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sales of equity securities will also be more difficult for at least the foreseeable future because of general volatility in the equity markets for companies like us, as well as the significant decline in the trading price of our stock following our announcement on October 21, 2022 of the Phase 1b interim analysis of izumerogant in moderate-to-severe psoriasis. Debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt or other terms that are not favorable to us or our stockholders. Also, the cost of debt financing has increased due to the rise in interest rates beginning in March 2022. If we raise additional funds through collaborations and licensing arrangements with third parties, we would expect to relinquish substantial rights to our technologies or our future products, or grant licenses on terms that may not be favorable to us. If we were to complete a merger, we may relinquish all control over the organization and could experience detrimental tax effects.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we are unable to raise adequate funds, we may have to curtail our product development programs and liquidate some or all of our assets. Any of these factors could harm our operating results and could result in substantial declines in the trading price of our common stock.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2023, we had cash and cash equivalents of approximately $77.3 million </span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows a summary of our cash flows for the six months ended June 30, 2023 and 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(unaudited)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,489)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,444)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,719&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2023, operating activities used $39.5 million of cash. The use of cash primarily resulted from (i) our net loss of $49.3 million adjusted for non-cash charges of $4.5 million related to $0.7 million for an unrealized foreign currency loss and $3.8 million related to stock-based compensation and depreciation and amortization as well as a $5.3 million net increase in our operating assets and liabilities. Changes in our operating assets and liabilities during the six months ended June 30, 2023 consisted primarily of (i) a $5.0 million increase in our other current liabilities and an increase in other current assets and prepaid expenses of $0.3 million.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2022, operating activities used $36.4 million of cash. The use of cash primarily resulted from (i) our net loss of $42.7 million adjusted for non-cash charges of $6.3 million related to $2.1 million for an unrealized foreign currency loss and $4.2 million related to stock-based compensation and depreciation and amortization while our net change in operating assets and liabilities remained flat. Changes in our operating assets and liabilities during the six months ended June 30, 2022 consisted primarily of (i) a $0.1 million increase in our other current assets and prepaid expenses  partially offset by an decrease of $0.1 million in our other current liabilities.   </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2023, net investing activities provided $9.7 million of cash, primarily due to the sale of $9.8 million of time deposits partially offset by the purchase of $125,000 of property and equipment. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $40,000 during the six months ended June 30 2022, which was related to the purchase of property and equipment.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $147,000 during the six months ended June 30, 2023 consisting of net cash proceeds of $51,000 from the issuance of common stock related to the exercise of pre-funded warrants and $96,000 related to the issuance of shares related to our Employee stock purchase plan.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $39.7 million during the six months ended June 30, 2022 consisting primarily of net cash proceeds from the sale of common stock under our ATM facility. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through June 30, 2023, we have not entered into and did not have any relationships with unconsolidated entities or financial collaborations, such as entities often referred to as structured finance or special purpose entities, established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purpose.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the operating lease obligation are as follows as of June 30, 2023:</span></div><div style="margin-top:12pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:84.294%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PV of obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,877,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2023, we have non-cancelable contractual obligations under certain agreements related to our development programs vidofludimus calcium and IMU-856 totaling approximately $3.4 million, all of which is expected to be paid in the next twelve months.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unaudited condensed consolidated financial statements are prepared in conformity with U.S. GAAP. The preparation of our unaudited condensed consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. We have reviewed these critical accounting policies and related disclosures with the Audit Committee of our Board.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first six months of 2023, there were no significant changes in our critical accounting policies or in the methodology used for estimates. Our significant accounting policies are described in more detail in (i) Note 2 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report and (ii) our audited consolidated financial statements for the years ended December 31, 2022 and 2021 filed in our Annual Report on Form 10-K on February 23, 2023.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recently issued accounting standards that would have a significant impact on the company's consolidated financial statements. </span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div id="ic553ef50e5794a188740fd92ee6a6b79_73"></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Sensitivity</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had cash and cash equivalents of $77.3 million as of June 30, 2023, which were held for working capital purposes. We do not enter into investments for trading or speculative purposes. We do not believe that we have any material exposure to changes in the fair value of these investments as a result of changes in interest rates due to their short-term nature. However, $14.4 million of these funds are held in German bank accounts that were earning between 1.75%-2.75% interest as of June 30, 2023.  Decreases or increases in interest rates, however, will reduce or increase future investment income, respectively, to the extent we have funds available for investment.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary research and development operations are conducted in our facilities in Germany. We have entered into and may continue to enter into international agreements, primarily related to our clinical studies. Accordingly, we have exposure to foreign currency exchange rates and fluctuations between the U.S. dollar and foreign currencies, primarily the euro and the Australian dollar, which could adversely affect our financial results, including income and losses as well as assets and liabilities. To date, we have not entered into, and do not have any current plans to enter into, any foreign currency hedging transactions or derivative financial transactions. Our exposure to foreign currency risk will fluctuate in future periods as our research and clinical development activities in Europe and Australia change. We currently maintain a significant amount of our assets outside of the U.S.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currencies of our foreign subsidiaries are the applicable local currencies. Accordingly, the effects of exchange rate fluctuations on the net assets of these operations are accounted for as translation gains or losses in accumulated other comprehensive income (loss) within stockholders&#8217; equity.  Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). Our German subsidiary is currently a significant portion of our business and, accordingly, a change of 10% in the currency exchange rates, primarily the euro, could have a material impact on their financial position or results of operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although operating in local currencies may limit the impact of currency rate fluctuations on the results of operations of our German and Australian subsidiaries, rate fluctuations may impact the consolidated financial position as the assets and liabilities of our foreign operations are translated into U.S. dollars in preparing our condensed consolidated balance sheets. As of June 30, 2023, our German and Australian subsidiaries had net current assets (defined as current assets less current </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liabilities), subject to foreign currency translation risk, of $5.7 million. A decrease of approximately $0.5 million in net current assets would result as of June 30, 2023, from a hypothetical 10% adverse change in quoted foreign currency exchange rates, primarily due to the euro.  In addition, a 10% change in the foreign currency exchange rates for the six months ended June 30, 2023, would have impacted our net loss by approximately $4.3 million, primarily due to the euro.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effects of Inflation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced a general increase in costs as a result of global inflation, however, we do not believe that inflation and changing prices had a material impact on our results of operations for any periods presented herein.</span></div><div id="ic553ef50e5794a188740fd92ee6a6b79_76"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;4. Controls and Procedures</span></div><div style="margin-bottom:8.85pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An evaluation was carried out, under the supervision of and with the participation of our management, including our Chief Executive Officer and our Principal Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15 (e)) under the Securities Exchange Act of 1934 ("the Exchange Act"), as of the end of the period covered by this report. Based on such evaluation, our Chief Executive Officer and our Principal Financial Officer have concluded that our disclosure controls and procedures are effective to ensure that the information required to be disclosed by us in the reports we file or submit under the Exchange Act was recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:0.2pt;margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no change in our internal control over financial reporting that occurred during the six months ended June 30, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="ic553ef50e5794a188740fd92ee6a6b79_79"></div><div><span><br/></span></div><div id="ic553ef50e5794a188740fd92ee6a6b79_82"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Part II - OTHER INFORMATION</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1. Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not currently a party to any litigation, nor are we aware of any pending or threatened litigation against us, that we believe would materially affect our business, operating results, financial condition or cash flows. Our industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, we may be involved in various legal proceedings from time to time.</span></div><div id="ic553ef50e5794a188740fd92ee6a6b79_85"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;Risk Factors</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our business is subject to various risks, including those described in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which we strongly encourage you to review. Other than as set forth below, there have been no material changes to the risk factors described in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC on February 23, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Adverse developments affecting the financial services industry, including events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional counterparties, could adversely affect our business, financial condition, or results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Events involving limited liquidity, defaults, non-performance, or other adverse developments that affect financial institutions, transactional counterparties, or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have recently led to market-wide liquidity problems. In March 2023, Silicon Valley Bank, Signature Bank and Silvergate Capital Corp. were each swept into receivership. Although financial regulators have taken measures to prevent further bank closures, these risks remain. If we were to borrow money in the future and if any of our lenders or counterparties to any such instruments were to be placed into receivership, or if we had cash deposits at any such banks, we may be unable to access our funds. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Although we assess our banking and financing relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations, clinical programs and product development could be significantly impaired by factors that affect us, the financial services industry or economy in general. These factors could include, among others, events such as liquidity constraints or </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">failures, the ability to perform obligations under various types of financial, credit, or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and stricter financial and operating covenants, or limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all. Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our financial and/or contractual obligations or result in violations of federal or state wage and hour laws if, for example, we were unable to obtain access to deposits used for payroll. Any of these impacts, or any other impacts resulting from the factors described above or other related or similar factors not described above, could have material adverse impacts on our liquidity and our current and/or projected business operations and financial condition and results of operations.</span></div><div id="ic553ef50e5794a188740fd92ee6a6b79_88"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ic553ef50e5794a188740fd92ee6a6b79_91"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ic553ef50e5794a188740fd92ee6a6b79_94"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ic553ef50e5794a188740fd92ee6a6b79_97"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5. Other Information</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ic553ef50e5794a188740fd92ee6a6b79_100"></div><div style="margin-top:12pt"><span><br/></span></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6. Exhibits </span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBITS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filing Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex3-1.htm">Amended and Restated Certificate of Incorporation.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000646/e618557_ex3-2.htm">Third Amended and Restated Bylaws.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 17, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380519000837/e618652_ex4-2.htm">2019 Omnibus Equity Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380522001344/e621975_ex4-1.htm">Form of Pre-Funded Warrant</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 11, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380523000064/e618207_ex10-1.htm">Fourth Addendum dated January 16, 2023 to the Service Agreement, between Immunic AG and Dr. Daniel Vitt</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 16, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380523000064/e618207_ex10-2.htm">Fourth Addendum dated January 16, 2023 to the Service Agreement, between Immunic AG and Dr. Andreas Muehler</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 16, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1280776/000119380523000064/e618207_ex10-3.htm">Fourth Addendum dated January 16, 2023 to the Service Agreement, between Immunic AG and Dr. Hella Kohlhof</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 16, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit23120231.htm">Consent of Baker Tilly U.S. LLP, Independent Registered Public Accounting Firm.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Power of Attorney (included on the signature page)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-63023xexhibit311.htm">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-6x3023xexhibit312.htm">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-6x30x23xexhibit321.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="imux-63023xexhibit322.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Database.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicates a management contract or compensatory plan or arrangement.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In accordance with Item 601(b)(32)(ii) of Regulation S-K and SEC Release No. 33-8238 and 34-47986, Final Rule: Management&#8217;s Reports on Internal Control Over Financial Reporting and Certification of Disclosure in Exchange Act Periodic Reports, the certifications furnished in Exhibits 32.1 and 32.2 hereto are deemed to accompany this Form 10-Q and will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><div id="ic553ef50e5794a188740fd92ee6a6b79_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:12pt;text-indent:49.5pt"><span><br/></span></div><div style="text-indent:288pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMMUNIC, INC.</span></div><div><span><br/></span></div><div style="text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: August 3, 2023&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By:   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">/s/ Daniel Vitt                                 </span></div><div style="text-indent:288pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">         &#160;&#160;&#160;&#160;Daniel Vitt</span></div><div style="text-indent:288pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">         &#160;&#160;&#160;&#160;Chief Executive Officer and President</span></div><div style="text-indent:288pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:49.5pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:49.5pt"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>exhibit23120231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ie035177e2b784cfb8796cae098d42503_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 23.1</font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">We consent to the incorporation by reference in the Registration Statements on Form S&#8209;3 (File No. 333&#8209;</font><font style="background-color:#ffffff;color:#373739;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">225230, 333-250083, 333-255303, and 333-268737), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Form S&#8209;4 (File No. 333&#8209;</font><font style="background-color:#ffffff;color:#373739;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">229510</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">), and Form S-8 (File No. 333&#8209;</font><font style="background-color:#ffffff;color:#373739;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">233864 and 333-258235</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">) of Immunic, Inc. of our report dated February 23, 2023, relating to the consolidated financial statements of Immunic, Inc., which appears in this annual report on Form 10-K for the year ended December 31, 2022. </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#47;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">s&#47; Baker Tilly US, LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Minneapolis, Minnesota </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">February 23, 2023</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>imux-63023xexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i4cdf85f524ac420db26fea828496f07e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Daniel Vitt, certify that&#58;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Quarterly Report on Form 10-Q of Immunic, Inc.&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 3, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Daniel Vitt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel Vitt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>imux-6x3023xexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i0b3c780eeeb14b719b2ba274dfb04b53_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Glenn Whaley, certify that&#58;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.  I have reviewed this Quarterly Report on Form 10-Q of Immunic, Inc.&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of and for the periods presented in this report&#59;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 3, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Glenn Whaley</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glenn Whaley</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>imux-6x30x23xexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i3d8ea5571e00451d95cebcdceff96e85_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-Q of Immunic, Inc. (the &#8220;Company&#8221;) for the period ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Daniel Vitt, as Chief Executive Officer and President of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to my knowledge&#58;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 3, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Daniel Vitt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daniel Vitt</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>imux-63023xexhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i55f342da716d4a399942d939603e016a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form 10-K of Immunic, Inc. (the &#8220;Company&#8221;) for the period ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, Glenn Whaley as Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to my knowledge&#58;&#58;</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) the Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:56.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.171%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; August 3, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Glenn Whaley</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Glenn Whaley</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>vtl-20230630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:c5b7d08b-4d18-4b53-b740-daba2f6d29fd,g:398611d2-4d63-409b-b481-5daa2ae6bce9-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:vtl="http://vitaltherapies.com/20230630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://vitaltherapies.com/20230630">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtl-20230630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtl-20230630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtl-20230630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vtl-20230630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://vitaltherapies.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveLoss" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquityParenthetical" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical">
        <link:definition>0000007 - Statement - Condensed Consolidated Statements of Stockholders&#8217; Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofCashFlows" roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows">
        <link:definition>0000008 - Statement - Condensed Consolidated Statement of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandBasisofFinancialStatements" roleURI="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements">
        <link:definition>0000009 - Disclosure - Description of Business and Basis of Financial Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetails" roleURI="http://vitaltherapies.com/role/BalanceSheetDetails">
        <link:definition>0000011 - Disclosure - Balance Sheet Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://vitaltherapies.com/role/CommitmentsandContingencies">
        <link:definition>0000012 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValue" roleURI="http://vitaltherapies.com/role/FairValue">
        <link:definition>0000013 - Disclosure - Fair Value</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStock" roleURI="http://vitaltherapies.com/role/CommonStock">
        <link:definition>0000014 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlans" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlans">
        <link:definition>0000015 - Disclosure - Stock-Based Compensation Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://vitaltherapies.com/role/RelatedPartyTransactions">
        <link:definition>0000016 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://vitaltherapies.com/role/SubsequentEvents">
        <link:definition>0000017 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9954701 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9954702 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsTables" roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsTables">
        <link:definition>9954703 - Disclosure - Balance Sheet Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesTables">
        <link:definition>9954704 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueTables" roleURI="http://vitaltherapies.com/role/FairValueTables">
        <link:definition>9954705 - Disclosure - Fair Value (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockTables" roleURI="http://vitaltherapies.com/role/CommonStockTables">
        <link:definition>9954706 - Disclosure - Common Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansTables" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansTables">
        <link:definition>9954707 - Disclosure - Stock-Based Compensation Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessandBasisofFinancialStatementsDetails" roleURI="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails">
        <link:definition>9954708 - Disclosure - Description of Business and Basis of Financial Statements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>9954709 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesInvestmentsDetails" roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails">
        <link:definition>9954710 - Disclosure - Summary of Significant Accounting Policies - Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails">
        <link:definition>9954711 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail" roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail">
        <link:definition>9954712 - Disclosure - Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleofAccountsPayableDetail" roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail">
        <link:definition>9954713 - Disclosure - Balance Sheet Details - Schedule of Accounts Payable (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleofAccruedExpensesDetail" roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail">
        <link:definition>9954714 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail">
        <link:definition>9954715 - Disclosure - Balance Sheet Details - Schedule of Other Current Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>9954716 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails" roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails">
        <link:definition>9954717 - Disclosure - Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1" roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1">
        <link:definition>9954717 - Disclosure - Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>9954718 - Disclosure - Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueAdditionalInformationDetail" roleURI="http://vitaltherapies.com/role/FairValueAdditionalInformationDetail">
        <link:definition>9954719 - Disclosure - Fair Value - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockShelfRegistrationStatementDetails" roleURI="http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails">
        <link:definition>9954720 - Disclosure - Common Stock - Shelf Registration Statement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockEquityOfferingDetails" roleURI="http://vitaltherapies.com/role/CommonStockEquityOfferingDetails">
        <link:definition>9954721 - Disclosure - Common Stock - Equity Offering (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockCommonStockDetails" roleURI="http://vitaltherapies.com/role/CommonStockCommonStockDetails">
        <link:definition>9954722 - Disclosure - Common Stock - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockPreferredStockDetails" roleURI="http://vitaltherapies.com/role/CommonStockPreferredStockDetails">
        <link:definition>9954723 - Disclosure - Common Stock - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockSharesReservedforFutureIssuanceDetails" roleURI="http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails">
        <link:definition>9954724 - Disclosure - Common Stock - Shares Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansAdditionalInformationDetails" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails">
        <link:definition>9954725 - Disclosure - Stock-Based Compensation Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansSummaryofStockOptionActivityDetails" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails">
        <link:definition>9954726 - Disclosure - Stock-Based Compensation Plans - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail">
        <link:definition>9954727 - Disclosure - Stock-Based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails">
        <link:definition>9954728 - Disclosure - Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>9954729 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="vtl_LegalAndAuditCostsPayableCurrent" abstract="false" name="LegalAndAuditCostsPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_NumberOfVotesPerEachShareOfCommonStock" abstract="false" name="NumberOfVotesPerEachShareOfCommonStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vtl_IncentiveEmployeeStockOptionMember" abstract="true" name="IncentiveEmployeeStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_ResearchAndDevelopmentTaxIncentiveCurrent" abstract="false" name="ResearchAndDevelopmentTaxIncentiveCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_OperatingAndVariableLeasesCost" abstract="false" name="OperatingAndVariableLeasesCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_ClinicalCostsPayableCurrent" abstract="false" name="ClinicalCostsPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_EmployeeStockOptionsforFutureGrantMember" abstract="true" name="EmployeeStockOptionsforFutureGrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" abstract="false" name="LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vtl_AccruedClinicalCostsCurrent" abstract="false" name="AccruedClinicalCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_ShelfRegistrationStatementAmountRemaining" abstract="false" name="ShelfRegistrationStatementAmountRemaining" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_LesseeOperatingLeaseLiabilityPaymentsAfterDueYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsAfterDueYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" abstract="false" name="ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="vtl_AccruedLegalAndAuditCostsCurrent" abstract="false" name="AccruedLegalAndAuditCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_A2017InducementEquityIncentivePlanMember" abstract="true" name="A2017InducementEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_NewYorkCityMember" abstract="true" name="NewYorkCityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_PlaneggGermanyMember" abstract="true" name="PlaneggGermanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_GrafelfingGermanyMember" abstract="true" name="GrafelfingGermanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" abstract="false" name="ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_AccruedCompensationCurrent" abstract="false" name="AccruedCompensationCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_ExecutiveChairmanAgreementMember" abstract="true" name="ExecutiveChairmanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_OperatingLeaseIncrementalBorrowingRate" abstract="false" name="OperatingLeaseIncrementalBorrowingRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="vtl_A2019OmnibusEquityIncentivePlanMember" abstract="true" name="A2019OmnibusEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_EmployeeMember" abstract="true" name="EmployeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" abstract="true" name="TwoThousandNineteenOmnibusEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_GovernmentAssistanceRate" abstract="false" name="GovernmentAssistanceRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="vtl_PreFundedWarrantsMember" abstract="true" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_SharesIssuedWeightedAverageSharePricePerShare" abstract="false" name="SharesIssuedWeightedAverageSharePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="vtl_ShelfRegistrationTerminationPriorWrittenNotice" abstract="false" name="ShelfRegistrationTerminationPriorWrittenNotice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vtl_SalaryCostsMonthlyBaseSalary" abstract="false" name="SalaryCostsMonthlyBaseSalary" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_PrepaidClinicalAndRelatedCostsCurrent" abstract="false" name="PrepaidClinicalAndRelatedCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" abstract="false" name="CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="vtl_December2020ATMMember" abstract="true" name="December2020ATMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_May2022ATMMember" abstract="true" name="May2022ATMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" abstract="true" name="TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_TwoThousandFourteenEquityIncentivePlanMember" abstract="true" name="TwoThousandFourteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_AustraliaAndGermanyMember" abstract="true" name="AustraliaAndGermanyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" abstract="false" name="MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" abstract="false" name="LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="vtl_A2021EmployeeStockPurchasePlanMember" abstract="true" name="A2021EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="vtl_DuaneNashMDJDMBAMember" abstract="true" name="DuaneNashMDJDMBAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_SaleOfStockRemainingCapacity" abstract="false" name="SaleOfStockRemainingCapacity" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="vtl_NumberOfDevelopmentPrograms" abstract="false" name="NumberOfDevelopmentPrograms" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vtl_NonStatutoryEmployeeStockOptionMember" abstract="true" name="NonStatutoryEmployeeStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="vtl_LesseeOperatingLeasesNumberOfExistingLeases" abstract="false" name="LesseeOperatingLeasesNumberOfExistingLeases" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="vtl_NumberOfFinancialInstitutionsUsedForCashDeposit" abstract="false" name="NumberOfFinancialInstitutionsUsedForCashDeposit" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>vtl-20230630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:c5b7d08b-4d18-4b53-b740-daba2f6d29fd,g:398611d2-4d63-409b-b481-5daa2ae6bce9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vtl-20230630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_70607dde-679a-4397-af1c-e19f6cd59972" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_4a38815c-3133-4d12-a7c4-6f9d987e0633" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_70607dde-679a-4397-af1c-e19f6cd59972" xlink:to="loc_us-gaap_PreferredStockValue_4a38815c-3133-4d12-a7c4-6f9d987e0633" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ef85421d-091a-4fe5-87cd-5afa8acfed11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_70607dde-679a-4397-af1c-e19f6cd59972" xlink:to="loc_us-gaap_CommonStockValue_ef85421d-091a-4fe5-87cd-5afa8acfed11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ab00d881-ce76-47f1-8902-ca86be7d23c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_70607dde-679a-4397-af1c-e19f6cd59972" xlink:to="loc_us-gaap_AdditionalPaidInCapital_ab00d881-ce76-47f1-8902-ca86be7d23c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bdd1c1db-1e40-4088-8746-2445f914a867" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_70607dde-679a-4397-af1c-e19f6cd59972" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bdd1c1db-1e40-4088-8746-2445f914a867" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bff8b143-c1ca-4967-a7c0-d8a7801dc8f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_70607dde-679a-4397-af1c-e19f6cd59972" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_bff8b143-c1ca-4967-a7c0-d8a7801dc8f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7d445521-e21d-4765-b694-12847af5bd33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_27a9a1f3-9010-48a0-a99d-347767e7b300" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7d445521-e21d-4765-b694-12847af5bd33" xlink:to="loc_us-gaap_StockholdersEquity_27a9a1f3-9010-48a0-a99d-347767e7b300" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d93ff1b9-a34d-42b9-acfd-22585fe6874f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7d445521-e21d-4765-b694-12847af5bd33" xlink:to="loc_us-gaap_Liabilities_d93ff1b9-a34d-42b9-acfd-22585fe6874f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_6a8477d8-ab02-4c4a-9496-c50ae07e5ab0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7d445521-e21d-4765-b694-12847af5bd33" xlink:to="loc_us-gaap_CommitmentsAndContingencies_6a8477d8-ab02-4c4a-9496-c50ae07e5ab0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c681bd1d-76dd-478f-bf1d-2655d5f1d543" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_84c9d812-bf60-4a06-8b35-3056693775e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c681bd1d-76dd-478f-bf1d-2655d5f1d543" xlink:to="loc_us-gaap_LiabilitiesCurrent_84c9d812-bf60-4a06-8b35-3056693775e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_d8e881f6-7de2-425a-aec3-6fe37619c036" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_c681bd1d-76dd-478f-bf1d-2655d5f1d543" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_d8e881f6-7de2-425a-aec3-6fe37619c036" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2ee25784-42b9-492e-9063-88576eccc1d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_5bda56c7-0c12-477b-a292-a7a3573efeb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2ee25784-42b9-492e-9063-88576eccc1d3" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_5bda56c7-0c12-477b-a292-a7a3573efeb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_19919342-c303-4c38-af87-ac5f6af18f56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2ee25784-42b9-492e-9063-88576eccc1d3" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_19919342-c303-4c38-af87-ac5f6af18f56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_7f9f4435-2a56-44de-b46e-422472aa74c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_2ee25784-42b9-492e-9063-88576eccc1d3" xlink:to="loc_us-gaap_AccountsPayableCurrent_7f9f4435-2a56-44de-b46e-422472aa74c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_59f734c5-9d06-4643-9d82-bb8e28a338cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_00a9838d-fe0d-43f8-b834-6cff55b1a6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_59f734c5-9d06-4643-9d82-bb8e28a338cc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_00a9838d-fe0d-43f8-b834-6cff55b1a6c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_3909d15c-bca1-4374-80ec-1c3d32636d11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_59f734c5-9d06-4643-9d82-bb8e28a338cc" xlink:to="loc_us-gaap_OtherShortTermInvestments_3909d15c-bca1-4374-80ec-1c3d32636d11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a440c06c-5205-4b91-be54-a0f37648fef3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_59f734c5-9d06-4643-9d82-bb8e28a338cc" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a440c06c-5205-4b91-be54-a0f37648fef3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5a092c13-2057-4660-b113-5214f321aca8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_4d912ece-a0c4-4f0e-9817-02d4ae373ea7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5a092c13-2057-4660-b113-5214f321aca8" xlink:to="loc_us-gaap_AssetsCurrent_4d912ece-a0c4-4f0e-9817-02d4ae373ea7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c281fa6f-3602-47d6-8de3-1acd4c8d444d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5a092c13-2057-4660-b113-5214f321aca8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c281fa6f-3602-47d6-8de3-1acd4c8d444d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_832487e0-73f3-475f-bb04-cd68e2793ced" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5a092c13-2057-4660-b113-5214f321aca8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_832487e0-73f3-475f-bb04-cd68e2793ced" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_536993ea-0b66-4841-b8e3-33fd7443907e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5a092c13-2057-4660-b113-5214f321aca8" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_536993ea-0b66-4841-b8e3-33fd7443907e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_be810d69-1a38-4233-8e2e-995cd646f893" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fc765189-b89b-4c36-ae51-ffeb06191a34" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_be810d69-1a38-4233-8e2e-995cd646f893" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_fc765189-b89b-4c36-ae51-ffeb06191a34" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="vtl-20230630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_cb877fc7-5e63-4c88-9cea-50bed9059f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1d9fce33-0969-468d-9877-12cce16b1fce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_cb877fc7-5e63-4c88-9cea-50bed9059f3f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1d9fce33-0969-468d-9877-12cce16b1fce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_93ef2b48-9e8c-4f4d-8f64-f48cedd7f9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_cb877fc7-5e63-4c88-9cea-50bed9059f3f" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_93ef2b48-9e8c-4f4d-8f64-f48cedd7f9fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4c24c2f2-81b3-4a75-83b3-cc1c3fa15a93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_b8dbbddb-1295-4dd4-8872-19b43b723d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_4c24c2f2-81b3-4a75-83b3-cc1c3fa15a93" xlink:to="loc_us-gaap_OperatingExpenses_b8dbbddb-1295-4dd4-8872-19b43b723d7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8cae686e-dfd4-4767-9cbb-7b59a169c3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e65e458e-3913-47eb-9d99-1894dff98a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8cae686e-dfd4-4767-9cbb-7b59a169c3a4" xlink:to="loc_us-gaap_OperatingIncomeLoss_e65e458e-3913-47eb-9d99-1894dff98a0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_63b7cd3c-f117-40f9-b18a-9af4ab75c650" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8cae686e-dfd4-4767-9cbb-7b59a169c3a4" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_63b7cd3c-f117-40f9-b18a-9af4ab75c650" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_90c6840a-6587-4a32-8002-2a721d14d0e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_f2accceb-3e8c-4dd0-8b4d-ff8c854a0441" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_90c6840a-6587-4a32-8002-2a721d14d0e8" xlink:to="loc_us-gaap_InvestmentIncomeInterest_f2accceb-3e8c-4dd0-8b4d-ff8c854a0441" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_ed70965a-c40f-4eda-a332-5368fc6f20f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_90c6840a-6587-4a32-8002-2a721d14d0e8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_ed70965a-c40f-4eda-a332-5368fc6f20f8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="vtl-20230630.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_a89b324b-5e7c-4398-af80-dda2338764a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7a5ae286-3e12-49d8-8cac-9dc14a7d44d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_a89b324b-5e7c-4398-af80-dda2338764a5" xlink:to="loc_us-gaap_NetIncomeLoss_7a5ae286-3e12-49d8-8cac-9dc14a7d44d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_24151fd7-f188-46ea-9802-d50feb3661e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_a89b324b-5e7c-4398-af80-dda2338764a5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_24151fd7-f188-46ea-9802-d50feb3661e3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows" xlink:type="simple" xlink:href="vtl-20230630.xsd#CondensedConsolidatedStatementofCashFlows"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c2e0ab59-f5b2-4673-be9a-39e68c66a69f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_4973aee8-b260-404a-8729-0528d77feda2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c2e0ab59-f5b2-4673-be9a-39e68c66a69f" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_4973aee8-b260-404a-8729-0528d77feda2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b1ff480c-c0f4-4ef7-9d60-c77e3c5585c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c2e0ab59-f5b2-4673-be9a-39e68c66a69f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_b1ff480c-c0f4-4ef7-9d60-c77e3c5585c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_03970dae-f8fa-43ee-8c0b-f1b961f27763" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c2e0ab59-f5b2-4673-be9a-39e68c66a69f" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_03970dae-f8fa-43ee-8c0b-f1b961f27763" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_35d4076d-f121-4275-a825-e4bdc190d198" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c2e0ab59-f5b2-4673-be9a-39e68c66a69f" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_35d4076d-f121-4275-a825-e4bdc190d198" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5da42179-8447-4cb6-92e5-8b1e4883bb48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_4cb78b67-d798-4af8-8788-514f98fa6dca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5da42179-8447-4cb6-92e5-8b1e4883bb48" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_4cb78b67-d798-4af8-8788-514f98fa6dca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_eed24cac-b879-472e-8666-74d9db3179fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5da42179-8447-4cb6-92e5-8b1e4883bb48" xlink:to="loc_us-gaap_NetIncomeLoss_eed24cac-b879-472e-8666-74d9db3179fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a313e078-cabc-4b6b-a864-9441b395d132" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5da42179-8447-4cb6-92e5-8b1e4883bb48" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a313e078-cabc-4b6b-a864-9441b395d132" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7b2caeab-6b2a-4b0c-860c-6191db39af77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5da42179-8447-4cb6-92e5-8b1e4883bb48" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7b2caeab-6b2a-4b0c-860c-6191db39af77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_5b8469d3-f597-45d7-893f-c1bf3a9fdfc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5da42179-8447-4cb6-92e5-8b1e4883bb48" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_5b8469d3-f597-45d7-893f-c1bf3a9fdfc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_27044657-018b-4767-8909-568a26962415" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5da42179-8447-4cb6-92e5-8b1e4883bb48" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_27044657-018b-4767-8909-568a26962415" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d619288e-ca55-4f5f-b6ca-16eb820fa0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5da42179-8447-4cb6-92e5-8b1e4883bb48" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d619288e-ca55-4f5f-b6ca-16eb820fa0ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_854fb356-408b-41f8-87fd-c78095900544" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5da42179-8447-4cb6-92e5-8b1e4883bb48" xlink:to="loc_us-gaap_ShareBasedCompensation_854fb356-408b-41f8-87fd-c78095900544" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c61df8e6-2e47-482d-bc56-ed2d0f0fe868" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_1dcd73e3-269d-4db5-8025-d223bfa6c362" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c61df8e6-2e47-482d-bc56-ed2d0f0fe868" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_1dcd73e3-269d-4db5-8025-d223bfa6c362" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_55acda69-c52b-40c2-b518-4b27a4518bee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c61df8e6-2e47-482d-bc56-ed2d0f0fe868" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_55acda69-c52b-40c2-b518-4b27a4518bee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f84f2f6f-cce0-4a7b-826f-22349fe2a562" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e78d52c1-db74-4f5c-950e-1bb0e410e26f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f84f2f6f-cce0-4a7b-826f-22349fe2a562" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e78d52c1-db74-4f5c-950e-1bb0e410e26f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4840bdd-be54-4096-bf83-5d7a472673f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f84f2f6f-cce0-4a7b-826f-22349fe2a562" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4840bdd-be54-4096-bf83-5d7a472673f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21926b27-b680-4c4c-b78b-4d0f91df8f33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f84f2f6f-cce0-4a7b-826f-22349fe2a562" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21926b27-b680-4c4c-b78b-4d0f91df8f33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ba86167b-3d40-4646-82a8-09ff4547bee3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f84f2f6f-cce0-4a7b-826f-22349fe2a562" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ba86167b-3d40-4646-82a8-09ff4547bee3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail" xlink:type="simple" xlink:href="vtl-20230630.xsd#BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fc1d35b2-27d8-4652-9afb-476a8ab0f9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent_97a05448-6eab-4088-bd63-5dc0056645bf" xlink:href="vtl-20230630.xsd#vtl_PrepaidClinicalAndRelatedCostsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fc1d35b2-27d8-4652-9afb-476a8ab0f9a4" xlink:to="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent_97a05448-6eab-4088-bd63-5dc0056645bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_cfd06e8f-05a2-4b9f-aa12-27c56df194aa" xlink:href="vtl-20230630.xsd#vtl_ResearchAndDevelopmentTaxIncentiveCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fc1d35b2-27d8-4652-9afb-476a8ab0f9a4" xlink:to="loc_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_cfd06e8f-05a2-4b9f-aa12-27c56df194aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_8b60565c-af7e-4108-9aef-86626d978a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fc1d35b2-27d8-4652-9afb-476a8ab0f9a4" xlink:to="loc_us-gaap_OtherAssetsCurrent_8b60565c-af7e-4108-9aef-86626d978a1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_43f9b254-0f57-497f-afab-a8976bd8f807" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fc1d35b2-27d8-4652-9afb-476a8ab0f9a4" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_43f9b254-0f57-497f-afab-a8976bd8f807" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail" xlink:type="simple" xlink:href="vtl-20230630.xsd#BalanceSheetDetailsScheduleofAccountsPayableDetail"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1d0aa29a-0a72-427c-a4ba-0caa85da7fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ClinicalCostsPayableCurrent_26873e2f-2061-4af1-bdb8-312b2ae7cfb8" xlink:href="vtl-20230630.xsd#vtl_ClinicalCostsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableCurrent_1d0aa29a-0a72-427c-a4ba-0caa85da7fd9" xlink:to="loc_vtl_ClinicalCostsPayableCurrent_26873e2f-2061-4af1-bdb8-312b2ae7cfb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LegalAndAuditCostsPayableCurrent_59aaf5bb-22a3-4dd0-a198-0e474644e2eb" xlink:href="vtl-20230630.xsd#vtl_LegalAndAuditCostsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableCurrent_1d0aa29a-0a72-427c-a4ba-0caa85da7fd9" xlink:to="loc_vtl_LegalAndAuditCostsPayableCurrent_59aaf5bb-22a3-4dd0-a198-0e474644e2eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_22fe5d89-eb9d-4f6d-a750-0a00167a4131" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableCurrent_1d0aa29a-0a72-427c-a4ba-0caa85da7fd9" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_22fe5d89-eb9d-4f6d-a750-0a00167a4131" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail" xlink:type="simple" xlink:href="vtl-20230630.xsd#BalanceSheetDetailsScheduleofAccruedExpensesDetail"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_bdf1baeb-2d86-4012-b11d-3cda5de7155f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_43f97270-5c57-4410-b448-8e7ccf06d911" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_bdf1baeb-2d86-4012-b11d-3cda5de7155f" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_43f97270-5c57-4410-b448-8e7ccf06d911" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedClinicalCostsCurrent_d16b8956-950c-4e69-82c9-ee99ab9cafdd" xlink:href="vtl-20230630.xsd#vtl_AccruedClinicalCostsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_bdf1baeb-2d86-4012-b11d-3cda5de7155f" xlink:to="loc_vtl_AccruedClinicalCostsCurrent_d16b8956-950c-4e69-82c9-ee99ab9cafdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedCompensationCurrent_d180fde6-f9e6-4b83-b554-e9c904bef6ff" xlink:href="vtl-20230630.xsd#vtl_AccruedCompensationCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_bdf1baeb-2d86-4012-b11d-3cda5de7155f" xlink:to="loc_vtl_AccruedCompensationCurrent_d180fde6-f9e6-4b83-b554-e9c904bef6ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedLegalAndAuditCostsCurrent_efdfc649-af18-48dc-918c-f04fd9fe7b63" xlink:href="vtl-20230630.xsd#vtl_AccruedLegalAndAuditCostsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_bdf1baeb-2d86-4012-b11d-3cda5de7155f" xlink:to="loc_vtl_AccruedLegalAndAuditCostsCurrent_efdfc649-af18-48dc-918c-f04fd9fe7b63" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="vtl-20230630.xsd#BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_58f8909f-32e6-4f3b-b577-db70ff7e8793" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_898357d7-7a17-4197-bbd9-b83b95afda87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_58f8909f-32e6-4f3b-b577-db70ff7e8793" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_898357d7-7a17-4197-bbd9-b83b95afda87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f86b359d-8913-44cf-9ef1-ec5b633a60b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_58f8909f-32e6-4f3b-b577-db70ff7e8793" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f86b359d-8913-44cf-9ef1-ec5b633a60b2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails" xlink:type="simple" xlink:href="vtl-20230630.xsd#CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f472020c-c00f-4a45-88dc-d303a4628468" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7038cde0-cbae-4580-8e38-cf54dad34824" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f472020c-c00f-4a45-88dc-d303a4628468" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_7038cde0-cbae-4580-8e38-cf54dad34824" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5be990e5-dd5b-42e3-9306-7f81586dc7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f472020c-c00f-4a45-88dc-d303a4628468" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5be990e5-dd5b-42e3-9306-7f81586dc7cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a5390cef-0180-4bc0-8fb0-c231caaddf42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f472020c-c00f-4a45-88dc-d303a4628468" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a5390cef-0180-4bc0-8fb0-c231caaddf42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5bebede4-e515-476e-b47b-f15e285e7031" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f472020c-c00f-4a45-88dc-d303a4628468" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5bebede4-e515-476e-b47b-f15e285e7031" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_969e1b7a-f327-49de-978f-59dc80430ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f472020c-c00f-4a45-88dc-d303a4628468" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_969e1b7a-f327-49de-978f-59dc80430ad7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseLiabilityPaymentsAfterDueYearFour_e9e84248-272f-4618-a547-ad13884e3fd4" xlink:href="vtl-20230630.xsd#vtl_LesseeOperatingLeaseLiabilityPaymentsAfterDueYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f472020c-c00f-4a45-88dc-d303a4628468" xlink:to="loc_vtl_LesseeOperatingLeaseLiabilityPaymentsAfterDueYearFour_e9e84248-272f-4618-a547-ad13884e3fd4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1" xlink:type="simple" xlink:href="vtl-20230630.xsd#CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1"/>
  <link:calculationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_85ddf3a4-e20a-46a7-9b18-b1a0ddee23a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c1f5587b-089c-4a6b-af4c-506f80493cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_85ddf3a4-e20a-46a7-9b18-b1a0ddee23a3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c1f5587b-089c-4a6b-af4c-506f80493cf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_cbbe6a16-6b9e-457d-aeda-ced9ae47571a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_85ddf3a4-e20a-46a7-9b18-b1a0ddee23a3" xlink:to="loc_us-gaap_OperatingLeaseLiability_cbbe6a16-6b9e-457d-aeda-ced9ae47571a" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>vtl-20230630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:c5b7d08b-4d18-4b53-b740-daba2f6d29fd,g:398611d2-4d63-409b-b481-5daa2ae6bce9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="vtl-20230630.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="ie1305fe5cff7498c903528ecdee82920_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_82e8c090-0fe6-4892-b41d-4c338101ecf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de513d23-2dd3-460a-a593-4dbf472ebde2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_82e8c090-0fe6-4892-b41d-4c338101ecf4" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de513d23-2dd3-460a-a593-4dbf472ebde2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1aa4c5f9-8840-4b84-9bf3-64284b182174" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de513d23-2dd3-460a-a593-4dbf472ebde2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1aa4c5f9-8840-4b84-9bf3-64284b182174" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d2daaf09-20d9-4873-8e07-62e9bb7a19b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de513d23-2dd3-460a-a593-4dbf472ebde2" xlink:to="loc_us-gaap_StockholdersEquity_d2daaf09-20d9-4873-8e07-62e9bb7a19b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8ee0b4e2-4223-42f5-8e86-ac6a11b1215c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de513d23-2dd3-460a-a593-4dbf472ebde2" xlink:to="loc_us-gaap_NetIncomeLoss_8ee0b4e2-4223-42f5-8e86-ac6a11b1215c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_eaa2a082-f109-49f6-b4d1-2c0bc36bc3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de513d23-2dd3-460a-a593-4dbf472ebde2" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_eaa2a082-f109-49f6-b4d1-2c0bc36bc3cf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_98b90f01-2d9e-4f58-ae52-3d55d280ffe4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de513d23-2dd3-460a-a593-4dbf472ebde2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_98b90f01-2d9e-4f58-ae52-3d55d280ffe4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ec7e9930-d83d-4bfb-8ea1-a27e18f4a3be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de513d23-2dd3-460a-a593-4dbf472ebde2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ec7e9930-d83d-4bfb-8ea1-a27e18f4a3be" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_597b868b-9ff9-49a3-9db3-fcfecd3e40f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de513d23-2dd3-460a-a593-4dbf472ebde2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_597b868b-9ff9-49a3-9db3-fcfecd3e40f1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_b2c4edfb-f5e5-4cca-abd3-6944e8ffdd37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de513d23-2dd3-460a-a593-4dbf472ebde2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_b2c4edfb-f5e5-4cca-abd3-6944e8ffdd37" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0fb31f34-72a1-4201-bd4f-6ae8b2cdceae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de513d23-2dd3-460a-a593-4dbf472ebde2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0fb31f34-72a1-4201-bd4f-6ae8b2cdceae" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_69342b64-2a49-49b7-a816-2a4c55a2b50c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de513d23-2dd3-460a-a593-4dbf472ebde2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_69342b64-2a49-49b7-a816-2a4c55a2b50c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_bf7d74b2-ea88-4d03-8acc-9ad797d35faf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de513d23-2dd3-460a-a593-4dbf472ebde2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_bf7d74b2-ea88-4d03-8acc-9ad797d35faf" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_89d7be51-54a2-40ee-9315-bc7c5a10cbed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5048c143-4731-4656-aae5-3c40d5711e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_95b1259a-54e6-4d1c-951b-c9b5a78c2fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_82e8c090-0fe6-4892-b41d-4c338101ecf4" xlink:to="loc_us-gaap_StatementTable_95b1259a-54e6-4d1c-951b-c9b5a78c2fcf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9e173ca3-aaf5-42b1-93eb-e3cdef76f770" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_95b1259a-54e6-4d1c-951b-c9b5a78c2fcf" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9e173ca3-aaf5-42b1-93eb-e3cdef76f770" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9e173ca3-aaf5-42b1-93eb-e3cdef76f770_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9e173ca3-aaf5-42b1-93eb-e3cdef76f770" xlink:to="loc_us-gaap_EquityComponentDomain_9e173ca3-aaf5-42b1-93eb-e3cdef76f770_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d080c61b-6ab3-49ee-abf4-99f7be96e891" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9e173ca3-aaf5-42b1-93eb-e3cdef76f770" xlink:to="loc_us-gaap_EquityComponentDomain_d080c61b-6ab3-49ee-abf4-99f7be96e891" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cf77a5ee-90a7-4000-b3de-5b59d29f502f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d080c61b-6ab3-49ee-abf4-99f7be96e891" xlink:to="loc_us-gaap_CommonStockMember_cf77a5ee-90a7-4000-b3de-5b59d29f502f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a00d9a5e-d502-451c-bd77-63259340b82d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d080c61b-6ab3-49ee-abf4-99f7be96e891" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a00d9a5e-d502-451c-bd77-63259340b82d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_edbbc88d-14b6-41db-9684-9be06953f475" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d080c61b-6ab3-49ee-abf4-99f7be96e891" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_edbbc88d-14b6-41db-9684-9be06953f475" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d70f2179-7dc6-49f8-9511-023fbb196ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d080c61b-6ab3-49ee-abf4-99f7be96e891" xlink:to="loc_us-gaap_RetainedEarningsMember_d70f2179-7dc6-49f8-9511-023fbb196ef1" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20230630.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" id="ie2f8acd8d92f426f9c9838e420f0b858_SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_330cd288-f3bc-4458-b0ab-f78495741f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f553b8d3-817d-4277-be08-3fe7f723fa5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_330cd288-f3bc-4458-b0ab-f78495741f7d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f553b8d3-817d-4277-be08-3fe7f723fa5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfFinancialInstitutionsUsedForCashDeposit_887f22a1-0cec-4e9e-8fd0-5b7e574ee289" xlink:href="vtl-20230630.xsd#vtl_NumberOfFinancialInstitutionsUsedForCashDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_330cd288-f3bc-4458-b0ab-f78495741f7d" xlink:to="loc_vtl_NumberOfFinancialInstitutionsUsedForCashDeposit_887f22a1-0cec-4e9e-8fd0-5b7e574ee289" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentInterestRate_69b77da7-a81e-4953-8331-3c71d2db8ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_330cd288-f3bc-4458-b0ab-f78495741f7d" xlink:to="loc_us-gaap_InvestmentInterestRate_69b77da7-a81e-4953-8331-3c71d2db8ee8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_741edadf-91b5-45d8-9fb9-6d3849fe8d84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_330cd288-f3bc-4458-b0ab-f78495741f7d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_741edadf-91b5-45d8-9fb9-6d3849fe8d84" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_b5a382d7-6312-4f4a-9213-ce9dd6c5699d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_330cd288-f3bc-4458-b0ab-f78495741f7d" xlink:to="loc_us-gaap_Depreciation_b5a382d7-6312-4f4a-9213-ce9dd6c5699d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_76e66187-761d-4d36-aed9-1497412e8726" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_330cd288-f3bc-4458-b0ab-f78495741f7d" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_76e66187-761d-4d36-aed9-1497412e8726" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_41090d20-7232-4276-96f6-53c81d883e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_330cd288-f3bc-4458-b0ab-f78495741f7d" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_41090d20-7232-4276-96f6-53c81d883e2d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GovernmentAssistanceRate_71cfdf30-a0e8-4b41-9281-5a3c0d409cd7" xlink:href="vtl-20230630.xsd#vtl_GovernmentAssistanceRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_330cd288-f3bc-4458-b0ab-f78495741f7d" xlink:to="loc_vtl_GovernmentAssistanceRate_71cfdf30-a0e8-4b41-9281-5a3c0d409cd7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceAmount_ee5b2055-6282-48a5-ba71-23bf0e52c65e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_330cd288-f3bc-4458-b0ab-f78495741f7d" xlink:to="loc_us-gaap_GovernmentAssistanceAmount_ee5b2055-6282-48a5-ba71-23bf0e52c65e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_0970d902-3aec-41d9-af8a-1570782cb665" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_330cd288-f3bc-4458-b0ab-f78495741f7d" xlink:to="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_0970d902-3aec-41d9-af8a-1570782cb665" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_d93d2928-6934-4b14-94b0-4c2cc46e8f78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_330cd288-f3bc-4458-b0ab-f78495741f7d" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_d93d2928-6934-4b14-94b0-4c2cc46e8f78" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases_d7af4395-5a36-40d0-a0f0-247037981e77" xlink:href="vtl-20230630.xsd#vtl_LesseeOperatingLeasesNumberOfExistingLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_330cd288-f3bc-4458-b0ab-f78495741f7d" xlink:to="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases_d7af4395-5a36-40d0-a0f0-247037981e77" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2f8aefa7-1f2d-4e15-9ccf-8167ae03e26c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_330cd288-f3bc-4458-b0ab-f78495741f7d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2f8aefa7-1f2d-4e15-9ccf-8167ae03e26c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2835e1fd-4215-4f00-8f5c-c02ac1aa984e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_330cd288-f3bc-4458-b0ab-f78495741f7d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2835e1fd-4215-4f00-8f5c-c02ac1aa984e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4267c5a8-e4b3-4e42-a216-ef5fff7b1e51" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2835e1fd-4215-4f00-8f5c-c02ac1aa984e" xlink:to="loc_srt_RangeAxis_4267c5a8-e4b3-4e42-a216-ef5fff7b1e51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4267c5a8-e4b3-4e42-a216-ef5fff7b1e51_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4267c5a8-e4b3-4e42-a216-ef5fff7b1e51" xlink:to="loc_srt_RangeMember_4267c5a8-e4b3-4e42-a216-ef5fff7b1e51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d0318217-25cd-42e9-8883-9cd4f96c9b77" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4267c5a8-e4b3-4e42-a216-ef5fff7b1e51" xlink:to="loc_srt_RangeMember_d0318217-25cd-42e9-8883-9cd4f96c9b77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e6f0cf61-1936-4927-ac93-4db6622043b5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d0318217-25cd-42e9-8883-9cd4f96c9b77" xlink:to="loc_srt_MaximumMember_e6f0cf61-1936-4927-ac93-4db6622043b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4e6c0870-d26d-4945-a345-7de30fbf9ba2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d0318217-25cd-42e9-8883-9cd4f96c9b77" xlink:to="loc_srt_MinimumMember_4e6c0870-d26d-4945-a345-7de30fbf9ba2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4688963f-5ea0-4bfe-8a38-0c77e3032f71" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2835e1fd-4215-4f00-8f5c-c02ac1aa984e" xlink:to="loc_srt_StatementGeographicalAxis_4688963f-5ea0-4bfe-8a38-0c77e3032f71" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4688963f-5ea0-4bfe-8a38-0c77e3032f71_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_4688963f-5ea0-4bfe-8a38-0c77e3032f71" xlink:to="loc_srt_SegmentGeographicalDomain_4688963f-5ea0-4bfe-8a38-0c77e3032f71_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_47923446-5400-4f5e-894c-6af10de93668" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_4688963f-5ea0-4bfe-8a38-0c77e3032f71" xlink:to="loc_srt_SegmentGeographicalDomain_47923446-5400-4f5e-894c-6af10de93668" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AustraliaAndGermanyMember_d26e1334-1508-4f12-ad31-7b257739900e" xlink:href="vtl-20230630.xsd#vtl_AustraliaAndGermanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_47923446-5400-4f5e-894c-6af10de93668" xlink:to="loc_vtl_AustraliaAndGermanyMember_d26e1334-1508-4f12-ad31-7b257739900e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_59e42aa1-4bb1-4ab7-8b44-322c257b6395" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_47923446-5400-4f5e-894c-6af10de93668" xlink:to="loc_country_US_59e42aa1-4bb1-4ab7-8b44-322c257b6395" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_4277eddd-9347-48db-a669-dc1911ad9613" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_47923446-5400-4f5e-894c-6af10de93668" xlink:to="loc_country_DE_4277eddd-9347-48db-a669-dc1911ad9613" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_AU_626f49ad-e26e-47ea-8d8f-df6082455c85" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AU"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_47923446-5400-4f5e-894c-6af10de93668" xlink:to="loc_country_AU_626f49ad-e26e-47ea-8d8f-df6082455c85" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_b98854ba-2c26-45e2-b345-941cb8958121" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2835e1fd-4215-4f00-8f5c-c02ac1aa984e" xlink:to="loc_us-gaap_InvestmentTypeAxis_b98854ba-2c26-45e2-b345-941cb8958121" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_b98854ba-2c26-45e2-b345-941cb8958121_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_b98854ba-2c26-45e2-b345-941cb8958121" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_b98854ba-2c26-45e2-b345-941cb8958121_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_6e9562fe-0cd6-4d50-8178-623b5d96324e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_b98854ba-2c26-45e2-b345-941cb8958121" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_6e9562fe-0cd6-4d50-8178-623b5d96324e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7ca5b0d7-8f5c-4a64-8bba-c1867d86df10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6e9562fe-0cd6-4d50-8178-623b5d96324e" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7ca5b0d7-8f5c-4a64-8bba-c1867d86df10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_abd88bef-29db-4d62-8743-4ba1f3db6dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6e9562fe-0cd6-4d50-8178-623b5d96324e" xlink:to="loc_us-gaap_BankTimeDepositsMember_abd88bef-29db-4d62-8743-4ba1f3db6dcb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_386ae748-f8cd-4f77-9b65-a6492a7e189c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2835e1fd-4215-4f00-8f5c-c02ac1aa984e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_386ae748-f8cd-4f77-9b65-a6492a7e189c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_386ae748-f8cd-4f77-9b65-a6492a7e189c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_386ae748-f8cd-4f77-9b65-a6492a7e189c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_386ae748-f8cd-4f77-9b65-a6492a7e189c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b7b62058-4bad-48db-8c95-2816956483c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_386ae748-f8cd-4f77-9b65-a6492a7e189c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b7b62058-4bad-48db-8c95-2816956483c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PreFundedWarrantsMember_096aca2a-7acc-4289-8167-08a44ed2f31e" xlink:href="vtl-20230630.xsd#vtl_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b7b62058-4bad-48db-8c95-2816956483c3" xlink:to="loc_vtl_PreFundedWarrantsMember_096aca2a-7acc-4289-8167-08a44ed2f31e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails" xlink:type="simple" xlink:href="vtl-20230630.xsd#SummaryofSignificantAccountingPoliciesInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails" xlink:type="extended" id="idf2ab987054c4e9a9d56f633fe825d44_SummaryofSignificantAccountingPoliciesInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_199403de-b63f-4de3-a069-adc2803000f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_7c87467c-a21b-43a5-9c31-4f5707a54d21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_199403de-b63f-4de3-a069-adc2803000f6" xlink:to="loc_us-gaap_OtherShortTermInvestments_7c87467c-a21b-43a5-9c31-4f5707a54d21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_3cecce3c-a631-4d77-8588-f81e9f562845" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_199403de-b63f-4de3-a069-adc2803000f6" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_3cecce3c-a631-4d77-8588-f81e9f562845" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_a261496f-f3df-4075-a72e-cf03a94192de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_3cecce3c-a631-4d77-8588-f81e9f562845" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_a261496f-f3df-4075-a72e-cf03a94192de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a261496f-f3df-4075-a72e-cf03a94192de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_a261496f-f3df-4075-a72e-cf03a94192de" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_a261496f-f3df-4075-a72e-cf03a94192de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_79da02d6-7ae5-4228-8d04-5afad39ea191" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_a261496f-f3df-4075-a72e-cf03a94192de" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_79da02d6-7ae5-4228-8d04-5afad39ea191" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_c41ebff4-9bcf-44fe-b638-6c4d2e4c0350" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_79da02d6-7ae5-4228-8d04-5afad39ea191" xlink:to="loc_us-gaap_BankTimeDepositsMember_c41ebff4-9bcf-44fe-b638-6c4d2e4c0350" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" xlink:type="simple" xlink:href="vtl-20230630.xsd#SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" xlink:type="extended" id="i2e7aa52c800c41adbbe381a297cfbef2_SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_68d86c96-ce4e-412e-8faf-bb271c4bc7e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_36cc80b4-8f6f-483b-aff8-a61b41a122d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_68d86c96-ce4e-412e-8faf-bb271c4bc7e9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_36cc80b4-8f6f-483b-aff8-a61b41a122d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_19f7b243-3c4f-493c-aba2-61cbe7db9f65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_68d86c96-ce4e-412e-8faf-bb271c4bc7e9" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_19f7b243-3c4f-493c-aba2-61cbe7db9f65" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_41e0e997-599d-4dd0-b9f8-7b45d0321af7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_19f7b243-3c4f-493c-aba2-61cbe7db9f65" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_41e0e997-599d-4dd0-b9f8-7b45d0321af7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_41e0e997-599d-4dd0-b9f8-7b45d0321af7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_41e0e997-599d-4dd0-b9f8-7b45d0321af7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_41e0e997-599d-4dd0-b9f8-7b45d0321af7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f3f5543f-cb9a-46c9-85d1-87c9966c689b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_41e0e997-599d-4dd0-b9f8-7b45d0321af7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f3f5543f-cb9a-46c9-85d1-87c9966c689b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_c09ac432-0de2-498d-b43d-ca84df2f28da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f3f5543f-cb9a-46c9-85d1-87c9966c689b" xlink:to="loc_us-gaap_StockOptionMember_c09ac432-0de2-498d-b43d-ca84df2f28da" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20230630.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended" id="i0c76778e517a44578a6e331f89614d71_CommitmentsandContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_54487f64-26e9-409e-a21d-330f2c085f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_59b450c0-01ba-4eb3-9fba-801703e53d81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_54487f64-26e9-409e-a21d-330f2c085f9f" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_59b450c0-01ba-4eb3-9fba-801703e53d81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod_5c585af8-bb38-4f91-9d3a-993d48adfe80" xlink:href="vtl-20230630.xsd#vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_54487f64-26e9-409e-a21d-330f2c085f9f" xlink:to="loc_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod_5c585af8-bb38-4f91-9d3a-993d48adfe80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod_0c83614b-9216-4413-9158-1ecf3e56db22" xlink:href="vtl-20230630.xsd#vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_54487f64-26e9-409e-a21d-330f2c085f9f" xlink:to="loc_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod_0c83614b-9216-4413-9158-1ecf3e56db22" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_0b839157-c437-4331-b47a-4e68e0df3856" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_54487f64-26e9-409e-a21d-330f2c085f9f" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_0b839157-c437-4331-b47a-4e68e0df3856" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_33446d60-0f4d-44fa-b153-bf69a693e57e" xlink:href="vtl-20230630.xsd#vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_54487f64-26e9-409e-a21d-330f2c085f9f" xlink:to="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_33446d60-0f4d-44fa-b153-bf69a693e57e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingLeaseIncrementalBorrowingRate_1293517b-59f8-41c3-8751-b8abf4d5983c" xlink:href="vtl-20230630.xsd#vtl_OperatingLeaseIncrementalBorrowingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_54487f64-26e9-409e-a21d-330f2c085f9f" xlink:to="loc_vtl_OperatingLeaseIncrementalBorrowingRate_1293517b-59f8-41c3-8751-b8abf4d5983c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingAndVariableLeasesCost_1029f20c-b43c-458d-8552-f42ceae2671f" xlink:href="vtl-20230630.xsd#vtl_OperatingAndVariableLeasesCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_54487f64-26e9-409e-a21d-330f2c085f9f" xlink:to="loc_vtl_OperatingAndVariableLeasesCost_1029f20c-b43c-458d-8552-f42ceae2671f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_c6773f05-7d50-4289-8253-f9e4610d7f31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_54487f64-26e9-409e-a21d-330f2c085f9f" xlink:to="loc_us-gaap_ContractualObligation_c6773f05-7d50-4289-8253-f9e4610d7f31" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_3d6761f3-938a-4ca3-b8c2-55bdf8aa0da2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_54487f64-26e9-409e-a21d-330f2c085f9f" xlink:to="loc_us-gaap_LossContingenciesTable_3d6761f3-938a-4ca3-b8c2-55bdf8aa0da2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a27c886c-e62f-4d9f-83c7-37d7a71bb075" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_3d6761f3-938a-4ca3-b8c2-55bdf8aa0da2" xlink:to="loc_srt_StatementGeographicalAxis_a27c886c-e62f-4d9f-83c7-37d7a71bb075" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a27c886c-e62f-4d9f-83c7-37d7a71bb075_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_a27c886c-e62f-4d9f-83c7-37d7a71bb075" xlink:to="loc_srt_SegmentGeographicalDomain_a27c886c-e62f-4d9f-83c7-37d7a71bb075_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4a98d67b-f543-4fee-af73-33532f60010f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_a27c886c-e62f-4d9f-83c7-37d7a71bb075" xlink:to="loc_srt_SegmentGeographicalDomain_4a98d67b-f543-4fee-af73-33532f60010f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GrafelfingGermanyMember_c092db4d-689b-41f5-b046-0f13e11211c3" xlink:href="vtl-20230630.xsd#vtl_GrafelfingGermanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4a98d67b-f543-4fee-af73-33532f60010f" xlink:to="loc_vtl_GrafelfingGermanyMember_c092db4d-689b-41f5-b046-0f13e11211c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NewYorkCityMember_d5092612-eab9-4ffb-97fd-945bb8f3a882" xlink:href="vtl-20230630.xsd#vtl_NewYorkCityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4a98d67b-f543-4fee-af73-33532f60010f" xlink:to="loc_vtl_NewYorkCityMember_d5092612-eab9-4ffb-97fd-945bb8f3a882" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PlaneggGermanyMember_fc98613c-31ab-447b-a1ed-51f0da99a53f" xlink:href="vtl-20230630.xsd#vtl_PlaneggGermanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_4a98d67b-f543-4fee-af73-33532f60010f" xlink:to="loc_vtl_PlaneggGermanyMember_fc98613c-31ab-447b-a1ed-51f0da99a53f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="vtl-20230630.xsd#FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="i8006e64322554444985eddcd3fcf46d6_FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8c1e91b7-de1d-4650-9a52-38380e744693" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_6bf82870-1409-415c-b69d-3b1ce3742897" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8c1e91b7-de1d-4650-9a52-38380e744693" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_6bf82870-1409-415c-b69d-3b1ce3742897" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_42791401-fabb-485e-be12-23ae9e8a79ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_6bf82870-1409-415c-b69d-3b1ce3742897" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_42791401-fabb-485e-be12-23ae9e8a79ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1eafa265-26b1-434f-9bae-9f444eb74fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8c1e91b7-de1d-4650-9a52-38380e744693" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1eafa265-26b1-434f-9bae-9f444eb74fa7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1d2cfe79-8b4e-4ed0-8615-80459355d88a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1eafa265-26b1-434f-9bae-9f444eb74fa7" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1d2cfe79-8b4e-4ed0-8615-80459355d88a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1d2cfe79-8b4e-4ed0-8615-80459355d88a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1d2cfe79-8b4e-4ed0-8615-80459355d88a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1d2cfe79-8b4e-4ed0-8615-80459355d88a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_16f67809-fd68-41c5-bc4a-5c23b80b4a08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1d2cfe79-8b4e-4ed0-8615-80459355d88a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_16f67809-fd68-41c5-bc4a-5c23b80b4a08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6052158b-e44a-4d20-a162-cd15c2331fba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_16f67809-fd68-41c5-bc4a-5c23b80b4a08" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_6052158b-e44a-4d20-a162-cd15c2331fba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_6b9068a3-a6ae-4b18-8cb4-588c6d40d4c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1eafa265-26b1-434f-9bae-9f444eb74fa7" xlink:to="loc_us-gaap_InvestmentTypeAxis_6b9068a3-a6ae-4b18-8cb4-588c6d40d4c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_6b9068a3-a6ae-4b18-8cb4-588c6d40d4c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_6b9068a3-a6ae-4b18-8cb4-588c6d40d4c6" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_6b9068a3-a6ae-4b18-8cb4-588c6d40d4c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_cc4f22bc-d9b6-48ec-abe0-3e5bc5e75c96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_6b9068a3-a6ae-4b18-8cb4-588c6d40d4c6" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_cc4f22bc-d9b6-48ec-abe0-3e5bc5e75c96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_91711c19-4f28-48d2-b619-48e967bdca49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_cc4f22bc-d9b6-48ec-abe0-3e5bc5e75c96" xlink:to="loc_us-gaap_MoneyMarketFundsMember_91711c19-4f28-48d2-b619-48e967bdca49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a9c77e69-2d14-4598-ac72-0ae310a5d548" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1eafa265-26b1-434f-9bae-9f444eb74fa7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a9c77e69-2d14-4598-ac72-0ae310a5d548" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a9c77e69-2d14-4598-ac72-0ae310a5d548_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a9c77e69-2d14-4598-ac72-0ae310a5d548" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a9c77e69-2d14-4598-ac72-0ae310a5d548_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a9914b4-1b6d-4e08-87b3-032671de5fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a9c77e69-2d14-4598-ac72-0ae310a5d548" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a9914b4-1b6d-4e08-87b3-032671de5fe3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3236ace6-dc69-4d2b-ba9a-ea347f324013" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a9914b4-1b6d-4e08-87b3-032671de5fe3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3236ace6-dc69-4d2b-ba9a-ea347f324013" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b94ee2b4-dda0-4961-b7a8-1e77bb6c5038" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a9914b4-1b6d-4e08-87b3-032671de5fe3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b94ee2b4-dda0-4961-b7a8-1e77bb6c5038" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3b5631ae-ae5a-471c-986f-d75f43135d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a9914b4-1b6d-4e08-87b3-032671de5fe3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3b5631ae-ae5a-471c-986f-d75f43135d4d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/FairValueAdditionalInformationDetail" xlink:type="simple" xlink:href="vtl-20230630.xsd#FairValueAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/FairValueAdditionalInformationDetail" xlink:type="extended" id="i3a0daff9682c4fc0b8c96abc0c234f13_FairValueAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff6a1bb7-4822-4d5b-94db-31ac87b1a2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentInterestRate_9e95c463-c325-44cb-aad1-68ed199b0557" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff6a1bb7-4822-4d5b-94db-31ac87b1a2f6" xlink:to="loc_us-gaap_InvestmentInterestRate_9e95c463-c325-44cb-aad1-68ed199b0557" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_376f828e-67cc-46a8-9cbb-55059a800525" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff6a1bb7-4822-4d5b-94db-31ac87b1a2f6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_376f828e-67cc-46a8-9cbb-55059a800525" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8847ea3e-89be-4874-a0ef-4ebf3c3d3636" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_376f828e-67cc-46a8-9cbb-55059a800525" xlink:to="loc_srt_StatementGeographicalAxis_8847ea3e-89be-4874-a0ef-4ebf3c3d3636" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8847ea3e-89be-4874-a0ef-4ebf3c3d3636_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_8847ea3e-89be-4874-a0ef-4ebf3c3d3636" xlink:to="loc_srt_SegmentGeographicalDomain_8847ea3e-89be-4874-a0ef-4ebf3c3d3636_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1f44bdf5-76f5-41d9-9c06-4484e92f3be7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_8847ea3e-89be-4874-a0ef-4ebf3c3d3636" xlink:to="loc_srt_SegmentGeographicalDomain_1f44bdf5-76f5-41d9-9c06-4484e92f3be7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ce26e782-ed36-4299-b547-95e7c0391538" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1f44bdf5-76f5-41d9-9c06-4484e92f3be7" xlink:to="loc_country_US_ce26e782-ed36-4299-b547-95e7c0391538" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_d0be6786-219e-4287-b355-a5a7c75fcf2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_376f828e-67cc-46a8-9cbb-55059a800525" xlink:to="loc_us-gaap_InvestmentTypeAxis_d0be6786-219e-4287-b355-a5a7c75fcf2f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_d0be6786-219e-4287-b355-a5a7c75fcf2f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_d0be6786-219e-4287-b355-a5a7c75fcf2f" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_d0be6786-219e-4287-b355-a5a7c75fcf2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_e7eba104-7ad2-45f7-8bb0-a82462e9528e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_d0be6786-219e-4287-b355-a5a7c75fcf2f" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_e7eba104-7ad2-45f7-8bb0-a82462e9528e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_bf5add1e-ad66-435e-8127-d1f7b9fd0b92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_e7eba104-7ad2-45f7-8bb0-a82462e9528e" xlink:to="loc_us-gaap_MoneyMarketFundsMember_bf5add1e-ad66-435e-8127-d1f7b9fd0b92" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails" xlink:type="simple" xlink:href="vtl-20230630.xsd#CommonStockShelfRegistrationStatementDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails" xlink:type="extended" id="i9f0f55648dd644a887649212f0be4c55_CommonStockShelfRegistrationStatementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_e738d51c-27be-4f54-ba42-eee7fc615aba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_ff4cecf0-f5c0-4797-aeb7-b215291dfa13" xlink:href="vtl-20230630.xsd#vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e738d51c-27be-4f54-ba42-eee7fc615aba" xlink:to="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_ff4cecf0-f5c0-4797-aeb7-b215291dfa13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationStatementAmountRemaining_40aea17a-2197-42a3-9c87-823a75c0f491" xlink:href="vtl-20230630.xsd#vtl_ShelfRegistrationStatementAmountRemaining"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e738d51c-27be-4f54-ba42-eee7fc615aba" xlink:to="loc_vtl_ShelfRegistrationStatementAmountRemaining_40aea17a-2197-42a3-9c87-823a75c0f491" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationTerminationPriorWrittenNotice_d4a7a108-3a46-49c9-9731-3103ff93059c" xlink:href="vtl-20230630.xsd#vtl_ShelfRegistrationTerminationPriorWrittenNotice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e738d51c-27be-4f54-ba42-eee7fc615aba" xlink:to="loc_vtl_ShelfRegistrationTerminationPriorWrittenNotice_d4a7a108-3a46-49c9-9731-3103ff93059c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SaleOfStockRemainingCapacity_5ff8bf67-e03a-42b1-83cb-153e55b6fb1f" xlink:href="vtl-20230630.xsd#vtl_SaleOfStockRemainingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e738d51c-27be-4f54-ba42-eee7fc615aba" xlink:to="loc_vtl_SaleOfStockRemainingCapacity_5ff8bf67-e03a-42b1-83cb-153e55b6fb1f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_9a168a88-6a9b-4426-8899-b018e8f3bc56" xlink:href="vtl-20230630.xsd#vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e738d51c-27be-4f54-ba42-eee7fc615aba" xlink:to="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_9a168a88-6a9b-4426-8899-b018e8f3bc56" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_81c6743e-5a24-4d2c-bddb-5c8d6fc852b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e738d51c-27be-4f54-ba42-eee7fc615aba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_81c6743e-5a24-4d2c-bddb-5c8d6fc852b3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d3af39f0-8fca-4d1c-b1a1-260d5889cec1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e738d51c-27be-4f54-ba42-eee7fc615aba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d3af39f0-8fca-4d1c-b1a1-260d5889cec1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SharesIssuedWeightedAverageSharePricePerShare_6ad7260d-fbbe-4e47-aaa6-079ad776a5c8" xlink:href="vtl-20230630.xsd#vtl_SharesIssuedWeightedAverageSharePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e738d51c-27be-4f54-ba42-eee7fc615aba" xlink:to="loc_vtl_SharesIssuedWeightedAverageSharePricePerShare_6ad7260d-fbbe-4e47-aaa6-079ad776a5c8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_da917ab9-7bc3-4d49-b794-765aa34b02b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e738d51c-27be-4f54-ba42-eee7fc615aba" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_da917ab9-7bc3-4d49-b794-765aa34b02b0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCommissions_a92e439b-9398-496b-b22d-c5ae79b29d81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForCommissions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_e738d51c-27be-4f54-ba42-eee7fc615aba" xlink:to="loc_us-gaap_PaymentsForCommissions_a92e439b-9398-496b-b22d-c5ae79b29d81" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_3c93ffd4-7e4c-4f4e-bf00-674469754a23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_e738d51c-27be-4f54-ba42-eee7fc615aba" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_3c93ffd4-7e4c-4f4e-bf00-674469754a23" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8c9c3f60-c895-42e5-b827-2d7d6c13c77a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3c93ffd4-7e4c-4f4e-bf00-674469754a23" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8c9c3f60-c895-42e5-b827-2d7d6c13c77a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8c9c3f60-c895-42e5-b827-2d7d6c13c77a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8c9c3f60-c895-42e5-b827-2d7d6c13c77a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8c9c3f60-c895-42e5-b827-2d7d6c13c77a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_03127b45-502a-4c02-976b-eb18aba72b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8c9c3f60-c895-42e5-b827-2d7d6c13c77a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_03127b45-502a-4c02-976b-eb18aba72b2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_December2020ATMMember_73efb2ff-6da2-4662-910f-139465618184" xlink:href="vtl-20230630.xsd#vtl_December2020ATMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_03127b45-502a-4c02-976b-eb18aba72b2e" xlink:to="loc_vtl_December2020ATMMember_73efb2ff-6da2-4662-910f-139465618184" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_May2022ATMMember_3a2e55f0-1f80-44d7-9627-5842d437f457" xlink:href="vtl-20230630.xsd#vtl_May2022ATMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_03127b45-502a-4c02-976b-eb18aba72b2e" xlink:to="loc_vtl_May2022ATMMember_3a2e55f0-1f80-44d7-9627-5842d437f457" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_48f147e3-6408-48cd-9325-b37f4df2c02b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3c93ffd4-7e4c-4f4e-bf00-674469754a23" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_48f147e3-6408-48cd-9325-b37f4df2c02b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_48f147e3-6408-48cd-9325-b37f4df2c02b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_48f147e3-6408-48cd-9325-b37f4df2c02b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_48f147e3-6408-48cd-9325-b37f4df2c02b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4de5d364-bf55-40bc-92f4-439caac8c9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_48f147e3-6408-48cd-9325-b37f4df2c02b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4de5d364-bf55-40bc-92f4-439caac8c9a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5b88004c-9cb1-47a6-ae7c-a1568a75f71a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4de5d364-bf55-40bc-92f4-439caac8c9a1" xlink:to="loc_us-gaap_SubsequentEventMember_5b88004c-9cb1-47a6-ae7c-a1568a75f71a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockEquityOfferingDetails" xlink:type="simple" xlink:href="vtl-20230630.xsd#CommonStockEquityOfferingDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CommonStockEquityOfferingDetails" xlink:type="extended" id="ib1d9e9f848eb44d6b06ef3e7602c3d8f_CommonStockEquityOfferingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_8f139a18-7f60-404e-9c89-3742f8e25ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b0dd668f-9c0d-4137-aa79-7c22ba20839a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f139a18-7f60-404e-9c89-3742f8e25ccf" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b0dd668f-9c0d-4137-aa79-7c22ba20839a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_388036e6-fb32-4796-9334-d581fb52bda7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f139a18-7f60-404e-9c89-3742f8e25ccf" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_388036e6-fb32-4796-9334-d581fb52bda7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_40c8bd0d-45a2-4a51-93bf-3bc49a870eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f139a18-7f60-404e-9c89-3742f8e25ccf" xlink:to="loc_us-gaap_SharePrice_40c8bd0d-45a2-4a51-93bf-3bc49a870eb8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_bd71d29d-5c71-4560-8ef9-bd9de202bfa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f139a18-7f60-404e-9c89-3742f8e25ccf" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_bd71d29d-5c71-4560-8ef9-bd9de202bfa5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_06deb004-9121-45c4-b140-897aeedbac0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bd71d29d-5c71-4560-8ef9-bd9de202bfa5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_06deb004-9121-45c4-b140-897aeedbac0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_06deb004-9121-45c4-b140-897aeedbac0e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_06deb004-9121-45c4-b140-897aeedbac0e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_06deb004-9121-45c4-b140-897aeedbac0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7e81c1ef-49c1-437b-b512-08d086dc5060" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_06deb004-9121-45c4-b140-897aeedbac0e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7e81c1ef-49c1-437b-b512-08d086dc5060" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f365ddc2-418d-4001-a87f-f46ca1594672" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7e81c1ef-49c1-437b-b512-08d086dc5060" xlink:to="loc_us-gaap_CommonStockMember_f365ddc2-418d-4001-a87f-f46ca1594672" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PreFundedWarrantsMember_b05be385-d22f-4b1c-884f-b887ec176a4d" xlink:href="vtl-20230630.xsd#vtl_PreFundedWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7e81c1ef-49c1-437b-b512-08d086dc5060" xlink:to="loc_vtl_PreFundedWarrantsMember_b05be385-d22f-4b1c-884f-b887ec176a4d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="vtl-20230630.xsd#CommonStockSharesReservedforFutureIssuanceDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails" xlink:type="extended" id="icac03bb098bf4f91bbe90f8d7fd21ff3_CommonStockSharesReservedforFutureIssuanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_0a508018-9eec-4aa7-8eb5-2bf57b38a50d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6b025bd2-bee9-47a1-9b50-134b81ac1782" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0a508018-9eec-4aa7-8eb5-2bf57b38a50d" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6b025bd2-bee9-47a1-9b50-134b81ac1782" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_dfe10daf-4eb6-42dc-bfd1-43fc2583835a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_0a508018-9eec-4aa7-8eb5-2bf57b38a50d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_dfe10daf-4eb6-42dc-bfd1-43fc2583835a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c2b5a30a-9711-4ea0-9310-cdf31671289b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_dfe10daf-4eb6-42dc-bfd1-43fc2583835a" xlink:to="loc_us-gaap_AwardTypeAxis_c2b5a30a-9711-4ea0-9310-cdf31671289b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2b5a30a-9711-4ea0-9310-cdf31671289b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c2b5a30a-9711-4ea0-9310-cdf31671289b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2b5a30a-9711-4ea0-9310-cdf31671289b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7e52dfb-86a2-46e3-9390-f8b489b08272" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c2b5a30a-9711-4ea0-9310-cdf31671289b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7e52dfb-86a2-46e3-9390-f8b489b08272" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e218b95c-1d71-4f9a-9be0-7cc9d75caa8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7e52dfb-86a2-46e3-9390-f8b489b08272" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e218b95c-1d71-4f9a-9be0-7cc9d75caa8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeStockOptionsforFutureGrantMember_24fc63bc-42ac-493c-9f95-c78a1eae4c7a" xlink:href="vtl-20230630.xsd#vtl_EmployeeStockOptionsforFutureGrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7e52dfb-86a2-46e3-9390-f8b489b08272" xlink:to="loc_vtl_EmployeeStockOptionsforFutureGrantMember_24fc63bc-42ac-493c-9f95-c78a1eae4c7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_5b9d11fc-d28a-431c-8d97-b431f8927ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_dfe10daf-4eb6-42dc-bfd1-43fc2583835a" xlink:to="loc_us-gaap_PlanNameAxis_5b9d11fc-d28a-431c-8d97-b431f8927ae8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_5b9d11fc-d28a-431c-8d97-b431f8927ae8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_5b9d11fc-d28a-431c-8d97-b431f8927ae8" xlink:to="loc_us-gaap_PlanNameDomain_5b9d11fc-d28a-431c-8d97-b431f8927ae8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7ceb4841-d7f5-4650-bd08-c0299919b86a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_5b9d11fc-d28a-431c-8d97-b431f8927ae8" xlink:to="loc_us-gaap_PlanNameDomain_7ceb4841-d7f5-4650-bd08-c0299919b86a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2021EmployeeStockPurchasePlanMember_179be7dc-d2af-4e88-9de8-42ef2e5e5075" xlink:href="vtl-20230630.xsd#vtl_A2021EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7ceb4841-d7f5-4650-bd08-c0299919b86a" xlink:to="loc_vtl_A2021EmployeeStockPurchasePlanMember_179be7dc-d2af-4e88-9de8-42ef2e5e5075" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_98bd4ebb-42a3-4ece-b010-d9dc947ada22" xlink:href="vtl-20230630.xsd#vtl_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7ceb4841-d7f5-4650-bd08-c0299919b86a" xlink:to="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_98bd4ebb-42a3-4ece-b010-d9dc947ada22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2017InducementEquityIncentivePlanMember_96ed3c5a-49aa-4102-90ea-001478f7f284" xlink:href="vtl-20230630.xsd#vtl_A2017InducementEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7ceb4841-d7f5-4650-bd08-c0299919b86a" xlink:to="loc_vtl_A2017InducementEquityIncentivePlanMember_96ed3c5a-49aa-4102-90ea-001478f7f284" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_b91826b4-67ed-4072-9bd4-3dee639d7304" xlink:href="vtl-20230630.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7ceb4841-d7f5-4650-bd08-c0299919b86a" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_b91826b4-67ed-4072-9bd4-3dee639d7304" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20230630.xsd#StockBasedCompensationPlansAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails" xlink:type="extended" id="i6806ea9763f945ffa8537f9a8102d114_StockBasedCompensationPlansAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c9d610-1335-4ddd-88b6-ff7192066b69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_b7b85510-a859-4c08-bfb1-64e82b9f87ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c9d610-1335-4ddd-88b6-ff7192066b69" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_b7b85510-a859-4c08-bfb1-64e82b9f87ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_26569d53-e889-4394-8b47-7ac66823b714" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c9d610-1335-4ddd-88b6-ff7192066b69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_26569d53-e889-4394-8b47-7ac66823b714" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4a04d74f-8e08-42a9-a248-497fe0b7ce09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c9d610-1335-4ddd-88b6-ff7192066b69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4a04d74f-8e08-42a9-a248-497fe0b7ce09" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a386f9be-017b-49aa-976c-474d4ba2a263" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c9d610-1335-4ddd-88b6-ff7192066b69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a386f9be-017b-49aa-976c-474d4ba2a263" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_75c5d12c-b8ce-47eb-855a-04db59970ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c9d610-1335-4ddd-88b6-ff7192066b69" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_75c5d12c-b8ce-47eb-855a-04db59970ffe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_3efd5030-c330-4308-8073-355a229823cb" xlink:href="vtl-20230630.xsd#vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c9d610-1335-4ddd-88b6-ff7192066b69" xlink:to="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_3efd5030-c330-4308-8073-355a229823cb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_4b0577f6-0a60-47f0-adab-b9757ddfe767" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c9d610-1335-4ddd-88b6-ff7192066b69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_4b0577f6-0a60-47f0-adab-b9757ddfe767" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_e7908415-3568-4f2a-97b3-79bf325acedd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c9d610-1335-4ddd-88b6-ff7192066b69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_e7908415-3568-4f2a-97b3-79bf325acedd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_95498cbf-68ee-49ac-b526-58fc2a26637a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c9d610-1335-4ddd-88b6-ff7192066b69" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_95498cbf-68ee-49ac-b526-58fc2a26637a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_268f5f73-6a96-488a-8e70-b43aa334bf77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c9d610-1335-4ddd-88b6-ff7192066b69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_268f5f73-6a96-488a-8e70-b43aa334bf77" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d0cbeda8-b15e-40ea-a0f4-2f98ac89866e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c9d610-1335-4ddd-88b6-ff7192066b69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d0cbeda8-b15e-40ea-a0f4-2f98ac89866e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4f10bc13-8d9d-4b75-9586-1a9a81f3cfdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c9d610-1335-4ddd-88b6-ff7192066b69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4f10bc13-8d9d-4b75-9586-1a9a81f3cfdd" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6cf447bc-fbd1-4ac7-afad-22ad7fb9cf6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c9d610-1335-4ddd-88b6-ff7192066b69" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6cf447bc-fbd1-4ac7-afad-22ad7fb9cf6e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_35657e09-0d58-485a-acec-bebef3d14b12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c9d610-1335-4ddd-88b6-ff7192066b69" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_35657e09-0d58-485a-acec-bebef3d14b12" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3b2fe310-18f8-44a4-b009-57a75136b8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c9d610-1335-4ddd-88b6-ff7192066b69" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3b2fe310-18f8-44a4-b009-57a75136b8e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_37937fda-7c4b-4c5e-b6b8-7194665d8318" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3b2fe310-18f8-44a4-b009-57a75136b8e3" xlink:to="loc_us-gaap_PlanNameAxis_37937fda-7c4b-4c5e-b6b8-7194665d8318" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_37937fda-7c4b-4c5e-b6b8-7194665d8318_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_37937fda-7c4b-4c5e-b6b8-7194665d8318" xlink:to="loc_us-gaap_PlanNameDomain_37937fda-7c4b-4c5e-b6b8-7194665d8318_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_568bd638-d36d-46ba-839a-f3ea323edc8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_37937fda-7c4b-4c5e-b6b8-7194665d8318" xlink:to="loc_us-gaap_PlanNameDomain_568bd638-d36d-46ba-839a-f3ea323edc8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2021EmployeeStockPurchasePlanMember_387d3219-ca24-4084-ae5b-76ef9336895f" xlink:href="vtl-20230630.xsd#vtl_A2021EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_568bd638-d36d-46ba-839a-f3ea323edc8f" xlink:to="loc_vtl_A2021EmployeeStockPurchasePlanMember_387d3219-ca24-4084-ae5b-76ef9336895f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2019OmnibusEquityIncentivePlanMember_aad20f3f-7261-43e0-96ba-85943a96fd94" xlink:href="vtl-20230630.xsd#vtl_A2019OmnibusEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_568bd638-d36d-46ba-839a-f3ea323edc8f" xlink:to="loc_vtl_A2019OmnibusEquityIncentivePlanMember_aad20f3f-7261-43e0-96ba-85943a96fd94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_8010e7d8-64e7-4f9f-b990-f12a023a9ea5" xlink:href="vtl-20230630.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_vtl_A2019OmnibusEquityIncentivePlanMember_aad20f3f-7261-43e0-96ba-85943a96fd94" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_8010e7d8-64e7-4f9f-b990-f12a023a9ea5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_116aae54-ce62-4b15-abe2-a24179723adf" xlink:href="vtl-20230630.xsd#vtl_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_568bd638-d36d-46ba-839a-f3ea323edc8f" xlink:to="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_116aae54-ce62-4b15-abe2-a24179723adf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2017InducementEquityIncentivePlanMember_ded195d2-cef6-44d2-a616-bd479ae2fcfd" xlink:href="vtl-20230630.xsd#vtl_A2017InducementEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_568bd638-d36d-46ba-839a-f3ea323edc8f" xlink:to="loc_vtl_A2017InducementEquityIncentivePlanMember_ded195d2-cef6-44d2-a616-bd479ae2fcfd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cc0da4f2-5f0b-4de3-b35e-385ffbf75712" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3b2fe310-18f8-44a4-b009-57a75136b8e3" xlink:to="loc_srt_RangeAxis_cc0da4f2-5f0b-4de3-b35e-385ffbf75712" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cc0da4f2-5f0b-4de3-b35e-385ffbf75712_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_cc0da4f2-5f0b-4de3-b35e-385ffbf75712" xlink:to="loc_srt_RangeMember_cc0da4f2-5f0b-4de3-b35e-385ffbf75712_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a2ff7d3d-e798-4896-a961-b62a89b289b1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_cc0da4f2-5f0b-4de3-b35e-385ffbf75712" xlink:to="loc_srt_RangeMember_a2ff7d3d-e798-4896-a961-b62a89b289b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_93e23195-abf6-4889-a945-511b187e7eb3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a2ff7d3d-e798-4896-a961-b62a89b289b1" xlink:to="loc_srt_MinimumMember_93e23195-abf6-4889-a945-511b187e7eb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6d95c8e9-1363-4eda-b7b4-c7326476bcf8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a2ff7d3d-e798-4896-a961-b62a89b289b1" xlink:to="loc_srt_MaximumMember_6d95c8e9-1363-4eda-b7b4-c7326476bcf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2c668564-3cdc-473c-a965-bf6fd64252c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3b2fe310-18f8-44a4-b009-57a75136b8e3" xlink:to="loc_us-gaap_AwardTypeAxis_2c668564-3cdc-473c-a965-bf6fd64252c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2c668564-3cdc-473c-a965-bf6fd64252c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2c668564-3cdc-473c-a965-bf6fd64252c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2c668564-3cdc-473c-a965-bf6fd64252c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd9fd945-5293-480a-a8e9-a483868b996b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2c668564-3cdc-473c-a965-bf6fd64252c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd9fd945-5293-480a-a8e9-a483868b996b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncentiveEmployeeStockOptionMember_4356d677-9416-42e6-9e1b-ee8058fe0753" xlink:href="vtl-20230630.xsd#vtl_IncentiveEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd9fd945-5293-480a-a8e9-a483868b996b" xlink:to="loc_vtl_IncentiveEmployeeStockOptionMember_4356d677-9416-42e6-9e1b-ee8058fe0753" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NonStatutoryEmployeeStockOptionMember_e92cdd28-6a69-41b1-81a5-6b223af470f8" xlink:href="vtl-20230630.xsd#vtl_NonStatutoryEmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd9fd945-5293-480a-a8e9-a483868b996b" xlink:to="loc_vtl_NonStatutoryEmployeeStockOptionMember_e92cdd28-6a69-41b1-81a5-6b223af470f8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="vtl-20230630.xsd#StockBasedCompensationPlansSummaryofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails" xlink:type="extended" id="i444248fbcf9547529a02f2131fcc7ed5_StockBasedCompensationPlansSummaryofStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38377ea4-6d43-4756-83c4-d0dfffe86dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7971d8b8-28d6-447c-90b9-0b520bf0bba1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38377ea4-6d43-4756-83c4-d0dfffe86dd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7971d8b8-28d6-447c-90b9-0b520bf0bba1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2020b11b-80e6-4689-903c-a6ce7c17e26c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7971d8b8-28d6-447c-90b9-0b520bf0bba1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2020b11b-80e6-4689-903c-a6ce7c17e26c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_28c313f3-60b3-4b09-adfb-ddd53a98012e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7971d8b8-28d6-447c-90b9-0b520bf0bba1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_28c313f3-60b3-4b09-adfb-ddd53a98012e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3c35c49f-69e0-4a67-a048-9ab6ba383efe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7971d8b8-28d6-447c-90b9-0b520bf0bba1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3c35c49f-69e0-4a67-a048-9ab6ba383efe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c92df319-1c36-4ff2-a0e0-90674ee3d369" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7971d8b8-28d6-447c-90b9-0b520bf0bba1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c92df319-1c36-4ff2-a0e0-90674ee3d369" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_52721806-9d66-41f9-a06a-20cd11e664b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_26ef5cab-3106-4573-ac1d-5a978b97c760" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38377ea4-6d43-4756-83c4-d0dfffe86dd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_26ef5cab-3106-4573-ac1d-5a978b97c760" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9c5ed6c9-af26-47fb-b1ad-5f675ef8f1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38377ea4-6d43-4756-83c4-d0dfffe86dd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9c5ed6c9-af26-47fb-b1ad-5f675ef8f1f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9e6b5a2c-029e-4a0e-be11-38cfc53cf78b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38377ea4-6d43-4756-83c4-d0dfffe86dd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9e6b5a2c-029e-4a0e-be11-38cfc53cf78b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c209884a-275d-4b7d-ac43-8822f3a0642a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9e6b5a2c-029e-4a0e-be11-38cfc53cf78b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c209884a-275d-4b7d-ac43-8822f3a0642a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_32baeb1b-8ce3-4930-aef5-6287bd27468b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9e6b5a2c-029e-4a0e-be11-38cfc53cf78b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_32baeb1b-8ce3-4930-aef5-6287bd27468b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ab38bc66-7a69-4850-94a1-6597c6e4722b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9e6b5a2c-029e-4a0e-be11-38cfc53cf78b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ab38bc66-7a69-4850-94a1-6597c6e4722b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_83863218-31f2-44af-a3da-8d66fc110144" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9e6b5a2c-029e-4a0e-be11-38cfc53cf78b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_83863218-31f2-44af-a3da-8d66fc110144" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_eac9ad26-69db-4325-a73a-1c7dc2b51727" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_dcb2e38e-5dc4-4c79-9150-389df9b187a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38377ea4-6d43-4756-83c4-d0dfffe86dd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_dcb2e38e-5dc4-4c79-9150-389df9b187a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_90f3d083-427e-40ae-8b67-20425d4901c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38377ea4-6d43-4756-83c4-d0dfffe86dd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_90f3d083-427e-40ae-8b67-20425d4901c1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ba222853-bf1e-418b-9122-efc779de9c41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38377ea4-6d43-4756-83c4-d0dfffe86dd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ba222853-bf1e-418b-9122-efc779de9c41" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_09c14cf0-cc08-41d8-9974-9231bb14441d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ba222853-bf1e-418b-9122-efc779de9c41" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_09c14cf0-cc08-41d8-9974-9231bb14441d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_ec8c8f12-c66e-4f8e-b1d6-9e3918b07a59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ba222853-bf1e-418b-9122-efc779de9c41" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_ec8c8f12-c66e-4f8e-b1d6-9e3918b07a59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_cd9902f3-3e29-4cac-9ffe-d63e115ab58d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ba222853-bf1e-418b-9122-efc779de9c41" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_cd9902f3-3e29-4cac-9ffe-d63e115ab58d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_295b254d-acaa-4cdd-9254-f99325622afb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ba222853-bf1e-418b-9122-efc779de9c41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_295b254d-acaa-4cdd-9254-f99325622afb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_0a603a94-2ea5-4a24-bc74-aaadfa70cbdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ba222853-bf1e-418b-9122-efc779de9c41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_0a603a94-2ea5-4a24-bc74-aaadfa70cbdc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f97d87f8-3c0e-4530-a7cf-17d792048620" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ba222853-bf1e-418b-9122-efc779de9c41" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f97d87f8-3c0e-4530-a7cf-17d792048620" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cac52ec3-df56-448d-9cbc-ad0fc3f8c9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38377ea4-6d43-4756-83c4-d0dfffe86dd1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cac52ec3-df56-448d-9cbc-ad0fc3f8c9cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_81ff37a2-1afa-4dec-a5e6-bfb4f4daa59e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cac52ec3-df56-448d-9cbc-ad0fc3f8c9cc" xlink:to="loc_us-gaap_PlanNameAxis_81ff37a2-1afa-4dec-a5e6-bfb4f4daa59e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_81ff37a2-1afa-4dec-a5e6-bfb4f4daa59e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_81ff37a2-1afa-4dec-a5e6-bfb4f4daa59e" xlink:to="loc_us-gaap_PlanNameDomain_81ff37a2-1afa-4dec-a5e6-bfb4f4daa59e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_bdbdc5ab-4c50-4259-9d5f-d08d3253113c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_81ff37a2-1afa-4dec-a5e6-bfb4f4daa59e" xlink:to="loc_us-gaap_PlanNameDomain_bdbdc5ab-4c50-4259-9d5f-d08d3253113c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_a563c571-57c2-4c3f-a65b-5827bfef9322" xlink:href="vtl-20230630.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_bdbdc5ab-4c50-4259-9d5f-d08d3253113c" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_a563c571-57c2-4c3f-a65b-5827bfef9322" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d4de9201-1aa3-455b-b078-c34252808964" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cac52ec3-df56-448d-9cbc-ad0fc3f8c9cc" xlink:to="loc_us-gaap_AwardTypeAxis_d4de9201-1aa3-455b-b078-c34252808964" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d4de9201-1aa3-455b-b078-c34252808964_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d4de9201-1aa3-455b-b078-c34252808964" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d4de9201-1aa3-455b-b078-c34252808964_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a3bc989-5c72-42e5-b0ee-adb9872c742d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d4de9201-1aa3-455b-b078-c34252808964" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a3bc989-5c72-42e5-b0ee-adb9872c742d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d77d369e-e3a6-4c8c-a887-d36deba11bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a3bc989-5c72-42e5-b0ee-adb9872c742d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d77d369e-e3a6-4c8c-a887-d36deba11bb0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail" xlink:type="simple" xlink:href="vtl-20230630.xsd#StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail" xlink:type="extended" id="ie8f9d629d57f45ddb24915401c75b843_StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6afa730a-12e0-4a82-a536-9c43a3a5505e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9c9f1e25-55fc-4e6f-964f-23591bc58adb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6afa730a-12e0-4a82-a536-9c43a3a5505e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9c9f1e25-55fc-4e6f-964f-23591bc58adb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_305fe672-1fa2-41f6-b631-ee636629927a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6afa730a-12e0-4a82-a536-9c43a3a5505e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_305fe672-1fa2-41f6-b631-ee636629927a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5bb3b23c-a732-4e9d-b1d2-adc157dff24c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6afa730a-12e0-4a82-a536-9c43a3a5505e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5bb3b23c-a732-4e9d-b1d2-adc157dff24c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_43546050-7637-46b7-bad3-b6288eeefae3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6afa730a-12e0-4a82-a536-9c43a3a5505e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_43546050-7637-46b7-bad3-b6288eeefae3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a17c45bb-e534-4fc9-9674-829bf9541990" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6afa730a-12e0-4a82-a536-9c43a3a5505e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a17c45bb-e534-4fc9-9674-829bf9541990" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_54fe13fa-c555-4164-af9b-f3a8c948bf00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a17c45bb-e534-4fc9-9674-829bf9541990" xlink:to="loc_us-gaap_PlanNameAxis_54fe13fa-c555-4164-af9b-f3a8c948bf00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_54fe13fa-c555-4164-af9b-f3a8c948bf00_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_54fe13fa-c555-4164-af9b-f3a8c948bf00" xlink:to="loc_us-gaap_PlanNameDomain_54fe13fa-c555-4164-af9b-f3a8c948bf00_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c1727c44-6666-41d5-b486-ac98a8b3917b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_54fe13fa-c555-4164-af9b-f3a8c948bf00" xlink:to="loc_us-gaap_PlanNameDomain_c1727c44-6666-41d5-b486-ac98a8b3917b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2019OmnibusEquityIncentivePlanMember_a86a97d8-a97c-4118-962e-d5f8e0a4d78c" xlink:href="vtl-20230630.xsd#vtl_A2019OmnibusEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c1727c44-6666-41d5-b486-ac98a8b3917b" xlink:to="loc_vtl_A2019OmnibusEquityIncentivePlanMember_a86a97d8-a97c-4118-962e-d5f8e0a4d78c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" xlink:type="simple" xlink:href="vtl-20230630.xsd#StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" xlink:type="extended" id="ie0c6eadf7d3d4d0790962c1bdbb38a2a_StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ec20940d-1a34-438d-83f1-bf93fe149d90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f08222e4-9d40-4021-b7b4-a8a6be27101a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ec20940d-1a34-438d-83f1-bf93fe149d90" xlink:to="loc_us-gaap_ShareBasedCompensation_f08222e4-9d40-4021-b7b4-a8a6be27101a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_49ffc662-f30d-4e58-bfed-834da60c8c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ec20940d-1a34-438d-83f1-bf93fe149d90" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_49ffc662-f30d-4e58-bfed-834da60c8c3d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_10d9bfd2-bbcf-49b6-9d56-5ef7acab10cf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_49ffc662-f30d-4e58-bfed-834da60c8c3d" xlink:to="loc_srt_TitleOfIndividualAxis_10d9bfd2-bbcf-49b6-9d56-5ef7acab10cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_10d9bfd2-bbcf-49b6-9d56-5ef7acab10cf_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_10d9bfd2-bbcf-49b6-9d56-5ef7acab10cf" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_10d9bfd2-bbcf-49b6-9d56-5ef7acab10cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_af8b51d3-b879-460e-a4fa-a3456eacedba" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_10d9bfd2-bbcf-49b6-9d56-5ef7acab10cf" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_af8b51d3-b879-460e-a4fa-a3456eacedba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeMember_b4008d49-61f4-436b-9368-c5aa0bbb81db" xlink:href="vtl-20230630.xsd#vtl_EmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_af8b51d3-b879-460e-a4fa-a3456eacedba" xlink:to="loc_vtl_EmployeeMember_b4008d49-61f4-436b-9368-c5aa0bbb81db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8a0892cd-f53f-41f9-b99b-0e15a38079c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_49ffc662-f30d-4e58-bfed-834da60c8c3d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8a0892cd-f53f-41f9-b99b-0e15a38079c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8a0892cd-f53f-41f9-b99b-0e15a38079c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8a0892cd-f53f-41f9-b99b-0e15a38079c6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8a0892cd-f53f-41f9-b99b-0e15a38079c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ec82dedc-7a55-4522-9c18-52ce91f1ce37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8a0892cd-f53f-41f9-b99b-0e15a38079c6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ec82dedc-7a55-4522-9c18-52ce91f1ce37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2074ed19-e2ff-41f7-b7ea-16e2d9ea13f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ec82dedc-7a55-4522-9c18-52ce91f1ce37" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2074ed19-e2ff-41f7-b7ea-16e2d9ea13f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7833a18e-13c3-40cd-a297-9da63c036295" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ec82dedc-7a55-4522-9c18-52ce91f1ce37" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7833a18e-13c3-40cd-a297-9da63c036295" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20230630.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended" id="id58e781e9c1246ca8eda7f9530a11728_RelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_3c6bf0c8-fe0e-41e9-bee6-317214640d47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SalaryCostsMonthlyBaseSalary_5c30a583-c558-42bb-aaab-612f0661c783" xlink:href="vtl-20230630.xsd#vtl_SalaryCostsMonthlyBaseSalary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_3c6bf0c8-fe0e-41e9-bee6-317214640d47" xlink:to="loc_vtl_SalaryCostsMonthlyBaseSalary_5c30a583-c558-42bb-aaab-612f0661c783" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3d16030d-b205-4335-aa73-179f4dd0d188" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_3c6bf0c8-fe0e-41e9-bee6-317214640d47" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3d16030d-b205-4335-aa73-179f4dd0d188" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_805d2e9a-d50d-4bb2-8ae9-fb9737e1ee1f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3d16030d-b205-4335-aa73-179f4dd0d188" xlink:to="loc_srt_CounterpartyNameAxis_805d2e9a-d50d-4bb2-8ae9-fb9737e1ee1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_805d2e9a-d50d-4bb2-8ae9-fb9737e1ee1f_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_805d2e9a-d50d-4bb2-8ae9-fb9737e1ee1f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_805d2e9a-d50d-4bb2-8ae9-fb9737e1ee1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_11c15060-2412-408b-8cc5-0d2df448772b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_805d2e9a-d50d-4bb2-8ae9-fb9737e1ee1f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_11c15060-2412-408b-8cc5-0d2df448772b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_DuaneNashMDJDMBAMember_767c3f04-4eac-4605-afce-1eec6e6b1312" xlink:href="vtl-20230630.xsd#vtl_DuaneNashMDJDMBAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_11c15060-2412-408b-8cc5-0d2df448772b" xlink:to="loc_vtl_DuaneNashMDJDMBAMember_767c3f04-4eac-4605-afce-1eec6e6b1312" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_702d7b77-0f07-4c10-9dae-7cac51672de2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3d16030d-b205-4335-aa73-179f4dd0d188" xlink:to="loc_srt_StatementScenarioAxis_702d7b77-0f07-4c10-9dae-7cac51672de2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_702d7b77-0f07-4c10-9dae-7cac51672de2_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_702d7b77-0f07-4c10-9dae-7cac51672de2" xlink:to="loc_srt_ScenarioUnspecifiedDomain_702d7b77-0f07-4c10-9dae-7cac51672de2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_65ddd69c-63c4-41fd-be5f-6b5e90ec19fe" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_702d7b77-0f07-4c10-9dae-7cac51672de2" xlink:to="loc_srt_ScenarioUnspecifiedDomain_65ddd69c-63c4-41fd-be5f-6b5e90ec19fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_dadc173b-baf0-4cae-8d3b-19dd37f54d21" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_65ddd69c-63c4-41fd-be5f-6b5e90ec19fe" xlink:to="loc_srt_ScenarioForecastMember_dadc173b-baf0-4cae-8d3b-19dd37f54d21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_0b6de7fe-14ff-4970-bf61-9b3e92dc1805" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3d16030d-b205-4335-aa73-179f4dd0d188" xlink:to="loc_srt_TitleOfIndividualAxis_0b6de7fe-14ff-4970-bf61-9b3e92dc1805" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0b6de7fe-14ff-4970-bf61-9b3e92dc1805_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_0b6de7fe-14ff-4970-bf61-9b3e92dc1805" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0b6de7fe-14ff-4970-bf61-9b3e92dc1805_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0168d55f-020a-4bab-9243-ed77e1476852" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_0b6de7fe-14ff-4970-bf61-9b3e92dc1805" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0168d55f-020a-4bab-9243-ed77e1476852" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_b5f687e6-374c-436c-a6da-cb59dd2f03ce" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0168d55f-020a-4bab-9243-ed77e1476852" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_b5f687e6-374c-436c-a6da-cb59dd2f03ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_7bbda15c-3910-404f-81a2-a15721c09299" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3d16030d-b205-4335-aa73-179f4dd0d188" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_7bbda15c-3910-404f-81a2-a15721c09299" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_7bbda15c-3910-404f-81a2-a15721c09299_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_7bbda15c-3910-404f-81a2-a15721c09299" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_7bbda15c-3910-404f-81a2-a15721c09299_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_069f0c31-5a87-488d-a712-4538e5052fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_7bbda15c-3910-404f-81a2-a15721c09299" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_069f0c31-5a87-488d-a712-4538e5052fbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ExecutiveChairmanAgreementMember_efc6491d-b919-426d-9982-d6c7161daeb4" xlink:href="vtl-20230630.xsd#vtl_ExecutiveChairmanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_069f0c31-5a87-488d-a712-4538e5052fbf" xlink:to="loc_vtl_ExecutiveChairmanAgreementMember_efc6491d-b919-426d-9982-d6c7161daeb4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bc1eee45-85ea-4185-9aed-6bfcb7e44dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3d16030d-b205-4335-aa73-179f4dd0d188" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bc1eee45-85ea-4185-9aed-6bfcb7e44dc4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_bc1eee45-85ea-4185-9aed-6bfcb7e44dc4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bc1eee45-85ea-4185-9aed-6bfcb7e44dc4" xlink:to="loc_us-gaap_RelatedPartyDomain_bc1eee45-85ea-4185-9aed-6bfcb7e44dc4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_30239615-6b28-44ed-8dd9-3c32dcaab47a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bc1eee45-85ea-4185-9aed-6bfcb7e44dc4" xlink:to="loc_us-gaap_RelatedPartyDomain_30239615-6b28-44ed-8dd9-3c32dcaab47a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_fb349945-c6ae-4ff1-bd7b-1792808861a0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_30239615-6b28-44ed-8dd9-3c32dcaab47a" xlink:to="loc_srt_AffiliatedEntityMember_fb349945-c6ae-4ff1-bd7b-1792808861a0" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>vtl-20230630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:c5b7d08b-4d18-4b53-b740-daba2f6d29fd,g:398611d2-4d63-409b-b481-5daa2ae6bce9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_OtherShortTermInvestments_5716c8b9-5825-4175-b8fb-9e884d7f80db_terseLabel_en-US" xlink:label="lab_us-gaap_OtherShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments - other</link:label>
    <link:label id="lab_us-gaap_OtherShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_OtherShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherShortTermInvestments" xlink:to="lab_us-gaap_OtherShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_f9306460-5a74-4b92-9ad6-cf2078c1e78d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in other share (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Other Share Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_b353148e-06f4-49e0-9f66-1037571efb36_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_95b491ff-32d3-4a94-bac4-9cfe51f60ce8_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_cc9a056c-3293-4b3b-8f05-f912627392ce_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_15b79dc9-4749-4ff9-8e69-d07d27c627c0_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_66a8e51b-6cd1-4162-9c81-9e47b845c41c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b1d187e7-8d14-4699-8ce8-a18b7aba9ec5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_5395308c-7d84-422b-8936-59aabf6962cd_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e527e231-5bbe-41c1-bcdd-c96b335fc4a5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_4530ddcf-b9e6-4b90-aa87-48abdfe9b243_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_d7d86c59-9e5a-42d7-9a8f-c2673993ddf9_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_c3563e64-a898-4f54-af39-14fbb7cd4d46_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_6f924300-a881-45f7-8eb3-91a9fdfadfc4_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_ecc1cd34-b6af-480c-a7c8-43ebad973e96_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_efe52b40-db86-4f07-a5e8-f0e277bbce37_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_ad6d4ba5-9858-4800-aa1f-ac564fdbbc05_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_68dc2e1d-bacf-471f-a33c-16e9d3b1a740_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_da1c8170-1e93-40d7-9099-e3da6c3cdbc6_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_24858c75-ef4e-4f57-820a-d47aa09e3a8c_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_bf65397d-6239-4cc7-bb01-e7070bf02b9b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, weighted-average remaining contractual term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_90f6f3ca-756b-4c35-8b6a-a18c4f00ff4a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherSundryLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Sundry Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_56f2da6e-836c-45b6-88f5-92466cafd227_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_a4d1bdd8-96c1-42ef-8105-68385bf71935_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ClinicalCostsPayableCurrent_1aaa8a9d-55ff-448f-ba7f-d861412d5de6_terseLabel_en-US" xlink:label="lab_vtl_ClinicalCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical costs</link:label>
    <link:label id="lab_vtl_ClinicalCostsPayableCurrent_label_en-US" xlink:label="lab_vtl_ClinicalCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Costs Payable, Current</link:label>
    <link:label id="lab_vtl_ClinicalCostsPayableCurrent_documentation_en-US" xlink:label="lab_vtl_ClinicalCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical Costs Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ClinicalCostsPayableCurrent" xlink:href="vtl-20230630.xsd#vtl_ClinicalCostsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ClinicalCostsPayableCurrent" xlink:to="lab_vtl_ClinicalCostsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_05adc9bb-b037-42c2-b36f-8b7ab2bb8f44_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 4)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4b12705e-6e56-4b69-b67e-fb792ccfb22c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_2a85cbc4-53e6-4e60-944c-ba31d3508340_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTableTextBlock_a7275e84-c231-433b-a9c8-8aec2900d9ec_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investment</link:label>
    <link:label id="lab_us-gaap_InvestmentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTableTextBlock" xlink:to="lab_us-gaap_InvestmentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_194b348c-d332-45d3-a866-25c9bf0c5e94_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_64ebe790-638a-4b96-a9f9-2c371b9aa64e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from shares issued in connection with the Company's employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_a3345a5a-ee8d-4c20-9fa7-203838bcff49_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_650f2efd-a3cb-4690-9608-1406908082be_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_491720dc-6217-4634-bc7b-ee683e2edc78_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest , aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_3edeec26-90e5-47a4-9953-9512a75a8993_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from public offering of common stock through At The Market Sales Agreement, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_8f151393-58f0-48f7-992d-1299b46ed3fb_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_729983b5-80d9-46db-af28-45cb7923d610_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_b60195fb-24f5-4a01-a4ac-230b15e3165a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business and Basis of Financial Statements</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_9aa1a4b4-9812-4cc2-82cd-e77fc487391d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f64e6563-8e78-4231-a93f-290717edeb10_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_A2019OmnibusEquityIncentivePlanMember_95f67e79-582a-458d-bce4-37019258a1bf_terseLabel_en-US" xlink:label="lab_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan</link:label>
    <link:label id="lab_vtl_A2019OmnibusEquityIncentivePlanMember_label_en-US" xlink:label="lab_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_vtl_A2019OmnibusEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:href="vtl-20230630.xsd#vtl_A2019OmnibusEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:to="lab_vtl_A2019OmnibusEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_7ce4618c-8764-41e3-9390-117a889e3305_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_b5408351-8980-4a46-9f05-ddef019211ac_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_2fd61a6a-0cf8-4dc4-aac8-d6b618e8fe25_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_b2957d57-dce3-49e6-bbe4-a6b03b0ba14f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_May2022ATMMember_174eb5d8-9f36-411c-aba9-6aed2fdb1fa2_terseLabel_en-US" xlink:label="lab_vtl_May2022ATMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2022 ATM</link:label>
    <link:label id="lab_vtl_May2022ATMMember_label_en-US" xlink:label="lab_vtl_May2022ATMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2022 ATM [Member]</link:label>
    <link:label id="lab_vtl_May2022ATMMember_documentation_en-US" xlink:label="lab_vtl_May2022ATMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2022 ATM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_May2022ATMMember" xlink:href="vtl-20230630.xsd#vtl_May2022ATMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_May2022ATMMember" xlink:to="lab_vtl_May2022ATMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_e86f9cf1-c332-4a38-b7c4-46f6c7055cd7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of pre-funded warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_58cef5ca-8013-4da8-a49e-dce91a94abc9_terseLabel_en-US" xlink:label="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in operating lease, right-of-use asset</link:label>
    <link:label id="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:href="vtl-20230630.xsd#vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lab_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_ba2698df-3b8d-4d25-9454-74bc4075ffce_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_d4f3ed9b-beef-455e-8f95-81184f32d038_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_d7075e3d-51ae-45ad-aa4a-cb1bda179a4e_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_810c1112-cd78-4417-a5be-367eaac1978c_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_e3d0c541-5b82-41c4-b83b-9302a8eeac9a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding as of June 30, 2023 and December 31, 2022</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_0050e477-3e6d-4bfb-b368-aba93ef55120_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_89d55120-ef57-4e77-942c-17153abbc448_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_d5148de8-10ff-4e0e-9db4-930a366ad5bb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_4e940688-38eb-4386-bcc2-45248751c6ff_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, impairment loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityNumberOfEmployees_3249d0cb-f458-4709-9d4d-ee58b50c2888_terseLabel_en-US" xlink:label="lab_dei_EntityNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees</link:label>
    <link:label id="lab_dei_EntityNumberOfEmployees_label_en-US" xlink:label="lab_dei_EntityNumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Number of Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityNumberOfEmployees" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityNumberOfEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityNumberOfEmployees" xlink:to="lab_dei_EntityNumberOfEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_9f7a808e-3bfc-487d-b6d5-7e35d5b2047e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e1e3d35c-3d9f-41e9-b722-63802a90582d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_aeacf182-862e-4ac8-bbf2-7d4769fda4e4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_90d5a76a-85d7-4752-a6ac-3bc558b141ea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest, Weighted-Average Exercise Price, Ending balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_2e6d3532-d248-48e2-91de-3ef0649e5c46_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_eccf25b5-6551-4694-9cf2-cff3f957f857_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term of options (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_f8c4d8e1-a574-4728-aea7-8d787c8c8214_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ExecutiveChairmanAgreementMember_ec51a8f1-7633-4c30-bac0-ba20bbf18483_terseLabel_en-US" xlink:label="lab_vtl_ExecutiveChairmanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Chairman Agreement</link:label>
    <link:label id="lab_vtl_ExecutiveChairmanAgreementMember_label_en-US" xlink:label="lab_vtl_ExecutiveChairmanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Chairman Agreement [Member]</link:label>
    <link:label id="lab_vtl_ExecutiveChairmanAgreementMember_documentation_en-US" xlink:label="lab_vtl_ExecutiveChairmanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Chairman Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ExecutiveChairmanAgreementMember" xlink:href="vtl-20230630.xsd#vtl_ExecutiveChairmanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ExecutiveChairmanAgreementMember" xlink:to="lab_vtl_ExecutiveChairmanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_1075d03e-d456-4538-95c7-3ea10e30eee0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b874e907-56c8-4e57-9435-d854c51dbab2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e5d246c1-c959-44f5-b039-e644be5373ac_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_EmployeeMember_f75a980f-c2a0-464d-9865-e2bf14d7fa15_terseLabel_en-US" xlink:label="lab_vtl_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employees</link:label>
    <link:label id="lab_vtl_EmployeeMember_label_en-US" xlink:label="lab_vtl_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee [Member]</link:label>
    <link:label id="lab_vtl_EmployeeMember_documentation_en-US" xlink:label="lab_vtl_EmployeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeMember" xlink:href="vtl-20230630.xsd#vtl_EmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_EmployeeMember" xlink:to="lab_vtl_EmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_d6cdd617-6d0c-4c48-b5db-bd20bbbfec24_terseLabel_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment losses</link:label>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tangible Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:to="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_a589ec0a-161a-4f19-9327-60a9abb3b718_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_57745a7e-b650-4c70-9dbb-6e79f2f4c7fc_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_86f7c5d3-7981-4bf3-b6ed-b3c63a936f4d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_afb70c9a-8bda-402c-8bf1-7dc71bd0bf97_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Assets and Prepaid Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_5facc0b6-2665-407a-95e1-9d17f04ee9c4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued from exercise of pre-funded warrants and issuance of common stock - at the market Sales Agreement net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_80ff0315-2a1a-4bdd-9870-8a4572f51108_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted in period, weighted-average grant date fair value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_6a09a4ea-4b7a-4e8d-a5a0-cc03115d7dd7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_d092ff0b-e9d8-4ad6-a397-0b68a5ab5ce8_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b1399436-297d-4fdc-bfce-4c76452e0b1b_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_d8a0c0ae-caee-49cf-814e-5891607b7cee_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_e8fce96e-98c5-4022-8498-1d313b200f42_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_395ed68a-83b2-4412-9132-d184726390bb_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases_824c4cbc-d7a4-4cd3-9b56-0a79f8fa1df6_terseLabel_en-US" xlink:label="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of existing leases</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases_label_en-US" xlink:label="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases, Number Of Existing Leases</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases_documentation_en-US" xlink:label="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases, Number Of Existing Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:href="vtl-20230630.xsd#vtl_LesseeOperatingLeasesNumberOfExistingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:to="lab_vtl_LesseeOperatingLeasesNumberOfExistingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_a5ebda4a-a57c-4ea3-b5d4-89d289e33131_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation and Presentation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposit_be9b6ef9-c46f-491f-9ad2-56851ed34a79_terseLabel_en-US" xlink:label="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of financial institutions used for cash deposits</link:label>
    <link:label id="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposit_label_en-US" xlink:label="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Financial Institutions Used For Cash Deposit</link:label>
    <link:label id="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposit_documentation_en-US" xlink:label="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Financial Institutions Used For Cash Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfFinancialInstitutionsUsedForCashDeposit" xlink:href="vtl-20230630.xsd#vtl_NumberOfFinancialInstitutionsUsedForCashDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_NumberOfFinancialInstitutionsUsedForCashDeposit" xlink:to="lab_vtl_NumberOfFinancialInstitutionsUsedForCashDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8b4eb448-3f0c-4dae-ae98-7d725f9058fa_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7135bfdb-8896-4e87-bdfe-35f24df93689_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e8b37613-0447-4a4d-b77b-8d8fae43a596_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_263ad974-df70-4f37-9d80-83c11bad5353_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2f7047ef-6594-4338-828d-67d837b02184_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_A2017InducementEquityIncentivePlanMember_5f0358b9-ca5d-4193-9adf-b901cef15799_terseLabel_en-US" xlink:label="lab_vtl_A2017InducementEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Inducement Equity Incentive Plan</link:label>
    <link:label id="lab_vtl_A2017InducementEquityIncentivePlanMember_label_en-US" xlink:label="lab_vtl_A2017InducementEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Inducement Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_vtl_A2017InducementEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_vtl_A2017InducementEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 Inducement Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2017InducementEquityIncentivePlanMember" xlink:href="vtl-20230630.xsd#vtl_A2017InducementEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_A2017InducementEquityIncentivePlanMember" xlink:to="lab_vtl_A2017InducementEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_ce1611ee-17b9-42bb-b9e3-9b45f50f287a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_98a57467-f32b-480c-9b0f-ec080bd9bafc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8f8655d6-755c-4a2b-bcb1-7ca0a90ea6a4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_e669cce4-6b24-4434-8163-a3cc7f995d20_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_619f709b-0ad4-4b8c-abad-e88869f6db2e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of the stock, at discount from market price at purchase date (as a percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ab9f74df-33f3-4a8e-9608-9cb144e56cf4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0a95fe9d-7c58-4c0b-89ea-390c082fc3b6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f4c3112e-3bbd-453e-93a9-5daa07250c5c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, ending balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_087395ce-fb59-428a-aec3-7c9f87a605d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_06d52cb7-f962-41ff-9d08-e67435d2395b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_PlaneggGermanyMember_36317d94-4094-4e7d-90c8-ef88bd91bc6f_terseLabel_en-US" xlink:label="lab_vtl_PlaneggGermanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Planegg, Germany</link:label>
    <link:label id="lab_vtl_PlaneggGermanyMember_label_en-US" xlink:label="lab_vtl_PlaneggGermanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Planegg, Germany [Member]</link:label>
    <link:label id="lab_vtl_PlaneggGermanyMember_documentation_en-US" xlink:label="lab_vtl_PlaneggGermanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Planegg, Germany</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PlaneggGermanyMember" xlink:href="vtl-20230630.xsd#vtl_PlaneggGermanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_PlaneggGermanyMember" xlink:to="lab_vtl_PlaneggGermanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_53556560-252c-466d-b81e-5a21f2c5bd92_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_GrafelfingGermanyMember_7254e9b1-ed98-4471-a909-27213dada165_terseLabel_en-US" xlink:label="lab_vtl_GrafelfingGermanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grafelfing, Germany</link:label>
    <link:label id="lab_vtl_GrafelfingGermanyMember_label_en-US" xlink:label="lab_vtl_GrafelfingGermanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grafelfing, Germany [Member]</link:label>
    <link:label id="lab_vtl_GrafelfingGermanyMember_documentation_en-US" xlink:label="lab_vtl_GrafelfingGermanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grafelfing, Germany</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GrafelfingGermanyMember" xlink:href="vtl-20230630.xsd#vtl_GrafelfingGermanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_GrafelfingGermanyMember" xlink:to="lab_vtl_GrafelfingGermanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_52a0678a-2433-48ae-af4e-b28e1c755e49_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_ef896c85-e79f-41ec-a1e2-a6c73dc06cbc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_94f9af4b-c64c-4185-b7cb-22a037a43cff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_92b73f02-0f6a-4452-ae2c-95b76989985b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_46a78667-0eb6-431d-9855-9159ef164bbc_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_57e8bfa8-5da3-4f20-9cae-c216b86ce453_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_0ecfa7cb-677c-4059-9f47-b66847250361_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_7b0be860-80ce-4437-b6f2-4ac6ba55262d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_486b221a-e6e4-4f02-8cea-2e351f569dbf_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_caf53e20-f0f0-4bf9-aeb9-8b669d59303c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_a726feea-0971-456c-ad7f-1f8b093fad01_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_795c1378-2bad-4c86-bb50-bba26ffb9aee_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_0d929e7c-c58f-481c-b4af-335f850f5b31_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_70734bce-2820-42d8-ad5f-e290ed7a15d4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_2a20ec64-37bb-4053-ad76-80da29a49adf_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term (in months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_ddeb0c50-0538-428f-a6bb-b619d32ae08e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_a1d649f4-19b0-42ff-b6f8-7bf518187317_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_4a4e0f38-f870-4b7e-9334-e41a0f4b1ace_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_e670ea21-624d-47c4-ba93-1bb738a57d6f_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_363d0598-206a-4d4d-9b29-30905b20ff4a_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_GovernmentAssistanceRate_d2a66a43-afbd-4985-9815-706c0f04709c_terseLabel_en-US" xlink:label="lab_vtl_GovernmentAssistanceRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government assistance rate</link:label>
    <link:label id="lab_vtl_GovernmentAssistanceRate_label_en-US" xlink:label="lab_vtl_GovernmentAssistanceRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance Rate</link:label>
    <link:label id="lab_vtl_GovernmentAssistanceRate_documentation_en-US" xlink:label="lab_vtl_GovernmentAssistanceRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GovernmentAssistanceRate" xlink:href="vtl-20230630.xsd#vtl_GovernmentAssistanceRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_GovernmentAssistanceRate" xlink:to="lab_vtl_GovernmentAssistanceRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_1d647fa3-4d9e-4843-9dd0-833142a59e16_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized foreign currency loss</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3e91c700-6ef3-466b-bd0e-3b04fa0cc8c6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_057ab3e5-8321-4629-95f5-dbb31ee67746_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_812f8831-f7c7-49d2-9eec-4f12ee2de1aa_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_4a9a2754-5d01-43fe-a01b-48df1dbab21d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, cash dividends paid (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_024e5883-0610-4ea6-bbb0-983c9d4fe9c6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, cash dividends declared (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_439ee57d-dfce-4d32-95df-0538570222be_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_f3d51d53-a396-46a6-a35c-767e2d342204_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_aff72cd6-9df4-4d6b-b69d-8b6e33a4a4d0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_671f628e-32ab-4406-b21e-a4f63c4ee06f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_c7b718a2-f64d-4686-b4d5-d7c6fcc29117_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_7bfe9090-41fa-4c49-9dca-f27a51f77d59_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_e260bc26-2b8d-4b4f-9d05-04f92b84448f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_6f84a872-b33f-4774-9d2c-c433b5821451_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c59cded4-f11c-4b6d-b1a5-c40a5beb41a6_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_b48cfc3f-f463-4ddf-9b95-477c05fa996d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_b4ca17b2-483d-47ed-961e-2a9652927189_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock_ba50ebc3-c7ae-434d-b1ee-983e373817ea_terseLabel_en-US" xlink:label="lab_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments- other</link:label>
    <link:label id="lab_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock_label_en-US" xlink:label="lab_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents And Other Investments [Policy Text Block]</link:label>
    <link:label id="lab_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock_documentation_en-US" xlink:label="lab_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents And Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" xlink:href="vtl-20230630.xsd#vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" xlink:to="lab_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_AccruedLegalAndAuditCostsCurrent_c44cf49f-35b5-4eca-8c23-7af79e6133c3_terseLabel_en-US" xlink:label="lab_vtl_AccruedLegalAndAuditCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued legal and audit costs</link:label>
    <link:label id="lab_vtl_AccruedLegalAndAuditCostsCurrent_label_en-US" xlink:label="lab_vtl_AccruedLegalAndAuditCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Legal And Audit Costs, Current</link:label>
    <link:label id="lab_vtl_AccruedLegalAndAuditCostsCurrent_documentation_en-US" xlink:label="lab_vtl_AccruedLegalAndAuditCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Legal And Audit Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedLegalAndAuditCostsCurrent" xlink:href="vtl-20230630.xsd#vtl_AccruedLegalAndAuditCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_AccruedLegalAndAuditCostsCurrent" xlink:to="lab_vtl_AccruedLegalAndAuditCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember_2f59f8bb-025c-4a3b-9bae-ed6ef2b105f0_terseLabel_en-US" xlink:label="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Equity Incentive Plan</link:label>
    <link:label id="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember_label_en-US" xlink:label="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Fourteen Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Fourteen Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:href="vtl-20230630.xsd#vtl_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:to="lab_vtl_TwoThousandFourteenEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_92d48c2f-3cb8-47d2-bbc8-90b1a1fca8b2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-based Compensation Expense for Stock Awards Recognized</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_6e6982a0-e478-49a4-9f5e-9532538f7852_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_December2020ATMMember_d8fd086d-9837-4dbb-aa57-303d1b629e8f_terseLabel_en-US" xlink:label="lab_vtl_December2020ATMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2020 ATM</link:label>
    <link:label id="lab_vtl_December2020ATMMember_label_en-US" xlink:label="lab_vtl_December2020ATMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2020 ATM [Member]</link:label>
    <link:label id="lab_vtl_December2020ATMMember_documentation_en-US" xlink:label="lab_vtl_December2020ATMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 2020 ATM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_December2020ATMMember" xlink:href="vtl-20230630.xsd#vtl_December2020ATMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_December2020ATMMember" xlink:to="lab_vtl_December2020ATMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent_559d0586-2d96-4fb2-a74e-14f6b4d4f58a_terseLabel_en-US" xlink:label="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid clinical and related costs</link:label>
    <link:label id="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent_label_en-US" xlink:label="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Clinical And Related Costs, Current</link:label>
    <link:label id="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent_documentation_en-US" xlink:label="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Clinical And Related Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:href="vtl-20230630.xsd#vtl_PrepaidClinicalAndRelatedCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:to="lab_vtl_PrepaidClinicalAndRelatedCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_1ac580ac-6ae5-46f6-80e8-220b3c50c723_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_a7e66150-9ffb-4482-8538-e7d7d4194a7f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1bb542ac-dd23-4b6a-ac39-719809f4eb39_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Operating Lease Obligation</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0a075e93-0481-4713-943b-295518fb833e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_7ab8f08d-a1d3-4d48-8f93-3ef57aba4f97_terseLabel_en-US" xlink:label="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Reserved for Future Issuance</link:label>
    <link:label id="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_label_en-US" xlink:label="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</link:label>
    <link:label id="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_documentation_en-US" xlink:label="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:href="vtl-20230630.xsd#vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:to="lab_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_ea1540ea-d186-4cb4-9ee6-2267baa9e999_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_b8033f39-619f-4c92-8f48-2cc6aceaaf06_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_f46f4c95-6187-4c74-9616-b4b791234b37_terseLabel_en-US" xlink:label="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares authorized (as a percent)</link:label>
    <link:label id="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_label_en-US" xlink:label="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent</link:label>
    <link:label id="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_documentation_en-US" xlink:label="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:href="vtl-20230630.xsd#vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:to="lab_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_c783c2e9-953a-4b0f-9824-0258645b57e2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in connection with the Company's Employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_cb045c9a-4be1-4221-8460-ea393a2ff036_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_bc45a293-2a5d-4e35-ba02-97b86bb98347_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_25d21897-a9fa-4084-b543-54a52b145c05_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_d8ce1d37-e417-4076-9687-e716ebef3514_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_5e9a4b49-c8fd-4a3d-97a7-e3c6e1bc153f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6ed4e024-428e-4c57-8d66-afb74ca07e20_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare_5900c781-4a74-4a39-88fe-e6ed78f20fee_terseLabel_en-US" xlink:label="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">common stock at a weighted average price (in dollar per share)</link:label>
    <link:label id="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare_label_en-US" xlink:label="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Weighted Average Share Price Per Share</link:label>
    <link:label id="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare_documentation_en-US" xlink:label="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Weighted Average Share Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SharesIssuedWeightedAverageSharePricePerShare" xlink:href="vtl-20230630.xsd#vtl_SharesIssuedWeightedAverageSharePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_SharesIssuedWeightedAverageSharePricePerShare" xlink:to="lab_vtl_SharesIssuedWeightedAverageSharePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_e76c9535-6770-4bc5-99c4-5bf9f27a46bc_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod_f009f4e1-ed2a-41ed-ac94-d4bfc51768c9_terseLabel_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, extended rent holiday period</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod_label_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Extension of Lease, Rent Holiday Period</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod_documentation_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Extension of Lease, Rent Holiday Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" xlink:href="vtl-20230630.xsd#vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" xlink:to="lab_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_52935b55-af56-4c8f-b743-65643a79ea5c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_d478452e-56cf-4a7c-b1be-0595a20f517f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_AccruedCompensationCurrent_d3e6acdc-70ec-4baa-9189-a844ed7a24cb_terseLabel_en-US" xlink:label="lab_vtl_AccruedCompensationCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_vtl_AccruedCompensationCurrent_label_en-US" xlink:label="lab_vtl_AccruedCompensationCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Compensation, Current</link:label>
    <link:label id="lab_vtl_AccruedCompensationCurrent_documentation_en-US" xlink:label="lab_vtl_AccruedCompensationCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Compensation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedCompensationCurrent" xlink:href="vtl-20230630.xsd#vtl_AccruedCompensationCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_AccruedCompensationCurrent" xlink:to="lab_vtl_AccruedCompensationCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_2b765bd3-bb87-4c5f-9406-70826dccd535_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_349b67bd-9b8a-4f22-be2e-71c561a3c77e_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_NewYorkCityMember_b280dbe1-100b-4e74-acab-9875f2cd8a53_terseLabel_en-US" xlink:label="lab_vtl_NewYorkCityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York City</link:label>
    <link:label id="lab_vtl_NewYorkCityMember_label_en-US" xlink:label="lab_vtl_NewYorkCityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York City [Member]</link:label>
    <link:label id="lab_vtl_NewYorkCityMember_documentation_en-US" xlink:label="lab_vtl_NewYorkCityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York City</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NewYorkCityMember" xlink:href="vtl-20230630.xsd#vtl_NewYorkCityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_NewYorkCityMember" xlink:to="lab_vtl_NewYorkCityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_4a0198d2-d7a8-4325-964c-2f244c30a171_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c21c89f4-2839-4dfe-96a8-a504172a0a4f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock ( in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_78c46de2-319c-4627-a623-1beae7435f67_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3e9c3c0d-0a35-4017-b3c9-b198fbebe5c0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_14186171-1463-4819-b71c-d18243a8c771_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_8f9d962f-197f-4e16-b154-09a0994ea984_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_5e122a1c-f99a-444a-80e4-369ab2838feb_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_f5c00b01-fa82-4847-9d04-4593668f6553_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Details</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_66376fe3-434f-4342-91b8-fd788a2875af_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_cc3f2108-5407-4dad-a846-4a53805052ef_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of noncash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_6f289376-db3d-4b10-87fb-83b0c8ee4ffc_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5789bedd-5c20-4cf9-b308-b8eb767f03f9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_5ec7a874-8e0d-410d-8fd2-a3121c5a6241_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_ef403dc6-3ef2-4db4-8929-f9c1fb8ab40a_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_751155b2-882e-45bc-bd25-edb85fd542dd_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, weighted-average remaining contractual term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_842f899a-120d-4fd4-b7d5-20e64c368da5_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of use asset obtained in exchange for lease obligation</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_205636f4-fc9a-46c7-9f8a-01d723db23ec_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_a0dc3aea-5eea-4079-8267-99f733dfc17f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_62f270a1-aa70-4a3b-9135-113da6b19755_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_e6d32c6e-cffc-4d36-a01b-51472d583118_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_70b06bf3-59ee-4181-a072-588a0878e3a9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_b94a46ee-02c8-4113-a4b7-3c14d1606331_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableOtherCurrent_bda34f48-cc34-4df6-96e2-9f6329ca28f4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_AccountsPayableOtherCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Other, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableOtherCurrent" xlink:to="lab_us-gaap_AccountsPayableOtherCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_d9519b71-cdbc-4315-ad54-19860c531c05_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_a5b9fd35-a550-44a6-a958-2c1a069f8f63_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_76978eda-ba18-423c-b4c7-5b9b1568c59b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_880f05eb-246d-4c99-b628-2f32ca1c9363_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6c688ea2-7199-4175-bf1b-b4cc5c19422f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistancePolicyTextBlock_5faacb38-5f32-4b0b-bdbe-2288aabd0c10_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government assistance</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistancePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:to="lab_us-gaap_GovernmentAssistancePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_6c7334d7-dd18-46e7-97cb-42e1a6678d4d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in connection with the Company's employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_9d52525d-478f-4935-a891-23eaf188b160_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9141a427-95a3-435d-9cf5-2936ecab3850_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_3813f294-e2b1-4ad7-9629-c612733578e1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_40026b28-4063-4b25-9d42-bbb63b03d3b9_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Issued and/or Adopted Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_bfcfd156-c3b3-493b-b588-f54a11bb94e2_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_country_AU_6bd0ce4f-158a-4d17-9eb5-3617c4036b7b_terseLabel_en-US" xlink:label="lab_country_AU" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australia</link:label>
    <link:label id="lab_country_AU_label_en-US" xlink:label="lab_country_AU" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AUSTRALIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_AU" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AU"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_AU" xlink:to="lab_country_AU" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_59a94ca2-12c7-4968-b405-aee5ed90e50c_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_35903229-4062-4806-acbf-8009ca540d07_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_ccad5623-9060-4b20-ac74-ba913eb65e77_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentInterestRate_e934f257-e66e-4ede-b926-b3d5795e691b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment interest rate</link:label>
    <link:label id="lab_us-gaap_InvestmentInterestRate_label_en-US" xlink:label="lab_us-gaap_InvestmentInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentInterestRate" xlink:to="lab_us-gaap_InvestmentInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_14e8b174-9d94-429d-bd41-03da0352342d_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_918cfcf6-39bd-4ed4-b1d8-498ee496edcb_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2c1ddf2f-7252-4fa3-8a6f-61c77073a7fc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_da3e4876-695c-4be1-b816-831c11da268e_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in private placement transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_0ea2e901-809a-4d42-86aa-c933cb860317_terseLabel_en-US" xlink:label="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission, percent of gross proceeds from sale of common stock</link:label>
    <link:label id="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_label_en-US" xlink:label="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock</link:label>
    <link:label id="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_documentation_en-US" xlink:label="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:href="vtl-20230630.xsd#vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:to="lab_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_OperatingAndVariableLeasesCost_412f18da-0b29-47b3-bb90-a2f538fffdbf_terseLabel_en-US" xlink:label="lab_vtl_OperatingAndVariableLeasesCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating and variable lease costs</link:label>
    <link:label id="lab_vtl_OperatingAndVariableLeasesCost_label_en-US" xlink:label="lab_vtl_OperatingAndVariableLeasesCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Variable Leases, Cost</link:label>
    <link:label id="lab_vtl_OperatingAndVariableLeasesCost_documentation_en-US" xlink:label="lab_vtl_OperatingAndVariableLeasesCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Variable Leases, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingAndVariableLeasesCost" xlink:href="vtl-20230630.xsd#vtl_OperatingAndVariableLeasesCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_OperatingAndVariableLeasesCost" xlink:to="lab_vtl_OperatingAndVariableLeasesCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_158d91e1-8bc3-46d8-a7dc-bf31cc4dfc21_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_8c9792b7-6cbe-4bc8-b22b-3135cfd9c19c_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_d5ab88a0-e2a0-447f-ba28-929dae502bd1_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_c4be8550-4d8c-4e7b-a53b-404c50f954f4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_12a56cd8-53b3-4722-9d13-c66998209e89_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_bd6d504d-9dd2-4b64-8fd3-4210ac6857cb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Assumptions Used</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_5c38b387-77a9-4047-b4da-eb8619fdeaa7_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_465427c7-ae68-4e09-aa9d-da7e2288f6b1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_672f3745-36b4-455b-986a-3aa1f68e3d3e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_9b4393bd-47e0-4a47-9987-263af55c7c91_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_376e6cfa-4681-4f41-ba29-b79f2b10f567_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f3d203bc-a7fb-4bd8-ad6a-532cbdb63902_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_2e7b3654-3000-4601-8133-ef1c01c8830e_terseLabel_en-US" xlink:label="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australian research and development tax incentive</link:label>
    <link:label id="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_label_en-US" xlink:label="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Incentive, Current</link:label>
    <link:label id="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_documentation_en-US" xlink:label="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Development Tax Incentive, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:href="vtl-20230630.xsd#vtl_ResearchAndDevelopmentTaxIncentiveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:to="lab_vtl_ResearchAndDevelopmentTaxIncentiveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ShelfRegistrationStatementAmountRemaining_dd021c81-60a5-425a-9eb1-e7b8dafdc0a9_terseLabel_en-US" xlink:label="lab_vtl_ShelfRegistrationStatementAmountRemaining" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf registration statement, amount remaining</link:label>
    <link:label id="lab_vtl_ShelfRegistrationStatementAmountRemaining_label_en-US" xlink:label="lab_vtl_ShelfRegistrationStatementAmountRemaining" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Statement, Amount Remaining</link:label>
    <link:label id="lab_vtl_ShelfRegistrationStatementAmountRemaining_documentation_en-US" xlink:label="lab_vtl_ShelfRegistrationStatementAmountRemaining" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration Statement, Amount Remaining</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationStatementAmountRemaining" xlink:href="vtl-20230630.xsd#vtl_ShelfRegistrationStatementAmountRemaining"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ShelfRegistrationStatementAmountRemaining" xlink:to="lab_vtl_ShelfRegistrationStatementAmountRemaining" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_902b5d4e-0b45-4284-b786-7dcdf6a855e4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_EmployeeStockOptionsforFutureGrantMember_6c81d766-a766-4f2a-b661-f2c6818d6033_terseLabel_en-US" xlink:label="lab_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options available for future grant:</link:label>
    <link:label id="lab_vtl_EmployeeStockOptionsforFutureGrantMember_label_en-US" xlink:label="lab_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options for Future Grant [Member]</link:label>
    <link:label id="lab_vtl_EmployeeStockOptionsforFutureGrantMember_documentation_en-US" xlink:label="lab_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options for Future Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:href="vtl-20230630.xsd#vtl_EmployeeStockOptionsforFutureGrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:to="lab_vtl_EmployeeStockOptionsforFutureGrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_96318222-3350-4ff8-b0a6-f71e8bcd6030_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_fdd2b2a3-34ab-4101-aa44-4ce64551284b_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_70dcf677-4763-407f-ba2e-d23b1b12987c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_7bd9e2d6-5c72-40f0-bdf1-5e39ce26445d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_575a6c45-373c-4455-94c0-9adb62068c2f_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3186ca24-be9b-4da0-8f09-5f1e93d377d5_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_eb1b0646-308a-4920-acb6-d7b4317be95f_terseLabel_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan</link:label>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_label_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Omnibus Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Omnibus Equity Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:href="vtl-20230630.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:to="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_AccruedClinicalCostsCurrent_d1657895-a0a6-42da-80a5-5ade87ee40ff_terseLabel_en-US" xlink:label="lab_vtl_AccruedClinicalCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical and related costs</link:label>
    <link:label id="lab_vtl_AccruedClinicalCostsCurrent_label_en-US" xlink:label="lab_vtl_AccruedClinicalCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Costs, Current</link:label>
    <link:label id="lab_vtl_AccruedClinicalCostsCurrent_documentation_en-US" xlink:label="lab_vtl_AccruedClinicalCostsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Costs, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedClinicalCostsCurrent" xlink:href="vtl-20230630.xsd#vtl_AccruedClinicalCostsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_AccruedClinicalCostsCurrent" xlink:to="lab_vtl_AccruedClinicalCostsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7721c8f9-690f-4756-961e-21a3ac4cf89b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period over which compensation cost will be recognized, in years</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_99130c1a-4490-4910-add8-c5eee187bcb5_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_bf5f40a4-368f-40fb-8980-06df4eabb43a_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice_5016fc5e-1f60-4859-8d7e-1cd977a18a9e_terseLabel_en-US" xlink:label="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf registration, termination, prior written notice</link:label>
    <link:label id="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice_label_en-US" xlink:label="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration, Termination, Prior Written Notice</link:label>
    <link:label id="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice_documentation_en-US" xlink:label="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shelf Registration, Termination, Prior Written Notice</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationTerminationPriorWrittenNotice" xlink:href="vtl-20230630.xsd#vtl_ShelfRegistrationTerminationPriorWrittenNotice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_ShelfRegistrationTerminationPriorWrittenNotice" xlink:to="lab_vtl_ShelfRegistrationTerminationPriorWrittenNotice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_ee6b61b7-c33c-40a0-a77f-599aa5aa71d2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_d1e2c825-f144-4bcc-a557-f1e467a12eb8_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_2b89b3d1-2bf3-4c2f-ad46-6f867a451021_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6d35c5fb-54e1-41e2-b40d-843e19a54f8e_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_30af4ca9-ceb5-43a2-b25b-a66589b19de6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_333b320d-e64a-4a3b-b8f6-5d30453e2752_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_c2bcf299-cac9-4b7d-b507-3e98540e3116_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_bfa1a68f-8522-4417-a400-19b993bce76e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_90f46e4a-2fa2-4521-a197-55ab20596ad3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_55e05c65-1f1d-49f3-ac8e-336abc68e62c_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0052363e-1478-49e0-ac0f-e7d6a2de1f81_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Consolidation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_0887d036-851e-4d57-8fb7-ef0a98303bb8_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e1da5c82-8876-4473-bbf7-ba4193710511_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_25d9680f-d250-4e60-8256-2c4aa34b3da5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3eb33131-518d-4c5c-8d62-2a81976196e8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, Weighted-Average Exercise Price, Ending balance (usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_NumberOfDevelopmentPrograms_49294c67-c41f-4057-ba51-9eabbde137bd_terseLabel_en-US" xlink:label="lab_vtl_NumberOfDevelopmentPrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of development programs</link:label>
    <link:label id="lab_vtl_NumberOfDevelopmentPrograms_label_en-US" xlink:label="lab_vtl_NumberOfDevelopmentPrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Development Programs</link:label>
    <link:label id="lab_vtl_NumberOfDevelopmentPrograms_documentation_en-US" xlink:label="lab_vtl_NumberOfDevelopmentPrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Development Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfDevelopmentPrograms" xlink:href="vtl-20230630.xsd#vtl_NumberOfDevelopmentPrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_NumberOfDevelopmentPrograms" xlink:to="lab_vtl_NumberOfDevelopmentPrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_50e1b708-f7a1-4e19-95cc-780b36903e5b_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_cb30f24d-8dda-4c2c-8f23-1bc0db62917c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_8e96c082-8081-4446-a037-4db69e9aab17_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_297330f7-a058-4ebf-91d2-6e320eb0b206_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_63879fb5-4899-4b0d-b287-73ccd9cd9f65_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_a123a22a-6479-4ad6-90d7-fbb6171e7d7d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8bf7f3bb-9941-446e-a842-e3c7e01556c3_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in connection with the Company's stock option plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_84935ec1-72a7-44fc-83cb-6625578316be_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_1b306a7d-9290-42c0-a677-42548ad0e4fa_terseLabel_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VAT receivable</link:label>
    <link:label id="lab_us-gaap_ValueAddedTaxReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value Added Tax Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValueAddedTaxReceivableCurrent" xlink:to="lab_us-gaap_ValueAddedTaxReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_8c3ff981-a049-4744-90b5-a565401489a2_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_NonStatutoryEmployeeStockOptionMember_9f7b9aef-38e0-4240-8f84-377f7b596c08_terseLabel_en-US" xlink:label="lab_vtl_NonStatutoryEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-statutory options</link:label>
    <link:label id="lab_vtl_NonStatutoryEmployeeStockOptionMember_label_en-US" xlink:label="lab_vtl_NonStatutoryEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Statutory Employee Stock Option [Member]</link:label>
    <link:label id="lab_vtl_NonStatutoryEmployeeStockOptionMember_documentation_en-US" xlink:label="lab_vtl_NonStatutoryEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Statutory Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NonStatutoryEmployeeStockOptionMember" xlink:href="vtl-20230630.xsd#vtl_NonStatutoryEmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_NonStatutoryEmployeeStockOptionMember" xlink:to="lab_vtl_NonStatutoryEmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_b61bacae-7fb7-4819-b1ae-44e85d889f00_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_9657a6c0-5513-44ba-896d-95b796373651_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_719e6f1c-30de-4d4f-b10e-ad07ad4745fa_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="lab_us-gaap_StockholdersEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_f96310a7-0c67-4c42-b1bf-c2bdc1790ba2_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in connection with the Company's stock option plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_c1ad6ba2-dc18-49a8-88d7-37cf2a3a339b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_7b145a43-7776-4b4a-92a1-75110dbe8d25_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_1e3d2966-219b-42f5-a88c-c9c0a81e09fa_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_e815feee-d5fb-4695-b7ce-64d2b3950bf7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_3d7208ab-785e-40dc-9b2a-a5e85ee5f199_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_16736a8e-cb78-4734-9de6-805d3f642f86_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistanceAmount_92d4d966-3e5e-4a5e-923f-bc0ce54c7c09_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government assistance, amount</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistanceAmount_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceAmount" xlink:to="lab_us-gaap_GovernmentAssistanceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_15e2e813-df30-46e8-8e63-3c97c689bdaf_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_A2021EmployeeStockPurchasePlanMember_8304beb4-0110-48f2-9859-1fad7d31901f_terseLabel_en-US" xlink:label="lab_vtl_A2021EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_vtl_A2021EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_vtl_A2021EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_vtl_A2021EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_vtl_A2021EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2021EmployeeStockPurchasePlanMember" xlink:href="vtl-20230630.xsd#vtl_A2021EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_A2021EmployeeStockPurchasePlanMember" xlink:to="lab_vtl_A2021EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_64f14980-6a4c-4edd-8398-f9eebdcfd4ea_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_37471cfb-51b5-4d10-91f6-668c369aa737_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_608d5872-bcf8-463f-b573-851e9df19545_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_AustraliaAndGermanyMember_e71fd19d-00d6-443a-97f2-f88af2d75c53_terseLabel_en-US" xlink:label="lab_vtl_AustraliaAndGermanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australia and Germany</link:label>
    <link:label id="lab_vtl_AustraliaAndGermanyMember_label_en-US" xlink:label="lab_vtl_AustraliaAndGermanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australia and Germany [Member]</link:label>
    <link:label id="lab_vtl_AustraliaAndGermanyMember_documentation_en-US" xlink:label="lab_vtl_AustraliaAndGermanyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Australia and Germany</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AustraliaAndGermanyMember" xlink:href="vtl-20230630.xsd#vtl_AustraliaAndGermanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_AustraliaAndGermanyMember" xlink:to="lab_vtl_AustraliaAndGermanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_IncentiveEmployeeStockOptionMember_772e23f3-aed2-4687-a3f2-8e3533a935c2_terseLabel_en-US" xlink:label="lab_vtl_IncentiveEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive stock options</link:label>
    <link:label id="lab_vtl_IncentiveEmployeeStockOptionMember_label_en-US" xlink:label="lab_vtl_IncentiveEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Employee Stock Option [Member]</link:label>
    <link:label id="lab_vtl_IncentiveEmployeeStockOptionMember_documentation_en-US" xlink:label="lab_vtl_IncentiveEmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncentiveEmployeeStockOptionMember" xlink:href="vtl-20230630.xsd#vtl_IncentiveEmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_IncentiveEmployeeStockOptionMember" xlink:to="lab_vtl_IncentiveEmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_LesseeOperatingLeaseLiabilityPaymentsAfterDueYearFour_364314ff-eea4-4101-8909-c78101e46744_terseLabel_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseLiabilityPaymentsAfterDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeaseLiabilityPaymentsAfterDueYearFour_label_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseLiabilityPaymentsAfterDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee &#8203;Operating&#8203; Lease &#8203;Liability &#8203;Payments After &#8203;Due &#8203;Year &#8203;Four</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeaseLiabilityPaymentsAfterDueYearFour_documentation_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseLiabilityPaymentsAfterDueYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee &#8203;Operating&#8203; Lease &#8203;Liability &#8203;Payments After &#8203;Due &#8203;Year &#8203;Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseLiabilityPaymentsAfterDueYearFour" xlink:href="vtl-20230630.xsd#vtl_LesseeOperatingLeaseLiabilityPaymentsAfterDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_LesseeOperatingLeaseLiabilityPaymentsAfterDueYearFour" xlink:to="lab_vtl_LesseeOperatingLeaseLiabilityPaymentsAfterDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_f73edf5d-608d-4d21-b246-6b5daee60776_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_7562d337-309e-461b-8aad-dea1f2300f03_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of private placement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_73ab5365-cad5-444a-81c2-2dd3d2feadab_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_DuaneNashMDJDMBAMember_b09a7be8-322e-45ad-893f-22c243c132da_terseLabel_en-US" xlink:label="lab_vtl_DuaneNashMDJDMBAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duane Nash, MD, JD, MBA</link:label>
    <link:label id="lab_vtl_DuaneNashMDJDMBAMember_label_en-US" xlink:label="lab_vtl_DuaneNashMDJDMBAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duane Nash, MD, JD, MBA [Member]</link:label>
    <link:label id="lab_vtl_DuaneNashMDJDMBAMember_documentation_en-US" xlink:label="lab_vtl_DuaneNashMDJDMBAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duane Nash, MD, JD, MBA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_DuaneNashMDJDMBAMember" xlink:href="vtl-20230630.xsd#vtl_DuaneNashMDJDMBAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_DuaneNashMDJDMBAMember" xlink:to="lab_vtl_DuaneNashMDJDMBAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_c725789e-c98f-4a53-82e4-39c28079d253_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_4888cb44-bf61-4ebe-a5a8-0fb6777db041_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_04814194-b4f8-4c50-b92c-f4b91c259517_terseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Deposits</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_7c20313a-59d8-4398-a8b8-de1f5d646938_verboseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Deposits</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_label_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank Time Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BankTimeDepositsMember" xlink:to="lab_us-gaap_BankTimeDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfOtherInvestments_6d70eb71-1f17-4f35-9a3b-c09819b0a1e7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of investments - other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_a1ae8574-ba0a-4651-906f-4d1d1eef0c06_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful life (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_e1a059f2-3cc0-4d2e-a0e6-cda06f2ac237_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_05f771cd-3c9f-4393-af38-b56725ac12a4_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_912698a7-3397-44b9-b130-c3273332c8cf_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_PreFundedWarrantsMember_a7bc8ae8-910a-4141-a175-555e3d4fbdc3_terseLabel_en-US" xlink:label="lab_vtl_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:label id="lab_vtl_PreFundedWarrantsMember_label_en-US" xlink:label="lab_vtl_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrants [Member]</link:label>
    <link:label id="lab_vtl_PreFundedWarrantsMember_documentation_en-US" xlink:label="lab_vtl_PreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-Funded Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PreFundedWarrantsMember" xlink:href="vtl-20230630.xsd#vtl_PreFundedWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_PreFundedWarrantsMember" xlink:to="lab_vtl_PreFundedWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ab9a38f2-203a-495b-aa97-7dd332220f4e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38973955-4a07-4eff-ab64-ad937c22c5a5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_ca082180-e18a-4da1-8051-ab866c868a5a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_ec9b64af-50ec-4e4a-bebf-5b8bfcf66bac_terseLabel_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of Directors Chairman</link:label>
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_label_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of Directors Chairman [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_BoardOfDirectorsChairmanMember" xlink:to="lab_srt_BoardOfDirectorsChairmanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_SaleOfStockRemainingCapacity_e20d35b9-8acd-4310-b88e-4db5b980ac54_terseLabel_en-US" xlink:label="lab_vtl_SaleOfStockRemainingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, remaining capacity</link:label>
    <link:label id="lab_vtl_SaleOfStockRemainingCapacity_label_en-US" xlink:label="lab_vtl_SaleOfStockRemainingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Remaining Capacity</link:label>
    <link:label id="lab_vtl_SaleOfStockRemainingCapacity_documentation_en-US" xlink:label="lab_vtl_SaleOfStockRemainingCapacity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Remaining Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SaleOfStockRemainingCapacity" xlink:href="vtl-20230630.xsd#vtl_SaleOfStockRemainingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_SaleOfStockRemainingCapacity" xlink:to="lab_vtl_SaleOfStockRemainingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_69b704fc-fed2-406b-aaf1-1cfae46343a3_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c04e5bba-57a5-4f82-ae37-2825f3936c17_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_536915ff-22a3-48c7-92ff-8cbdedbb8a08_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_0c1831be-309c-494e-9a9e-c5b39335e6a8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8a113b62-15e3-4643-bb89-bded37c829e5_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ab6b8bb0-5b4e-4a5d-bd40-32c938686114_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_c5642ac7-dec7-4065-9d65-5d601bae5244_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_539a0da2-406b-4625-86bb-d0e70720924a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_3a08173d-caba-41ea-bedd-c2ed683748ab_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_428f7acb-dbc5-473d-ac0b-fdc185773685_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_6694b1fb-28e4-4ee8-ab18-55803a934c01_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_e6db7e0a-67a6-4396-8a3a-fc599c40600b_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_05406f08-e860-4939-a465-8919701c76fb_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForCommissions_1444476b-bf4a-42f0-93b6-e271926075f0_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForCommissions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underwriter commissions</link:label>
    <link:label id="lab_us-gaap_PaymentsForCommissions_label_en-US" xlink:label="lab_us-gaap_PaymentsForCommissions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Commissions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCommissions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForCommissions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForCommissions" xlink:to="lab_us-gaap_PaymentsForCommissions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9a3a0a9f-c0da-41c5-b88c-1012ad784ded_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_5657400b-d233-4a2b-9285-c323339ed1f2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_e6462e3c-0da8-4207-95ca-21967e5b5c44_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest , weighted-average remaining contractual term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_a5634525-ef7c-4c5c-a489-d2eb80eb7db1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1d25d87f-476d-421f-84fd-99e27e54d94c_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_368772b0-02c2-470a-b4d6-9d03ed705997_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_44f4a35a-c42d-4213-ac80-e94c2c2fef21_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_cffd0b93-69dd-4b40-92ea-08f93a937b9a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_eb227514-1e31-4a17-8e38-566c258ec806_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d956bdc7-b3e6-4c3c-adf4-ac04823def7b_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_6f987bee-5bb3-4858-8221-1c56deeab2ea_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_ff8c57b8-4454-4f31-880d-34bfedce868a_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited or expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_257aa170-3e02-41e3-9ae6-88de9099682e_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_847298dd-fe7e-4b80-9a46-459f8bfb65ae_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_16cf6f21-72ed-4e01-9f00-da42e2e06276_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_53a1866a-5e30-47d4-a48f-639597930cd8_terseLabel_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 Omnibus Equity Incentive Plan, Evergreen Provision</link:label>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_label_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision [Member]</link:label>
    <link:label id="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_documentation_en-US" xlink:label="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:href="vtl-20230630.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:to="lab_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_6f9317cb-0df8-4421-a063-9d4ddcdfca71_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in USD per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_781bf80d-f3a4-422c-9110-e2a27d2c85f1_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum annual contributions per employee (as a percent)</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_bde3b863-fb95-4a0b-8fb7-08bcb24a4860_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_3cff1fed-ddd6-479a-a80e-f9b89caea6ba_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_ff3b8380-c1ae-46d6-8942-a4b1860dd1a5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Renewal option period (in months)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_d2d60bb1-0848-40dc-a7f8-ea5e060bd724_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_LegalAndAuditCostsPayableCurrent_22abbdc0-6624-45b7-87c2-848473c3fb61_terseLabel_en-US" xlink:label="lab_vtl_LegalAndAuditCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal and audit costs</link:label>
    <link:label id="lab_vtl_LegalAndAuditCostsPayableCurrent_label_en-US" xlink:label="lab_vtl_LegalAndAuditCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal And Audit Costs Payable, Current</link:label>
    <link:label id="lab_vtl_LegalAndAuditCostsPayableCurrent_documentation_en-US" xlink:label="lab_vtl_LegalAndAuditCostsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal And Audit Costs Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LegalAndAuditCostsPayableCurrent" xlink:href="vtl-20230630.xsd#vtl_LegalAndAuditCostsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_LegalAndAuditCostsPayableCurrent" xlink:to="lab_vtl_LegalAndAuditCostsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_8b374de6-707d-411f-8b78-742a6f8d5194_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_fac8bd46-ac83-4fd9-bed8-0d8c7e743485_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_31681684-ccf5-4db9-8e26-1989a8b26a58_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual obligation</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_d6f6973d-1eab-49e1-ba37-09ab266be0f0_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_country_DE_93d948e7-ab15-49d4-9888-44ad73904434_terseLabel_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Germany</link:label>
    <link:label id="lab_country_DE_label_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GERMANY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DE" xlink:to="lab_country_DE" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3f60460d-7cff-49a4-ad52-aea60fcfaa3a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_66044089-90c9-4f2b-8e06-06d32bffd100_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_3cf1c089-45d3-4e64-9082-ab2b2d661b8c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PV of obligation</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_5b2fa541-95cd-4960-9bfd-5bef7e7f96c4_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_d2670f34-41bd-46ee-b7fa-8b0c2c1733eb_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_29ec202f-f20c-4762-bda4-72968e42f3b6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_80bead53-8f71-4005-b547-02308225d46d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7c424c36-5ee1-4f2f-b63e-ed5d64fdc3cb_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets and prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_bc2d0aa7-1919-443d-aeaf-8da338f93b42_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_d2817bea-e7ff-4358-9d80-0fee2db0db72_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total common shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_f95840a7-0397-4f8a-86ef-722b14dd72f6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_bba8493c-de09-47d0-8bbc-7ae8e56bcfbe_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_fdac8b3b-0d54-4b16-a0a0-0a9d491924ee_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_NumberOfVotesPerEachShareOfCommonStock_8cb7bf6a-41c9-4ee3-8c18-d7ef0c519375_terseLabel_en-US" xlink:label="lab_vtl_NumberOfVotesPerEachShareOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes per each share of common stock</link:label>
    <link:label id="lab_vtl_NumberOfVotesPerEachShareOfCommonStock_label_en-US" xlink:label="lab_vtl_NumberOfVotesPerEachShareOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Votes Per Each Share of Common Stock</link:label>
    <link:label id="lab_vtl_NumberOfVotesPerEachShareOfCommonStock_documentation_en-US" xlink:label="lab_vtl_NumberOfVotesPerEachShareOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Votes Per Each Share of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfVotesPerEachShareOfCommonStock" xlink:href="vtl-20230630.xsd#vtl_NumberOfVotesPerEachShareOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_NumberOfVotesPerEachShareOfCommonStock" xlink:to="lab_vtl_NumberOfVotesPerEachShareOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_2c03e016-43ac-47ef-b796-e51e5c65cdb2_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_ed79f02e-9bcb-41de-9c30-53c08b7ef238_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_176475db-78c6-43e8-b20b-4a039b425822_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_eb60ce2f-f3de-474e-b402-23902ec1eaf5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued from exercise of pre-funded warrants and issuance of common stock - at the market Sales Agreement net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_385d78d1-94c9-4ccb-9396-acadafbb0975_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_42a2b714-760f-4071-83c4-ed47d77eea4f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_69cd9a21-15d7-47f9-8725-6d103144f199_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest, Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_OperatingLeaseIncrementalBorrowingRate_f8535194-da1d-4acd-82b2-2607f8d9f4e9_terseLabel_en-US" xlink:label="lab_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental borrowing rate on operating leases</link:label>
    <link:label id="lab_vtl_OperatingLeaseIncrementalBorrowingRate_label_en-US" xlink:label="lab_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Incremental Borrowing Rate</link:label>
    <link:label id="lab_vtl_OperatingLeaseIncrementalBorrowingRate_documentation_en-US" xlink:label="lab_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Incremental Borrowing Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:href="vtl-20230630.xsd#vtl_OperatingLeaseIncrementalBorrowingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:to="lab_vtl_OperatingLeaseIncrementalBorrowingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_SalaryCostsMonthlyBaseSalary_094e13b1-4344-4660-9a96-daa0f186737c_terseLabel_en-US" xlink:label="lab_vtl_SalaryCostsMonthlyBaseSalary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly base salary</link:label>
    <link:label id="lab_vtl_SalaryCostsMonthlyBaseSalary_label_en-US" xlink:label="lab_vtl_SalaryCostsMonthlyBaseSalary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salary Costs, Monthly Base Salary</link:label>
    <link:label id="lab_vtl_SalaryCostsMonthlyBaseSalary_documentation_en-US" xlink:label="lab_vtl_SalaryCostsMonthlyBaseSalary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salary Costs, Monthly Base Salary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SalaryCostsMonthlyBaseSalary" xlink:href="vtl-20230630.xsd#vtl_SalaryCostsMonthlyBaseSalary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_SalaryCostsMonthlyBaseSalary" xlink:to="lab_vtl_SalaryCostsMonthlyBaseSalary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_fefc35f7-bca0-4886-a8ca-8f5e946b7d18_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_2da14e65-ad12-4445-b332-735e5f489744_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e32c0128-e388-4078-b8d7-faf096d8ad12_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod_279c698c-9738-408f-adc2-bef1524daaf8_terseLabel_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent holiday period</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod_label_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Beginning of Lease, Rent Holiday Period</link:label>
    <link:label id="lab_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod_documentation_en-US" xlink:label="lab_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Beginning of Lease, Rent Holiday Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" xlink:href="vtl-20230630.xsd#vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" xlink:to="lab_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_f6e26421-f5e4-4c3b-add0-6d9a8f6785e0_terseLabel_en-US" xlink:label="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum aggregate offering price of common stock, preferred stock, warrants, debt securities, and/or units</link:label>
    <link:label id="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_label_en-US" xlink:label="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Aggregate Offering Price Of Securities Under Shelf Registration</link:label>
    <link:label id="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_documentation_en-US" xlink:label="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Aggregate Offering Price Of Securities Under Shelf Registration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:href="vtl-20230630.xsd#vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:to="lab_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_feef8f31-4fc9-45a4-86fb-05d3d670bc52_terseLabel_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_dfc262a1-2cc0-4275-81af-7012fe66145e_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_2d604038-6153-4007-bfc9-30fc0901459c_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 130,000,000 shares authorized and 44,488,371 and 39,307,286 shares issued and outstanding as of June 30, 2023 and December&#160;31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_ff999ef0-8af4-4f9a-8ab9-6e72b850d228_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_89e143b0-e0bf-45df-a475-dfb1016418e0_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>vtl-20230630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:c5b7d08b-4d18-4b53-b740-daba2f6d29fd,g:398611d2-4d63-409b-b481-5daa2ae6bce9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://vitaltherapies.com/role/CoverPage" xlink:type="simple" xlink:href="vtl-20230630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_3a06e414-a9ee-4ae9-baea-578cceb56ea6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_bcebfbd0-f2c1-4296-9387-ffcee838fac3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a06e414-a9ee-4ae9-baea-578cceb56ea6" xlink:to="loc_dei_DocumentType_bcebfbd0-f2c1-4296-9387-ffcee838fac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_c20ffb4b-f295-4052-af25-9313a5c6c682" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a06e414-a9ee-4ae9-baea-578cceb56ea6" xlink:to="loc_dei_DocumentQuarterlyReport_c20ffb4b-f295-4052-af25-9313a5c6c682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_8ae99b77-7b4b-4d1b-bc80-949ff7ca1f8f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a06e414-a9ee-4ae9-baea-578cceb56ea6" xlink:to="loc_dei_DocumentPeriodEndDate_8ae99b77-7b4b-4d1b-bc80-949ff7ca1f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_55b59d11-f9b6-453f-8f1c-14f1993bd24e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a06e414-a9ee-4ae9-baea-578cceb56ea6" xlink:to="loc_dei_DocumentTransitionReport_55b59d11-f9b6-453f-8f1c-14f1993bd24e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_32f375d7-633c-45b5-acde-32dff13841fd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a06e414-a9ee-4ae9-baea-578cceb56ea6" xlink:to="loc_dei_EntityFileNumber_32f375d7-633c-45b5-acde-32dff13841fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b839602c-8f0e-4a88-9d11-591871d770d7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a06e414-a9ee-4ae9-baea-578cceb56ea6" xlink:to="loc_dei_EntityRegistrantName_b839602c-8f0e-4a88-9d11-591871d770d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_3b883492-ba44-4e27-a8d3-2802808a01d5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a06e414-a9ee-4ae9-baea-578cceb56ea6" xlink:to="loc_dei_EntityIncorporationStateCountryCode_3b883492-ba44-4e27-a8d3-2802808a01d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d972cea1-c5c1-4977-abd3-4019ed282475" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a06e414-a9ee-4ae9-baea-578cceb56ea6" xlink:to="loc_dei_EntityTaxIdentificationNumber_d972cea1-c5c1-4977-abd3-4019ed282475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_93b38c1a-3d98-42bc-8372-d571d962cfc2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a06e414-a9ee-4ae9-baea-578cceb56ea6" xlink:to="loc_dei_EntityAddressAddressLine1_93b38c1a-3d98-42bc-8372-d571d962cfc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_d0517a83-31f8-47e1-8522-5ca79ca916ba" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a06e414-a9ee-4ae9-baea-578cceb56ea6" xlink:to="loc_dei_EntityAddressAddressLine2_d0517a83-31f8-47e1-8522-5ca79ca916ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_82ddc3d2-db48-4557-bb0f-06e7b502e1f9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a06e414-a9ee-4ae9-baea-578cceb56ea6" xlink:to="loc_dei_EntityAddressCityOrTown_82ddc3d2-db48-4557-bb0f-06e7b502e1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_a59fe67e-d2f3-43f1-8602-e8dafa39abc6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a06e414-a9ee-4ae9-baea-578cceb56ea6" xlink:to="loc_dei_EntityAddressStateOrProvince_a59fe67e-d2f3-43f1-8602-e8dafa39abc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_beecf84a-d113-4973-a155-31fcdd0f71d2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a06e414-a9ee-4ae9-baea-578cceb56ea6" xlink:to="loc_dei_EntityAddressPostalZipCode_beecf84a-d113-4973-a155-31fcdd0f71d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_24fde033-77c9-49e0-962d-5695ca276d24" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a06e414-a9ee-4ae9-baea-578cceb56ea6" xlink:to="loc_dei_CityAreaCode_24fde033-77c9-49e0-962d-5695ca276d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_a5a90d8c-9f70-4035-9712-c2a2b4b4bd8c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a06e414-a9ee-4ae9-baea-578cceb56ea6" xlink:to="loc_dei_LocalPhoneNumber_a5a90d8c-9f70-4035-9712-c2a2b4b4bd8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_bb2f2e2e-7e11-45d3-8849-4b6ce4bb2b06" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a06e414-a9ee-4ae9-baea-578cceb56ea6" xlink:to="loc_dei_Security12bTitle_bb2f2e2e-7e11-45d3-8849-4b6ce4bb2b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_fc703096-47e9-4718-a29e-c3cac035ae14" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a06e414-a9ee-4ae9-baea-578cceb56ea6" xlink:to="loc_dei_TradingSymbol_fc703096-47e9-4718-a29e-c3cac035ae14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_efd31553-61ec-46ef-b24b-4c2611475c92" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a06e414-a9ee-4ae9-baea-578cceb56ea6" xlink:to="loc_dei_SecurityExchangeName_efd31553-61ec-46ef-b24b-4c2611475c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_ccf19431-0e73-4b0b-af94-2cd548736bbf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a06e414-a9ee-4ae9-baea-578cceb56ea6" xlink:to="loc_dei_EntityCurrentReportingStatus_ccf19431-0e73-4b0b-af94-2cd548736bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_e523e469-c5c1-4ced-a4fe-0ed18528863e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a06e414-a9ee-4ae9-baea-578cceb56ea6" xlink:to="loc_dei_EntityInteractiveDataCurrent_e523e469-c5c1-4ced-a4fe-0ed18528863e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_09bd8fda-549f-45dc-80a5-d2ee9731747c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a06e414-a9ee-4ae9-baea-578cceb56ea6" xlink:to="loc_dei_EntityFilerCategory_09bd8fda-549f-45dc-80a5-d2ee9731747c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_7ecff432-cb21-4042-a050-8b7a6f9459ab" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a06e414-a9ee-4ae9-baea-578cceb56ea6" xlink:to="loc_dei_EntitySmallBusiness_7ecff432-cb21-4042-a050-8b7a6f9459ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_1e90bfa7-1ca0-42c5-a851-daf630d1536b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a06e414-a9ee-4ae9-baea-578cceb56ea6" xlink:to="loc_dei_EntityEmergingGrowthCompany_1e90bfa7-1ca0-42c5-a851-daf630d1536b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_979359d2-7890-4bbe-9705-76724b67223d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a06e414-a9ee-4ae9-baea-578cceb56ea6" xlink:to="loc_dei_EntityShellCompany_979359d2-7890-4bbe-9705-76724b67223d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_0d8a7320-390e-4822-a337-cd6f6b5cefd9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a06e414-a9ee-4ae9-baea-578cceb56ea6" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_0d8a7320-390e-4822-a337-cd6f6b5cefd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_0fdfc3e3-ec61-4d68-bb5f-a12c985dd19e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a06e414-a9ee-4ae9-baea-578cceb56ea6" xlink:to="loc_dei_DocumentFiscalYearFocus_0fdfc3e3-ec61-4d68-bb5f-a12c985dd19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_43bb437b-3aa7-4e23-a1f9-4ef488888f4c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a06e414-a9ee-4ae9-baea-578cceb56ea6" xlink:to="loc_dei_DocumentFiscalPeriodFocus_43bb437b-3aa7-4e23-a1f9-4ef488888f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_c4920771-6955-4266-81ec-9e56b462e901" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a06e414-a9ee-4ae9-baea-578cceb56ea6" xlink:to="loc_dei_AmendmentFlag_c4920771-6955-4266-81ec-9e56b462e901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_3fcb73ba-c198-40ee-b736-13f091c2cd41" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a06e414-a9ee-4ae9-baea-578cceb56ea6" xlink:to="loc_dei_CurrentFiscalYearEndDate_3fcb73ba-c198-40ee-b736-13f091c2cd41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_794226d6-cd69-43b7-9bf7-7fa6086dbeb0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_3a06e414-a9ee-4ae9-baea-578cceb56ea6" xlink:to="loc_dei_EntityCentralIndexKey_794226d6-cd69-43b7-9bf7-7fa6086dbeb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="vtl-20230630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c713b0aa-0ea5-44b7-b3a3-dc83c89a79f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_009f201b-a016-4f97-b8c0-a6350991dda0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c713b0aa-0ea5-44b7-b3a3-dc83c89a79f5" xlink:to="loc_us-gaap_AssetsAbstract_009f201b-a016-4f97-b8c0-a6350991dda0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_79089ece-ccac-4143-a99d-249857623eee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_009f201b-a016-4f97-b8c0-a6350991dda0" xlink:to="loc_us-gaap_AssetsCurrentAbstract_79089ece-ccac-4143-a99d-249857623eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e7fffddb-bb74-4ba8-9177-30e039fb97eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_79089ece-ccac-4143-a99d-249857623eee" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e7fffddb-bb74-4ba8-9177-30e039fb97eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_ca142562-62a6-4aee-b4f8-51aa4f9609ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_79089ece-ccac-4143-a99d-249857623eee" xlink:to="loc_us-gaap_OtherShortTermInvestments_ca142562-62a6-4aee-b4f8-51aa4f9609ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4c75f276-bf65-41ac-aefe-529ab11837be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_79089ece-ccac-4143-a99d-249857623eee" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_4c75f276-bf65-41ac-aefe-529ab11837be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6d23280e-de3b-4de9-88be-f5bf5e0ef0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_79089ece-ccac-4143-a99d-249857623eee" xlink:to="loc_us-gaap_AssetsCurrent_6d23280e-de3b-4de9-88be-f5bf5e0ef0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_34b37a65-d995-4716-aba0-ab7e2eff67e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_009f201b-a016-4f97-b8c0-a6350991dda0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_34b37a65-d995-4716-aba0-ab7e2eff67e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_548ef088-7a34-462b-a28d-68876ee6a789" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_009f201b-a016-4f97-b8c0-a6350991dda0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_548ef088-7a34-462b-a28d-68876ee6a789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8bba640f-01e4-4d1f-ac8e-4afba60c0fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_009f201b-a016-4f97-b8c0-a6350991dda0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_8bba640f-01e4-4d1f-ac8e-4afba60c0fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_1e66cbca-0b18-4836-b638-ae41940fd0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_009f201b-a016-4f97-b8c0-a6350991dda0" xlink:to="loc_us-gaap_Assets_1e66cbca-0b18-4836-b638-ae41940fd0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9d35740e-dd25-4c96-b89f-74c5fe47f564" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c713b0aa-0ea5-44b7-b3a3-dc83c89a79f5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9d35740e-dd25-4c96-b89f-74c5fe47f564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_81e847cb-7aee-4b31-8a60-a4d32e8a2126" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9d35740e-dd25-4c96-b89f-74c5fe47f564" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_81e847cb-7aee-4b31-8a60-a4d32e8a2126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_00c2d1c9-2360-43f6-b916-a4613bf77aac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_81e847cb-7aee-4b31-8a60-a4d32e8a2126" xlink:to="loc_us-gaap_AccountsPayableCurrent_00c2d1c9-2360-43f6-b916-a4613bf77aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f9e3c7c4-90f1-44f8-8a65-be7ac2e76c10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_81e847cb-7aee-4b31-8a60-a4d32e8a2126" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_f9e3c7c4-90f1-44f8-8a65-be7ac2e76c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_a85a5118-c015-4573-8b68-30843ab70884" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_81e847cb-7aee-4b31-8a60-a4d32e8a2126" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_a85a5118-c015-4573-8b68-30843ab70884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_2453c9b8-d4b8-474d-8eff-a84eaa0c3053" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_81e847cb-7aee-4b31-8a60-a4d32e8a2126" xlink:to="loc_us-gaap_LiabilitiesCurrent_2453c9b8-d4b8-474d-8eff-a84eaa0c3053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_293b17de-ce74-43d6-a0c9-e7d9c39cf83f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9d35740e-dd25-4c96-b89f-74c5fe47f564" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_293b17de-ce74-43d6-a0c9-e7d9c39cf83f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d6f9a946-daac-496e-aa67-50fc5d2ffd51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_293b17de-ce74-43d6-a0c9-e7d9c39cf83f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d6f9a946-daac-496e-aa67-50fc5d2ffd51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_778e661d-c658-4f2b-b762-367aef56d9dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_293b17de-ce74-43d6-a0c9-e7d9c39cf83f" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_778e661d-c658-4f2b-b762-367aef56d9dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6cc4b88a-c5b6-4d3f-a4e6-138ba45be636" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9d35740e-dd25-4c96-b89f-74c5fe47f564" xlink:to="loc_us-gaap_Liabilities_6cc4b88a-c5b6-4d3f-a4e6-138ba45be636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_24981ab9-0609-4476-adca-0a29bff52b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9d35740e-dd25-4c96-b89f-74c5fe47f564" xlink:to="loc_us-gaap_CommitmentsAndContingencies_24981ab9-0609-4476-adca-0a29bff52b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_889e6f3f-b528-429d-9656-aa86728d3cb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9d35740e-dd25-4c96-b89f-74c5fe47f564" xlink:to="loc_us-gaap_StockholdersEquityAbstract_889e6f3f-b528-429d-9656-aa86728d3cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_6748678a-addd-407a-ae17-52c538a0544c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_889e6f3f-b528-429d-9656-aa86728d3cb7" xlink:to="loc_us-gaap_PreferredStockValue_6748678a-addd-407a-ae17-52c538a0544c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3720ac9d-34b8-45c6-b64f-57fcfacca47a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_889e6f3f-b528-429d-9656-aa86728d3cb7" xlink:to="loc_us-gaap_CommonStockValue_3720ac9d-34b8-45c6-b64f-57fcfacca47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_30ddcaa2-68d1-4fb7-a796-60250f64be0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_889e6f3f-b528-429d-9656-aa86728d3cb7" xlink:to="loc_us-gaap_AdditionalPaidInCapital_30ddcaa2-68d1-4fb7-a796-60250f64be0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_abd4f7d5-b547-42c3-9833-3d5c3f4e5f95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_889e6f3f-b528-429d-9656-aa86728d3cb7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_abd4f7d5-b547-42c3-9833-3d5c3f4e5f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5f30bcb2-eacf-414e-909c-9ede58b74b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_889e6f3f-b528-429d-9656-aa86728d3cb7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5f30bcb2-eacf-414e-909c-9ede58b74b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_de42c2a5-3493-4070-ad42-dafb2894b35e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_889e6f3f-b528-429d-9656-aa86728d3cb7" xlink:to="loc_us-gaap_StockholdersEquity_de42c2a5-3493-4070-ad42-dafb2894b35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae8b3a43-d0dd-4ca2-bc82-ce64158f309e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9d35740e-dd25-4c96-b89f-74c5fe47f564" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_ae8b3a43-d0dd-4ca2-bc82-ce64158f309e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="vtl-20230630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_664be001-d350-47be-9e90-e3d5cba9989e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1d1ed972-4c70-4458-8fee-dcefa9a660fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_664be001-d350-47be-9e90-e3d5cba9989e" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1d1ed972-4c70-4458-8fee-dcefa9a660fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_12561eb2-fbb5-4f89-b63c-a13309f7399b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_664be001-d350-47be-9e90-e3d5cba9989e" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_12561eb2-fbb5-4f89-b63c-a13309f7399b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_c84ea603-1eea-40fb-8732-7ed1059d9adc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_664be001-d350-47be-9e90-e3d5cba9989e" xlink:to="loc_us-gaap_PreferredStockSharesIssued_c84ea603-1eea-40fb-8732-7ed1059d9adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_a08867c8-0197-42c9-b1f8-365cfe97709a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_664be001-d350-47be-9e90-e3d5cba9989e" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_a08867c8-0197-42c9-b1f8-365cfe97709a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_8ff1d03c-fe47-4663-9049-ed59f0635253" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_664be001-d350-47be-9e90-e3d5cba9989e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_8ff1d03c-fe47-4663-9049-ed59f0635253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0e72cd4a-5f1a-46b2-9277-af5c20531d32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_664be001-d350-47be-9e90-e3d5cba9989e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0e72cd4a-5f1a-46b2-9277-af5c20531d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_2519d52c-5d53-451a-8361-ff05d4eae194" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_664be001-d350-47be-9e90-e3d5cba9989e" xlink:to="loc_us-gaap_CommonStockSharesIssued_2519d52c-5d53-451a-8361-ff05d4eae194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f2619fce-c9fa-48d6-a5cd-8268520ac9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_664be001-d350-47be-9e90-e3d5cba9989e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f2619fce-c9fa-48d6-a5cd-8268520ac9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="vtl-20230630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_f7b56aab-6a11-417c-a5f5-276ec61bf946" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_a93eb50c-8fbc-4648-9036-866aef390804" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f7b56aab-6a11-417c-a5f5-276ec61bf946" xlink:to="loc_us-gaap_OperatingExpensesAbstract_a93eb50c-8fbc-4648-9036-866aef390804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_0d806c01-f44e-4ba4-8c79-d36ed2f23278" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a93eb50c-8fbc-4648-9036-866aef390804" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_0d806c01-f44e-4ba4-8c79-d36ed2f23278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_a3103653-e644-4860-93d8-2e66cd8d935c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a93eb50c-8fbc-4648-9036-866aef390804" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_a3103653-e644-4860-93d8-2e66cd8d935c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_3fb7eec0-4ee8-46f4-a311-474e278a0df1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a93eb50c-8fbc-4648-9036-866aef390804" xlink:to="loc_us-gaap_OperatingExpenses_3fb7eec0-4ee8-46f4-a311-474e278a0df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_600cc825-1bcd-4c0d-8594-3455017f21b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f7b56aab-6a11-417c-a5f5-276ec61bf946" xlink:to="loc_us-gaap_OperatingIncomeLoss_600cc825-1bcd-4c0d-8594-3455017f21b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c4358fbd-70e8-4afc-b154-92a7de4ae0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f7b56aab-6a11-417c-a5f5-276ec61bf946" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c4358fbd-70e8-4afc-b154-92a7de4ae0fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_4d34be4e-8bb5-4637-a274-8e127832971a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c4358fbd-70e8-4afc-b154-92a7de4ae0fb" xlink:to="loc_us-gaap_InvestmentIncomeInterest_4d34be4e-8bb5-4637-a274-8e127832971a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6cd643d2-7b1b-40c0-86e3-a8fec09fb6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c4358fbd-70e8-4afc-b154-92a7de4ae0fb" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6cd643d2-7b1b-40c0-86e3-a8fec09fb6e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_3d185dcc-5fd3-4e54-ab91-2997fc97fca4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_c4358fbd-70e8-4afc-b154-92a7de4ae0fb" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_3d185dcc-5fd3-4e54-ab91-2997fc97fca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1f2532c8-5bb6-48ff-b66c-0735a27ad950" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f7b56aab-6a11-417c-a5f5-276ec61bf946" xlink:to="loc_us-gaap_NetIncomeLoss_1f2532c8-5bb6-48ff-b66c-0735a27ad950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_62dd44f6-1c5e-46ed-af06-a47c0e0c8a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f7b56aab-6a11-417c-a5f5-276ec61bf946" xlink:to="loc_us-gaap_EarningsPerShareBasic_62dd44f6-1c5e-46ed-af06-a47c0e0c8a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ebbcdcb4-8659-4755-bbc0-e1cd6b56791e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f7b56aab-6a11-417c-a5f5-276ec61bf946" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ebbcdcb4-8659-4755-bbc0-e1cd6b56791e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3b523a7e-ba8a-47a9-b216-b8a12dc0dadd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f7b56aab-6a11-417c-a5f5-276ec61bf946" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3b523a7e-ba8a-47a9-b216-b8a12dc0dadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c843b114-cb3c-40b2-a004-8e1a3a929bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f7b56aab-6a11-417c-a5f5-276ec61bf946" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c843b114-cb3c-40b2-a004-8e1a3a929bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="vtl-20230630.xsd#CondensedConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_389065a6-c954-4ce2-b31e-1fcc55874602" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_72d9fc2c-9394-4c42-b9f2-548f99700da5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_389065a6-c954-4ce2-b31e-1fcc55874602" xlink:to="loc_us-gaap_NetIncomeLoss_72d9fc2c-9394-4c42-b9f2-548f99700da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_d8335743-9523-4e88-a0c7-5048df110359" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_389065a6-c954-4ce2-b31e-1fcc55874602" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_d8335743-9523-4e88-a0c7-5048df110359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_6d049e10-b366-48f6-98d8-bec8e234c7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_d8335743-9523-4e88-a0c7-5048df110359" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_6d049e10-b366-48f6-98d8-bec8e234c7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_31dbba52-32e5-4e18-9f72-1f7681a9f7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_389065a6-c954-4ce2-b31e-1fcc55874602" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_31dbba52-32e5-4e18-9f72-1f7681a9f7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="vtl-20230630.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_c1ba136a-3052-4f75-b637-7f075be2785c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_95b1259a-54e6-4d1c-951b-c9b5a78c2fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_c1ba136a-3052-4f75-b637-7f075be2785c" xlink:to="loc_us-gaap_StatementTable_95b1259a-54e6-4d1c-951b-c9b5a78c2fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9e173ca3-aaf5-42b1-93eb-e3cdef76f770" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_95b1259a-54e6-4d1c-951b-c9b5a78c2fcf" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9e173ca3-aaf5-42b1-93eb-e3cdef76f770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d080c61b-6ab3-49ee-abf4-99f7be96e891" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9e173ca3-aaf5-42b1-93eb-e3cdef76f770" xlink:to="loc_us-gaap_EquityComponentDomain_d080c61b-6ab3-49ee-abf4-99f7be96e891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_cf77a5ee-90a7-4000-b3de-5b59d29f502f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d080c61b-6ab3-49ee-abf4-99f7be96e891" xlink:to="loc_us-gaap_CommonStockMember_cf77a5ee-90a7-4000-b3de-5b59d29f502f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_a00d9a5e-d502-451c-bd77-63259340b82d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d080c61b-6ab3-49ee-abf4-99f7be96e891" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_a00d9a5e-d502-451c-bd77-63259340b82d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_edbbc88d-14b6-41db-9684-9be06953f475" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d080c61b-6ab3-49ee-abf4-99f7be96e891" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_edbbc88d-14b6-41db-9684-9be06953f475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d70f2179-7dc6-49f8-9511-023fbb196ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d080c61b-6ab3-49ee-abf4-99f7be96e891" xlink:to="loc_us-gaap_RetainedEarningsMember_d70f2179-7dc6-49f8-9511-023fbb196ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_82e8c090-0fe6-4892-b41d-4c338101ecf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_95b1259a-54e6-4d1c-951b-c9b5a78c2fcf" xlink:to="loc_us-gaap_StatementLineItems_82e8c090-0fe6-4892-b41d-4c338101ecf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de513d23-2dd3-460a-a593-4dbf472ebde2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_82e8c090-0fe6-4892-b41d-4c338101ecf4" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de513d23-2dd3-460a-a593-4dbf472ebde2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1aa4c5f9-8840-4b84-9bf3-64284b182174" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de513d23-2dd3-460a-a593-4dbf472ebde2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1aa4c5f9-8840-4b84-9bf3-64284b182174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d2daaf09-20d9-4873-8e07-62e9bb7a19b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de513d23-2dd3-460a-a593-4dbf472ebde2" xlink:to="loc_us-gaap_StockholdersEquity_d2daaf09-20d9-4873-8e07-62e9bb7a19b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8ee0b4e2-4223-42f5-8e86-ac6a11b1215c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de513d23-2dd3-460a-a593-4dbf472ebde2" xlink:to="loc_us-gaap_NetIncomeLoss_8ee0b4e2-4223-42f5-8e86-ac6a11b1215c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_eaa2a082-f109-49f6-b4d1-2c0bc36bc3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de513d23-2dd3-460a-a593-4dbf472ebde2" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_eaa2a082-f109-49f6-b4d1-2c0bc36bc3cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_98b90f01-2d9e-4f58-ae52-3d55d280ffe4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de513d23-2dd3-460a-a593-4dbf472ebde2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_98b90f01-2d9e-4f58-ae52-3d55d280ffe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ec7e9930-d83d-4bfb-8ea1-a27e18f4a3be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de513d23-2dd3-460a-a593-4dbf472ebde2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_ec7e9930-d83d-4bfb-8ea1-a27e18f4a3be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_597b868b-9ff9-49a3-9db3-fcfecd3e40f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de513d23-2dd3-460a-a593-4dbf472ebde2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_597b868b-9ff9-49a3-9db3-fcfecd3e40f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_b2c4edfb-f5e5-4cca-abd3-6944e8ffdd37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de513d23-2dd3-460a-a593-4dbf472ebde2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_b2c4edfb-f5e5-4cca-abd3-6944e8ffdd37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0fb31f34-72a1-4201-bd4f-6ae8b2cdceae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de513d23-2dd3-460a-a593-4dbf472ebde2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_0fb31f34-72a1-4201-bd4f-6ae8b2cdceae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_69342b64-2a49-49b7-a816-2a4c55a2b50c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de513d23-2dd3-460a-a593-4dbf472ebde2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_69342b64-2a49-49b7-a816-2a4c55a2b50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_bf7d74b2-ea88-4d03-8acc-9ad797d35faf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de513d23-2dd3-460a-a593-4dbf472ebde2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_bf7d74b2-ea88-4d03-8acc-9ad797d35faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_89d7be51-54a2-40ee-9315-bc7c5a10cbed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de513d23-2dd3-460a-a593-4dbf472ebde2" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_89d7be51-54a2-40ee-9315-bc7c5a10cbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5048c143-4731-4656-aae5-3c40d5711e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_de513d23-2dd3-460a-a593-4dbf472ebde2" xlink:to="loc_us-gaap_StockholdersEquity_5048c143-4731-4656-aae5-3c40d5711e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="simple" xlink:href="vtl-20230630.xsd#CondensedConsolidatedStatementsofStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_e03e216b-1a71-4509-a647-f856c003240e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_57666e2c-65b1-48ee-8969-40c99f6fdb59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_e03e216b-1a71-4509-a647-f856c003240e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_57666e2c-65b1-48ee-8969-40c99f6fdb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows" xlink:type="simple" xlink:href="vtl-20230630.xsd#CondensedConsolidatedStatementofCashFlows"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_586c5181-7fca-4170-9965-e1d378579133" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_e41a8542-5af3-48c9-891f-f3abe06299a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_586c5181-7fca-4170-9965-e1d378579133" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_e41a8542-5af3-48c9-891f-f3abe06299a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ce1c3ca8-2090-4eff-b4a8-bab22a2cf8d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_e41a8542-5af3-48c9-891f-f3abe06299a0" xlink:to="loc_us-gaap_NetIncomeLoss_ce1c3ca8-2090-4eff-b4a8-bab22a2cf8d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b0b895fe-5d15-4d8d-b012-5d75d887b27e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_e41a8542-5af3-48c9-891f-f3abe06299a0" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b0b895fe-5d15-4d8d-b012-5d75d887b27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4de256ec-7bb0-43d0-baca-470951c44357" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b0b895fe-5d15-4d8d-b012-5d75d887b27e" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4de256ec-7bb0-43d0-baca-470951c44357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_2e710103-f63c-45a8-b48b-cda3038a2729" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b0b895fe-5d15-4d8d-b012-5d75d887b27e" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossUnrealized_2e710103-f63c-45a8-b48b-cda3038a2729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_987ac85f-2abf-4979-be67-8f83340d50ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b0b895fe-5d15-4d8d-b012-5d75d887b27e" xlink:to="loc_us-gaap_ShareBasedCompensation_987ac85f-2abf-4979-be67-8f83340d50ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3e154ec7-e96b-44a9-bc23-49321544f66a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b0b895fe-5d15-4d8d-b012-5d75d887b27e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3e154ec7-e96b-44a9-bc23-49321544f66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_74e9879c-c98b-46f3-952d-bf7bf26ef0c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3e154ec7-e96b-44a9-bc23-49321544f66a" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_74e9879c-c98b-46f3-952d-bf7bf26ef0c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_3ed47ace-870a-4370-adcc-0255987e685f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3e154ec7-e96b-44a9-bc23-49321544f66a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_3ed47ace-870a-4370-adcc-0255987e685f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3b939456-8031-440d-9eed-c1a13fa36322" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3e154ec7-e96b-44a9-bc23-49321544f66a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_3b939456-8031-440d-9eed-c1a13fa36322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_6694604d-eb7e-43e1-9181-f3eaf24fb109" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3e154ec7-e96b-44a9-bc23-49321544f66a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_6694604d-eb7e-43e1-9181-f3eaf24fb109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ddd20247-e722-41fb-9607-ca7e483694b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_e41a8542-5af3-48c9-891f-f3abe06299a0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ddd20247-e722-41fb-9607-ca7e483694b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_50be6aba-9e87-45b9-ab56-dbe90880544c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_586c5181-7fca-4170-9965-e1d378579133" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_50be6aba-9e87-45b9-ab56-dbe90880544c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_f4a17e41-1199-4fd0-aa53-e065d06ff5df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_50be6aba-9e87-45b9-ab56-dbe90880544c" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_f4a17e41-1199-4fd0-aa53-e065d06ff5df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6b02b147-24a1-4fb7-9066-2ae040deab4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_50be6aba-9e87-45b9-ab56-dbe90880544c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6b02b147-24a1-4fb7-9066-2ae040deab4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e429cf1e-8540-4c87-b719-41179e0fe265" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_50be6aba-9e87-45b9-ab56-dbe90880544c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e429cf1e-8540-4c87-b719-41179e0fe265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_e4ff1bd3-385c-4bc0-bec9-996e9e6f0fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_586c5181-7fca-4170-9965-e1d378579133" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_e4ff1bd3-385c-4bc0-bec9-996e9e6f0fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e0cd2ca8-7189-42fe-96cb-fa5eebce073d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_e4ff1bd3-385c-4bc0-bec9-996e9e6f0fc4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_e0cd2ca8-7189-42fe-96cb-fa5eebce073d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_9c78f6f9-07b0-42a6-9d49-05dfe1e25c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_e4ff1bd3-385c-4bc0-bec9-996e9e6f0fc4" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_9c78f6f9-07b0-42a6-9d49-05dfe1e25c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_00a97463-34f3-4df7-b7c2-aa0b2dcf6ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_e4ff1bd3-385c-4bc0-bec9-996e9e6f0fc4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans_00a97463-34f3-4df7-b7c2-aa0b2dcf6ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_21a30169-b3db-4dda-b0f8-3352d787feb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_e4ff1bd3-385c-4bc0-bec9-996e9e6f0fc4" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_21a30169-b3db-4dda-b0f8-3352d787feb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_87a80b34-a938-4e77-8d3e-b81092443ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_e4ff1bd3-385c-4bc0-bec9-996e9e6f0fc4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_87a80b34-a938-4e77-8d3e-b81092443ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_26b4da2b-6f68-4866-8a9a-3ddbacc2c8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_586c5181-7fca-4170-9965-e1d378579133" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_26b4da2b-6f68-4866-8a9a-3ddbacc2c8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_269c2422-dc34-47ab-b068-f39817853561" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_586c5181-7fca-4170-9965-e1d378579133" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_269c2422-dc34-47ab-b068-f39817853561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3419c7d9-844f-462e-b8d5-147ef51c29c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_586c5181-7fca-4170-9965-e1d378579133" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3419c7d9-844f-462e-b8d5-147ef51c29c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a955534e-ba94-4a83-88d4-71d0a292dfdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_586c5181-7fca-4170-9965-e1d378579133" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a955534e-ba94-4a83-88d4-71d0a292dfdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_e5120df5-2197-4601-9aab-79640ae972f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_586c5181-7fca-4170-9965-e1d378579133" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_e5120df5-2197-4601-9aab-79640ae972f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_40b6efbc-a9d8-4def-b901-3395b67e3b88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_e5120df5-2197-4601-9aab-79640ae972f8" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_40b6efbc-a9d8-4def-b901-3395b67e3b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements" xlink:type="simple" xlink:href="vtl-20230630.xsd#DescriptionofBusinessandBasisofFinancialStatements"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7baae1c7-8736-4e0f-84a5-3be859f802e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_09661466-4f28-412c-9925-e4e3ea2d28d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7baae1c7-8736-4e0f-84a5-3be859f802e3" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_09661466-4f28-412c-9925-e4e3ea2d28d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="vtl-20230630.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d9202032-003b-45cb-a960-ec3fadb7f124" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_a0b08ae0-7d51-4a00-95e3-61ed4bedf664" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d9202032-003b-45cb-a960-ec3fadb7f124" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_a0b08ae0-7d51-4a00-95e3-61ed4bedf664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetails" xlink:type="simple" xlink:href="vtl-20230630.xsd#BalanceSheetDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0cd3ed0f-79a0-40f8-941e-63ef8f40cd74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_df678a4b-2ac3-4388-9eba-f8f0a93c655a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0cd3ed0f-79a0-40f8-941e-63ef8f40cd74" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_df678a4b-2ac3-4388-9eba-f8f0a93c655a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="vtl-20230630.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_cb2cbab4-591f-4f24-987c-f76357854d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3b4fb59b-6b0f-4636-9469-8d8e588a7f35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_cb2cbab4-591f-4f24-987c-f76357854d9c" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3b4fb59b-6b0f-4636-9469-8d8e588a7f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/FairValue" xlink:type="simple" xlink:href="vtl-20230630.xsd#FairValue"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/FairValue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8e0872e5-0a5f-47ce-96e3-18e35f14b8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_fc608ea5-e760-47b0-9c2b-a6e2fac49183" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8e0872e5-0a5f-47ce-96e3-18e35f14b8a9" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_fc608ea5-e760-47b0-9c2b-a6e2fac49183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStock" xlink:type="simple" xlink:href="vtl-20230630.xsd#CommonStock"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c2c69144-d009-49bb-affe-2e9a1fde4855" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7aa8e980-7fb0-488a-8347-5e000bf223ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c2c69144-d009-49bb-affe-2e9a1fde4855" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_7aa8e980-7fb0-488a-8347-5e000bf223ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlans" xlink:type="simple" xlink:href="vtl-20230630.xsd#StockBasedCompensationPlans"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1c8534a9-15a4-4003-b64f-a740a6bb2d72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_21038dfe-8f18-41fb-86c1-fcb9e60f2dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1c8534a9-15a4-4003-b64f-a740a6bb2d72" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_21038dfe-8f18-41fb-86c1-fcb9e60f2dfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="vtl-20230630.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_2784791c-b68b-4b1b-b5ef-8d8a824e3a4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1e19b7c8-5e3c-43f3-87c4-b93db5ff9cab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_2784791c-b68b-4b1b-b5ef-8d8a824e3a4a" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1e19b7c8-5e3c-43f3-87c4-b93db5ff9cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SubsequentEvents" xlink:type="simple" xlink:href="vtl-20230630.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_ee683f71-a7d6-4a65-9078-c25e54dcbb0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_c9e9071c-1668-419a-8b06-33f0c18756db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_ee683f71-a7d6-4a65-9078-c25e54dcbb0a" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_c9e9071c-1668-419a-8b06-33f0c18756db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="vtl-20230630.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cde7798f-3b0a-43ab-89a0-f5544c137218" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_929b4d21-8ea7-4abc-8656-1e818b062907" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cde7798f-3b0a-43ab-89a0-f5544c137218" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_929b4d21-8ea7-4abc-8656-1e818b062907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_c46b295f-6904-415d-a608-66089ed9d928" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cde7798f-3b0a-43ab-89a0-f5544c137218" xlink:to="loc_us-gaap_UseOfEstimates_c46b295f-6904-415d-a608-66089ed9d928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_b529afd6-575d-4ef9-b454-17f85752e0be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cde7798f-3b0a-43ab-89a0-f5544c137218" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_b529afd6-575d-4ef9-b454-17f85752e0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock_496900d5-7817-434e-b699-88e07eebce46" xlink:href="vtl-20230630.xsd#vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cde7798f-3b0a-43ab-89a0-f5544c137218" xlink:to="loc_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock_496900d5-7817-434e-b699-88e07eebce46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_dd5cbecf-d032-4232-a543-ad998914e8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cde7798f-3b0a-43ab-89a0-f5544c137218" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_dd5cbecf-d032-4232-a543-ad998914e8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_bbe1132d-b636-4b17-8d13-12e93801b7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cde7798f-3b0a-43ab-89a0-f5544c137218" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_bbe1132d-b636-4b17-8d13-12e93801b7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_76c13027-fba3-467a-be31-567fecbea969" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cde7798f-3b0a-43ab-89a0-f5544c137218" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_76c13027-fba3-467a-be31-567fecbea969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_5a80cb91-da6b-4509-9435-5fe7a74a5e73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cde7798f-3b0a-43ab-89a0-f5544c137218" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_5a80cb91-da6b-4509-9435-5fe7a74a5e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_b5bba670-d01b-4611-ac11-3aac1b9c2387" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cde7798f-3b0a-43ab-89a0-f5544c137218" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_b5bba670-d01b-4611-ac11-3aac1b9c2387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_c5be060d-678d-4f75-9d5a-224aaf5ad04a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cde7798f-3b0a-43ab-89a0-f5544c137218" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_c5be060d-678d-4f75-9d5a-224aaf5ad04a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistancePolicyTextBlock_929e2129-4032-4f1b-afd6-c5dd8fe702fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistancePolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cde7798f-3b0a-43ab-89a0-f5544c137218" xlink:to="loc_us-gaap_GovernmentAssistancePolicyTextBlock_929e2129-4032-4f1b-afd6-c5dd8fe702fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_4d47f5df-9009-4bc0-bf80-92a913262ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cde7798f-3b0a-43ab-89a0-f5544c137218" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_4d47f5df-9009-4bc0-bf80-92a913262ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b8088212-d3ca-4cc0-827a-0414456889a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cde7798f-3b0a-43ab-89a0-f5544c137218" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b8088212-d3ca-4cc0-827a-0414456889a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_8a17cdc4-ee83-4b51-820c-a1725b4e879d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cde7798f-3b0a-43ab-89a0-f5544c137218" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_8a17cdc4-ee83-4b51-820c-a1725b4e879d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_76576652-ebb5-44a6-bb4f-e817785f442d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cde7798f-3b0a-43ab-89a0-f5544c137218" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_76576652-ebb5-44a6-bb4f-e817785f442d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_ec585ad8-f7ed-4bc2-87be-6449aec1c770" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cde7798f-3b0a-43ab-89a0-f5544c137218" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_ec585ad8-f7ed-4bc2-87be-6449aec1c770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityPolicyTextBlock_316a3ba0-d8af-4eb0-8f22-278a08fbe42e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cde7798f-3b0a-43ab-89a0-f5544c137218" xlink:to="loc_us-gaap_StockholdersEquityPolicyTextBlock_316a3ba0-d8af-4eb0-8f22-278a08fbe42e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_e669130e-1ca5-495d-9c30-7537ca0da153" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cde7798f-3b0a-43ab-89a0-f5544c137218" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_e669130e-1ca5-495d-9c30-7537ca0da153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3aa2d865-32c0-4eea-bb20-956bc3e0d05d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cde7798f-3b0a-43ab-89a0-f5544c137218" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3aa2d865-32c0-4eea-bb20-956bc3e0d05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="vtl-20230630.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f7880d95-f057-42fd-9978-ece5993cb67b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTableTextBlock_a641c554-4c2a-4f4b-8133-1ee917a28f59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f7880d95-f057-42fd-9978-ece5993cb67b" xlink:to="loc_us-gaap_InvestmentTableTextBlock_a641c554-4c2a-4f4b-8133-1ee917a28f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_26623bff-7631-4b0d-948b-010c980a7448" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f7880d95-f057-42fd-9978-ece5993cb67b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_26623bff-7631-4b0d-948b-010c980a7448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsTables" xlink:type="simple" xlink:href="vtl-20230630.xsd#BalanceSheetDetailsTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bb91a120-629c-4703-946c-8baa4d62db27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_c5ca2add-474e-4569-97fd-c6599c98bd6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bb91a120-629c-4703-946c-8baa4d62db27" xlink:to="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_c5ca2add-474e-4569-97fd-c6599c98bd6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_af8d39ea-975c-43c6-a96a-2ea25a7d08a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bb91a120-629c-4703-946c-8baa4d62db27" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_af8d39ea-975c-43c6-a96a-2ea25a7d08a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_20bc462f-ffa1-421b-8c52-bb98dbee05f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bb91a120-629c-4703-946c-8baa4d62db27" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesTableTextBlock_20bc462f-ffa1-421b-8c52-bb98dbee05f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="vtl-20230630.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_66edf55e-37e8-4589-b8b3-e135dede3ef6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_dd2e2d34-b0d2-4d1e-9f94-96cdc2420b7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_66edf55e-37e8-4589-b8b3-e135dede3ef6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_dd2e2d34-b0d2-4d1e-9f94-96cdc2420b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/FairValueTables" xlink:type="simple" xlink:href="vtl-20230630.xsd#FairValueTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/FairValueTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4a21d680-b88d-46bf-8ea4-5f9ce1704ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2278224c-85ab-4d7b-b9da-61721a538edd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4a21d680-b88d-46bf-8ea4-5f9ce1704ba3" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_2278224c-85ab-4d7b-b9da-61721a538edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockTables" xlink:type="simple" xlink:href="vtl-20230630.xsd#CommonStockTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e6ed73e5-2d4c-4895-b9e4-2cfd7c65cb9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_51cae0be-48c0-41eb-ba63-44448913f43c" xlink:href="vtl-20230630.xsd#vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e6ed73e5-2d4c-4895-b9e4-2cfd7c65cb9c" xlink:to="loc_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock_51cae0be-48c0-41eb-ba63-44448913f43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansTables" xlink:type="simple" xlink:href="vtl-20230630.xsd#StockBasedCompensationPlansTables"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d1e0bca3-3cad-41bb-9c28-436c0fe59a78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_eb299b77-b06f-4ea9-a112-d473cf851e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d1e0bca3-3cad-41bb-9c28-436c0fe59a78" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_eb299b77-b06f-4ea9-a112-d473cf851e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ca1a36ba-3484-46b3-8c54-842d66c7c91e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d1e0bca3-3cad-41bb-9c28-436c0fe59a78" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ca1a36ba-3484-46b3-8c54-842d66c7c91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_6671dde6-313a-41c0-844f-a5dc1d34afc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d1e0bca3-3cad-41bb-9c28-436c0fe59a78" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_6671dde6-313a-41c0-844f-a5dc1d34afc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails" xlink:type="simple" xlink:href="vtl-20230630.xsd#DescriptionofBusinessandBasisofFinancialStatementsDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1eaa4c1f-dcf8-453b-90cb-fc9db0916188" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityNumberOfEmployees_8286d91c-f907-4e23-b165-8c2af4ff40d5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityNumberOfEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1eaa4c1f-dcf8-453b-90cb-fc9db0916188" xlink:to="loc_dei_EntityNumberOfEmployees_8286d91c-f907-4e23-b165-8c2af4ff40d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfDevelopmentPrograms_25b77a52-b4e0-4365-beea-835b2ab6dcee" xlink:href="vtl-20230630.xsd#vtl_NumberOfDevelopmentPrograms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1eaa4c1f-dcf8-453b-90cb-fc9db0916188" xlink:to="loc_vtl_NumberOfDevelopmentPrograms_25b77a52-b4e0-4365-beea-835b2ab6dcee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b960e7b7-65dd-4741-8a17-539350148c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1eaa4c1f-dcf8-453b-90cb-fc9db0916188" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b960e7b7-65dd-4741-8a17-539350148c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_e90acf66-5bbe-40c6-9b5f-8c6295c85507" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1eaa4c1f-dcf8-453b-90cb-fc9db0916188" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_e90acf66-5bbe-40c6-9b5f-8c6295c85507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bf50cc61-0113-4397-bab9-572278447931" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1eaa4c1f-dcf8-453b-90cb-fc9db0916188" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bf50cc61-0113-4397-bab9-572278447931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20230630.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5199e568-8a1b-4c1b-b9ae-c2e958151fef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2835e1fd-4215-4f00-8f5c-c02ac1aa984e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5199e568-8a1b-4c1b-b9ae-c2e958151fef" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2835e1fd-4215-4f00-8f5c-c02ac1aa984e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4267c5a8-e4b3-4e42-a216-ef5fff7b1e51" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2835e1fd-4215-4f00-8f5c-c02ac1aa984e" xlink:to="loc_srt_RangeAxis_4267c5a8-e4b3-4e42-a216-ef5fff7b1e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d0318217-25cd-42e9-8883-9cd4f96c9b77" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4267c5a8-e4b3-4e42-a216-ef5fff7b1e51" xlink:to="loc_srt_RangeMember_d0318217-25cd-42e9-8883-9cd4f96c9b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e6f0cf61-1936-4927-ac93-4db6622043b5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d0318217-25cd-42e9-8883-9cd4f96c9b77" xlink:to="loc_srt_MaximumMember_e6f0cf61-1936-4927-ac93-4db6622043b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4e6c0870-d26d-4945-a345-7de30fbf9ba2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d0318217-25cd-42e9-8883-9cd4f96c9b77" xlink:to="loc_srt_MinimumMember_4e6c0870-d26d-4945-a345-7de30fbf9ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4688963f-5ea0-4bfe-8a38-0c77e3032f71" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2835e1fd-4215-4f00-8f5c-c02ac1aa984e" xlink:to="loc_srt_StatementGeographicalAxis_4688963f-5ea0-4bfe-8a38-0c77e3032f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_47923446-5400-4f5e-894c-6af10de93668" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4688963f-5ea0-4bfe-8a38-0c77e3032f71" xlink:to="loc_srt_SegmentGeographicalDomain_47923446-5400-4f5e-894c-6af10de93668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AustraliaAndGermanyMember_d26e1334-1508-4f12-ad31-7b257739900e" xlink:href="vtl-20230630.xsd#vtl_AustraliaAndGermanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_47923446-5400-4f5e-894c-6af10de93668" xlink:to="loc_vtl_AustraliaAndGermanyMember_d26e1334-1508-4f12-ad31-7b257739900e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_59e42aa1-4bb1-4ab7-8b44-322c257b6395" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_47923446-5400-4f5e-894c-6af10de93668" xlink:to="loc_country_US_59e42aa1-4bb1-4ab7-8b44-322c257b6395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_4277eddd-9347-48db-a669-dc1911ad9613" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_DE"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_47923446-5400-4f5e-894c-6af10de93668" xlink:to="loc_country_DE_4277eddd-9347-48db-a669-dc1911ad9613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_AU_626f49ad-e26e-47ea-8d8f-df6082455c85" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_AU"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_47923446-5400-4f5e-894c-6af10de93668" xlink:to="loc_country_AU_626f49ad-e26e-47ea-8d8f-df6082455c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_b98854ba-2c26-45e2-b345-941cb8958121" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2835e1fd-4215-4f00-8f5c-c02ac1aa984e" xlink:to="loc_us-gaap_InvestmentTypeAxis_b98854ba-2c26-45e2-b345-941cb8958121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_6e9562fe-0cd6-4d50-8178-623b5d96324e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_b98854ba-2c26-45e2-b345-941cb8958121" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_6e9562fe-0cd6-4d50-8178-623b5d96324e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7ca5b0d7-8f5c-4a64-8bba-c1867d86df10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6e9562fe-0cd6-4d50-8178-623b5d96324e" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7ca5b0d7-8f5c-4a64-8bba-c1867d86df10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_abd88bef-29db-4d62-8743-4ba1f3db6dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_6e9562fe-0cd6-4d50-8178-623b5d96324e" xlink:to="loc_us-gaap_BankTimeDepositsMember_abd88bef-29db-4d62-8743-4ba1f3db6dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_386ae748-f8cd-4f77-9b65-a6492a7e189c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2835e1fd-4215-4f00-8f5c-c02ac1aa984e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_386ae748-f8cd-4f77-9b65-a6492a7e189c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b7b62058-4bad-48db-8c95-2816956483c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_386ae748-f8cd-4f77-9b65-a6492a7e189c" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b7b62058-4bad-48db-8c95-2816956483c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PreFundedWarrantsMember_096aca2a-7acc-4289-8167-08a44ed2f31e" xlink:href="vtl-20230630.xsd#vtl_PreFundedWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b7b62058-4bad-48db-8c95-2816956483c3" xlink:to="loc_vtl_PreFundedWarrantsMember_096aca2a-7acc-4289-8167-08a44ed2f31e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_330cd288-f3bc-4458-b0ab-f78495741f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2835e1fd-4215-4f00-8f5c-c02ac1aa984e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_330cd288-f3bc-4458-b0ab-f78495741f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f553b8d3-817d-4277-be08-3fe7f723fa5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_330cd288-f3bc-4458-b0ab-f78495741f7d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f553b8d3-817d-4277-be08-3fe7f723fa5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfFinancialInstitutionsUsedForCashDeposit_887f22a1-0cec-4e9e-8fd0-5b7e574ee289" xlink:href="vtl-20230630.xsd#vtl_NumberOfFinancialInstitutionsUsedForCashDeposit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_330cd288-f3bc-4458-b0ab-f78495741f7d" xlink:to="loc_vtl_NumberOfFinancialInstitutionsUsedForCashDeposit_887f22a1-0cec-4e9e-8fd0-5b7e574ee289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentInterestRate_69b77da7-a81e-4953-8331-3c71d2db8ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_330cd288-f3bc-4458-b0ab-f78495741f7d" xlink:to="loc_us-gaap_InvestmentInterestRate_69b77da7-a81e-4953-8331-3c71d2db8ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_741edadf-91b5-45d8-9fb9-6d3849fe8d84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_330cd288-f3bc-4458-b0ab-f78495741f7d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_741edadf-91b5-45d8-9fb9-6d3849fe8d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_b5a382d7-6312-4f4a-9213-ce9dd6c5699d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_330cd288-f3bc-4458-b0ab-f78495741f7d" xlink:to="loc_us-gaap_Depreciation_b5a382d7-6312-4f4a-9213-ce9dd6c5699d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_76e66187-761d-4d36-aed9-1497412e8726" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_330cd288-f3bc-4458-b0ab-f78495741f7d" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_76e66187-761d-4d36-aed9-1497412e8726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_41090d20-7232-4276-96f6-53c81d883e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_330cd288-f3bc-4458-b0ab-f78495741f7d" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_41090d20-7232-4276-96f6-53c81d883e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GovernmentAssistanceRate_71cfdf30-a0e8-4b41-9281-5a3c0d409cd7" xlink:href="vtl-20230630.xsd#vtl_GovernmentAssistanceRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_330cd288-f3bc-4458-b0ab-f78495741f7d" xlink:to="loc_vtl_GovernmentAssistanceRate_71cfdf30-a0e8-4b41-9281-5a3c0d409cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceAmount_ee5b2055-6282-48a5-ba71-23bf0e52c65e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_330cd288-f3bc-4458-b0ab-f78495741f7d" xlink:to="loc_us-gaap_GovernmentAssistanceAmount_ee5b2055-6282-48a5-ba71-23bf0e52c65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_0970d902-3aec-41d9-af8a-1570782cb665" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_330cd288-f3bc-4458-b0ab-f78495741f7d" xlink:to="loc_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_0970d902-3aec-41d9-af8a-1570782cb665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_d93d2928-6934-4b14-94b0-4c2cc46e8f78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_330cd288-f3bc-4458-b0ab-f78495741f7d" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_d93d2928-6934-4b14-94b0-4c2cc46e8f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases_d7af4395-5a36-40d0-a0f0-247037981e77" xlink:href="vtl-20230630.xsd#vtl_LesseeOperatingLeasesNumberOfExistingLeases"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_330cd288-f3bc-4458-b0ab-f78495741f7d" xlink:to="loc_vtl_LesseeOperatingLeasesNumberOfExistingLeases_d7af4395-5a36-40d0-a0f0-247037981e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2f8aefa7-1f2d-4e15-9ccf-8167ae03e26c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_330cd288-f3bc-4458-b0ab-f78495741f7d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2f8aefa7-1f2d-4e15-9ccf-8167ae03e26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails" xlink:type="simple" xlink:href="vtl-20230630.xsd#SummaryofSignificantAccountingPoliciesInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_9816ec17-b161-4411-9323-7e1f7d25acf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_3cecce3c-a631-4d77-8588-f81e9f562845" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_9816ec17-b161-4411-9323-7e1f7d25acf3" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_3cecce3c-a631-4d77-8588-f81e9f562845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_a261496f-f3df-4075-a72e-cf03a94192de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_3cecce3c-a631-4d77-8588-f81e9f562845" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_a261496f-f3df-4075-a72e-cf03a94192de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_79da02d6-7ae5-4228-8d04-5afad39ea191" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_a261496f-f3df-4075-a72e-cf03a94192de" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_79da02d6-7ae5-4228-8d04-5afad39ea191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_c41ebff4-9bcf-44fe-b638-6c4d2e4c0350" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_79da02d6-7ae5-4228-8d04-5afad39ea191" xlink:to="loc_us-gaap_BankTimeDepositsMember_c41ebff4-9bcf-44fe-b638-6c4d2e4c0350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_199403de-b63f-4de3-a069-adc2803000f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_3cecce3c-a631-4d77-8588-f81e9f562845" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_199403de-b63f-4de3-a069-adc2803000f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherShortTermInvestments_7c87467c-a21b-43a5-9c31-4f5707a54d21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_199403de-b63f-4de3-a069-adc2803000f6" xlink:to="loc_us-gaap_OtherShortTermInvestments_7c87467c-a21b-43a5-9c31-4f5707a54d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" xlink:type="simple" xlink:href="vtl-20230630.xsd#SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_4762e3c9-f927-4952-bd26-1e985d076d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_19f7b243-3c4f-493c-aba2-61cbe7db9f65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_4762e3c9-f927-4952-bd26-1e985d076d3f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_19f7b243-3c4f-493c-aba2-61cbe7db9f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_41e0e997-599d-4dd0-b9f8-7b45d0321af7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_19f7b243-3c4f-493c-aba2-61cbe7db9f65" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_41e0e997-599d-4dd0-b9f8-7b45d0321af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f3f5543f-cb9a-46c9-85d1-87c9966c689b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_41e0e997-599d-4dd0-b9f8-7b45d0321af7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f3f5543f-cb9a-46c9-85d1-87c9966c689b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_c09ac432-0de2-498d-b43d-ca84df2f28da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f3f5543f-cb9a-46c9-85d1-87c9966c689b" xlink:to="loc_us-gaap_StockOptionMember_c09ac432-0de2-498d-b43d-ca84df2f28da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_68d86c96-ce4e-412e-8faf-bb271c4bc7e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_19f7b243-3c4f-493c-aba2-61cbe7db9f65" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_68d86c96-ce4e-412e-8faf-bb271c4bc7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_36cc80b4-8f6f-483b-aff8-a61b41a122d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_68d86c96-ce4e-412e-8faf-bb271c4bc7e9" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_36cc80b4-8f6f-483b-aff8-a61b41a122d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail" xlink:type="simple" xlink:href="vtl-20230630.xsd#BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_12caccc1-62c9-4bbf-88d8-1a069b0a5bab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent_65c48469-2690-4dee-bc7c-b4a34507d615" xlink:href="vtl-20230630.xsd#vtl_PrepaidClinicalAndRelatedCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_12caccc1-62c9-4bbf-88d8-1a069b0a5bab" xlink:to="loc_vtl_PrepaidClinicalAndRelatedCostsCurrent_65c48469-2690-4dee-bc7c-b4a34507d615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_f170849d-6464-4ba8-b238-d88fffc79817" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ValueAddedTaxReceivableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_12caccc1-62c9-4bbf-88d8-1a069b0a5bab" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_f170849d-6464-4ba8-b238-d88fffc79817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_e6946a66-056a-4fab-a7e1-1e23f4948439" xlink:href="vtl-20230630.xsd#vtl_ResearchAndDevelopmentTaxIncentiveCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_12caccc1-62c9-4bbf-88d8-1a069b0a5bab" xlink:to="loc_vtl_ResearchAndDevelopmentTaxIncentiveCurrent_e6946a66-056a-4fab-a7e1-1e23f4948439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_287deb86-ec70-47af-8187-38f77c6f6771" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_12caccc1-62c9-4bbf-88d8-1a069b0a5bab" xlink:to="loc_us-gaap_OtherAssetsCurrent_287deb86-ec70-47af-8187-38f77c6f6771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1efb8ba2-669e-4cf2-b2d8-017b2cf0f2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_12caccc1-62c9-4bbf-88d8-1a069b0a5bab" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1efb8ba2-669e-4cf2-b2d8-017b2cf0f2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail" xlink:type="simple" xlink:href="vtl-20230630.xsd#BalanceSheetDetailsScheduleofAccountsPayableDetail"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c3f551b2-e73d-4a8f-b06c-62f4ccc3cffe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ClinicalCostsPayableCurrent_8630315b-2487-45bf-aa64-716c21160a85" xlink:href="vtl-20230630.xsd#vtl_ClinicalCostsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c3f551b2-e73d-4a8f-b06c-62f4ccc3cffe" xlink:to="loc_vtl_ClinicalCostsPayableCurrent_8630315b-2487-45bf-aa64-716c21160a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LegalAndAuditCostsPayableCurrent_dbb9cac2-6e9c-4bfb-8d8d-c2985b0514de" xlink:href="vtl-20230630.xsd#vtl_LegalAndAuditCostsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c3f551b2-e73d-4a8f-b06c-62f4ccc3cffe" xlink:to="loc_vtl_LegalAndAuditCostsPayableCurrent_dbb9cac2-6e9c-4bfb-8d8d-c2985b0514de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_9c61880d-0c2d-469c-a654-f4ce23cd8605" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableOtherCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c3f551b2-e73d-4a8f-b06c-62f4ccc3cffe" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_9c61880d-0c2d-469c-a654-f4ce23cd8605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0ed1e6ec-cdc1-4d86-a63b-94ba02f86a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c3f551b2-e73d-4a8f-b06c-62f4ccc3cffe" xlink:to="loc_us-gaap_AccountsPayableCurrent_0ed1e6ec-cdc1-4d86-a63b-94ba02f86a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail" xlink:type="simple" xlink:href="vtl-20230630.xsd#BalanceSheetDetailsScheduleofAccruedExpensesDetail"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2d8a3faa-341e-49db-af22-f3685c471915" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedClinicalCostsCurrent_5ced7943-3040-40d8-ba1b-eff6abeec117" xlink:href="vtl-20230630.xsd#vtl_AccruedClinicalCostsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2d8a3faa-341e-49db-af22-f3685c471915" xlink:to="loc_vtl_AccruedClinicalCostsCurrent_5ced7943-3040-40d8-ba1b-eff6abeec117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedLegalAndAuditCostsCurrent_36e76f29-6758-4cb8-a8f9-b60e73a4054f" xlink:href="vtl-20230630.xsd#vtl_AccruedLegalAndAuditCostsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2d8a3faa-341e-49db-af22-f3685c471915" xlink:to="loc_vtl_AccruedLegalAndAuditCostsCurrent_36e76f29-6758-4cb8-a8f9-b60e73a4054f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_AccruedCompensationCurrent_428b0e42-fd81-4ba0-992e-c239a67c14de" xlink:href="vtl-20230630.xsd#vtl_AccruedCompensationCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2d8a3faa-341e-49db-af22-f3685c471915" xlink:to="loc_vtl_AccruedCompensationCurrent_428b0e42-fd81-4ba0-992e-c239a67c14de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_66efb189-01b7-401a-ba07-34d251cf40b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2d8a3faa-341e-49db-af22-f3685c471915" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_66efb189-01b7-401a-ba07-34d251cf40b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_54047b05-6429-4eaa-8263-ced4bf0202cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2d8a3faa-341e-49db-af22-f3685c471915" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_54047b05-6429-4eaa-8263-ced4bf0202cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="simple" xlink:href="vtl-20230630.xsd#BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aeef9eb7-8116-4ad2-a8bd-5ce3c7b57b70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e242c228-2441-4900-985a-b2b6f03955ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aeef9eb7-8116-4ad2-a8bd-5ce3c7b57b70" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e242c228-2441-4900-985a-b2b6f03955ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_b4f06718-ee89-4f13-8543-2c2531f6a9f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherSundryLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aeef9eb7-8116-4ad2-a8bd-5ce3c7b57b70" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_b4f06718-ee89-4f13-8543-2c2531f6a9f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_c0c877d6-4f48-444a-890f-1c7f37948ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aeef9eb7-8116-4ad2-a8bd-5ce3c7b57b70" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_c0c877d6-4f48-444a-890f-1c7f37948ecd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_ec6bdd7e-d656-4f4f-989d-55ed90576d73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aeef9eb7-8116-4ad2-a8bd-5ce3c7b57b70" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_ec6bdd7e-d656-4f4f-989d-55ed90576d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20230630.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_64d94734-4a48-486f-bb34-adf64c20a1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_3d6761f3-938a-4ca3-b8c2-55bdf8aa0da2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_64d94734-4a48-486f-bb34-adf64c20a1f0" xlink:to="loc_us-gaap_LossContingenciesTable_3d6761f3-938a-4ca3-b8c2-55bdf8aa0da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a27c886c-e62f-4d9f-83c7-37d7a71bb075" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_3d6761f3-938a-4ca3-b8c2-55bdf8aa0da2" xlink:to="loc_srt_StatementGeographicalAxis_a27c886c-e62f-4d9f-83c7-37d7a71bb075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4a98d67b-f543-4fee-af73-33532f60010f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_a27c886c-e62f-4d9f-83c7-37d7a71bb075" xlink:to="loc_srt_SegmentGeographicalDomain_4a98d67b-f543-4fee-af73-33532f60010f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_GrafelfingGermanyMember_c092db4d-689b-41f5-b046-0f13e11211c3" xlink:href="vtl-20230630.xsd#vtl_GrafelfingGermanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4a98d67b-f543-4fee-af73-33532f60010f" xlink:to="loc_vtl_GrafelfingGermanyMember_c092db4d-689b-41f5-b046-0f13e11211c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NewYorkCityMember_d5092612-eab9-4ffb-97fd-945bb8f3a882" xlink:href="vtl-20230630.xsd#vtl_NewYorkCityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4a98d67b-f543-4fee-af73-33532f60010f" xlink:to="loc_vtl_NewYorkCityMember_d5092612-eab9-4ffb-97fd-945bb8f3a882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PlaneggGermanyMember_fc98613c-31ab-447b-a1ed-51f0da99a53f" xlink:href="vtl-20230630.xsd#vtl_PlaneggGermanyMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_4a98d67b-f543-4fee-af73-33532f60010f" xlink:to="loc_vtl_PlaneggGermanyMember_fc98613c-31ab-447b-a1ed-51f0da99a53f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_54487f64-26e9-409e-a21d-330f2c085f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_3d6761f3-938a-4ca3-b8c2-55bdf8aa0da2" xlink:to="loc_us-gaap_LossContingenciesLineItems_54487f64-26e9-409e-a21d-330f2c085f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_59b450c0-01ba-4eb3-9fba-801703e53d81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_54487f64-26e9-409e-a21d-330f2c085f9f" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_59b450c0-01ba-4eb3-9fba-801703e53d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod_5c585af8-bb38-4f91-9d3a-993d48adfe80" xlink:href="vtl-20230630.xsd#vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_54487f64-26e9-409e-a21d-330f2c085f9f" xlink:to="loc_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod_5c585af8-bb38-4f91-9d3a-993d48adfe80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod_0c83614b-9216-4413-9158-1ecf3e56db22" xlink:href="vtl-20230630.xsd#vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_54487f64-26e9-409e-a21d-330f2c085f9f" xlink:to="loc_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod_0c83614b-9216-4413-9158-1ecf3e56db22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_0b839157-c437-4331-b47a-4e68e0df3856" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_54487f64-26e9-409e-a21d-330f2c085f9f" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_0b839157-c437-4331-b47a-4e68e0df3856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_33446d60-0f4d-44fa-b153-bf69a693e57e" xlink:href="vtl-20230630.xsd#vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_54487f64-26e9-409e-a21d-330f2c085f9f" xlink:to="loc_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_33446d60-0f4d-44fa-b153-bf69a693e57e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingLeaseIncrementalBorrowingRate_1293517b-59f8-41c3-8751-b8abf4d5983c" xlink:href="vtl-20230630.xsd#vtl_OperatingLeaseIncrementalBorrowingRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_54487f64-26e9-409e-a21d-330f2c085f9f" xlink:to="loc_vtl_OperatingLeaseIncrementalBorrowingRate_1293517b-59f8-41c3-8751-b8abf4d5983c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_OperatingAndVariableLeasesCost_1029f20c-b43c-458d-8552-f42ceae2671f" xlink:href="vtl-20230630.xsd#vtl_OperatingAndVariableLeasesCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_54487f64-26e9-409e-a21d-330f2c085f9f" xlink:to="loc_vtl_OperatingAndVariableLeasesCost_1029f20c-b43c-458d-8552-f42ceae2671f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_c6773f05-7d50-4289-8253-f9e4610d7f31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_54487f64-26e9-409e-a21d-330f2c085f9f" xlink:to="loc_us-gaap_ContractualObligation_c6773f05-7d50-4289-8253-f9e4610d7f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails" xlink:type="simple" xlink:href="vtl-20230630.xsd#CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_373a0829-9156-47d9-a939-002524f81e68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4bbd8155-52b2-4bb8-929a-5621d1ddae62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_373a0829-9156-47d9-a939-002524f81e68" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_4bbd8155-52b2-4bb8-929a-5621d1ddae62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8a7d51fd-0cb1-4159-9ca2-2b1e339e91a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_373a0829-9156-47d9-a939-002524f81e68" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8a7d51fd-0cb1-4159-9ca2-2b1e339e91a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_05b399f2-04cc-4e28-866c-4eb31c63e4a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_373a0829-9156-47d9-a939-002524f81e68" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_05b399f2-04cc-4e28-866c-4eb31c63e4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2128aeaa-33c2-4f69-8d37-b1e7b48a5b11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_373a0829-9156-47d9-a939-002524f81e68" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2128aeaa-33c2-4f69-8d37-b1e7b48a5b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_bb02319f-57ca-49a7-9e8c-95847dfc998c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_373a0829-9156-47d9-a939-002524f81e68" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_bb02319f-57ca-49a7-9e8c-95847dfc998c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_LesseeOperatingLeaseLiabilityPaymentsAfterDueYearFour_63bd7d75-5758-4df7-88a3-855746aec587" xlink:href="vtl-20230630.xsd#vtl_LesseeOperatingLeaseLiabilityPaymentsAfterDueYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_373a0829-9156-47d9-a939-002524f81e68" xlink:to="loc_vtl_LesseeOperatingLeaseLiabilityPaymentsAfterDueYearFour_63bd7d75-5758-4df7-88a3-855746aec587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_141aa047-2e0b-46b6-9a84-f926060c6396" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_373a0829-9156-47d9-a939-002524f81e68" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_141aa047-2e0b-46b6-9a84-f926060c6396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c259db26-8224-4735-a421-658df9a6c704" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_373a0829-9156-47d9-a939-002524f81e68" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c259db26-8224-4735-a421-658df9a6c704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_aede6d13-0fad-4fbf-8734-df2911a5880e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_373a0829-9156-47d9-a939-002524f81e68" xlink:to="loc_us-gaap_OperatingLeaseLiability_aede6d13-0fad-4fbf-8734-df2911a5880e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1" xlink:type="simple" xlink:href="vtl-20230630.xsd#CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="vtl-20230630.xsd#FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_677413aa-de44-4abc-ba77-2f18592c4b18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1eafa265-26b1-434f-9bae-9f444eb74fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_677413aa-de44-4abc-ba77-2f18592c4b18" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1eafa265-26b1-434f-9bae-9f444eb74fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1d2cfe79-8b4e-4ed0-8615-80459355d88a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1eafa265-26b1-434f-9bae-9f444eb74fa7" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1d2cfe79-8b4e-4ed0-8615-80459355d88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_16f67809-fd68-41c5-bc4a-5c23b80b4a08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1d2cfe79-8b4e-4ed0-8615-80459355d88a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_16f67809-fd68-41c5-bc4a-5c23b80b4a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_6052158b-e44a-4d20-a162-cd15c2331fba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_16f67809-fd68-41c5-bc4a-5c23b80b4a08" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_6052158b-e44a-4d20-a162-cd15c2331fba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_6b9068a3-a6ae-4b18-8cb4-588c6d40d4c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1eafa265-26b1-434f-9bae-9f444eb74fa7" xlink:to="loc_us-gaap_InvestmentTypeAxis_6b9068a3-a6ae-4b18-8cb4-588c6d40d4c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_cc4f22bc-d9b6-48ec-abe0-3e5bc5e75c96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_6b9068a3-a6ae-4b18-8cb4-588c6d40d4c6" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_cc4f22bc-d9b6-48ec-abe0-3e5bc5e75c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_91711c19-4f28-48d2-b619-48e967bdca49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_cc4f22bc-d9b6-48ec-abe0-3e5bc5e75c96" xlink:to="loc_us-gaap_MoneyMarketFundsMember_91711c19-4f28-48d2-b619-48e967bdca49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a9c77e69-2d14-4598-ac72-0ae310a5d548" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1eafa265-26b1-434f-9bae-9f444eb74fa7" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a9c77e69-2d14-4598-ac72-0ae310a5d548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a9914b4-1b6d-4e08-87b3-032671de5fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a9c77e69-2d14-4598-ac72-0ae310a5d548" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a9914b4-1b6d-4e08-87b3-032671de5fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_3236ace6-dc69-4d2b-ba9a-ea347f324013" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a9914b4-1b6d-4e08-87b3-032671de5fe3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_3236ace6-dc69-4d2b-ba9a-ea347f324013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b94ee2b4-dda0-4961-b7a8-1e77bb6c5038" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a9914b4-1b6d-4e08-87b3-032671de5fe3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b94ee2b4-dda0-4961-b7a8-1e77bb6c5038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3b5631ae-ae5a-471c-986f-d75f43135d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4a9914b4-1b6d-4e08-87b3-032671de5fe3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3b5631ae-ae5a-471c-986f-d75f43135d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8c1e91b7-de1d-4650-9a52-38380e744693" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1eafa265-26b1-434f-9bae-9f444eb74fa7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8c1e91b7-de1d-4650-9a52-38380e744693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_6bf82870-1409-415c-b69d-3b1ce3742897" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8c1e91b7-de1d-4650-9a52-38380e744693" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_6bf82870-1409-415c-b69d-3b1ce3742897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_42791401-fabb-485e-be12-23ae9e8a79ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_6bf82870-1409-415c-b69d-3b1ce3742897" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_42791401-fabb-485e-be12-23ae9e8a79ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/FairValueAdditionalInformationDetail" xlink:type="simple" xlink:href="vtl-20230630.xsd#FairValueAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/FairValueAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a67a26c7-004e-4491-9868-adcb5695cce8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_376f828e-67cc-46a8-9cbb-55059a800525" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a67a26c7-004e-4491-9868-adcb5695cce8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_376f828e-67cc-46a8-9cbb-55059a800525" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8847ea3e-89be-4874-a0ef-4ebf3c3d3636" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_376f828e-67cc-46a8-9cbb-55059a800525" xlink:to="loc_srt_StatementGeographicalAxis_8847ea3e-89be-4874-a0ef-4ebf3c3d3636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1f44bdf5-76f5-41d9-9c06-4484e92f3be7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_8847ea3e-89be-4874-a0ef-4ebf3c3d3636" xlink:to="loc_srt_SegmentGeographicalDomain_1f44bdf5-76f5-41d9-9c06-4484e92f3be7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_ce26e782-ed36-4299-b547-95e7c0391538" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1f44bdf5-76f5-41d9-9c06-4484e92f3be7" xlink:to="loc_country_US_ce26e782-ed36-4299-b547-95e7c0391538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_d0be6786-219e-4287-b355-a5a7c75fcf2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_376f828e-67cc-46a8-9cbb-55059a800525" xlink:to="loc_us-gaap_InvestmentTypeAxis_d0be6786-219e-4287-b355-a5a7c75fcf2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_e7eba104-7ad2-45f7-8bb0-a82462e9528e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_d0be6786-219e-4287-b355-a5a7c75fcf2f" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_e7eba104-7ad2-45f7-8bb0-a82462e9528e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_bf5add1e-ad66-435e-8127-d1f7b9fd0b92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_e7eba104-7ad2-45f7-8bb0-a82462e9528e" xlink:to="loc_us-gaap_MoneyMarketFundsMember_bf5add1e-ad66-435e-8127-d1f7b9fd0b92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff6a1bb7-4822-4d5b-94db-31ac87b1a2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_376f828e-67cc-46a8-9cbb-55059a800525" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff6a1bb7-4822-4d5b-94db-31ac87b1a2f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentInterestRate_9e95c463-c325-44cb-aad1-68ed199b0557" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_ff6a1bb7-4822-4d5b-94db-31ac87b1a2f6" xlink:to="loc_us-gaap_InvestmentInterestRate_9e95c463-c325-44cb-aad1-68ed199b0557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails" xlink:type="simple" xlink:href="vtl-20230630.xsd#CommonStockShelfRegistrationStatementDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_73187fcd-4652-4de8-a977-f850725be6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_3c93ffd4-7e4c-4f4e-bf00-674469754a23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_73187fcd-4652-4de8-a977-f850725be6b8" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_3c93ffd4-7e4c-4f4e-bf00-674469754a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8c9c3f60-c895-42e5-b827-2d7d6c13c77a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3c93ffd4-7e4c-4f4e-bf00-674469754a23" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8c9c3f60-c895-42e5-b827-2d7d6c13c77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_03127b45-502a-4c02-976b-eb18aba72b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8c9c3f60-c895-42e5-b827-2d7d6c13c77a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_03127b45-502a-4c02-976b-eb18aba72b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_December2020ATMMember_73efb2ff-6da2-4662-910f-139465618184" xlink:href="vtl-20230630.xsd#vtl_December2020ATMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_03127b45-502a-4c02-976b-eb18aba72b2e" xlink:to="loc_vtl_December2020ATMMember_73efb2ff-6da2-4662-910f-139465618184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_May2022ATMMember_3a2e55f0-1f80-44d7-9627-5842d437f457" xlink:href="vtl-20230630.xsd#vtl_May2022ATMMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_03127b45-502a-4c02-976b-eb18aba72b2e" xlink:to="loc_vtl_May2022ATMMember_3a2e55f0-1f80-44d7-9627-5842d437f457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_48f147e3-6408-48cd-9325-b37f4df2c02b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3c93ffd4-7e4c-4f4e-bf00-674469754a23" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_48f147e3-6408-48cd-9325-b37f4df2c02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_4de5d364-bf55-40bc-92f4-439caac8c9a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_48f147e3-6408-48cd-9325-b37f4df2c02b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_4de5d364-bf55-40bc-92f4-439caac8c9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_5b88004c-9cb1-47a6-ae7c-a1568a75f71a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_4de5d364-bf55-40bc-92f4-439caac8c9a1" xlink:to="loc_us-gaap_SubsequentEventMember_5b88004c-9cb1-47a6-ae7c-a1568a75f71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_e738d51c-27be-4f54-ba42-eee7fc615aba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_3c93ffd4-7e4c-4f4e-bf00-674469754a23" xlink:to="loc_us-gaap_ClassOfStockLineItems_e738d51c-27be-4f54-ba42-eee7fc615aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_ff4cecf0-f5c0-4797-aeb7-b215291dfa13" xlink:href="vtl-20230630.xsd#vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e738d51c-27be-4f54-ba42-eee7fc615aba" xlink:to="loc_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration_ff4cecf0-f5c0-4797-aeb7-b215291dfa13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationStatementAmountRemaining_40aea17a-2197-42a3-9c87-823a75c0f491" xlink:href="vtl-20230630.xsd#vtl_ShelfRegistrationStatementAmountRemaining"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e738d51c-27be-4f54-ba42-eee7fc615aba" xlink:to="loc_vtl_ShelfRegistrationStatementAmountRemaining_40aea17a-2197-42a3-9c87-823a75c0f491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationTerminationPriorWrittenNotice_d4a7a108-3a46-49c9-9731-3103ff93059c" xlink:href="vtl-20230630.xsd#vtl_ShelfRegistrationTerminationPriorWrittenNotice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e738d51c-27be-4f54-ba42-eee7fc615aba" xlink:to="loc_vtl_ShelfRegistrationTerminationPriorWrittenNotice_d4a7a108-3a46-49c9-9731-3103ff93059c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SaleOfStockRemainingCapacity_5ff8bf67-e03a-42b1-83cb-153e55b6fb1f" xlink:href="vtl-20230630.xsd#vtl_SaleOfStockRemainingCapacity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e738d51c-27be-4f54-ba42-eee7fc615aba" xlink:to="loc_vtl_SaleOfStockRemainingCapacity_5ff8bf67-e03a-42b1-83cb-153e55b6fb1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_9a168a88-6a9b-4426-8899-b018e8f3bc56" xlink:href="vtl-20230630.xsd#vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e738d51c-27be-4f54-ba42-eee7fc615aba" xlink:to="loc_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock_9a168a88-6a9b-4426-8899-b018e8f3bc56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_81c6743e-5a24-4d2c-bddb-5c8d6fc852b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e738d51c-27be-4f54-ba42-eee7fc615aba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_81c6743e-5a24-4d2c-bddb-5c8d6fc852b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d3af39f0-8fca-4d1c-b1a1-260d5889cec1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e738d51c-27be-4f54-ba42-eee7fc615aba" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_d3af39f0-8fca-4d1c-b1a1-260d5889cec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SharesIssuedWeightedAverageSharePricePerShare_6ad7260d-fbbe-4e47-aaa6-079ad776a5c8" xlink:href="vtl-20230630.xsd#vtl_SharesIssuedWeightedAverageSharePricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e738d51c-27be-4f54-ba42-eee7fc615aba" xlink:to="loc_vtl_SharesIssuedWeightedAverageSharePricePerShare_6ad7260d-fbbe-4e47-aaa6-079ad776a5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_da917ab9-7bc3-4d49-b794-765aa34b02b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e738d51c-27be-4f54-ba42-eee7fc615aba" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_da917ab9-7bc3-4d49-b794-765aa34b02b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForCommissions_a92e439b-9398-496b-b22d-c5ae79b29d81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForCommissions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_e738d51c-27be-4f54-ba42-eee7fc615aba" xlink:to="loc_us-gaap_PaymentsForCommissions_a92e439b-9398-496b-b22d-c5ae79b29d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockEquityOfferingDetails" xlink:type="simple" xlink:href="vtl-20230630.xsd#CommonStockEquityOfferingDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockEquityOfferingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_89dc979b-d050-4a34-b1a6-9a7681e0237e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_bd71d29d-5c71-4560-8ef9-bd9de202bfa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_89dc979b-d050-4a34-b1a6-9a7681e0237e" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_bd71d29d-5c71-4560-8ef9-bd9de202bfa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_06deb004-9121-45c4-b140-897aeedbac0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bd71d29d-5c71-4560-8ef9-bd9de202bfa5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_06deb004-9121-45c4-b140-897aeedbac0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7e81c1ef-49c1-437b-b512-08d086dc5060" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_06deb004-9121-45c4-b140-897aeedbac0e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7e81c1ef-49c1-437b-b512-08d086dc5060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f365ddc2-418d-4001-a87f-f46ca1594672" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7e81c1ef-49c1-437b-b512-08d086dc5060" xlink:to="loc_us-gaap_CommonStockMember_f365ddc2-418d-4001-a87f-f46ca1594672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_PreFundedWarrantsMember_b05be385-d22f-4b1c-884f-b887ec176a4d" xlink:href="vtl-20230630.xsd#vtl_PreFundedWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7e81c1ef-49c1-437b-b512-08d086dc5060" xlink:to="loc_vtl_PreFundedWarrantsMember_b05be385-d22f-4b1c-884f-b887ec176a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_8f139a18-7f60-404e-9c89-3742f8e25ccf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_bd71d29d-5c71-4560-8ef9-bd9de202bfa5" xlink:to="loc_us-gaap_ClassOfStockLineItems_8f139a18-7f60-404e-9c89-3742f8e25ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b0dd668f-9c0d-4137-aa79-7c22ba20839a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f139a18-7f60-404e-9c89-3742f8e25ccf" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_b0dd668f-9c0d-4137-aa79-7c22ba20839a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_388036e6-fb32-4796-9334-d581fb52bda7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f139a18-7f60-404e-9c89-3742f8e25ccf" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_388036e6-fb32-4796-9334-d581fb52bda7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_40c8bd0d-45a2-4a51-93bf-3bc49a870eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8f139a18-7f60-404e-9c89-3742f8e25ccf" xlink:to="loc_us-gaap_SharePrice_40c8bd0d-45a2-4a51-93bf-3bc49a870eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockCommonStockDetails" xlink:type="simple" xlink:href="vtl-20230630.xsd#CommonStockCommonStockDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_28c915cc-b01b-46c0-abee-70674d41eacf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_adb595fc-6447-4b8c-beab-6c4e8a595252" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_28c915cc-b01b-46c0-abee-70674d41eacf" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_adb595fc-6447-4b8c-beab-6c4e8a595252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_bf7bb72a-3f26-49b9-a846-3a4d2f1d6b57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_28c915cc-b01b-46c0-abee-70674d41eacf" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_bf7bb72a-3f26-49b9-a846-3a4d2f1d6b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NumberOfVotesPerEachShareOfCommonStock_ca41ebf6-72aa-41ad-97e7-654e2e0600d5" xlink:href="vtl-20230630.xsd#vtl_NumberOfVotesPerEachShareOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_28c915cc-b01b-46c0-abee-70674d41eacf" xlink:to="loc_vtl_NumberOfVotesPerEachShareOfCommonStock_ca41ebf6-72aa-41ad-97e7-654e2e0600d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_7ce91a55-4660-46ef-a148-68a720892e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_28c915cc-b01b-46c0-abee-70674d41eacf" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_7ce91a55-4660-46ef-a148-68a720892e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_5ac9df36-87fd-4a1c-b8b1-4d6582599690" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_28c915cc-b01b-46c0-abee-70674d41eacf" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_5ac9df36-87fd-4a1c-b8b1-4d6582599690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockPreferredStockDetails" xlink:type="simple" xlink:href="vtl-20230630.xsd#CommonStockPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_39a489c8-4f8f-4a87-9ffa-13beab5573ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_b7ad5a78-188c-4545-b650-83331bc1f217" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_39a489c8-4f8f-4a87-9ffa-13beab5573ef" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_b7ad5a78-188c-4545-b650-83331bc1f217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_cce4b7f3-db69-4059-b433-a3a3b415a410" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_39a489c8-4f8f-4a87-9ffa-13beab5573ef" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_cce4b7f3-db69-4059-b433-a3a3b415a410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_a6a3a712-bc91-44e8-a334-4134c258eeeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_39a489c8-4f8f-4a87-9ffa-13beab5573ef" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_a6a3a712-bc91-44e8-a334-4134c258eeeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="vtl-20230630.xsd#CommonStockSharesReservedforFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8f1709e6-e540-4078-9543-bac9a6fcab26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_dfe10daf-4eb6-42dc-bfd1-43fc2583835a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8f1709e6-e540-4078-9543-bac9a6fcab26" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_dfe10daf-4eb6-42dc-bfd1-43fc2583835a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c2b5a30a-9711-4ea0-9310-cdf31671289b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_dfe10daf-4eb6-42dc-bfd1-43fc2583835a" xlink:to="loc_us-gaap_AwardTypeAxis_c2b5a30a-9711-4ea0-9310-cdf31671289b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7e52dfb-86a2-46e3-9390-f8b489b08272" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c2b5a30a-9711-4ea0-9310-cdf31671289b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7e52dfb-86a2-46e3-9390-f8b489b08272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e218b95c-1d71-4f9a-9be0-7cc9d75caa8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7e52dfb-86a2-46e3-9390-f8b489b08272" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e218b95c-1d71-4f9a-9be0-7cc9d75caa8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeStockOptionsforFutureGrantMember_24fc63bc-42ac-493c-9f95-c78a1eae4c7a" xlink:href="vtl-20230630.xsd#vtl_EmployeeStockOptionsforFutureGrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c7e52dfb-86a2-46e3-9390-f8b489b08272" xlink:to="loc_vtl_EmployeeStockOptionsforFutureGrantMember_24fc63bc-42ac-493c-9f95-c78a1eae4c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_5b9d11fc-d28a-431c-8d97-b431f8927ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_dfe10daf-4eb6-42dc-bfd1-43fc2583835a" xlink:to="loc_us-gaap_PlanNameAxis_5b9d11fc-d28a-431c-8d97-b431f8927ae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7ceb4841-d7f5-4650-bd08-c0299919b86a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_5b9d11fc-d28a-431c-8d97-b431f8927ae8" xlink:to="loc_us-gaap_PlanNameDomain_7ceb4841-d7f5-4650-bd08-c0299919b86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2021EmployeeStockPurchasePlanMember_179be7dc-d2af-4e88-9de8-42ef2e5e5075" xlink:href="vtl-20230630.xsd#vtl_A2021EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7ceb4841-d7f5-4650-bd08-c0299919b86a" xlink:to="loc_vtl_A2021EmployeeStockPurchasePlanMember_179be7dc-d2af-4e88-9de8-42ef2e5e5075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_98bd4ebb-42a3-4ece-b010-d9dc947ada22" xlink:href="vtl-20230630.xsd#vtl_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7ceb4841-d7f5-4650-bd08-c0299919b86a" xlink:to="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_98bd4ebb-42a3-4ece-b010-d9dc947ada22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2017InducementEquityIncentivePlanMember_96ed3c5a-49aa-4102-90ea-001478f7f284" xlink:href="vtl-20230630.xsd#vtl_A2017InducementEquityIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7ceb4841-d7f5-4650-bd08-c0299919b86a" xlink:to="loc_vtl_A2017InducementEquityIncentivePlanMember_96ed3c5a-49aa-4102-90ea-001478f7f284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_b91826b4-67ed-4072-9bd4-3dee639d7304" xlink:href="vtl-20230630.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7ceb4841-d7f5-4650-bd08-c0299919b86a" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_b91826b4-67ed-4072-9bd4-3dee639d7304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_0a508018-9eec-4aa7-8eb5-2bf57b38a50d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_dfe10daf-4eb6-42dc-bfd1-43fc2583835a" xlink:to="loc_us-gaap_ClassOfStockLineItems_0a508018-9eec-4aa7-8eb5-2bf57b38a50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6b025bd2-bee9-47a1-9b50-134b81ac1782" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0a508018-9eec-4aa7-8eb5-2bf57b38a50d" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6b025bd2-bee9-47a1-9b50-134b81ac1782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20230630.xsd#StockBasedCompensationPlansAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62fe8c0e-110e-4d2c-9d82-951624ed59a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3b2fe310-18f8-44a4-b009-57a75136b8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_62fe8c0e-110e-4d2c-9d82-951624ed59a9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3b2fe310-18f8-44a4-b009-57a75136b8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_37937fda-7c4b-4c5e-b6b8-7194665d8318" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3b2fe310-18f8-44a4-b009-57a75136b8e3" xlink:to="loc_us-gaap_PlanNameAxis_37937fda-7c4b-4c5e-b6b8-7194665d8318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_568bd638-d36d-46ba-839a-f3ea323edc8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_37937fda-7c4b-4c5e-b6b8-7194665d8318" xlink:to="loc_us-gaap_PlanNameDomain_568bd638-d36d-46ba-839a-f3ea323edc8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2021EmployeeStockPurchasePlanMember_387d3219-ca24-4084-ae5b-76ef9336895f" xlink:href="vtl-20230630.xsd#vtl_A2021EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_568bd638-d36d-46ba-839a-f3ea323edc8f" xlink:to="loc_vtl_A2021EmployeeStockPurchasePlanMember_387d3219-ca24-4084-ae5b-76ef9336895f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2019OmnibusEquityIncentivePlanMember_aad20f3f-7261-43e0-96ba-85943a96fd94" xlink:href="vtl-20230630.xsd#vtl_A2019OmnibusEquityIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_568bd638-d36d-46ba-839a-f3ea323edc8f" xlink:to="loc_vtl_A2019OmnibusEquityIncentivePlanMember_aad20f3f-7261-43e0-96ba-85943a96fd94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_8010e7d8-64e7-4f9f-b990-f12a023a9ea5" xlink:href="vtl-20230630.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_vtl_A2019OmnibusEquityIncentivePlanMember_aad20f3f-7261-43e0-96ba-85943a96fd94" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember_8010e7d8-64e7-4f9f-b990-f12a023a9ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_116aae54-ce62-4b15-abe2-a24179723adf" xlink:href="vtl-20230630.xsd#vtl_TwoThousandFourteenEquityIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_568bd638-d36d-46ba-839a-f3ea323edc8f" xlink:to="loc_vtl_TwoThousandFourteenEquityIncentivePlanMember_116aae54-ce62-4b15-abe2-a24179723adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2017InducementEquityIncentivePlanMember_ded195d2-cef6-44d2-a616-bd479ae2fcfd" xlink:href="vtl-20230630.xsd#vtl_A2017InducementEquityIncentivePlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_568bd638-d36d-46ba-839a-f3ea323edc8f" xlink:to="loc_vtl_A2017InducementEquityIncentivePlanMember_ded195d2-cef6-44d2-a616-bd479ae2fcfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cc0da4f2-5f0b-4de3-b35e-385ffbf75712" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3b2fe310-18f8-44a4-b009-57a75136b8e3" xlink:to="loc_srt_RangeAxis_cc0da4f2-5f0b-4de3-b35e-385ffbf75712" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a2ff7d3d-e798-4896-a961-b62a89b289b1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_cc0da4f2-5f0b-4de3-b35e-385ffbf75712" xlink:to="loc_srt_RangeMember_a2ff7d3d-e798-4896-a961-b62a89b289b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_93e23195-abf6-4889-a945-511b187e7eb3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a2ff7d3d-e798-4896-a961-b62a89b289b1" xlink:to="loc_srt_MinimumMember_93e23195-abf6-4889-a945-511b187e7eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6d95c8e9-1363-4eda-b7b4-c7326476bcf8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a2ff7d3d-e798-4896-a961-b62a89b289b1" xlink:to="loc_srt_MaximumMember_6d95c8e9-1363-4eda-b7b4-c7326476bcf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2c668564-3cdc-473c-a965-bf6fd64252c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3b2fe310-18f8-44a4-b009-57a75136b8e3" xlink:to="loc_us-gaap_AwardTypeAxis_2c668564-3cdc-473c-a965-bf6fd64252c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd9fd945-5293-480a-a8e9-a483868b996b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2c668564-3cdc-473c-a965-bf6fd64252c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd9fd945-5293-480a-a8e9-a483868b996b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_IncentiveEmployeeStockOptionMember_4356d677-9416-42e6-9e1b-ee8058fe0753" xlink:href="vtl-20230630.xsd#vtl_IncentiveEmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd9fd945-5293-480a-a8e9-a483868b996b" xlink:to="loc_vtl_IncentiveEmployeeStockOptionMember_4356d677-9416-42e6-9e1b-ee8058fe0753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_NonStatutoryEmployeeStockOptionMember_e92cdd28-6a69-41b1-81a5-6b223af470f8" xlink:href="vtl-20230630.xsd#vtl_NonStatutoryEmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd9fd945-5293-480a-a8e9-a483868b996b" xlink:to="loc_vtl_NonStatutoryEmployeeStockOptionMember_e92cdd28-6a69-41b1-81a5-6b223af470f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c9d610-1335-4ddd-88b6-ff7192066b69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3b2fe310-18f8-44a4-b009-57a75136b8e3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c9d610-1335-4ddd-88b6-ff7192066b69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_b7b85510-a859-4c08-bfb1-64e82b9f87ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c9d610-1335-4ddd-88b6-ff7192066b69" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_b7b85510-a859-4c08-bfb1-64e82b9f87ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_26569d53-e889-4394-8b47-7ac66823b714" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c9d610-1335-4ddd-88b6-ff7192066b69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_26569d53-e889-4394-8b47-7ac66823b714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4a04d74f-8e08-42a9-a248-497fe0b7ce09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c9d610-1335-4ddd-88b6-ff7192066b69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4a04d74f-8e08-42a9-a248-497fe0b7ce09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a386f9be-017b-49aa-976c-474d4ba2a263" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c9d610-1335-4ddd-88b6-ff7192066b69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a386f9be-017b-49aa-976c-474d4ba2a263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_75c5d12c-b8ce-47eb-855a-04db59970ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c9d610-1335-4ddd-88b6-ff7192066b69" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_75c5d12c-b8ce-47eb-855a-04db59970ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_3efd5030-c330-4308-8073-355a229823cb" xlink:href="vtl-20230630.xsd#vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c9d610-1335-4ddd-88b6-ff7192066b69" xlink:to="loc_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent_3efd5030-c330-4308-8073-355a229823cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_4b0577f6-0a60-47f0-adab-b9757ddfe767" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c9d610-1335-4ddd-88b6-ff7192066b69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_4b0577f6-0a60-47f0-adab-b9757ddfe767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_e7908415-3568-4f2a-97b3-79bf325acedd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c9d610-1335-4ddd-88b6-ff7192066b69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease_e7908415-3568-4f2a-97b3-79bf325acedd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_95498cbf-68ee-49ac-b526-58fc2a26637a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c9d610-1335-4ddd-88b6-ff7192066b69" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_95498cbf-68ee-49ac-b526-58fc2a26637a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_268f5f73-6a96-488a-8e70-b43aa334bf77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c9d610-1335-4ddd-88b6-ff7192066b69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_268f5f73-6a96-488a-8e70-b43aa334bf77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d0cbeda8-b15e-40ea-a0f4-2f98ac89866e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c9d610-1335-4ddd-88b6-ff7192066b69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d0cbeda8-b15e-40ea-a0f4-2f98ac89866e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4f10bc13-8d9d-4b75-9586-1a9a81f3cfdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c9d610-1335-4ddd-88b6-ff7192066b69" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4f10bc13-8d9d-4b75-9586-1a9a81f3cfdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6cf447bc-fbd1-4ac7-afad-22ad7fb9cf6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c9d610-1335-4ddd-88b6-ff7192066b69" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6cf447bc-fbd1-4ac7-afad-22ad7fb9cf6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_35657e09-0d58-485a-acec-bebef3d14b12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13c9d610-1335-4ddd-88b6-ff7192066b69" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_35657e09-0d58-485a-acec-bebef3d14b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="vtl-20230630.xsd#StockBasedCompensationPlansSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_037ff3b0-1137-4822-811a-dde2d316d375" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cac52ec3-df56-448d-9cbc-ad0fc3f8c9cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_037ff3b0-1137-4822-811a-dde2d316d375" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cac52ec3-df56-448d-9cbc-ad0fc3f8c9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_81ff37a2-1afa-4dec-a5e6-bfb4f4daa59e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cac52ec3-df56-448d-9cbc-ad0fc3f8c9cc" xlink:to="loc_us-gaap_PlanNameAxis_81ff37a2-1afa-4dec-a5e6-bfb4f4daa59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_bdbdc5ab-4c50-4259-9d5f-d08d3253113c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_81ff37a2-1afa-4dec-a5e6-bfb4f4daa59e" xlink:to="loc_us-gaap_PlanNameDomain_bdbdc5ab-4c50-4259-9d5f-d08d3253113c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_a563c571-57c2-4c3f-a65b-5827bfef9322" xlink:href="vtl-20230630.xsd#vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_bdbdc5ab-4c50-4259-9d5f-d08d3253113c" xlink:to="loc_vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember_a563c571-57c2-4c3f-a65b-5827bfef9322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d4de9201-1aa3-455b-b078-c34252808964" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cac52ec3-df56-448d-9cbc-ad0fc3f8c9cc" xlink:to="loc_us-gaap_AwardTypeAxis_d4de9201-1aa3-455b-b078-c34252808964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a3bc989-5c72-42e5-b0ee-adb9872c742d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d4de9201-1aa3-455b-b078-c34252808964" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a3bc989-5c72-42e5-b0ee-adb9872c742d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d77d369e-e3a6-4c8c-a887-d36deba11bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a3bc989-5c72-42e5-b0ee-adb9872c742d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d77d369e-e3a6-4c8c-a887-d36deba11bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38377ea4-6d43-4756-83c4-d0dfffe86dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cac52ec3-df56-448d-9cbc-ad0fc3f8c9cc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38377ea4-6d43-4756-83c4-d0dfffe86dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7971d8b8-28d6-447c-90b9-0b520bf0bba1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38377ea4-6d43-4756-83c4-d0dfffe86dd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7971d8b8-28d6-447c-90b9-0b520bf0bba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2020b11b-80e6-4689-903c-a6ce7c17e26c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7971d8b8-28d6-447c-90b9-0b520bf0bba1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2020b11b-80e6-4689-903c-a6ce7c17e26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_28c313f3-60b3-4b09-adfb-ddd53a98012e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7971d8b8-28d6-447c-90b9-0b520bf0bba1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_28c313f3-60b3-4b09-adfb-ddd53a98012e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3c35c49f-69e0-4a67-a048-9ab6ba383efe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7971d8b8-28d6-447c-90b9-0b520bf0bba1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3c35c49f-69e0-4a67-a048-9ab6ba383efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c92df319-1c36-4ff2-a0e0-90674ee3d369" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7971d8b8-28d6-447c-90b9-0b520bf0bba1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_c92df319-1c36-4ff2-a0e0-90674ee3d369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_52721806-9d66-41f9-a06a-20cd11e664b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7971d8b8-28d6-447c-90b9-0b520bf0bba1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_52721806-9d66-41f9-a06a-20cd11e664b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_26ef5cab-3106-4573-ac1d-5a978b97c760" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38377ea4-6d43-4756-83c4-d0dfffe86dd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_26ef5cab-3106-4573-ac1d-5a978b97c760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9c5ed6c9-af26-47fb-b1ad-5f675ef8f1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38377ea4-6d43-4756-83c4-d0dfffe86dd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9c5ed6c9-af26-47fb-b1ad-5f675ef8f1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9e6b5a2c-029e-4a0e-be11-38cfc53cf78b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38377ea4-6d43-4756-83c4-d0dfffe86dd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9e6b5a2c-029e-4a0e-be11-38cfc53cf78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c209884a-275d-4b7d-ac43-8822f3a0642a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9e6b5a2c-029e-4a0e-be11-38cfc53cf78b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c209884a-275d-4b7d-ac43-8822f3a0642a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_32baeb1b-8ce3-4930-aef5-6287bd27468b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9e6b5a2c-029e-4a0e-be11-38cfc53cf78b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_32baeb1b-8ce3-4930-aef5-6287bd27468b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ab38bc66-7a69-4850-94a1-6597c6e4722b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9e6b5a2c-029e-4a0e-be11-38cfc53cf78b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ab38bc66-7a69-4850-94a1-6597c6e4722b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_83863218-31f2-44af-a3da-8d66fc110144" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9e6b5a2c-029e-4a0e-be11-38cfc53cf78b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_83863218-31f2-44af-a3da-8d66fc110144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_eac9ad26-69db-4325-a73a-1c7dc2b51727" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9e6b5a2c-029e-4a0e-be11-38cfc53cf78b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_eac9ad26-69db-4325-a73a-1c7dc2b51727" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_dcb2e38e-5dc4-4c79-9150-389df9b187a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38377ea4-6d43-4756-83c4-d0dfffe86dd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_dcb2e38e-5dc4-4c79-9150-389df9b187a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_90f3d083-427e-40ae-8b67-20425d4901c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38377ea4-6d43-4756-83c4-d0dfffe86dd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_90f3d083-427e-40ae-8b67-20425d4901c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ba222853-bf1e-418b-9122-efc779de9c41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_38377ea4-6d43-4756-83c4-d0dfffe86dd1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ba222853-bf1e-418b-9122-efc779de9c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_09c14cf0-cc08-41d8-9974-9231bb14441d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ba222853-bf1e-418b-9122-efc779de9c41" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_09c14cf0-cc08-41d8-9974-9231bb14441d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_ec8c8f12-c66e-4f8e-b1d6-9e3918b07a59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ba222853-bf1e-418b-9122-efc779de9c41" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_ec8c8f12-c66e-4f8e-b1d6-9e3918b07a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_cd9902f3-3e29-4cac-9ffe-d63e115ab58d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ba222853-bf1e-418b-9122-efc779de9c41" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_cd9902f3-3e29-4cac-9ffe-d63e115ab58d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_295b254d-acaa-4cdd-9254-f99325622afb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ba222853-bf1e-418b-9122-efc779de9c41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_295b254d-acaa-4cdd-9254-f99325622afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_0a603a94-2ea5-4a24-bc74-aaadfa70cbdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ba222853-bf1e-418b-9122-efc779de9c41" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_0a603a94-2ea5-4a24-bc74-aaadfa70cbdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f97d87f8-3c0e-4530-a7cf-17d792048620" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_ba222853-bf1e-418b-9122-efc779de9c41" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f97d87f8-3c0e-4530-a7cf-17d792048620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail" xlink:type="simple" xlink:href="vtl-20230630.xsd#StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_df7090ef-c281-4a1c-8a86-a29653fea8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a17c45bb-e534-4fc9-9674-829bf9541990" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_df7090ef-c281-4a1c-8a86-a29653fea8a5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a17c45bb-e534-4fc9-9674-829bf9541990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_54fe13fa-c555-4164-af9b-f3a8c948bf00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a17c45bb-e534-4fc9-9674-829bf9541990" xlink:to="loc_us-gaap_PlanNameAxis_54fe13fa-c555-4164-af9b-f3a8c948bf00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c1727c44-6666-41d5-b486-ac98a8b3917b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_54fe13fa-c555-4164-af9b-f3a8c948bf00" xlink:to="loc_us-gaap_PlanNameDomain_c1727c44-6666-41d5-b486-ac98a8b3917b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_A2019OmnibusEquityIncentivePlanMember_a86a97d8-a97c-4118-962e-d5f8e0a4d78c" xlink:href="vtl-20230630.xsd#vtl_A2019OmnibusEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c1727c44-6666-41d5-b486-ac98a8b3917b" xlink:to="loc_vtl_A2019OmnibusEquityIncentivePlanMember_a86a97d8-a97c-4118-962e-d5f8e0a4d78c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6afa730a-12e0-4a82-a536-9c43a3a5505e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a17c45bb-e534-4fc9-9674-829bf9541990" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6afa730a-12e0-4a82-a536-9c43a3a5505e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9c9f1e25-55fc-4e6f-964f-23591bc58adb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6afa730a-12e0-4a82-a536-9c43a3a5505e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_9c9f1e25-55fc-4e6f-964f-23591bc58adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_305fe672-1fa2-41f6-b631-ee636629927a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6afa730a-12e0-4a82-a536-9c43a3a5505e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_305fe672-1fa2-41f6-b631-ee636629927a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5bb3b23c-a732-4e9d-b1d2-adc157dff24c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6afa730a-12e0-4a82-a536-9c43a3a5505e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5bb3b23c-a732-4e9d-b1d2-adc157dff24c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_43546050-7637-46b7-bad3-b6288eeefae3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6afa730a-12e0-4a82-a536-9c43a3a5505e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_43546050-7637-46b7-bad3-b6288eeefae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" xlink:type="simple" xlink:href="vtl-20230630.xsd#StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f35c4103-9a62-4813-a1df-b6b74316b352" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_49ffc662-f30d-4e58-bfed-834da60c8c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f35c4103-9a62-4813-a1df-b6b74316b352" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_49ffc662-f30d-4e58-bfed-834da60c8c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_10d9bfd2-bbcf-49b6-9d56-5ef7acab10cf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_49ffc662-f30d-4e58-bfed-834da60c8c3d" xlink:to="loc_srt_TitleOfIndividualAxis_10d9bfd2-bbcf-49b6-9d56-5ef7acab10cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_af8b51d3-b879-460e-a4fa-a3456eacedba" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_10d9bfd2-bbcf-49b6-9d56-5ef7acab10cf" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_af8b51d3-b879-460e-a4fa-a3456eacedba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_EmployeeMember_b4008d49-61f4-436b-9368-c5aa0bbb81db" xlink:href="vtl-20230630.xsd#vtl_EmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_af8b51d3-b879-460e-a4fa-a3456eacedba" xlink:to="loc_vtl_EmployeeMember_b4008d49-61f4-436b-9368-c5aa0bbb81db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8a0892cd-f53f-41f9-b99b-0e15a38079c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_49ffc662-f30d-4e58-bfed-834da60c8c3d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8a0892cd-f53f-41f9-b99b-0e15a38079c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ec82dedc-7a55-4522-9c18-52ce91f1ce37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8a0892cd-f53f-41f9-b99b-0e15a38079c6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ec82dedc-7a55-4522-9c18-52ce91f1ce37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2074ed19-e2ff-41f7-b7ea-16e2d9ea13f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ec82dedc-7a55-4522-9c18-52ce91f1ce37" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2074ed19-e2ff-41f7-b7ea-16e2d9ea13f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7833a18e-13c3-40cd-a297-9da63c036295" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ec82dedc-7a55-4522-9c18-52ce91f1ce37" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_7833a18e-13c3-40cd-a297-9da63c036295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ec20940d-1a34-438d-83f1-bf93fe149d90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_49ffc662-f30d-4e58-bfed-834da60c8c3d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ec20940d-1a34-438d-83f1-bf93fe149d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f08222e4-9d40-4021-b7b4-a8a6be27101a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_ec20940d-1a34-438d-83f1-bf93fe149d90" xlink:to="loc_us-gaap_ShareBasedCompensation_f08222e4-9d40-4021-b7b4-a8a6be27101a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="vtl-20230630.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_89d9f3ef-5419-41f0-a629-0e3d0036c548" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3d16030d-b205-4335-aa73-179f4dd0d188" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_89d9f3ef-5419-41f0-a629-0e3d0036c548" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3d16030d-b205-4335-aa73-179f4dd0d188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_805d2e9a-d50d-4bb2-8ae9-fb9737e1ee1f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3d16030d-b205-4335-aa73-179f4dd0d188" xlink:to="loc_srt_CounterpartyNameAxis_805d2e9a-d50d-4bb2-8ae9-fb9737e1ee1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_11c15060-2412-408b-8cc5-0d2df448772b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_805d2e9a-d50d-4bb2-8ae9-fb9737e1ee1f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_11c15060-2412-408b-8cc5-0d2df448772b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_DuaneNashMDJDMBAMember_767c3f04-4eac-4605-afce-1eec6e6b1312" xlink:href="vtl-20230630.xsd#vtl_DuaneNashMDJDMBAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_11c15060-2412-408b-8cc5-0d2df448772b" xlink:to="loc_vtl_DuaneNashMDJDMBAMember_767c3f04-4eac-4605-afce-1eec6e6b1312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_702d7b77-0f07-4c10-9dae-7cac51672de2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3d16030d-b205-4335-aa73-179f4dd0d188" xlink:to="loc_srt_StatementScenarioAxis_702d7b77-0f07-4c10-9dae-7cac51672de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_65ddd69c-63c4-41fd-be5f-6b5e90ec19fe" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_702d7b77-0f07-4c10-9dae-7cac51672de2" xlink:to="loc_srt_ScenarioUnspecifiedDomain_65ddd69c-63c4-41fd-be5f-6b5e90ec19fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_dadc173b-baf0-4cae-8d3b-19dd37f54d21" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_65ddd69c-63c4-41fd-be5f-6b5e90ec19fe" xlink:to="loc_srt_ScenarioForecastMember_dadc173b-baf0-4cae-8d3b-19dd37f54d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_0b6de7fe-14ff-4970-bf61-9b3e92dc1805" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3d16030d-b205-4335-aa73-179f4dd0d188" xlink:to="loc_srt_TitleOfIndividualAxis_0b6de7fe-14ff-4970-bf61-9b3e92dc1805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0168d55f-020a-4bab-9243-ed77e1476852" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_0b6de7fe-14ff-4970-bf61-9b3e92dc1805" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0168d55f-020a-4bab-9243-ed77e1476852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_b5f687e6-374c-436c-a6da-cb59dd2f03ce" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0168d55f-020a-4bab-9243-ed77e1476852" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_b5f687e6-374c-436c-a6da-cb59dd2f03ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_7bbda15c-3910-404f-81a2-a15721c09299" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3d16030d-b205-4335-aa73-179f4dd0d188" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_7bbda15c-3910-404f-81a2-a15721c09299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_069f0c31-5a87-488d-a712-4538e5052fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_7bbda15c-3910-404f-81a2-a15721c09299" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_069f0c31-5a87-488d-a712-4538e5052fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_ExecutiveChairmanAgreementMember_efc6491d-b919-426d-9982-d6c7161daeb4" xlink:href="vtl-20230630.xsd#vtl_ExecutiveChairmanAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_069f0c31-5a87-488d-a712-4538e5052fbf" xlink:to="loc_vtl_ExecutiveChairmanAgreementMember_efc6491d-b919-426d-9982-d6c7161daeb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bc1eee45-85ea-4185-9aed-6bfcb7e44dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3d16030d-b205-4335-aa73-179f4dd0d188" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bc1eee45-85ea-4185-9aed-6bfcb7e44dc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_30239615-6b28-44ed-8dd9-3c32dcaab47a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bc1eee45-85ea-4185-9aed-6bfcb7e44dc4" xlink:to="loc_us-gaap_RelatedPartyDomain_30239615-6b28-44ed-8dd9-3c32dcaab47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_fb349945-c6ae-4ff1-bd7b-1792808861a0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_30239615-6b28-44ed-8dd9-3c32dcaab47a" xlink:to="loc_srt_AffiliatedEntityMember_fb349945-c6ae-4ff1-bd7b-1792808861a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_3c6bf0c8-fe0e-41e9-bee6-317214640d47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_3d16030d-b205-4335-aa73-179f4dd0d188" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_3c6bf0c8-fe0e-41e9-bee6-317214640d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_vtl_SalaryCostsMonthlyBaseSalary_5c30a583-c558-42bb-aaab-612f0661c783" xlink:href="vtl-20230630.xsd#vtl_SalaryCostsMonthlyBaseSalary"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_3c6bf0c8-fe0e-41e9-bee6-317214640d47" xlink:to="loc_vtl_SalaryCostsMonthlyBaseSalary_5c30a583-c558-42bb-aaab-612f0661c783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>vtl-20230630_g1.jpg
<TEXT>
begin 644 vtl-20230630_g1.jpg
M_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B '
MS@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M]M8  0    #3+4A0("
M                     !%C<')T   !4    #-D97-C   !A    &QW='!T
M   !\    !1B:W!T   "!    !1R6%E:   "&    !1G6%E:   "+    !1B
M6%E:   "0    !1D;6YD   "5    '!D;61D   "Q    (AV=65D   #3
M (9V:65W   #U    "1L=6UI   #^    !1M96%S   $#    "1T96-H   $
M,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#   $/   " QT97AT
M     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N
M>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$              !)S
M4D="($E%0S8Q.38V+3(N,0
M                            6%E:(        /-1  $    !%LQ865H@
M                     %A96B        !OH@  ./4   .06%E:(
M &*9  "WA0  &-I865H@        )*    ^$  "VSV1E<V,         %DE%
M0R!H='1P.B\O=W=W+FEE8RYC:               %DE%0R!H='1P.B\O=W=W
M+FEE8RYC:
M          !D97-C         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="
M(&-O;&]U<B!S<&%C92 M('-21T(              "Y)14,@-C$Y-C8M,BXQ
M($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M            9&5S8P         L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET
M:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E9F5R96YC92!6:65W
M:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M             '9I97<      !.D_@ 47RX $,\4  /MS  $$PL  UR>
M 5A96B       $P)5@!0    5Q_G;65A<P         !
M         H\    "<VEG(     !#4E0@8W5R=@        0     !0 *  \
M%  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C &@ ;0!R '< ? "!
M (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -  U0#; .  Y0#K /
M]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%% 4P!4@%9 6 !9P%N 74!? &#
M 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!\@'Z @,"# (4 AT")@(O C@"
M00)+ E0"70)G G$">@*$ HX"F *B JP"M@+! LL"U0+@ NL"]0,  PL#%@,A
M RT#. -# T\#6@-F W(#?@.* Y8#H@.N [H#QP/3 ^ #[ /Y! 8$$P0@!"T$
M.P1(!%4$8P1Q!'X$C 2:!*@$M@3$!-,$X03P!/X%#04<!2L%.@5)!5@%9P5W
M!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&609J!GL&C :=!J\&P ;1!N,&
M]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E!_@("P@?"#((1@A:"&X(@@B6
M"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)N@G/">4)^PH1"B<*/0I4"FH*
M@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X +F NP"\@+X0OY#!(,*@Q##%P,=0R.
M#*<,P S9#/,-#0TF#4 -6@UT#8X-J0W##=X-^ X3#BX.20YD#G\.FPZV#M(.
M[@\)#R4/00]>#WH/E@^S#\\/[! )$"800Q!A$'X0FQ"Y$-<0]1$3$3$13Q%M
M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3(Q-#$V,3@Q.D$\43Y10&%"<4
M211J%(L4K13.%/ 5$A4T%585>!6;%;T5X!8#%B86219L%H\6LA;6%OH7'1=!
M%V47B1>N%](7]Q@;&$ 891B*&*\8U1CZ&2 911EK&9$9MQG=&@0:*AI1&G<:
MGAK%&NP;%!L[&V,;BANR&]H< APJ'%(<>QRC',P<]1T>'4<=<!V9'<,=[!X6
M'D >:AZ4'KX>Z1\3'SX?:1^4'[\?ZB 5($$@;""8(,0@\"$<(4@A=2&A(<XA
M^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_ D'R1-)'PDJR3:)0DE."5H)9<EQR7W
M)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$HHBC4*08I."EK*9TIT"H"*C4J
M:"J;*L\K BLV*VDKG2O1+ 4L.2QN+*(LURT,+4$M=BVK+>$N%BY,+H(NMR[N
M+R0O6B^1+\<O_C U,&PPI##;,1(Q2C&",;HQ\C(J,F,RFS+4,PTS1C-_,[@S
M\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I-R0W8#><-]<X%#A0.(PXR#D%
M.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\93RD/.,](CUA/:$]X#X@/F ^
MH#[@/R$_83^B/^) (T!D0*9 YT$I06I!K$'N0C!"<D*U0O=#.D-]0\!$ T1'
M1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(!4A+2)%(UTD=26-)J4GP2C=*
M?4K$2PQ+4TN:2^),*DQR3+I- DU*39--W$XE3FY.MT\ 3TE/DT_=4"=0<5"[
M40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4VU4H5755PE8/5EQ6J5;W5T17
MDE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N56^5<-5R&7-9=)UUX7<E>&EYL
M7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB\&-#8Y=CZV1 9)1DZ64]99)E
MYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(:I]J]VM/:Z=K_VQ7;*]M"&U@
M;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R2W*F<P%S77.X=!1T<'3,=2AU
MA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&>J5[!'MC>\)\(7R!?.%]07VA
M?@%^8G["?R-_A'_E@$> J($*@6N!S8(P@I*"](-7@[J$'82 A..%1X6KA@Z&
M<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6B_R,8XS*C3&-F(W_CF:.SH\V
MCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4])5?E<F6-):?EPJ7=9?@F$R8
MN)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY GJZ?'9^+G_J@::#8H4>AMJ(F
MHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H4JC$J3>IJ:H<JH^K JMUJ^FL
M7*S0K42MN*XMKJ&O%J^+L "P=;#JL6"QUK)+LL*S.+.NM"6TG+43M8JV ;9Y
MMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]%;V/O@J^A+[_OWJ_]<!PP.S!
M9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_R#W(O,DZR;G*.,JWRS;+MLPU
MS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'31-/&U$G4R]5.U='65=;8UUS7
MX-ADV.C9;-GQVG;:^]N W 7<BMT0W9;>'-ZBWRG?K^ VX+WA1.',XE/BV^-C
MX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJY>MPZ_OLANT1[9SN*.ZT[T#O
MS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[]XKX&?BH^3CYQ_I7^N?[=_P'
M_)C]*?VZ_DO^W/]M____[@ A061O8F4 9$     ! P 0 P(#!@
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M8G.B@-)3D$.#XO)CDR3_V@ , P$! A$#$0   /=8T(D           #Z/D
M                 'T?(                  /H^0
M                     ?1\@                              &W$:6
ME/;>EX4@          "MF'-9/-A                   %<<66QV7$
M             *W8<UD<V$                  5MPYK(9L/T
M        <Q5_%FLUEP@                              :XK+3(8\NPK
MBEX4@          "M>#-93/A                   %<,66Q^7$
M          *VX<UDLV$                  5LPYK(YL/T
M     <R*O8<]F\V$                              #6E7:=_'EV%<4O
M"D =:?/4]><IXR        "M>#-93/A     Q_KQR)[GGT  (-GUL[XR9S'E
M&$R8LWCR@"#9]:<X-D    "N&++8_+B     '4GSPS$?R8Y3BR]B/0   Z?K
MSVO,_20    !6W#FLEFP@    #AF,;Z\9CQD@^?6G&#9   &-]>/TR/GV
M  *V8<UD<V'Z     !A?>++^,D)SZ\YP;(   Z\^<7[\9S'E     ',BKV'/
M9O-A        '1]>/P[_ )]@ =/UY[7F?I/1]>.EZ\X')CG.OL@
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M=T',YS'F^9BS-5;UGM:B38<^N=K2XDR''D[#SF<>>W-->TXNJ.UU1;YGQE
M   %;<.:R6;"     *WV=3I3?K;-55S7>RJN[Y];)U=S0%E5;'U=W<NCOT>O
M^9W#I6%YJ#I8'L:U<+.IN727X     K9AS61S8?H     YHGRFZ[B+<4]_JK
M;T>]YFP-=;4EO><M)4W77F*[V=1G\>7T,YKJM?[.M0+HN9]*N7ZSO^?8
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M=A60?8P6PJ+GDB0    *UX,UE,^$                   5PQ9;'Y<0
M              K;AS62S80                 !6S#FLCFP_0
M        !S(J]ASV;S80         !#<^OU9B>:^R                  !
MK2KM._CR[,MJ7A           !6?#GLQFP                   "MN+-9+
M+A                  %:<6>RV7                   *TX<]D\V#[
M               .8JWBSV>RX                               -65M
MKVL6;J^O/X           "O$38>8                   $3)8
M         ")$M                  !$26GZ                  8[UXJ
M]<T-LJ3H0                              ,9Y]9TMD@           "
MHJ;=(                   $)E-H                  "#RG$
M          !"93:                   PN3%2+H>7OOS76@
M                   563UBV2            *BIMT@
M   0F4V@                  (/*<0                  $)E-H
M            #"Y,5(NAY>^_-=:                              !59
M/6+9(            HSL:^3N*$                   1M,D0
M        (TF2H                  $;)(                  #I^O.*]
MX[Z<UU@          Z1W0   ".DB          .B=X   %5D]8MD@
M    #RFNZ'QW^J_&
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M<VO,<&UN#0L:^6E18VJN-"V53--?:V+J[F@[.HD6+/KG:TOR8VSH6FIM^K
M                                     RN/)[O_ #?ZM>WF^KI_>\Y1
M7H^5]G^!^E]OSZH,F2$;)^5F39%$3,\1T^"0ETD4J3!4[H1K4C">F;.1V"!)
MD2)N;#-9ED44N3M\QQOU&4/+AZL$CE.<NNBD"=0IM@BH:?1%Y\SGJUJ+8HIL
MG"$D)*:D3-D7+0   *K)ZQ;)            'E-=T/CO]5^,>@'+]G/=7<J1
M><]+\&>48-K6FYH=+UXW=7V>I-W0V/J[NN]K2R7C))\.;7>WI[+T]VD/1\I[
M;?//J/DAV_S[TTY#N*#]-R).XM"TWQ6VF@+.IC&?4D.'8_40[8U^K/G0=G3^
MB/*]K1?I.3LG47GZB$;.KU9\[,T]^(9]?/8\FMMO2AFQJ[JK[7&>\=3KSFKM
M<YUL@QY9_J[FM-S1C677WI6VW5]17.UI\YCFJEU08S)C_8GB]8_1[DNZI]>\
MWZ<<AW%;K6GZ/OQ7>TIMY5UG4"^YN\?.=7(,6>-9L$LP;/G5U?$<9>SF^MPN
M3%'LN#2EA6[IK[/.8L^!RZ]9;BAC.?6
M         RN/)[O_ #?ZM>WF^K  KNF4&%((8@WTC#)X <YUC=J*0)V>;11I
MY.N#99/359@B?&9/PVBBJZ=\'9-FHI,GLET4:-3I0EAE25G*;U12!-C41U/
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M^;ZSIR3BQ'KW8.KN=+V%5Q3&H]^JT%:4P
M          &5QY/=_P";_5KV\WU8          $3)2?8
M  *K)ZQ;)            'E-=T/CO]5^,2S7VOB8[_C)/-;;UOMZ6P]7<@.S
MK7BYWIJ,]'RNX-&RT_O5WR?2+F4'42#%G\YNLX:6:^US/7"B08\O/Y]1C-@E
MN'/'<N*SE/>Z.L:J$[.IG\6;O^?>K=RNL357==K6EW_67&I-VNS^/-W_ #[B
M.;7YX3#!L]#WXPOO'V8]337V=$6=/;*BZ6O%K2?9^O7TC"9,4JP;$UU]J?ZN
MY4J]YS]0!MW0M/V)AFSJ9#Q[YHG-X\NN]O2WA6VN@K2HRGCWG<6?:6E8:5L:
MF-YM>7Z^W\(2R?CW),.Q"-C5VKI[^C+&IZ/O&
M              !E<>3W?^;_ %:]O-]6 .,UF38S1H]-=21FTCOFHS"EWD<Y
MCRL2;1([!USL'2,@8\RABRL";;(P9H].M2UZ.X94Z1V"I2;?HPI69/?)T;K1
M@RO*9>?ADS'&\D84S0    *K)ZQ;)            'EG<T?E%].^0   #Y3]
M(  ^4CZ0   !\I^D      #B3RH 'X?H  !^'Z            <2>5
M             XCE                  !D?/OVJ^??3;W<WU8 X3S/>IHC
M:9V351&D[ 1DR.&$3=]YIZF(IG2.\:V3P$]1JA.VT5138I&.3F47/1Y#O5HT
M8].T$4Z3*BX*+)H\QGK>"*YI_3<*+AHKBF-FG$^B3S3-ZW.C3IA$ZJ+MHLV@
M   "JR>L6R0           !49-N4                   "&$S
M         !"I36                   AA,P                  8;)BI
M#T/+WWYKK0!QE&4V@1K!.>-JHT,GO&2-6F.+(HJ\GI&WS6A(2<'"<)^FJ2RY
M5I,]1L(K0G>"-EFK#7I/RT*.T5T3#37"<>6&19=%:DZB)D7 171.#-L(KPGK
MEM42D    JLGK%LD            5%3;I                    A,IM
M                0>4X@                  (3*;0
M  &%R8J1=#R]]^:ZT       :L-I@                      JLGK%LD
M          5%3;I                    A,IM                   0>
M4X@                  (3*;0                  &%R8J1=#R]]^:ZT
M  0DRI'388!KDGQV     :K.T;*-8FS@#5YPI["*Z)NRBD2;NH   K"FSR
M($:43:A    %5D]8MD@           "HJ;=(                   $)E-H
M                  "#RG$                  !"93:
M     PN3%2+H>7OOS76@#B/+=ZW^C1B>F;:->FMS:!/$:<3:1&C$^D;S0E,E
M.D1Y,<!M1&G$\A)"O1,RPB*K)WJ8HM:C>:*-)V$:E+^HIRG12=EHJ^G?AI(R
MYO\ 1%4W->=9)U^:=39%%ID    563PEKT            5(3;=
M           A,IM                   0>4X@                  (3*
M;0                  &%R8J3=#S%\^:ZP <)Y1O5C4:43/T;5-&)G*)26+
M12E.XBM2?3MYH2F5F'/PWZ0HUV:83L%$A,D9<Q9U"3&K$VF1"30*;&HJ(GTY
M>:3IAJ=Q(U.;[-.F3.4F1AB9&LS\+)(V4    583U"V2            *BIM
MT@                   0F4V@                  (/*<0
M       $)E-H                  #"Y,5(NAY>^_-=: /@TJG=J
M !BC7J=KH                  JLGK%LD5OMJ6Q]3=5"O>=VEI;^S]/>T)9
MU%F*B\'FMUO$[8TK"Z//],!4V[Y_GB;5TM^   !45-ND
M   "$RFT                  !!Y3B                   A,IM
M             87)BI%T/+WWYKK0 (R28  C1)0  "-$E  ,"=HBI/@ 1DDP
M!K<RYKQ,G1LT BII)-ET:12-W(J^G9:-;)V(:7+'HKBFQ:)L  "JR>L6R1YV
M]5QTDPYH)LZDJP[%>[2GS>/+RQ.U-+?K#<4>T=/>V]HV/&:0L:KBEO6MM:XV
MM+SQ.ZZ^TS./)WO/O5>[7WSYKK-KZ5@*BIMT@                   0F4V
M@                  (/*<0                  $)E-H
M     #"Y,5(NAY>^_-=: (L><#UMA&;,6;[-2%9$V.1"B1&R#71E3I&D4^E;
MS(2I2<&=0@Z9"CG,,G*HVL:3(RG?Z((2TT2F[#S3)ZVHB+$U-KFL3H$%)\?1
M<9'"463*S!%O$5E3W3N%ID  "JR>L6R1#\^M_/1]1^/^W_SSZA0+IN2^B&9]
M;:&GO[ UMN,Y<'1]^=*6%7/=7;BN?!L/5W,IX]Y#Q[ZOKS^IU=N:&5\9)5@S
M[VK;:^'-]6*.9\&=MZ(                   1I,E0
M (PF3H                  '3Q;%TJ:\                  &%R8J1=#R
M]]^:ZT #SQ>ME(U2GG.4UT;4)JCK&/->ISAL9'"1HLB;=1Y?O6TD9$TPFUZ*
MC)NHC$E%DZ]3=AYZAJY,^1\%J311B3$&7+S(KTG2Y3!ZO<\\Q<A'F<]7'159
M,M1HU/HL\ZF3KLN^@  563UBV2!A<F+*>,G#,8CWCRGCW@<N*6X-C&^_ Q_K
MQDO'O&>_&3\>_F0 Z/KQW_/O$>\<DQ9N2)'E-=T/CO\ 5?C
M                                              W)4WO]/OR7[0
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MD>+-B_>.9Z^SJ7>KX+LZEO*+H=2;VA7VTI]NZ-CJ3>K=IZ5A"MC6P.7
M             -R5-[_3[\E^T                  #"Y,5(NAY>^_-=:
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MIUSM:5">GXZ]G-=?JC=T>K,9_'DF6OM]J/%4[OGX+LZ8
M W)4WO\ 3[\E^T                  #"Y,5(NAY>^_-=:
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MI4W6;Q^Z!]1QM\>9Z["9/%(>BY?TKY'M]P:-EK#<K:"]-R,%VM,
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MO^,N?Q9L1DQ8SWBXY@                 ;DJ;W^GWY+]H
M     &%R8J1=#R]]^:ZWRU[+A/&GO?FO]9WQ/]!=7Q[IDFS:*V)EA%"R"("G
M6IT".IX"X3S3AZRB+Y(\MWJRZ/LW$:L,87!13-,T.H5B3L-&RR&DN-CD.*B)
MNFB/'?*K)]-GGRR>KF(C!;5%+4RXQY/C F'*])WXB4DJ,>463ZKO/( 563UB
MV2            /+&YHO)OZA\@                   '&<@
M       .,Y                   ;:JKK^ECY7]B                  &
M%R8J1=#R]]^:ZW36_6Z$LZF[7/=/&HFLJ;2(\VWJ1&Q46.1 DZT(269*Y)N>
M\T3>MAHNXBDB>8RAD302=V(M&CS6>K0HU42(X3+G*8TR9J9.QT:O3NI$9,67
MT12)/V=<O$BFB=8IVBC]-5IV$C!&7.4R!'#,EU$ "JR>L6R1$<^OKW:TY;@V
M."8FVOLP?9U>YY]=B/4PU]GZ*\VE/OFMMM&6-5OFMMM!6=1D?'O=-?9Y#S[
M  J,FW*                   !#"9@                  A4IK
M            0J4U@                  ,+DQ4BZ'E[[\UUH %=T]TVJC"
MFK$RPU4;I1F2=&@T\A/D<9/C0*=B(Y"/)AQM)$V*UID9@2:'"B4GT<9$4],X
M21D1)"8(L"C0*9 8PWBB#G0-:ID1QG&=DQA-41!.9,.;U1R@%5D]8MDCSGZK
MC-G:F_3N]YO3-A6W?YWJ-2;U?D?'N7X-CT!YCK]$653Y;=EPGI'R?:4-Z7D[
M*5%W3R^YST!YCKI+ASW'H>D   J*FW2                   !"93:
M              @\IQ                   0F4V@
M,+DQ4BZ'E[[\UUH    UZ;"!T31B=]HU.G;2-1)VHC6B=L(B9+
M          563UBV2/+7LN#M52W]$NDY3]3UI\[(U=W7.UI9G'EN/0])7&VI
M=)6%7;:DZ&LUO2=>?.*]^+>T?0]:8OUS/6@  5%3;I
M  A,IM                   0>4X@                  (3*;0
M           &%R8J1=#R]]^:ZT ?)3!.Y30A8TKX=,M8BL:>H;+-UHI@G+$[
M,F:2+K(\MGKUY>0                  !59/6+9(J]<475]>=EZF])\.?$>
M\?XC%>_$>RX;#U=QA<F*K-S0V(J[FOMG3V/JKJMEM2X7)BWY66VW-&Q   J*
MFW2                   !"93:                   @\IQ
M         0F4V@                  ,+DQ4BZ'E[[\UUH @!1AZWPB2%1D
MW:1H4[);A'FH]>ASS*RFR>(L"0D@P*SI]3WG,@                  %5D]
M8MD@           "HJ;=(                   $)E-H
M   "#RG$                  !"93:                   PN3%2+H>7O
MOS76@ 583MA$F,4:*3O%$G*M)LBC.$)-(IWFC2B=LFH"TJ(:;"
M         !55/$6O0           !4A-MT                   "$RFT
M                !!Y3B                   A,IM
M   87)BI-T/,7SYKK                               *L)ZA;)
M       %14VZ0                   (3*;0                  $'E.(
M                  "$RFT                  !A<F*D70\O??FNM
M                           JLGK%LD            5%3;I
M           A,IM                   0>4X@                  (3*
M;0                  &%R8J1=#R]]^:ZT          8TR0   !#29$.)B
M           #&&3 *K)ZQ;)            %14VZ0
M(5*:P                  $'E.(                  "$RFT
M         !A<F*D70\O??FNM\QNOX?Q_[KYS_5/\9^]Y+Q[I4F3DZ-)&V#:*
M-%IE)^'4):;B15%-@45_389%;4](L2C]-.IR9,CN(V45)3M$IVF[SSYK/5RT
M2XBYK,MHBL*<T:>3<)YIL]2I$_+@HJ"FO"=X(TBF]",(:^,R=XRI+30Y<9 %
M5D]8MD@           #S-M*CS]^A?,                   !U(GMS
M              ZD3VY@                  ; KK;WT^=?4
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M/ZC[B?I/%/D                          #<E3>_T^_)?M
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M_-<;CG=I:-K9ZFOJ'=/QNXM"RXGK"9,,YUMS<]?9QG-@T?95&M-RO
M                    W)4WO]/OR7[0                  ,+DQ4BZ'E[
M[\UUH X3S1>K4(@))"HZ;1HTZG:*,8=PV^:3-H%;TV+17],O1F3 F6-#IWXC
M@, 71111ZDJ-I JFF<&^T6012M,$3O!&B4[L14Q-VT:S.B5%3=-$:.D9PV@5
MF3LE$#3F$3TAY/RV: *K)ZQ;)            'E-=T/CO]5^,
M  "3X-F,9]8 9?'EXYC&>\8
M   &Y*F]_I]^2_:                  !A<F*D70\O??FNM 'P583O1$%3E
MR9(K,G;YB"/D*+"HK$GG-U$-,>;+!^'$:Y-I&FC/&^45)3N<GJ-1IAYM<V B
M9E(DS T4FRZ*PIL:C?2*JIF9P&5),?!UR.$2,\9,_26%4$^B3SS %5D]8MD@
M           "@&YI:XZ7D0                  !@YG.1
M     P,SGH@                  =[6W?3CE^N                  &%R
M8J1=#R]]^:ZT       10E8          .@=,[YCC.@      $1)< "JR>L6
MR0           !45-ND                   "$RFT
M !!Y3B                   A,IM                   87)BI%T/+WWY
MKK0!PGG\]7Y>=3IPQ5Q-B4631J-.E"5GR;;14-ZOR\ZK3M]'R:C3L- C9GR*
MF7*RIL&B=G:-1IVVC6"<LC,&9,610[1D#HF5*9/5^GD:T)J:Y3J$_2T2(0"4
M&$*\IM>C, %5D]8MD@           "HJ;=(                   $)E-H
M                 "#RG$                  !"93:
M    PN3%2+H>7OOS76@#A/.UZGB-:)ZQ^'HH\U'3*2L*?2QYI6FXB*+O4(,H
M6:1K0U*F=DV16U.[T85,I1'SX3<=YK:F4%<TWC160W(9<JVF?(@1&4Y4V B$
M)](7D>2CU8-&H$[/.D99$83V#>:*L)V ;Q1O9&;!59/6+9(            J
M*FW2                   !"93:                   @\IQ
M          0F4V@                  ,+DQ4BZ'E[[\UUH XROR8^:N).9
M8MRC0*=-$_+2(T>GL&%(<1DM:C7:=8FX2$D!-VD?!K4E)-#I&FC9!T2+&X30
M1,3=1"S F8(J04VH6=125.]"NQ/CI$_.L<)&R($T+$HD@!59/6+9(
M     J*FW2                   !"93:                   @\IQ
M                0F4V@                  ,+DQ4BZ'E[[\UUH
M                CA(P       563U3[            *Z)L6@
M          1>4H@                  (M*4P                  $7E)
MX?H                 !CO?B&]%RM\^:ZP #6QL4U^5^3O1%37JV3S/R.DA
M*P)W"C6J=XHCALTU@533M<U&62-&EL44O>K_ +R                *K)ZQ
M;)            %14VZ0                   (3*;0
M  $'E.(                  "$RFT                  !A<F*D70\O??
MFNM $-/,AZG9NE$>-]HIB]6L10Q/H*C<Z*.)K@G>1.4:=3<E&]$453W24%C$
M5(3$$XL](WD                563UBV2            *BIMT@
M           0F4V@                  (/*<0                  $)E
M-H                  #"Y,5(NAY>^_-=: .@4A38,T ;.-RHT^G7!P%V4?
M!1E.+3NI'&18M>C0*=?$X->F6)2;M17=-P4                "JR>L6R0
M          !45-ND                   "$RFT                  !!
MY3B                   A,IM                   87)BI%T/+WWYKK0
M                              *K)ZQ;)            %14VZ0
M              (3*;0                  $'E.(
M"$RFT                  !A<F*D70\O??FNM
M         JLGK%LD            5%3;I                    A,IM
M                0>4X@                  (3*;0
M  &%R8J1=#R]]^:ZT                              "JR>L6R0
M      !45-ND                   "$RFT                  !!Y3B
M                  A,IM                   87)BI%T/+WWYKK:AWO.
MT9Z+EO9?@OI/;\^O/I-MT:#3M B1.CB/HAI%"?D0+>HUH:H3:)&MC9)@C'DM
M*SILP@ :W,L9LRX -:FR@"L:;.(UN;(    *P)L^@   563UBV2
M   //+>T-"];Q                    Q!EP                  ;AKK:
M]-%T0                  C,>]QZ>V                  ,+DQ4BZ'E[[
M\UUOF?UW$>17<_//ZE/C?W?(^/?E,]>D+SY7/5D"7HV2:S/TA!%$SM&Z#.FT
MD5&3=5'EP];%1LTRI2--J4731YA/4I(H=TR)*41).;+'(H&G9)LU%:$[^1I%
M/K2\^9CUMM&,+*(JZG*E>$VU15]-@$5\3?1&Q42   %5D]8MD@
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M[2?/_IE2+N@@.UJ6UI+_ $YOUTHPY^M/GZ3F,?O'^_'FMUW"@
M               "]'.]7[#\5]!                  &(QY+$U5J
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M]MJ(                           7HYWJ_8?BOH(
M Q&/)8FJM0                 !A<F*D70\O??FNM & *,O6R$9(AAHU/J@
M\^4CUO\ 1JM.\4:C3F$6<-$F+,4GT&>:TIK@GTD>:5)X38AKHNRCD//9ZLPB
MM:?A&:.P9LN6BBR:UIO BIB?0IYYS!D33U2,$(/@Z!(B")V$B["   !59/6+
M9(            \IKNA\=_JOQ@
M    "]'.]7[#\5]!                  &(QY+$U5J
M ,+DQ4BZ'E[[\UUH C)1I.S#3*=A(BJ?0UY\PGJZ"-=F--2)F2-Z&FR1&;-Y
MH\VGJQJ,*?!K)-OD5B+,F[T423N@UZ1LDYJY.P$<IL@C1&S3J;YO.?/,IZ]&
M'GKE'GJ6HR!@$S)$B. N"@   563UBV2            /-NRJZ8=U\Y
M              &/3D$                  "Q=1>^C7-]8
M      (_X][NT=X                  87)BI%T/+WWYKK0
M -2)VV@               "JR>L6R0           !45-ND
M      "$RFT                  !!Y3B                   A,IM
M                87)BI%T/+WWYKK0 (D:Y3O-    J FQZ)@
M            "JR>L6R0           !45-ND                   "$RF
MT                  !!Y3B                   A,IM
M      87)BI%T/+WWYKK0!%CS@>I8;*1Q'(:[3LU$8-S$)*MI[Q9)$?(\F[3
MS+                     563UBV2            *BIMT@
M       0F4V@                  (/*<0                  $)E-H
M                #"Y,5(NAY>^_-=: !YUO6T$=<KHFP*,F:63*D:]3FC:R
M(JF &RT2@N4@                    "JR>L6R0           !45-ND
M                "$RFT                  !!Y3B
M   A,IM                   87)BI%T/+WWYKK0 ,<=L'$<9V3Z,<?9W =
M0[9TCNG,                     563UBV2            *BIMT@
M             0F4V@                  (/*<0                  $
M)E-H                  #"Y,5(NAY>^_-=:
M       !59/6+9(            J*FW2                   !"93:
M               @\IQ                   0F4V@
M ,+DQ4BZ'E[[\UUH                              %5D]8MD@
M     "HZ;<(                   $-E,H                  "%RFD
M                !#93*                   PV3%2'H>7OOS76@
M                         563U3@            *[)L2@
M        1>4H@                  (M*4P                  $6E*(?
MH                 !CO>.,=%RU\N:ZP
M   "JZ>J6R0           !45-ND                   "$RFT
M          !!Y3B                   A,IM                   87)
MBI%T/+WWYKK0                              *K)ZQ;)
M %14VZ0                   (3*;0                  $'E.(
M            "$RFT                  !A<F*D70\O??FNM
M                     JLGK%LD            5%3;I
M     A,IM                   0>4X@                  (3*;0
M              &%R8J1=#R]]^:ZT                              "
MJR>L6R0           !45-ND                   "$RFT
M      !!Y3B                   A,IM                   87)BI%T
M/+WWYKK0                              *K)ZQ;)            %14
MVZ0                   (3*;0                  $'E.(
M        "$RFT                  !A<F*D70\O??FNM
M                 JLGK%LD            5"F;4>L0
M   C4>YUYD                  0>4X@                  (3*;0
M              &%R8J1=#R]]^:ZT                              "
MJR>L6R0           !Y37=!X[_5?C(                   ]\_EGV.]U%
MT0                  @\IQ                   0F4V@
M      ,+DQ4BZ'E[[\UUH                              %5D]8MDC5
MNYH#XEF<>2/9</+$\,QM[1L81L:NA[.IWS66V@K.IL[3WFL-S1W+H60    \
MIKNA\=_JOQC+8\MH*:_K%<T.&R80.]XR='WC VAI6.KMVO\ U'>\9.C[Q@?I
MW/&38FKNZNW:X"58-GO>?>8QY=F:>]H&TI\KXR0S8U    ![Y_+/L=[J+H@
M                !!Y3B                   A,IM
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M[SZK#<\[[E?,_K5[J+H@                 !!Y3B
M A,IM                   87)BI%T/+WWYKK0
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M                  "$RFT                  !A<F*D70\O??FNM
M                           JLGK%LD0[/K<<QD?/O]B<9[QX++BR?CWL
M#5W(KFUX#M:FPM7<UOMZ4UU]J";.IO2MM0   !Y37=#X[_5?C'8\^]WUUMJ#
M?K=GZ6_$<^LF,ICRQ3/K]+UCV-J;T(V=3Y3^H[WGWQ(V%J[L3SZV&R8Y)ASQ
M7/K#\)YK;D.SZV&R8<UCS2+%GUUMZ$KP;67Q^\=[\<L3G,>:&[&K-=;:@FUJ
M337VNUY]:FWJWWI^7?8+W471                  "#RG$
M     !"93:                   PN3%2+H>7OOS76@
M              563UBV2            /*:[H?'?ZK\8
M    'OG\L^QWNHNB                  $'E.(                  "$R
MFT                  !A<F*D70\O??FNM
M      JLGK%LD            4KRX]H[]6                   );HV6UL
M.8                  0>4X@                  (3*;0
M      &%R8J1=#R]]^:ZT                              "JR>L6R0
M          !45-ND                   "$RFT                  !!
MY3B                   A,IM                   87)BI%T/+WWYKK0
M                              *K)ZQ;)            %14VZ0
M              (3*;0                  $'E.(
M"$RFT                  !A<F*D70\O??FNM
M         JLGK%LD            5%3;I                    A,IM
M                0>4X@                  (3*;0
M  &%R8J1=#R]]^:ZT                              "JR>L6R0
M      !45-ND                   "$RFT                  !!Y3B
M                  A,IM                   87)BI%T/+WWYKK0
M                          *K)ZQ;)            %14VZ0
M          (3*;0                  $'E.(                  "$RF
MT                  !A<F*D70\O??FNM
M     JLGK%LD            5%3;I                    A,IM
M            0>4X@                  (3*;0                  &%
MR8J1=#R]]^:ZT                              "JR<V1P_
M   :;3N1                    PAFP                  8,S@
M            ,$9T                  '1]>=#6E/8>IN@
M                  .<M6@      =,[@  .J=H
M       Z9W    =4[0
M                                     !H.SJ?'7N_G"7OG\S^LY/QD
M\_7K=J,H;,1JM.2)NB#)EZ*_)F1^'4,H;V1H).NB[B*J)WLB")WBBL:=](T.
MG?Z*X)V^C4"9B;%1J5.SD:53:I   XIC6=C7#8&CO9''DITG:1*T;(*YIVFC
M3B=A'91$4S=&LT[Q1H9.4)24[385&:-H(TLG?B)"58381&F$V*171.T45<3-
M3?:--IW&C3B=\HT$G=:/-MZ]3GD
M                                              "J%WS_ /.;]5^-
M#^L;XG^@.WCRTW3<Q%-4]8Q)QDE,2=@UJG)G6+(HJRG-EDT:>)0641Y)/7K<
M\Z_3UBO1)S6R=8&PB]CSY?O5DD9 B:>^B_*  !P3&E+BG&V:NTS.++1]/4,R
M7211)/9,<:[3M='4.R9XB9\$X(>9DQ)G##' 9DFAM]%#WJR*+0HH<G*$4(BG
M/&^T5O39M%-D[.,RCK)OZ\@
M                                          :9WZWR_P"QX7\/9?@?
MI.0\^Z:IFIKPVR=LYCKE.4VN1W34QOP@1K\L(5V-L&T$5?3GBW2,44U3NPRA
M7,QID3(FPB1G(5F.<]!$  #CF(#NZ(FFIN=[Q[T$G('&;Q1Y8/5RT9(@Y-2F
M*;<(U2;2,Z:<-C$4-A&G3;1WCX-FHJ2G;1L1&P#RM>KGH@1##;)MU&CT[W1H
M].,)X5Z/0)
M                                    $3)8        =<K"FRZ.^ #5
MR<&;M0      !$B6@ B1+0       "(DN
M
M
M
M   !_]H " $"  $% /WZA_. P& P& P& P& P& P& P& P& P& P& P& P&
M-A_G 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8"2'_+ 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MB@.* XH#B@.* XH#B@.* XH#B@.* XH#B@.* XH#B@"8PA#B@.* XH#B@.*
MXH#B@.* XH#B@.* XH#B@.* XH#B@.* XH#B@.* XH#B@.* XH#B@.* XH#B
M@.* XH#B@.* XH#B@.* XH#B@.* XH#B@.* XH#B@.* XH#B@.* XH#B@.*
MXH#B@.* XH#B@.* XH#B@.* XH#B@.* XH [WAQQ''$<<1QQ''$<<1QQ''$<
M<1QQ''$<<1QQ''$<<1QQ''$<<1QQ''$<<1QQ''$<<1QQ'%$<<1QQ''$<<1QQ
M''$<<1QQ''$<<1QQ''$<<1QQ''$<<1QQ''$<<1QQ''$<<1QQ''$<<1QQ''$<
M<1QQ''$<<1QQ''$<<1QQ''$<<1QQ''$<<1Q1''$<<1QQ''$<<1QQ''$<<1QQ
M''$<<1QQ''$<<1QQ''$<<1QQ''$<<1QQ''$<<1QQ''$<<1QQ''$<<1QQ''$<
M<1QQ''$<<1QQ''$<<1Q1''$<<1QQ''$<<1QQ''$<<1QQ''$<<1QQ''$<<1QQ
M''$<<1QQ''$<<1QQ''$<<1QQ''$<<1QQ''$<<1QQ''$<<1QQ''$<<1QQ''$<
M<1Q1B..(XXCCB..(XXCCB..(XXCCB..(XXCCB..(XXCCB..(XXCCB..(XXCC
MB..(XXCCB..(XXCCB..(XXCCB..(XXCCB..(XXCCB..(XX@N,9HW ED2'\<1
MQQ''$<<1QQ''$<<1QQ''$<<1QQ''$<<1QQ''$<<1QQ''$<<1QQ''$<<1QQ''
M$<<1QQ''$<<1QQ''$<<1QQ''$<<1QQ''$<<1QQ''$<<1QQ''$<<1QQ''$<<1
MQQ''$<<1QQ''$<<1QQ''$<<1QQ''$<<1QQ''$<<1QQ''$8X_JN'4\.IRO>NO
MM/[50ZGAU.5[UU]I_329-.IGTPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0T
MPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F
M%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TP
MJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%
M0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ
M&F50TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0
MTPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&
MF%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0T
MPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F
M%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ&F%0TPJ$EMJI(W7VG]-6]VK]G3/=NGM M(
MF4R?(E"?^?TM;W:@KJ)*0)JF0ICT17RP/]%4N+31]$JHDFF"%0)B9T07RQ/Q
MAB:N+*,Z)UTLAW2;7$Q4Q9D#("==+(=Z48X!&M+5R]"M= B=74B4L4U2)4Q5
MKBDL))X3P5+"TLL%,D9"JXF-F4+H$&>@JJI":9+52%,Q:\J<Q2JD3RGJ)")4
MM83J9C%4A<\TT)8$JRSI):\EB(&RQEU E"=1(HE5U(E+'4"4$'RGRK%Q:27H
MBOE@?^CS/=NGM H=6EI\VL"A-'&/Z6M[M0J\\DBNHQ*4G+ZC,5.54#B39OJ*
M@]5-/3*C,I">KGJA3:G,?,14E*N%26?!C4JK,E-A4SR#5U0GD,)J*GXXFEB5
M,I62DDH4\2E$B^:*I2OF*42_42#%.<E6G2J%]5G3G0JAZ<U3]04U$R8U'4#(
MFGRQGDH:LDF0TPM"46O63RGQQ7J:B9,:CJ!D39ZP=.<HJAI0C4STL]07SE3H
MISXA#4X99*I5F=!4?C5"ISR2+%T2E*BOE0-,M\V,)*O'.&*B)S:<B5I5\MR2
M8IR3/B2\4(#BAT*CRB5Z)40?$XB;XM<4RJ4=PR1EBE.3K14>VJ/<HWT^FJDL
MB6C$SEHZ/4$I:<J,L99RI9Q1R98GFU8R0Y>L,((6G'2 FI'%'3_49J@>>8GF
MGFD_1IGNW3VC]-6]VH58J4Q6M*EI9]1*AGOE14)YOJ)1QBXZW\/C6ZKDE"$R
M4Y:K3RHY*H=$Z"[MUP>]5CHEJZ9) TX4DF!P33SJ0M[=$R!515J9#5\OU$F>
M$E071Q6KE$A"^OFRGS*?J!2:$5B:G%%'&FRE2KY4JLJ$IAU,3U$GX)\<5Y2:
M$5B:G%%'4OM9QD$]0N,V4V2H)"54:4J,^+0XEY0Z6:E1"&' NJ)4IJU45"EJ
M*U_=5#OEJDE-$I!3E99":XBB99:Z9&5&CDX"E%!3GSZ92@HJ!4IG!\P)B5"-
M(AB?5)(H08K++FJ119*FM3_ 4+EY115-(F)04^D%*D=-6S*4M#@3EI(PC 4;
MM"+MUR_TU169 X\J!2R?ZBJ0ESS4=9,K(_1IGNW3VC]-6]VH&)I)YU":11*>
MC+/E34=.FFRLGQ%-((43$I"R8TNER'R)TLB>6%"30F.2R'1G2R3SGII#@NDF
M*4R$9L\$II"8R)"Y)YTLD\ZNGE*X%TTDL963XBJFDJHQ1EQF5I?BK4M+(2QF
M3233JZ>4J"2FDI1-+":'R)+Q0EA"$M$30FF3233JZ>4J"2FDI06FD+F4I"U,
MJ2ED)8JZ<2K"5&6EA(A*DD3T=.GF"U/.6IG323SJ4LBF4Q+(9%2E+4RF%2F2
MSH2IRT]'3IYJNGG53>@IIA"F9-2R$\Q2:0J92C+4A4A*5024PE+$TJ4V4JAI
MBYIY(3P((E)ED1%R1^1)00GD(E!260J:1-)).H32*(*T1:J!-*()$4TD3#J*
MF.FDDA)#]&F>[=/:/TU0)X2J<X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4
M,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4
M,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4
M,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4
M,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4
M,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4
M,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4
M,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4,X4
M,X4,X4,X4,X4,X4#%9<873VC]@\.I\.IX0QZG*]ZZ^T_M5#J>'4Y7O77VG]J
MH=3PZG*]ZZ^T_M5#J>'4Y7O77VG]JH=3PZG*]ZZNT_M5#J>'4Y7O77VG]!(J
M.8K+!E ,*GJ:#(F$E_$FK-,@@,Z-.E$25BC2H9.E=28)TZZCQ2D_IF'4\.IR
MO>NOM/Z"M-5\,XFEX+ZF;*M7K*1),M,)0%'5]'%6L.DIZ0RH4TFG*+HG(A)<
M,,4]R4XI)&ITTLI,H0HJ;)<4DLB2J4XHE,NIZ%!%=2T245RFDR$U2G%$I/EY
M603TXA,F7S$S3_I*'4\.IRO>NOM/Z"2GQ(,.E+*C2IXSJE"B4BIK*#/,JJ*J
M5.OJ5NFJ%%TJY3#+P_FX8X)JU39JG+7,"$];I4U3C<)<"TE;['>'O7'V:H_3
M3D<U20KDN6I](*6IY;HD+E/Z$R:=1/II4--*AII4--*AII4--*AII4--*AII
M4--*AII4--*AII4--*AII4--*AII4--*AII4--*AII4--*AII4--*AII4--*
MAII4--*AII4--*AII4--*AII4--*AII4--*AII4--*AII4--*AII6--*AII4
M--*AII4--*AII4--*AII4--*AII4--*AII4--*AII4--*AII4--*AII4--*A
MII4--*AII4--*AII4--*AII4--*AII4--*AII4--*AII4--*AII4--*AII4-
M-*AII4--*QII4--*AII4--*AII4--*AII4--*AII4--*AII4--*AII4--*AI
MI4--*AII4--*AII4--*AII4--*AII4--*AII4--*AII4--*AII4--*AII4--
M*AII4--*AII4--*AII4--*@?05!$O4Q7O77VG]!Q-FC"$8P$T\9HS'SS0GGC
M.)5)DL!.9-.)C)IH2GSRPC/&,)3YY81GC&$3)IH3F33B8R::$3)HP+/G+'Q(
MX%J)RX1CCTV]VK];5WLO4Q7O77VG]-6]VH+ZJ6CBEK1*B?U:]?!)+Z*:LDJ#
M056"C3NB1?&92F7P/GZ*94(K)>A0HD3R27"5&/13*A%9+Z2]=!')"./2B714
MF37$3"9&N+62IZT2>:"ZP28<LJY::9#4I%8IJZ*GT3Z\27,AJ):R"ZKE(I@D
M72*8JU4J4LN>!DN>D^,KK1:8Q%52E<5E:+3&(JM(JF-KY1<Z*HE+('FP*EFN
M4F4(ZM(JF"%?!7 5%7E2B#/B2=25WLO4Q7O77VG]!4FF17F'R4U-,M320..0
M'$PM<F0R4HJ8V)R8PB-8F*G@:3,5$TB<H01FQFBD,A.<GG(CZNWNU"J3PD65
MHZ1695*@<2>H6'H"E$5J6195XP)6&JTDU67G)9OCG(2O_=^&IK4T2$9*@N9,
MI4KXU58:E*7K3$Q]563E3&JSE1R-8:6<(21DE75"4E.B29904LGF5J%D\BHG
MZA3UDYQR)6K70I2XR>>@FP)*3SK%DE*716%UY'.J(0ULI1&IKS))TI:HJ>@F
MP)*(G6+)"*I,<EIQRM9#-GKC$:XXL\I2H7&558<D3U1<85.B*/+BI-^$7;A?
M"FH:HLD47 U3\.,LJVH2DIT:6*90HGGIBE(K*52DQ^%4##)2X?-$X*7%&QK"
MB)">B)94Z>!<L(Y7YG-1%>93V_\ S<'94?\ 5_\ 8P.E*J$YDJM>H62I5Z*H
MR*PCJA*,^DR14*!</\UM;.C*0P5334E:8I+/D7%R5!5FD"+^KJ2N]EZF*]ZZ
M^T_H*SL,#<>*A14<=,+.FEM3W:7-DD*NL'*RZY_9=W:+K]VOU4Q%"L52=.16
MC<TA]7;W:A5BI35:=&6G"SM]PR32PJ%:(F)7IXIDB=01.;5X_P#LU]-,>F3%
M4XPN:9'(339X%*:A.C-EJ9LYB6NI<PGI!T:@?%*06JIQ"*4T40J!LJ"6<\Q5
MV\Q3*D7Q6R*EQ/U"D=HH53*3PI4V:54LF)Z:G$H9RJ7(1*6M7R(X5Y6G5EKI
MHHU)55).GI9,3TU.)0SE1D(E1T7LU*52(#"C8+EJ^9&?"HG3FH*E.FG%%,C
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M7VG]!4%;!(HJDV5535,Z8TU6888L7FJXG5 TZ1'5#D85UI0J@"C9BIHW(JC
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M2RS>AFI/B>KF]SUDT\)1*9+,%*F1/++-":'J)YX20]:7[OK(QA 0.DB(_P"
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M,!PP'# <,!PP'# 80'# <,!PP'# <,!PP'# <,!PP'# <,!PP'# <,!PP'#
M<,!PP'# <,!PP'# <,!PP'# <,!PP'# <,!PP'# <,!PP'# <,!PP'# <,!A
M <,!PP'# <,!PP'# <,!PP'# <,!PP'# <,!PP'# <,!PP'# <,!PP'# <,!
MPP'# <,!PP'# <,!PP'# <,!PP'# <,!PP'# <,!PP&$(#A@.& X8#A@.& X
M8#A@.& X8#A@.& X8#A@.& X8#A@.& X8#A@.& X8#A@.& X8#A@.& X8#A@
M.& X8#A@.& X8#A@.& X8#A@.& ,PEEME<8M3\,!PP'# <,!PP'# <,!PP'#
M <,!PP'# <,!PP'# <,!PP'# <,!PP'# <,!PP'# <,!PP'# <,!PP'# <,!
MPP'# <,!PP'# <,!PP'# <,!PP'# <,!PP'# <,!PP'# <,!PP'# <,!PP'#
M <,!PP'# <,!PP'# <,!PP'##HA[5#]GC_<LSLG7\1#VJ'[/'^Y9G9.OXB'M
M2I7(E+U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&K
MD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<
MC&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD
M8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C
M&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8
MU<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&
MKD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U
M<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&K
MD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<C&KD8U<
MC&KD8U<C&KD8U<C$]UI)X69#!+U_$0]JN;L?[.E>]9W9A>I\Y4GS \%^Z(C
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MFG33H*<:MFC##HEI<T4_Z/*]ZSNS"XJ+/4Y=#'"2&$!$1$1$1$1,/]1'^O\
M0P$?YB(],!_K^1 0$8"'1$1$.F,!$1$.B/\  C$1Z(Q$>B;^8C_6 B(^IB(>
MU7-V,4.2>=%2Y3DR>FTJ4^0ZE$'DR_3$R5'+)5Z3*EBHH:9(*M1Y4\JBDI$4
M:4A@=+2Z)(L*GHZ=053J5(84?2DF7A_,DWQI$B"8X^H*(&)IZ9+*D1TN4Y--
MA\L4E)8H9Z>3,EIE%D5$3T=.I*2_34E**D)7THN!*6>$AEPHE!\Y19M1.-IB
M$N9/+PTY)2BI"5]*+@2702)"4U&)-'R=.L+I=*D.DJ!:> J-'C%4L1HBH Z&
M7IM(+GG04^!J9+;9L2BKG(A&>BR11%)%$A-3J"-73I[5-Q4J2OA3PDC$?#CT
M(TQI].J"-2F@2HE^%;Z29(LMDR6:"TE4@%*[ C_LKGU*J)%DZRN'R&KJW3%A
MJ@^6:6<H^<L5P^>5.112C"*<A*/4TY,08%%)(.(+^F24M.G*5R223_HTKWK.
M[-Z,8B(C$1B,>B(Q&/1CT8B,1$8C$8B B,1CT1CT8C$1Z,1CT8C$8]&(QZ,>
MB,1CT1B(C$8B,1&/J8B'M5S=C%%-F*14]1-5T],.CD(U@Z8N7_-,G(+IY%R8
M_"N9"89"H%3$($2F9;/2B($!#V"VO<HY,#$E9,F()A_-7413P522)0@CC3X%
M1/IB)).13Y_I:@J8VFTZ6,J"F)IU%.MPB9/*GCC3CE<8(UE4..(((F/FID5B
M(V,Q1-55TD^)Z>2,E..5Q@C650XXBM=C3EQ54VUB)B)Z6M/1PK2,J)-PP,SA
M,TM7EFAA&HQ^)3J6=,2@1GQK":@PP(I!7S1*<K@=4*JB-4*K9-/FFMXJ$RZH
MSPG.37,I3R:N5@\Z)TQ/'\M4RGQA7)N%/23?F$"D)QLM,--.2T&3,IJ=2SC#
MJJHE/J-2K9R1=5$$J99<$5&:-EFEF@*_V9?].M/^^CH2XDISHG(ROIB)>9)+
M7D$B)1^C2O>L[LW7\1#VJYNQ@I:87(D6&)9D]1-3SJZ\I52P6F?#2UQ2EE-7
MFGBKUF=/.I6F*9XW&KC*0N,(A(N,D+3K3$\*>;*<DF4P1)PH6&'P,7FF%EK3
M"RT-4.11-JYYHBM,B6BJYZ.$*B;"5"L@0A65I0KEE6&2EHJH<C"VKGK(2S1E
MCJ17PQ,FC&:XE4TDJTR4M%5#D86U<]9 Y:8=(C7&I)EM94+((:J<B"RH&K)C
M*F<88IKZE3**>KD-22+#)"TBTQ),4N,*@D7&))BCYBIY*D=(8JKRE3+0U!:.
M2,<?025D])*KK2A5*>L,/E1U U($=2.216U@]9 @^8B8ZXE1LI9D9)E*F=1.
M9433(:F5A4JG4S@]:8?*8M,G+2K#$LR*HFHYCZVH.$%ID"R+@5$2&FS&S?HT
MKWK.[-Z,>F _P(0$8"$!& _QZZ/3 ?SZ4>F @(],!$0AB("/K8B'M5QR1G29
M$X9$X9$X9$X9$X9$X9$X9$X11'1&1.&1.&1.&1.&1.$$1T!%$=$9$X9$X9$X
M9$X9$X9$X9$X9$X9$X9(X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X
M9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X
M9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X
M9 X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X
M9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X
M9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X
M9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X9$X%HC836
M=V7T8_S&(B(=$/YZ(C^>B A'H@(B,1$1B(B(B(QP$>B&(@(1'\B(_P!QCT1B
M(C_(_P!PZ("$1#^<1*,1&(P_R(^JB(>U0ZIQZGQZGQPZG.]RS.R>C&/^8B(A
MT0$(B(CT1$!_'3$1Z(]'\]'\B(A'H@(='\B'3$8]&/\ F'1"/1"/1#HB(Q]9
M$0]JA^SQ_N69V3K^(A[5#]GC_<LSLGKH>L@(^E 1Z,.C#U$/3CZJ(A[5#]GC
M_<LSLGHQC@(]'\1Q$8?Y&'^<1#^1'H_@?R,>C$1C@(B,>C#_ "("'^>C 0B(
M]$!#T(PZ<.C_ '_ @(B Q'\1C'U41#VJ'[/'^Y9O9?1C 1$1C_F(C'_. AT8
M_P"<!_'1_(_@8#$1$1$1@,1B,! ?P,! 88"(@(P&(QZ(#$1B,,1_ P$!_(P$
M1 8#'_,?51$/:H?L\?[EF=D]&,<?9(]31$.BH5TI$:"KD*.DI%2^8%'F?"DH
M-6C4BNC5!R@RAUZ>H&=-/K452FG5V"P_U,/V>/\ <LSLG4D.B$/2CT0Z<!&
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M53/U,?[EF=D]&(_U ?Y$!'^/]?Z@(" _R/\ 4! 8=$!_D0Q'^\!_L1'^X8B
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MST?QT0$(C#U$1#VJYNQ^CA^BK2_NZF)][J8_W+,[)Z,88]$1B,.C^1_ @("
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MF LN/,!9<>8"RX\P%EQY@++CS 67'F LN/,!9<>8"RX\P%EQY@++CS 67'F
MLN/,!9<>8"RX\P%EQY@++CS 67'F LN/,!9<>8"RX\P%EQY@++CS 67'F LN
M/,!9<>8"RX\P%EQY@++CS 67'F LN/,!9<4C?<SB2I^8"RX\P%EQY@++CS 6
M7'F LN/,!9<>8"RX\P%EQY@++CS 67'F LN/,!9<>8"RX\P%EQY@++CS 67'
MF LN/,!9<>8"RX\P%EQY@++CS 67'F LN/,!9<>8"RX\P%EQY@++CS 67'F
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MX#NRO =V5X#NRO =V5X#NRO =V5X#NRO =V5X#NRO =V5X#NRO =V5X#NRO
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M,'Q==4TR9P77567?@N?= CI]::!Y;;>ZBW1N@IU/K[0/3;CUTI5O#IR@MO7
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M=;I]M4^RJ34MTET[N%$EK7AN"O*GV VK%01L:QK:6M6WYN_=):+C7I6WLO\
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MC\<7A*/R4VW5[DH/=;>@H\L94 V?N&YEN6'3ZE5:Q:C96_4K,8EP+AIUW/\
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MNW2\+)N=NFS<V6X:2PSG,TK9)DE#:*6$:16SU-:IJ%3>7#:C0JK>=-H;%O\
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M.BRQK,LB<VPVV-,K8QMV5:-6UBV]K.I3A4"A-)N"LFD6[M_I]D-8T]F&MS9
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M4]/HB,XF,HAKP#@A-EF4I/60P9?(SW#89#1Z]BNY3RD^(T,.C:LN,:XAC8%
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M%/(RH R!H)J :DR[E#*$0<V0>Z_ECTDZE&/U,8W9%A*)+ ]+J.3E &<GK+1
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MJ8-8L,; KS!ZGTLKS!]>GT/*(.T IXQ V !$@ /7T[4)$!Q4=(]'F +5.FD
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M:26O$DUT$KYV9.4 <,8%J.DZ5++S97XD,'Q4NX.OH1RI5Y<C'J%7#J])G*H
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M?N<;0OA'?^&X;>X_OHE(.8EP=7[)C*D&@H1B& H _"F9[I^YQM"^$=_X;&8
M[%VM6 6E8!:5@%I6 6E8!:5@%I6 6E8!:5@%I6 6E8!:5@%I6 6E8!:5@%I6
M 6E8!:5@%I6 6E8!:5@%I6 6E8!:5@%I6 6E8!:5@%I6 6E8!:5@%I6 6E8!
M:5@%I6 6E8!:5@%I6 6E8!:5@%I6 6E8!:5@%I6 6E8!:5@%I6 6E8!:5@%I
M6 6E8!:5@%I6 6E8!:5@%I6 6E8!:5@%I6 6E8!:5@%I6 6E8!:5@%I6 6E8
M!:5@%I6 6E8!:5@%I6 6E8!:5@%I6 6E8!:5@%I6 6E8!:5@%I6 6E8!:5@%
MI6 6E8!:5@%I6 6E8!:5@%I6 6E8!:5@%I6 6E8!:5@%I6 6E8!:5@%I6 6E
M8!:5@%I6 6E8!:5@%I6 6E8!:5@%I6 6E8!:5@%I6 6E8!:5@%I6 6E8!:5@
M%I6 6E8!:5@%I6 6E2RS$"\&=S]SC:%\([_SY&T+X1W_ )\C:%\([_SY&T+X
M1W_GR-H7PCO_ #Y#:POA'?\ GR-H7PCO_/D;0OA'?^?(VA?"._\ /D;0OA'?
M^?(VA?"._P#/D;0OA'?Z)"1(8"I8Y6!-^%XY9+.6?J*QGE\5C/+XK&>7Q6,\
MOBL9Y?%8SR^*QGE\5C/+XK&>7Q6,\OBL9Y?%8SR^*QGE\5C/+XK&>7Q6,\OB
ML9Y?%8SR^*QGE\5C/+XK&>7Q6,\OBL9Y?%8SR^*QGE\5C/+XK&>7Q6,\OBL9
MY?%8SR^*QGE\5C/+XK&>7Q6,\OBL9Y?%8SR^*QGE\5C/+XK&>7Q6,\OBOU#R
M^*QGE\5C/+XK&>7Q6,\OBL9Y?%8SR^*QGE\5C/+XK&>7Q6,\OBL9Y?%8SR^*
MQGE\5C/+XK&>7Q6,\OBL9Y?%8SR^*QGE\5C/+XK&>7Q6,\OBL9Y?%8SR^*QG
ME\5C/+XK&>7Q6,\OBL9Y?%8SR^*QGE\5C/+XK&>7Q6,\OBL9Y?%8SR^*QGE\
M5C/+XH2$B7+5-H/2JU6JU6JU6JU6JU6JU6JU6JU6JU6JU6JU6JU6JU6JU6JU
M6JU6JU6JU6JU6G?[G&T+X1W^B=X@4"LMI6*-H1V_A>&WN/X0'O#L/W.?N<;0
MOA'?^ Y1S X >LC2-2EES#Q%Y@^H@!1SLC"2QTT^H(4IYN" <[?X J RPPE7
M2=8UJ(R@S@O23IZ5F2S YC52:*#Z")X8ARVGH1R80,2'8N='6=X69EYH<0?6
M*BVA&[$NQ;%7HTHRF6A&D\.*E&$) L6E37HTZ^C[.&WN/HCE90><ZM0&L^NM
M7AF1D?Y3$ ; ?X*]-AK<T#K3PD);""A%RWRZM%:G>F"*&C0\=OK2FG*(.HD!
M.%=E*(.HD/Z,O+RI7;Y()8'5K5^]', I(9BW0WKM7S,J0@^D^S32#V(&9% #
MRJ&WK7DD);""GG(1VEE>B01K%*NRG$'42'3JY&42=0(=7I$ :R63P(D.@O\
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MGI82KL"C+2)46'A^U+9W_:9?RFO-0]7M(?[,A=!=HZ?76YZ%$?\ +^TH1B*
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MANWC6LT__P @[EE9F7",P 0;T;UTN.D,]?+K1A\N,8$AS&) >NMR-"$(!R:
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M:^HE2AJ)%GW+E^\.W[G.P]B^(]WX#OD.31$:SP"&=$Q -(BP#CK!-/24)_4
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MJP^IR 8A[LHDNQ9Z#60VOT0^GD:,S)B-D@Y!]=+(9,J&/FZ *^P]:SIQJOP
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M#^U$?\CVE3#G'+^HH9D@X#;X@=ZGG_39E^-<A2) ?\AI'3UMZ,@:+IM>+K/
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M$M>#/UC@L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K
ML<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K
ML<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K
ML<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K
ML<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K
ML<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K
ML<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K
ML<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K L<K
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M=0#ILR)CM!';]\GW3VQ^YQ]SG8>Q?$>[\!P][N*R]L/Z2LCZH52C$2Z@ ?\
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M@,:=CHB;7I%RVK0.T]:F,UO,0S%]:E/Z,@QEH+6%Z*-!!0^H^L(\K-$=%55
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M7(3(&I_5NI/(N2H?%_4?QJ=A[%\1[OPWF>[WC[IA\7]1_&IV'L7Q'N_#9A,
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M\"WS<?)V/ M\W'R=CP+?-Q\G8\"WS<?)V/ M\W'R=CP+?-Q\G8\"WS<?)V/
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M=B,Q0(YZ9*I:2IOI6U$%% .54\G"=UNF539DM:WF6[BVQ_R"W6$%;B4ND[0
MD\JF4\6S;A]G3D2^:AC1%J1)FVJWK<BMY30D.*IF [('_9A.J]!RC)@EPLN)
M<06W670 2AQ![DT((X01M!Q>(MPDRQ<+-<3:EPD1BN3*DBM1&;227$BFU1R@
M;.R,76<_->L;UE:+\Z+>&^@>0V#ES(%3TAJ0,J>74@9=N(NCDINEKDW%24V]
M^Z1#'8E%7<Y%$DISG8G,*$T%:G%#P_:[HOXMD_5KW])H?2.KXWCEHF6EU+[&
M=;>8)4\H<I!"AM .PXC;Z]R"Y.GKW:9\9I:&Y3KC4A#Q.PAQ2B2".4FI2M%0
M4[*XL>M-:)>89OBX+"$QF^D"'Y;87RJD94#;4G@&!NOTN9LR6I;S35Q1'_Y!
MUQA)4XE#M:D  T52AXL*T26KC?-2MH"WK=98IDNLI(K^-((2@T(.6M=HK3$M
MC2;LAFYV^GCMMGLF/+8J:5*%<*:[,R2:'8:;,186K7WWKM.3FBVV R7Y3J:T
MS9!W*200"3M(V [<.Z7LPG6[4$=OIUVVZQE1WRT"*K16H6!QT-1C>V6]B_W@
M;I]WI':8U?\ ]'84J)+;NWB]Y5*ST5)27" UF4?Q8.<BE.'[F+U!NLN4W/L<
M_P";'(B8RER)4G;R8K:22X!3:KD@;.R,/Z6LHFVW4$="G5VZZ,= \I">Z4C:
M0J@-2G8H#;2F-'C5D*4[O!>86JROMA7BZ4-%9'344$U2<Q34'AVX&I]?3?%(
MBU]$RA""X\^Y2N1IM.U1IM/ !QD8B:/=8NUDNEQ5E@)N\-3#<D\0;74C,KB!
MX>"M<2=$LLW2^ZAA&DJ%9H:Y!8-*Y7%[$I4!PC;3[N)D;2+LEFY6ZAF6^<R6
M)+22:!64U"DUV$@[#L(&S'_[I'\V?Z3>9^R-*?FY/]+H:W34YX\C4?1.(J1F
M0M"$J%1M%03B\ZOW=1I&G[_8XKUPBS(\U\[6!F*%=(M5 0" I)20:&IX,1-7
M:C5TMUD/0VI#M*%U;$HMAPC^\H)!5_Q5.+?9O_>5V$"#"9GR[7$+T6*L,(!2
MMXD)4I)V*"> [*XB:KTE*1-M4Y'2,/(J*BM""#0I4D@A23M2>'$FW:>B7O47
MB+BFY<BT0%NQVB@T5^-50*IQT'W*X.IM!25R(S;O0/M.MEM]EVE<CB#P$C:"
M"0H<!Q+T?;H=XU#<[<H)N LL,R6XIXTK<J 5#[X#@((X0<-:XTN^HVAWI:KD
MMEA;19)#J74K[@H(.:NRFVN)"K)"OUYM41:D2;K;K<MR&V4\)"R05 =D#_LQ
M&U?HV8B=:98):>14$%.Q2%I.U*TG8I)VC[E,<K@Q.WI;WM0*N5Z;G,QX%J@C
MH[9!8>6H'*DBKCI2!5>S[JL6C]F0/U9']+N@_:U]^K#_ $NJ/R,?]81BPSYM
MJ>C7BZVJ*ZY/CRWPXE]U /2)0I1;[K;ERTXA3&H]'ZJF*N*],7!Z!%EN+*UJ
M9R*Y!4:E02I)**DD).7@ PJV:@7*FWN7>K@['M=L8,B6ML!%7"@;$(V$9E';
MQ8DRM%O/)E05)3,@S&^BDL%6P%2:D%)((S \.PT.'=$NHN5YU*PE*GK=9X:Y
M#C04,P#BMB4D@@TJ=AVTQ+LNFE2XEZ@(Z23;;BP6)"45 *@"2% $@*H:IJ*B
MAKB-IFZ(G7344MKIF;5:8YD2>B_OK (" :;*[2-M*;<3E:<;G1)ML6VW.@W*
M,J/(84X"452=A2H T4#Q8.B5MW&]ZE0@..VVS1C)=9217\:00E!H0<M:T(K2
MN)<72KLABZV^GCEMGLF/+9!-,Q0>Z379F2=AX:5'V)NOMXB9=\>D);;C09,A
M:(D-M" G*TVV03F(S$D\)X./%DT/NR=>CZ=U'"#DZVEQ3B&TK;=-#7A"5-A;
M9552*D5I_2Z[_90_6&L-_DT?@C^D;_QI_P!N-77C>#:?G"7$U \PROQA]K*V
MK,HBC:T@[=M3MPG<II&;(>T7?[69Z8$ETN^*N%"UI*:\!"D$5H"M"J*J17&J
M]6ZWFH@VQG3,=)6H%2EK4AG*VV@;5K5]ZD<.&M"LMW.T7F5\C:NT4QQ)V5&0
MU-%*'<I53-P UV8CW+74IQDS'%-1(T=E3\B0M(J4MMIVFE14D@"HQ$TE>8EY
MT].N"PW#5>(18:>4H@) 74Y<Q( J*5(!(KAS5FNY1B0&W$LI"4%QUUU7 VTV
M-JUFE:<0VD@8BZ,7;;Y9;I<,Y@)NT!3#<G(DK(0NI .4$@'AQ%;U<^\Y<9Y(
MA6Z$RJ1+?H:52VG@379F) KL%<(T.6;E8M2.I*V(%YBF,X^ *_BE5*5*H*Y=
MA/%7[%MN&O%3)ENM;;@;M2'E-Q'75J!Z5X(HI2D@90*@4QH/5>Y:-\QZDG70
M1S"B+71]H*; 7T9)-%%1;5]ZL&E*C"P!0!1V?V_TB/\ $/\ ;B#^V-0?6;_]
M3WPZIU'(1$M<&.V_)D+X$H2M'^LDT"1PJ40!AO\ F'WF1%,Z/MRU-Z2LK^U*
M@A7RIU/ 1F&:OW[@%.0V*QGM:27E3K@HIAP(C2GY<E0-"4-IVTKL*B0*[!4X
M:T,\Q=+!J&0,T:%>HIC*D#AHTJI25&FQ)H3Q5.S'_1=XR6M2&'X\WTC-([K6
M3.>C<KRE 5J*<*5#BQ(UUK-;J+9'6TT0PCI'5K=51*4)J*GA)V[ "<1KJPAQ
MMJ4PW(0AY.1Q*7$A20M/$JAVCBQN]T[<21%GZ@7%<(X0EY+2"1]RM<7O<GJ9
M1^?-$7)Z%11VJB+<46R/>2L* ]Y2?>Q(MFGRHZBU*\BR6U"#R\\C8ZI--M4H
M)'W5C&O]!Q%9S:HENC+6?OG4D%P_<SDT][&N4[OH4J/J]AU";^\]FZ%:G'"K
M\151%"OE*H!_JQO,_0(?^UG#.E;IX[<]2/MAU%JM,<R9(014*6!0(!&T5-2-
MM*8DZ>L9F0-00T%Q^U72.8\I*!PJ2DU"P*[:&HX2*;<1M-W9$ZYZAF-EYBU6
MJ.9$DMBO+6!0(2:&E>&A-*;<7S6;<>[1T::#2KK;I$%:9S0>51&5K[\*[(--
MAKP8UE-U])U!<K9/N8>LS"8JY!BQZK_%E%?Q1H4C)[V&M6:[F^)PY(3XLWD4
MJ0^I20K(VT.45 $9JT"?OB,1[5J"->=/IF+"(TJ[05,QUUX"5@G*/?(H..@V
MXN&N-0EPVNV,>,/F.GI%E%0!D ("JU%-O!MPRJ +G>7%QF9<A%LB%WQ-IY(4
MGQE50E"P#RD5)''AC6.AY7C=L?4I%2DH<;<3W3;B#M2L=CL$$$@X=T2RS<[_
M *BCC-)@V2*9*HX[#JJA*5#C3M(XZ'9B4[HY]Y,R H)FP)C18E1R30%;:OO2
M=F8$BNPT.%Z'$:Z7W43+:79$&S1#)7'0JA!=54)2:$'+PT(K2N'-1Z2,D,L2
M%Q)#$QA3#[#Z "IMQM7 :$$'@(_J>][^)+?]41<7[]*LOUM%PK[6VY.Z^?HM
M*]GHW*?]N%:-U??--6.P3F4-2W[6AQV2Y'*15 JD4S#80%)KP$TQ?-":82H6
M^W06DI4Y3.XXJ2A3CJZ;,RU$DTV#@&P8TU!L49ME$Z!'G2E905O2'TA2W%J(
MJ378G^Z  ,;S]=WM(=O%LDMP(2E[3'9SJ;JW7:FJ&TI!' ":';B#K=65-\LU
MWB^)2?\ Q0'<Q4@*X<H*4KIQ$5&-T^\W432YS$5ER1*MC*.FDHS(0XN2AH5S
M!!-:]E%,:(TUN4$^?+L]X3<YEX5%>CMP6$Y<X+C@!!-*D<!(2!4G$)*R<KVH
M8@)XZ+0X#_;MQ#TW86&8-FMT9(;31(2A"456M2CPD[5+4=IVUPY'_E^T!=+]
MIR"^I@3HZF;="<6#R@RA0Y7#M)VT-2!C>9XU!-J6N]L.KMV8*$9Q2GLS=4\D
ME-:5&SL;,;TM5R8K;EW@7A;$22L54RAYUPN='7N2K* 5#;38#PXTBQ?H34MF
M79ES9+;B:I>?BID=$MP??9<B*@US916HQIZ\+'_.P]114QWAL4VE:59DI/$D
MY4F@V5 QG5M4JA)[)(J?M=T7\6R?JU[^DT4-VOB7[R_-#GB?SB2(U<SV;I*
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M8^HK\V46F JO_)0% !)(.U)4@!* =H151VK_ *77?[*'ZPUAO\FC\$?TC?\
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MCO+GP#VL=Y<^ >UCO+GP#VL=Y<^ >UCO+GP#VL=Y<^ >UC7:W6UI3\U#:I)
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M;SLNCD\@+4I)V#.$C8*XGW7>YJ-^R0(*&2Q$@13(F3EN%69+5>0@-@54I?\
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MZV75#:V1(9RE71N4S)(6%)(-!PCA .+O;=/W%Z)%O[)CW1ML)I);)42E=0:
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MZ@_S,>CUVZ@_S,>CUVZ@_P S'H]=NH/\S'H]=NH/\S'H]=NH/\S'H]=NH/\
M,QZ/7;J#_,QZ/7;J#_,QZ/7;J#_,QZ/7;J#_ #,>CUVZ@_S,>CUVZ@_S,>CU
MVZ@_S,>CUVZ@_P S'H]=NH/\S$5]ZP75#:'VU*4J"^  % DDE&P#$@C:#?9_
MX+?VKG^%7^S$NJ0I TOJJJ3P$=/-V?VXL$W>/;4ZEO=^T[;7)%TN1Z64RVY$
M06F8JSMCMQT$(:#67N<RLRB2;!*U/*<FW"$N?;%2G22XZB#,=CM*634E71H2
M%$DDD5)J<:Z_9#GX:<0-!;N]W,NS2YMJ8A)OM\N,),2*VMA*#(#3#CKSI Y2
M$94[:%7&DG=A9G5/Q;,JPQNF4D)+J_G2.IQPI%:9UE2J5-*TJ< G\7IK>S;A
MMVY&[[:6_@IZ>,?>+CB>,C :(Z32VZN(%GAR.W^Z-[/^%?BT7;V6W7>SA>E-
M1QT2K5<KAJ*)*87W+C3L]]"TG[H)V\(XL*.G2-XVZ:TM*4(3QZ&_6R&V.Y:<
M[W*;90#1)"5Y0$I"$C9;->:2>\8L]VC-RXSA!2HH<%:*2=J5).Q0/ H$8W2:
M59N4VT>/7ZY-.3+<YT4I#7S<X74M.#:A3B IO.-J0K,-H&)6^'<I:(NF=8:,
M5&N<&? 2IMUY+3J$NLR5@YGVW6U*"PX5%1[HG;7<Y=VTE*)5BU,^$GA <BQU
M '_7B/>]^L9%]U5-B)9@6EV/*NJT,(4:K9@-)=2V%*KF=+8S$4S[*8U_I?=+
M$N%HT,;?9[DS9IT1^$B-,=+K;ZV([X"FT.A"5&@"5*X-B0,;U;WO%2Y>+5;=
M5I$2QRCFMHDJ@L9I;K'<O.Y"$(Z0%+:<Q2,RJIUENAT*WXEH^;8+9J)FV-DB
M/$EK?<C/&.C@;2Z$A2DIV9@*   #>%K'>3&^?H\77^I8L"TSZ/6Z*KITEY],
M=54*?>J IQ85E2A*49>5FWJ;C=,YVM'V619+I:H16I2(9NL5;DAIK,3E:Z1&
M9*!R4U-!M.+QO9W^Z5O^L=1WFZ3T1RO3LZYP+? COK:CQ890VMD!*4YG%(&<
MN*4%DJ3C>+:M.VN^0=UMJ\5NNG6KU#E1%,=+'6J;%8$D!70H<;"D)&Q&<_WJ
MF-OAWY6B+J?5^L_&;C-FSPIQ;+;CRTLL15$YF&VFPD)#920:D'@IO;TDU.F7
M)J!J6*RW*N#I>DK;$-&0..':LH31&8[2$@G;BZ6G5LM<&R/174S9+<E413;
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M=0-!BZ6RQ6R%+:"DK"'V(K;;B<R24JHI)%02#PC$/1^N8HA7=JX79];(=;=
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M55:DC,3F).-,:UWX:DOM\E2K<TJW1XUSE06(+*:A! CN(4](5W3CSQ62:(2
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M:8@Z9O$&%/'1@S[6RTI49[-W)4,[9K0!=,Q J<)@N;JM=)U*3T:[>+%^*#O
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M7VSMTTA/8N,1B2]#==CKS)2^PK*XV3_>2=A^VGZ,M\YAZ^6MMAZ;#0JKK")
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M=4)F-LK989M3,%,-X9NE2VMM14XT:I">D&89:D\HXU-+TI?Q9H4*S7-ZYQC
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M94TRLA;B'$D%*T@I(X\:^2#M_=;3VS_Z[([>-#;V=\=N\?W;LQI]CN[Q#Q1
M=DY5Q)#O0D*#96%(4ON45!/",66)IUS34^^39T=%L8@7%VX.*DYZM'HV77<H
M"AW3@"!]\1BR[LM^5\>T]NJ>T\[.B 3G+;%N=V$CHU,2I;:VR4MLT6EDK0%*
M()*BH),%G^7EH*M"-)W9$R='=DR(<F2F7')#$AY:TO=&DC.II2D J J55IO
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M#@*55XL:$W"ZA<0-6IDRK[<8B5I6J(ET.Y$+*20*]-3AVE"B-FW&Z36=Z!3
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MTZ2Z/S9327C%BNK/BT2+G!Z)E#03R4TJ3RB0E-'=YNG+-%MVHI$1<*1(AIZ
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M@1W-6V"7IK4-KT#*@W"WR5H=;#GSBVXER-(1R7V%I4,K@"=H4E200<7?0?\
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ME9;+E4$\DJ! X]G!P5>WCVV\PW=,QPLO3^DHRCHS10432A!(%.$DBG",/QM
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MU;>63#<#C*B4$$A*A7*=AXQB$SKB(XN5;'2_;YT20[%F1'%4"E,R&5(<1F
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M.<RZZ0GNBE*5$J IM*:@?8AZ%N5V@L:CN#2GHEN<D-IDO-HKF4VT3F4!E5M
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M-^_+QOU=/N/8/\4S\S[CW#\FG\-/N//_ $5_\V<+_;,W\!K[4N.$)2D$DDT
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M6Q,74%[+BI\D.O++I=<#J^0M90G,L9CE2-OO8;?W@V9J9,91D;E(4MF0E/\
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MS)4K($BJE*HE()(&(7\QF\R([;M.VI+HT38)"<KK:'AE5<YJ#4"0\BG0M_\
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MR;?NW>(./^M;H$I- K5<@'Z,D^Y-^_+QOU=/N/8/\4S\S[CW#\FG\-/N//\
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M+$Q?_P!*LGUO$_K6Y[^+)'U9)]R;]^7C?JZ?<>P?XYGYGW'N'Y-/X:?<>?\
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M6=:.C75>VE:\  XL-Z:%VNM[Z-QQSQR]2O&I:ND5FHIS*FJ4\"138,:S(_\
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M?4#[,.,BPVUL**E*3^+4E+8 4MROWHX* \!.%:RU?IQ^+:&TA;SP=9=+"5$
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M@IP\RPZXAMW5<P.(0M24K CN$!0!HH#W\:E8:GS$M)U/*2$)DNA('C7  %4
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M/3Q% AI2Z4Z5JA34D(KBWZ]N<(6ZZK<DP[A$2K,AN5$>4R[T9))*"I.9-22
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MMFTV]I?4D2YKNK-_$QX0=K<R,EL16R4OMJH1FH2D#WQ9/_E[<OK2/C>CNOU
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MY\C8!JHC(*&IV8=FZ(O%NO,=A?1.NVZ6S*0A=*Y5*:4H!5-M#MQ^X_[U6/\
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MB->(#T&25)1PAET!12<U$J&PFHXCC2.FM60'X4UJ%(;DPYK*FG$YI+IRN-N
M$520:*&T'&C-#L6J3(W7Z8&I9UBNR&E+:C1+O&J83SM"$EB0"AL*5F4A:32F
M)VF->Z,U(W:$*2;;>[5!7=(DMLMI4K.(P+C#@65(R+2:Y<P50X?_ )C'+#/T
MYI6W:;.GK>+LQXM.N3CLH/K>4P3G;9;IE0'!55<PXTIU9J.?8;K?-W&N);-W
M3,LD5<Q^V7!+0:D(D1VZN%I[*E:7$)(3L20=I&EM*Z2T_>;3H&Q7N)?[S>KU
M#<@>,J@'.Q#BL/ .N=(X07',J4H"=A)V'<W=[3 E2H%MNUY<FR&65K:CI<@Y
M4*=6D$("CL25$ G8-N-/[Y]WT%ZXZKT#>&;JQ$BMER1*A/?B)\9M*05'I&59
MB!M/1[-N-":ET_:;G=&+5KK3]ZF1[?#=D2FX<<.K<7T" 5U2" 13NB :88MK
M>D==MJ?=0T''M+ST-I*U!(4M111*16I)X!MP9,V#&>>53,MQE"E&FP5)!.&K
MS*M=UN$8O(C(C6.W.SGDYDJ(/0L E* $T*NY!H.$C&\G5]WT=KA%LU;<;0[;
M7/W9GUR1X88<+@R<@!?9^]V_8T7OTG6JYW+2T:T76RSW;5$<F.Q'7RAUE;C#
M04X6UY5)S)20DTK2HKN<UAIVT75,,:O8G2&Y$)UM^+'\5?3TDENA+*=H[NE*
MBM":8U3 @-+?DOV.Y-M--)*UK6N*X$I2D;2HDT &TG&CM)6*V3I,R':M,&^6
M1G,Q-E08[3/CL,).50<4D$*;V*5E4BA)RE[07\ON["\-AM^V.2Y2=.JMHMS+
M$UE90VA;:''WB1E+<<*RH*W%K"4\K=6Y9(4F8B#O#M$N48[*W0PPAE\*=<*0
M<C::BJU42*BI^QK"]ZRTM/OV@]:S&+Q$NEKMAN3D":&0U(8E--I4ZE"RD+;<
M"2G;E[HJI+9T=I&\VFVQXX7\[W&T?-C#ZRH#H64NY'UFG**NC"!2F;-LQ<]W
M>]C=AJ>??VS(C1+:JQ.R2X[M2V[#N#25-("]A#P<1D%:\!KHZV:FCR[]K/2<
MVQWFXQ(Z@]+=:@R>D<90:GI76F3EV$EQ39RE1(KK].@[-?NF^:Y$1AB=:I,5
M^2ZIL*RL,N)#CE*Y24IIFV"M,:0L-NMTN1<XT[2!>BLL+6\V&)$<NE2$@J ;
M .<D<FAK3&L;%IR'(N%RD06TLQ8K2GGG"'VR0A" 5*- 30#@&-1VF#'=>G/:
M7GL-QVT*4ZMU4):4H2@"I45; D"I.S&B=*VNT3Y<B!#TVY?["R%,S9=NCI;,
MR&$$I5G4 ,S>Q1RE-">24:)_E_W8W=MIB=:'9DQ.G56Q-O99G,JR-(6TAQYT
MD!*D,)4$-YW%K"4[=![R;+;9EVB:/U9#NMSC6]HO21"Z-;;CK;2>4X6RI)*4
M\JE3P D1M7;K;5--ZTW?X5]M,"^0UP#/=MK@4IOHY 20VZA2TH4L!*EBAHGE
M82PWNWU6=2$956<:5=Z9+O 4EY2$Q\H/_B=+DIRJXW>_S(:4LLNXC2)FL7BR
MPD)<F?-]SCI;<4RVDT<<C*2#T:#RMN78"<+TQNAT;J&;:&+E:I5SN4VVR(92
M&YK65F+'=2E^0[F(4ZI*.B::2I2E$D4QNVWR1K9/NMGTE>IBKJU;&%29+4>=
M$4P'@R@%:TMKIGR D UIQC2^^C=%:[@J\Z/U"U?(EJND=<"1/CQRMJ0REMX)
M4@NH)+16!F V#E#$S1NZ/1FK'-<76,Y"88NEG?@QH+KR"@NRY+P#*4,U*CE6
MK.0$IX<PT]NT:=$@V6W,1''DB@<=2G\8L#B"EE2@.('&Z>_P84EZUP(6JDRY
M;;*U,L%Z*REL.N 94%9!"<Q&8[!7%RTCI532=0,NQ;E; _3HERH3R7D-KKLH
MYE**G8,U3L!PB/?]VVJ(^K G*_9FM+O/.=.-BDMOI1T"T%7<N%Q*2FBCEVTW
M=:KNFE;A<]!VZY(GZHTM'91(D):7&_$=+%:4I+Z8KIJZT@K2KL*3M&[-W=#N
M^NL#2]GUA D3KXY956Y*3T+J4M(84VA\L@$EUXI2RVH(152E"EC_ )E;3:)M
MZTX]8G],:A:M;"I$R*R9 DQY26$ K=0'*I<R;4)Y5#P8W:RM":0OHT79=>66
M;+N\^"]%=6XDK%6HKB0\(S:5*+TAQ*$)5E2DG:<>,3X<=]V@&=UI"U4' *D$
MX3&B-H:90*)0A(2D#W@-@^WWP?Q#:OJ6)B__ *59/K>)]BSWG=U.$"9+N?B[
MSA9:=);#*UY:.)4!M XJXT[O#TG+;CW^ZKM;<B26$+IXQ$6\X4(4"@$J0.(T
M!('$1>-U6^5YIZ^Q(S4^$ZEI#2EM$)*TD-A*5<EQM:"$URE5:BE+#H_=>ML:
MQU)-#$8K;2Z4-)(22$J!3F6XM"4E0(IGXQ4:MF[PIK<R?97$B,\&&VR,S3BB
M%!L)2H!2!397AVG%_N6\:>)\B%.9:84&6FLJ%ME1'XM*0=O9%<:&TUHBX)B6
MZ[O 36RPTYTH,EMNA*TJ(&51')(^Q%GZ49:<OMVE&+&<?3F;92A&9QPIV9E#
M8$I.RIJ:A.4VK>[JS55MN]LFO,(?M_0,E+:GFRXE"LK39(H""II>PBH)&W&B
MM?[KY M4S4[L5Q:7&FG2E$B+TP;_ !B5 4414TXL6]S4=VMBK2F6P9B?^2-6
M,XZ0<EH*[FO<FO8Q;;/HV*B?K'4#RH]O9<!4A 31*G"A)!4K,M*4)J I1).Q
M)2;1J/5NJ[1)MZYC"[E:2VT%(C*<'2I2I$8 J2BN7*YP\"CQ_P!%HC]NO?JJ
M_L7O>?O2G.VS=WI9L+N#S'?Y+RA5,=DT-"01F(Y55H2G:K,D:<N.@[QIVW+/
M1HO<6Y+?E-\0<=84I22.-03TGO X78=),R+JXM]UN(F.RM;S[:5$(6&T@J!4
MFBB*<FN&XNM[-<+.\\*MIGQG&,X_X2L '^S$F^F*Q\Y#6P9$KHD]-T?1(Y'2
M4S9?>K3&EH]HTC,M5[2X_P".:@>*_%[F$U!2U4Y59216@&3+05J<*NVDM.7>
MYP4 E4B)">=:V<-%I30T]XG#D.:TXQ(:44.-.H*%H4.%*DJ ((XP1A>I[%IV
M[3;.WM5,CP7G&:<%0M*2"/?%?L:]UQO3LSE\C:6MD>:Q$1)<CYLQ<SC,@C:<
MH )J!MV;<,Z+^8KQH*XW!:6(-R1/\;C)?70(2\ETF@4K9P4J=JT\(_Z?;U=.
M/ZO:@K=2;9;\^>:AUDJ8>:2""0 0LI)V$*2H\G$N#I*UR6S*FR/$[6TA;[[2
M"XHI9H 5*4VGDG979MPW'UO9;C9W'A5L3XKC&<?\)6 #_9A=OT3:)]WDMC,M
MN!&<?*!V59 <O]N'+-J.'(M]P9V.1Y;2V74_=0L _P!N%7_3NF;Q/MB4E1E1
MH+SC64<86$T(^Y7"F7TJ0XA10M"P4J2H&A!!V@@["#MKA&J+YIR[P[,L IF2
M(+S;-#P$K4D  ]DTPW9=,P9-QN#O>XT1E;SJO?"4 FGO\&$VO6EJG6B8I.9+
M4Z.XPI0[*0L"H^Y7W9N/["D?GV?<>7^2_P"\>X\_]%?_ #9PO]LS?P&O] -\
M'\0VKZEB8O\ ^E63ZWB?8T]^VC^K.8T7^7L?U<[C=+_,%$!1;;E9+5%N2@>Z
MZ*,VR]F^['<3EKQMUXL7'6K"Q)TSH6(6X:TJS-J<;!;;((V',\MUU)'"$)QO
M!_*-?F'L:J9"ATB;A%44\8"F5 '^VA_U8W:#CZ9/ZXUB9H9G1-YNZ8B65>.Q
MJAISI6TKY%&UU"<V4FO"#BU7O>3:)\6[7TK>LMN!")C$IK,@N*4I-.C2#RP4
M\M*T@)"B%)T=??YC8,V][MX#K>2U>/951PX.2T\4@K0K+L3FKE'XH+;)H-)S
MMUERC6RVLNM7**M]I0"6BR4(0$([E2#L*> 4(KLQ9[UK74S&J=/W%:DJ:6VG
M*OHBDN-FJ$K;5E55"TJ([(-"D[NI.BI#42;,M]L>M,B4D%IMZ1,<+;BTD*')
M.4GDG@X#BQZWO^MCJBW7"2M#\-Y!2R2V I390JN5*TDY5ME)!%:#96/<F@4H
MD-(>2#P@+2% '_7_ $6B/VZ]^JK^Q*-HK7][P;CE_N9TY<U.+O7#[WV+SO!T
M5?K1I;5E^O?S4;Y=Y!CB/#8I5EAT(<*7'%!1%!MKFJ"A--;:'WW;R]-ZLCO0
M!,L*6;J[/F1[@QF4G(IUM+E%G(  I7"H4"5*Q(*MA_?I-? HQN?2X>27;P#M
MXNE7BSW^]ZX@:(M_B3'S/#N5W9M25QV4!+:A%0#4$ %72BJJ[10TQN_L5\#*
M_P!YH-G-W=BD=')5TJTN*0H4J%H1E"O[M.QB\6?1%\EV.RZ<F&W6ZW0J-1D-
MQ@$<MFF5><@FBP0$T": #$_5=W#0G7*2Y+D!E ;;Z1TYE94#8D5XL;Y_X>C?
M[7L(;B F0HI#03PYR1EI[^:E,:!9VBXM:;*)QKMZ4L2CM_\ ).-X-KU%=TZ;
MN]^3<K?:-0.-A:8,A4IPDDGN,]4\HD"J:9A48AVS>K>7M1:,>E&5;;DB:;A$
M<D9% %#RZNH*D%1"%$).TIK0XT'H/=GKJP:&C3K2W>+JN;<G;?-N$J2E"\_2
M--J66T$D=TG[U-,J1C3T76VKK'JW>39[JY&1,M,LRGGK:\E1RO+*$+44*":E
M0X> E2E5MNJM9Z\M>CY"TL/0[5=+NQ;4EA- D>(MI* D@4*5IKQ*V[,6[66I
MH;:[*W\UW&XH9;"TEQ3:DEX('=%)2EP\:BFNTG&IMZ&[C6[FM-VUW1)\<3 F
M=*(T)X&K3T)54M!M')*F@%!(S*">5B%J'0&IK)H_46KKL^F;>KK+5$=,2*MQ
MM$:.\AM:DJJWFY.4Y2LUJ<:JT9OCW@Z=UA=XSD>?IA<2YN3IK+Z#1UO.ZVAP
MA8H$BJA12ZT%*>[%Q_84C\^S[CR_R7_>/<>?^BO_ )LX7^V9OX#7]%<[CI%3
MRV;3=IEED],T6R)4-02Z$@\*:D45Q_;[R](7Y;*K=I>[PH=N#;>1:6GH@=6%
MJKRCFV@_9>G/UZ)EM3BLHJ<J14T'9H,6??KJ#4-LB:0O?C+R-+-6L*6S$SN(
MCJ$[I>D+W)2I=4=&15(2.*;?O%94[Q*.[(\5A-]+(>Z-)5T;+=1F<53*E-15
M1&T8?WFZDW8,,Z1AMJDRX;5\;=O#,1"<RWBR&0R2A/*4T'<P ()V$X._27,I
MI'YL1=A(RG,IAQ 4@!!H>D5F"4HX<Y">'"MZCFZ]D:10SXXJ ;RGY\$,)S%X
MQ^AZ+/DY?0=)TGWG=XB;W]VUKGZI8N;$=VW0+>E(D/*D*"0E960EH-DGIE*-
M&@E9-:4,35^_C0T*UZ'DR&(\NX6J\"<]:R^X&VURVRRV%-YE *6THA)/&2E)
M:U;IZUHO5RF7*WVN)$<DB,VMV<\&D%3N5=$@GL?ZAMQ"B:@W;6>':W9+2)<E
MO4K;JF65* <<2V& 5E*:D)^^(ILK7[.E]UV['3,?4=]U*Q<9*$RKB(+;:(*4
M*5RBVNI(77BX..NR);MX6@+79M/N=)XS/CW]$IQJB"4960RDKS+ 2=HH#FKL
MH=/[K=0VA;MCND%N=<+TEZB;>V]+,1MQQO(?Q27,H<65IH%B@)%#>-7--"0J
MUV^5.2R590X8[*G G-0TS9:5H:8@?S'ZLANQXLRU0YXM\973.J?F! :CM&B<
MREN+"$D@<.95 #B'?-4;KHXL,MUM+T>W7QJ1<X;;B@ MQE33;;I2#5:6W*C;
MMV'&AMU;< 2&]8"\E<LNY3&^;(R'A1&4Y^DSY>%.6E=OV(V^"3;O$%/IN"U0
MTO=+00Y#K.QPI3W8:KW.RM-M,0MZ.GMU,2?IN>RJ2PF-J1E,M;25%)*6G&$U
M7R31%05'8.'#&]+2:'TPG6WRY%DIZ.0P_')2ZPZG;E6A22#M(.Q0)!&(&\/1
M.[&TO6.Z(6[$6]J5#:RA+BD<I!CU!JDXBW'>-:F+)J!SI/&8$:6)C;=%D(H\
M$H"LR %'9R2<M32N')*DJ4&TJ64H&91H*T '">P,.ZUL.ZMM%@9!=1;[C>4,
MWI]A.TJ3&0TXVVX4\#*W2NO)X3BU;S-(*6;7=6>E0ET .-K2HH<;6 2 MM:5
M(50D5&PD;?ZCO@_B&U?4L3%__2K)];Q/L6BPZ!1'<EPKEXRZ)#P:'1EE:*@D
M&IJH;,:<W8Z51%<O=K=MBI"77NC;I&AN,N9%D;>6H4K2HJ?>Q:MVL5,<:JLT
M6V*C%;E&O&(S267D])3N5(*P#3:<M:<4Z!JQ+(U'=I2GI/0K#B4--IR,MY@!
M6G*4??73BQJ.W[PVHJ5W25'<83'>#P*&T+2K-L% <PI_V@8N6I?Y8YL.78KH
M:JA2UMI4E&8J2VXAVB%=&5$(<2H*RUJ!4@P=]'\S\^*I5I4TY#ML525@J945
MM(HV.C0VE9SFA6I9V*X:_8M-TT9+:C:CL3CRXZ)!*6WD.Y2I.< Y5A3:2DD4
MX0:<(9W:[Q6[%;+$7F7)4MMQ&=WHC4%8;6X30\K*A* 54X!C2>GOY9[C$=BV
M"&Y#FP[D&QXX3D*7>6* Y@O8%HIGH"1BV3?YD9<&UZ:MA)$2 M!60HC.&TME
M8"G,H!6M9R@<E)X#8M6[K9#,'56FB$Q4.JR(<92I*T!*Z*RK:6FJ*C*<RLQ&
MS%F3_,<[;K5IBS**U,P%H+C^8ISY4MJ6,ZPD)S*4$H%2E%:@HC,)"&FTA"$C
M@"0* #[@_HM$?MU[]57]B];N-Y5M7>MWFID!-PB-$=,RX!E#S52 30#,*I55
M*%I4"FA.HV;AJS4C3:ND8LCK"(Z%D$%*'G\C9R<2J*J??X#J#<;OC@RXVBKQ
M<E7:VR;6 Z]:I155(2E>U;8 2*T)[H%)SU3..C]1W[4FI'&DBWCYO3"B,N%0
MJI\KY:Z)KR4\=/NX>W+*4_\ O*YJ@79*>B/0^+]&E->DX,U0>3PXW>;L[.IX
MWW3#L]<]+C)2T.G<4I&1? NM16F(6];7]VO]JO35OCQ+C8(D)+O3J9KR8TA1
MZ-I*B2,QV4Y12E5<:-WG;J&WXJM-6JW-ICRDD=#(BO*<Z',>^("2$E8[K;3#
MF]S4MRU)8;I/+;UUL42(A[IGTI"5EE[*4IS@"JLPKW5$$D"X3]*0UV^R/275
MP8CBRXME@GD(4LDE2@.$U.WCQKG1F].3<(<+5=OCP6W[=&#[B @N9S0U ("A
M2H(.W#&L],L:EUGJ*"L/0(]T;9APFWD[4+< 2"K(:$<E>W[VO!%W_P"]QYPM
MK>E.2C%:4YT25QELLM--UKD15*1M)IRC4UQJ56]6;=[4FX3G)5HN4!E+Z&DN
M/.+6F3'-5*SI4@@I-4D$5PW_ "\;HYUQO\5Z[_.TVZW!CQ9M!2*!J,R>4 2
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M0HTE0S%N/"0D,]"A1RY% YQ4DIS;+YI;>1=[E:]5Z2O%RLEXG:>E*M[LF1;
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M-D %H47RN+*<7/<MN>TU?KSJ+4K*8)$^T2H,2WA:TE4B4_);0A(9IF3D*R7
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MPKYGA1HF?NN@90W7[N4"N&Q=HC$H-*S-].TES*>RG,#0_<PIYM"4N*"4J4
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MK6B/VZ]^JJ]R8]/_ &A_\ZOW'L'^*9^9]Q[A^33^&GW'G_HK_P";.%_MF;^
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M<4&P7759$A2E;$[3MKP8G:#U>AIN[V]2$OI9<#J/QC:7$T6G8:I4/?' =O\
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M6SZ94Z;JQ4[4K#7XY8!KE_%J2LC:G-7@J1H_=IN#TVU;;_53DIYQEF*F,WD
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MDT!IE2"E:-E154G6%OMDQ^Q+LD%\3VH[BXX;3F2I2G0"E(!(!J1PCLC&Y?\
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M945M-2GBIIM1%"4MBB 2-E0*TQ^Y-MU7=6;(&^A3&1(/(:(IT:%]VE%-F4*
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MM"@%H6.-"TI4*C9M&+,5ZJCN?/Z0N &6)+I4V7S'"W AHEE!=24!3N0$@TJ
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&_P#Q3__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704911526784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jul. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Immunic, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">56-2358443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1200 Avenue of the Americas<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">255-9818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IMUX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,595,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001280776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704908842912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 77,294<span></span>
</td>
<td class="nump">$ 106,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Investments - other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,629<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other current assets and prepaid expenses</a></td>
<td class="nump">9,257<span></span>
</td>
<td class="nump">9,490<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">86,551<span></span>
</td>
<td class="nump">125,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">290<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets, net</a></td>
<td class="nump">1,855<span></span>
</td>
<td class="nump">1,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">88,739<span></span>
</td>
<td class="nump">127,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,700<span></span>
</td>
<td class="nump">4,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">12,613<span></span>
</td>
<td class="nump">7,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">928<span></span>
</td>
<td class="nump">810<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">18,241<span></span>
</td>
<td class="nump">13,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long term liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,214<span></span>
</td>
<td class="nump">992<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">1,214<span></span>
</td>
<td class="nump">992<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">19,455<span></span>
</td>
<td class="nump">14,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 4)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding as of June 30, 2023 and December 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 130,000,000 shares authorized and 44,488,371 and 39,307,286 shares issued and outstanding as of June 30, 2023 and December&#160;31, 2022, respectively</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">431,849<span></span>
</td>
<td class="nump">427,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">3,982<span></span>
</td>
<td class="nump">3,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(366,551)<span></span>
</td>
<td class="num">(317,280)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">69,284<span></span>
</td>
<td class="nump">113,684<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 88,739<span></span>
</td>
<td class="nump">$ 127,753<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704914001680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">130,000,000<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">44,488,371<span></span>
</td>
<td class="nump">39,307,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">44,488,371<span></span>
</td>
<td class="nump">39,307,286<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704908913968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 21,172<span></span>
</td>
<td class="nump">$ 16,538<span></span>
</td>
<td class="nump">$ 44,135<span></span>
</td>
<td class="nump">$ 33,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,849<span></span>
</td>
<td class="nump">4,072<span></span>
</td>
<td class="nump">8,137<span></span>
</td>
<td class="nump">8,062<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">25,021<span></span>
</td>
<td class="nump">20,610<span></span>
</td>
<td class="nump">52,272<span></span>
</td>
<td class="nump">42,045<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(25,021)<span></span>
</td>
<td class="num">(20,610)<span></span>
</td>
<td class="num">(52,272)<span></span>
</td>
<td class="num">(42,045)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">968<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="nump">1,768<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">54<span></span>
</td>
<td class="num">(1,397)<span></span>
</td>
<td class="nump">1,233<span></span>
</td>
<td class="num">(777)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">1,022<span></span>
</td>
<td class="num">(1,291)<span></span>
</td>
<td class="nump">3,001<span></span>
</td>
<td class="num">(664)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (23,999)<span></span>
</td>
<td class="num">$ (21,901)<span></span>
</td>
<td class="num">$ (49,271)<span></span>
</td>
<td class="num">$ (42,709)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in USD per share)</a></td>
<td class="num">$ (0.54)<span></span>
</td>
<td class="num">$ (0.72)<span></span>
</td>
<td class="num">$ (1.12)<span></span>
</td>
<td class="num">$ (1.49)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in USD per share)</a></td>
<td class="num">$ (0.54)<span></span>
</td>
<td class="num">$ (0.72)<span></span>
</td>
<td class="num">$ (1.12)<span></span>
</td>
<td class="num">$ (1.49)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding, basic (in shares)</a></td>
<td class="nump">44,432,955<span></span>
</td>
<td class="nump">30,248,767<span></span>
</td>
<td class="nump">44,036,352<span></span>
</td>
<td class="nump">28,686,910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding, diluted (in shares)</a></td>
<td class="nump">44,432,955<span></span>
</td>
<td class="nump">30,248,767<span></span>
</td>
<td class="nump">44,036,352<span></span>
</td>
<td class="nump">28,686,910<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704908804416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (23,999)<span></span>
</td>
<td class="num">$ (21,901)<span></span>
</td>
<td class="num">$ (49,271)<span></span>
</td>
<td class="num">$ (42,709)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation</a></td>
<td class="nump">171<span></span>
</td>
<td class="num">(350)<span></span>
</td>
<td class="nump">947<span></span>
</td>
<td class="num">(408)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (23,828)<span></span>
</td>
<td class="num">$ (22,251)<span></span>
</td>
<td class="num">$ (48,324)<span></span>
</td>
<td class="num">$ (43,117)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704909343920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,335,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 127,115<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 324,237<span></span>
</td>
<td class="num">$ (252)<span></span>
</td>
<td class="num">$ (196,873)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,808)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,808)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Foreign exchange translation adjustment</a></td>
<td class="num">(58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in connection with the Company's stock option plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued in connection with the Company's stock option plan</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares issued from exercise of pre-funded warrants and issuance of common stock - at the market Sales Agreement net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,904,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Shares issued from exercise of pre-funded warrants and issuance of common stock - at the market Sales Agreement net of issuance costs</a></td>
<td class="nump">29,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,240,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">137,961<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">355,949<span></span>
</td>
<td class="num">(310)<span></span>
</td>
<td class="num">(217,681)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,335,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">127,115<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">324,237<span></span>
</td>
<td class="num">(252)<span></span>
</td>
<td class="num">(196,873)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(42,709)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,564,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">127,848<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">368,087<span></span>
</td>
<td class="num">(660)<span></span>
</td>
<td class="num">(239,582)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,240,383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">137,961<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">355,949<span></span>
</td>
<td class="num">(310)<span></span>
</td>
<td class="num">(217,681)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(21,901)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21,901)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Foreign exchange translation adjustment</a></td>
<td class="num">(350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(350)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued in connection with the Company's employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares issued in connection with the Company's Employee stock purchase plan</a></td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares issued from exercise of pre-funded warrants and issuance of common stock - at the market Sales Agreement net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Shares issued from exercise of pre-funded warrants and issuance of common stock - at the market Sales Agreement net of issuance costs</a></td>
<td class="nump">9,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,564,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 127,848<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">368,087<span></span>
</td>
<td class="num">(660)<span></span>
</td>
<td class="num">(239,582)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">39,307,286<span></span>
</td>
<td class="nump">39,307,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 113,684<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">427,925<span></span>
</td>
<td class="nump">3,035<span></span>
</td>
<td class="num">(317,280)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(25,272)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,272)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Foreign exchange translation adjustment</a></td>
<td class="nump">776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Shares issued from exercise of pre-funded warrants and issuance of common stock - at the market Sales Agreement net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,096,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Shares issued from exercise of pre-funded warrants and issuance of common stock - at the market Sales Agreement net of issuance costs</a></td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,403,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 91,218<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">429,955<span></span>
</td>
<td class="nump">3,811<span></span>
</td>
<td class="num">(342,552)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">39,307,286<span></span>
</td>
<td class="nump">39,307,286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 113,684<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">427,925<span></span>
</td>
<td class="nump">3,035<span></span>
</td>
<td class="num">(317,280)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (49,271)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="nump">44,488,371<span></span>
</td>
<td class="nump">44,488,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="nump">$ 69,284<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">431,849<span></span>
</td>
<td class="nump">3,982<span></span>
</td>
<td class="num">(366,551)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,403,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2023</a></td>
<td class="nump">91,218<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">429,955<span></span>
</td>
<td class="nump">3,811<span></span>
</td>
<td class="num">(342,552)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(23,999)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23,999)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">1,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Foreign exchange translation adjustment</a></td>
<td class="nump">171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Shares issued in connection with the Company's employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares issued in connection with the Company's Employee stock purchase plan</a></td>
<td class="nump">$ 96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="nump">44,488,371<span></span>
</td>
<td class="nump">44,488,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="nump">$ 69,284<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 431,849<span></span>
</td>
<td class="nump">$ 3,982<span></span>
</td>
<td class="num">$ (366,551)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704914331776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders&#8217; Equity (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 308<span></span>
</td>
<td class="nump">$ 918<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704911726448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (49,271)<span></span>
</td>
<td class="num">$ (42,709)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Unrealized foreign currency loss</a></td>
<td class="nump">665<span></span>
</td>
<td class="nump">2,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">3,777<span></span>
</td>
<td class="nump">4,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Other current assets and prepaid expenses</a></td>
<td class="nump">312<span></span>
</td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">449<span></span>
</td>
<td class="nump">826<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">4,462<span></span>
</td>
<td class="num">(861)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">63<span></span>
</td>
<td class="num">(114)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(39,489)<span></span>
</td>
<td class="num">(36,444)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfOtherInvestments', window );">Sale of investments - other</a></td>
<td class="nump">9,796<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(125)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">9,671<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from public offering of common stock through At The Market Sales Agreement, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">39,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans', window );">Proceeds from shares issued in connection with the Company's employee stock purchase plan</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of pre-funded warrants</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">39,719<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">220<span></span>
</td>
<td class="num">(2,020)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(29,451)<span></span>
</td>
<td class="nump">1,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">106,745<span></span>
</td>
<td class="nump">86,863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">77,294<span></span>
</td>
<td class="nump">88,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of use asset obtained in exchange for lease obligation</a></td>
<td class="nump">$ 544<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the sale of investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704914006192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Financial Statements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business and Basis of Financial Statements</a></td>
<td class="text">Description of Business and Basis of Financial Statements<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Immunic, Inc. ("Immunic" or the "Company") is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is headquartered in New York City with its main operations in Gr&#228;felfing near Munich, Germany. The Company currently has approximately 75 employees.</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic is pursuing clinical development of orally administered, small molecule programs, each of which has unique features intended to directly address the unmet needs of patients with serious chronic inflammatory and autoimmune diseases. These include the vidofludimus calcium (IMU-838) program, which is in Phase 3 clinical development for patients with multiple sclerosis (&#8220;MS&#8221;) and which has shown therapeutic activity in Phase 2 clinical trials in patients suffering from relapsing-remitting MS and moderate-to-severe ulcerative colitis (&#8220;UC&#8221;); the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, UC, Crohn&#8217;s disease or irritable bowel syndrome with diarrhea; and the IMU-381 program, which is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of its clinical trials to meet their endpoints, failure to obtain regulatory approval and needing additional funding to complete the development and commercialization of the Company's three development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Financial Condition</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic has no products approved for commercial sale and has not generated any revenue from product sales. It has never been profitable and has incurred operating losses in each year since inception in 2016. The Company has an accumulated deficit of approximately $366.6 million as of June 30, 2023 and $317.3 million as of December 31, 2022. Substantially all of Immunic's operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic expects to incur significant expenses and increasing operating losses for the foreseeable future as it initiates and continues the development of its product candidates and adds personnel necessary to advance its pipeline of product candidates. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Immunic expects that its operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of development programs.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From inception through June 30, 2023, Immunic has raised net cash of approximately $355.6 million from private and public offerings of preferred and common stock. As of June 30, 2023, the Company had cash and cash equivalents of approximately $77.3 million.  With these funds, Immunic expects to be able to fund its operations beyond twelve months from the date of the issuance of the accompanying condensed consolidated financial statements.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles, ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG and Immunic Australia Pty Ltd.  All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions. </span></div><div style="padding-left:24.75pt"><span><br/></span></div><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic has prepared the accompanying interim unaudited condensed consolidated financial statements in accordance with United States generally accepted accounting principles, (&#8220;US GAAP&#8221;), for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to </span></div>present fairly Immunic&#8217;s consolidated financial position, consolidated results of operations, consolidated statement of stockholders&#8217; equity and consolidated cash flows for the periods and as of the dates presented. The Company&#8217;s fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2022 was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto included on the Company's Annual Report on Form 10-K filed on February 23, 2023. The nature of Immunic&#8217;s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139705004348912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements. The most significant estimates in the Company&#8217;s financial statements and accompanying notes relate to recoverability of goodwill, clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is United States (&#8220;U.S.&#8221;) dollars. Immunic AG is located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.&#8217;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; assets and liabilities at reporting period-end rates;</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; income statement accounts at average exchange rates for the reporting period; and</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; components of equity at historical rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#8217; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents and Investments - other</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  Time Deposits with an original maturity greater than three months are classified as Investments - other.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents and investments - other consist of cash on hand and deposits in banks located in the U.S. of approximately $62.7&#160;million, Germany of approximately $14.4&#160;million and Australia of approximately $0.2&#160;million as of June 30, 2023. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions. The Company currently deposits its cash and cash equivalents with two large financial institutions. Cash and Cash equivalents in the U.S. are held at J.P. Morgan and as of June 30, 2023 are primarily held in a U.S. Government money market fund account earning interest at a rate of 5.0%. Cash and cash equivalents in Germany are earning interest at a rate of 1.75% to 2.75% during the period ended June 30, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments - other consists of the following as of (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"></td><td style="width:22.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time Deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9,629</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9,629</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The time deposit accounts in our bank in Germany matured in January and April, 2023, respectively.   </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212;Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.</span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets, which range from <span style="-sec-ix-hidden:f-303">three</span> to thirteen years. Depreciation expense was $22,000 and $20,000 for the three months ended June 30, 2023 and 2022, respectively. Depreciation expense was $54,000 and $41,000 for the six months ended June 30, 2023 and 2022, respectively</span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#8217; carrying amount. Impaired assets are then recorded at their estimated fair value. There were no impairment losses during the three and six months ended June 30, 2023 and 2022.</span></div><div style="margin-top:12pt;padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Goodwill</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#8217;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, an unfavorable clinical trial result, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On October 20, 2022, the Company announced the outcome of a  significant interim analysis of its Phase 1b clinical trial of izumerogant (IMU-935) in patients with moderate-to-severe psoriasis that were not deemed positive progress. On October 21, 2022, the Company experienced a significant decrease in the Company's market capitalization.  The Company considered this to be a triggering event indicating that it is more likely than not that goodwill was impaired.  The Company performed an analysis of the fair value compared to the Company's book value, utilizing the Company's traded stock price (a level 1 fair value input). As a result of that analysis, the Company recorded an approximately $33.0&#160;million non-cash goodwill impairment charge in the fourth quarter of 2022, which represents a full write down of its previous goodwill balance.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These costs primarily include external development expenses and internal personnel expenses for its development programs, vidofludimus calcium, izumerogant and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program for clinical trials in MS, UC and COVID-19.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements with contract research organizations (&#8220;CROs&#8221;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#8220;MSA&#8221;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.</span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and ASU No. 2018-18, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856, for which the Company received a notice of allowance from the U.S. Patent &amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Government assistance</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government assistance relating to research and development performed by Immunic Australia is recorded as a component of other (income) expense. This government assistance is recognized at a rate of 43.5% of the qualified research and development expenditures which are incurred. We also receive government assistance from the German Government for reimbursement of research and development expenses up to one million Euros per year. We recognized $0.3&#160;million and $2.1&#160;million of <span style="-sec-ix-hidden:f-322"><span style="-sec-ix-hidden:f-323">other income</span></span> related to research activities performed during the three and six months ended June 30, 2023, respectively and  $0.6&#160;million and $1.4&#160;million  related to research activities performed during the three and six months ended June 30, 2022, respectively.</span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.</span></div><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#8217;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#8217;s common stock, the expected volatility of the price of the Company&#8217;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#8217;s judgment. If factors change and different assumptions are used, the Company&#8217;s stock-based compensation expense could be materially different in the future.</span></div><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#8217;s balance sheet. A right-of-use lease asset represents the Company&#8217;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.</span></div><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#8217; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).</span></div><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized.  As of June 30, 2023 and 2022, respectively, the Company maintained a full valuation allowance against the balance of deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the Company&#8217;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#8217;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2022 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#8220;ASC 480-10&#8221;) or ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock (&#8220;ASC 815-40&#8221;). Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable U.S. GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.  All of the Company's 5,096,552 pre-funded warrants were exercised in January 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:73.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,770,076&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,713,248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued and/or Adopted Accounting Standards</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recently issued accounting standards that would have a significant impact on the company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704917505472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Details</a></td>
<td class="text">Balance Sheet Details<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Assets and Prepaid Expenses</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Assets and Prepaid Expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:74.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.255%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian research and development tax incentive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,257&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Payable</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts Payable consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.474%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,749&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,700&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,281&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,807&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,613&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,986&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><span style="-sec-ix-hidden:f-372"><span style="-sec-ix-hidden:f-373">Other Current Liabilities</span></span></span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Liabilities consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.740%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-375"><span style="-sec-ix-hidden:f-376">Lease liabilities</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">928&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139705004157664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain office space under non-cancelable operating leases. The leases terminate on July 31, 2025 for the New York City office, June 30, 2025 for the Gr&#228;felfing, Germany office and November 30, 2028 related to the new lease of a research laboratory in Planegg, Germany. The Company formerly leased office space in Planegg-Martinsried, Germany pursuant to a modified lease that terminated on August 31, 2020. These agreements include both lease (e.g., fixed rent) and non-lease components (e.g., common-area and other maintenance costs). The non-lease components are deemed to be executory costs and are therefore excluded from the minimum lease payments used to determine the present value of the operating lease obligation and related right-of-use asset. The New York City lease was extended on December 22, 2022 for an additional 27 months resulting in the new lease termination date of July 31, 2025. The New York City lease has a renewal option, but this was not included in calculating the right of use asset and liabilities. On April 7, 2020, the Company signed a five year lease for its facility in Gr&#228;felfing, Germany. On March 1, 2021 and August 1, 2022 the Company added additional lease space at the Gr&#228;felfing, Germany office.  Renewal options were not included in calculating the right of use asset and liabilities for this facility. In February 2023, the Company leased space in Germany for a research laboratory. The leases do not have concessions, leasehold improvement incentives or other build-out clauses. Further, the leases do not contain contingent rent provisions. The New York City lease had a six month rent holiday at the beginning of the lease as well as a three month rent holiday upon the 27 month extension starting May 2023. There were net additions of $544,000 related to the addition of new laboratory space in Planegg, Germany in February 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The leases do not provide an implicit rate and, due to the lack of a commercially salable product, the Company is generally considered unable to obtain commercial credit. Therefore, the Company estimated its incremental interest rate to be 6% for the original leases and 8% for the New York City extension and German laboratory, considering the quoted rates for the lowest investment-grade debt and the interest rates implicit in recent financing leases. Immunic used its estimated incremental borrowing rate and other information available at the lease commencement date in determining the present value of the lease payments.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Immunic&#8217;s operating lease costs and variable lease costs were $238,000 and $136,000  for the three months ended June 30, 2023 and 2022, respectively and $433,000 and $266,000 for the six months ended June 30, 2023 and 2022, respectively. Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the operating lease obligation are as follows as of June 30, 2023 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:85.106%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.945%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PV of obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,877&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2023, the Company has non-cancelable contractual obligations under certain agreements related to its development programs for vidofludimus calcium and IMU-856 totaling approximately $3.4&#160;million, all of which is expected to be paid in the next twelve months.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Commitments and Obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Daiichi Sankyo Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856, for which the Company received a notice of allowance from the U.S. Patent &amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not currently a party to any litigation, nor is it aware of any pending or threatened litigation, that it believes would materially affect its business, operating results, financial condition or cash flows. However, its industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, the Company may be involved in various legal proceedings from time to time.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704916688000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value</a></td>
<td class="text">Fair Value<div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy tables present information about each major category of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:50.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,666&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,666&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:50.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at Fair&#160;Value&#160;Measurement&#160;at&#160;December&#160;31,&#160;2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Level&#160;1, Level&#160;2 or Level&#160;3 assets during the periods presented.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Company&#8217;s money market funds which are included as a component of cash and cash equivalents on the consolidated balance sheet, realized gains and losses are included in interest income (expense) on the consolidated statements of operations. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our money market fund account is held in our bank in the U.S. and was earning interest at a rate of 5.0% in a U.S. Government money market fund.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has cash balances in banks in excess of the maximum amount insured by the FDIC and other international agencies as of June 30, 2023. The Company has not historically experienced any credit losses with balances in excess of FDIC limits.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximate their fair values due to their short-term nature. The fair value and book value of the money market funds presented in the table above are the same.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704916669632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text">Common Stock<div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shelf Registration Statement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Immunic filed a shelf registration statement on Form S-3. The 2020 Shelf Registration Statement permits the offering, issuance and sale of up to $250.0&#160;million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing.  As of July 28, 2023, there is $75.0&#160;million remaining on this shelf registration statement.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $50.0&#160;million of common stock that may be issued and sold under an at-the-market sales agreement ("December 2020 ATM") with SVB Leerink LLC (now Leerink Partners) as agent. The Company has used, and intends to continue to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink LLC on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon ten days&#8217; prior notice, or by SVB Leerink LLC at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of July 28, 2023, $8.1&#160;million in capacity remains under the December 2020 ATM.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $80.0&#160;million of common stock that may be issued and sold under another at-the-market sales agreement ("May 2022 ATM") with SVB Leerink LLC as agent. The Company intends to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The May 2022 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Securities LLC on the terms and subject to the conditions set forth in the May 2022 ATM or (ii) termination of the May 2022 ATM as otherwise permitted thereby. The May 2022 ATM may be terminated at any time by either party upon ten days&#8217; prior notice, or by SVB Securities LLC at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.  As of July 28, 2023, $80.0&#160;million in capacity remains under the May 2022 ATM.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company has agreed to pay SVB Securities LLC a commission equal to 3.0% of the gross proceeds from the sales of common shares pursuant to both ATM's and has agreed to provide SVB Securities LLC with customary indemnification and contribution rights.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any ATM activity during the three or six months ended June 30, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended June 30, 2022, the Company raised gross proceeds of $10.3&#160;million pursuant to the December 2020 ATM through the sale of 1,300,000 shares of common stock at a weighted average price of $7.90 per share. The net proceeds from the December 2020 ATM were $10.0&#160;million after deducting underwriter commissions of $0.3&#160;million.  In the six months ended June 30, 2022, the Company raised gross proceeds of $40.9&#160;million pursuant to the December 2020 ATM through the sale of 4,204,113 shares of common stock at a weighted average price of $9.72 per share. The net proceeds from the December 2020 ATM were $39.6&#160;million after deducting underwriter commissions of $1.2&#160;million. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Offerings</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">$60 Million Private Placement Equity Financing</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 10, 2022, Immunic entered into a Securities Purchase Agreement (the &#8220;Purchase Agreement&#8221;) for a private placement (the &#8220;Private Placement&#8221;) with select accredited investors and certain existing investors (each, a &#8220;Purchaser&#8221; and collectively, the &#8220;Purchasers&#8221;). Pursuant to the Purchase Agreement, the Company agreed to sell to the Purchasers (i) 8,696,552 shares of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;Shares&#8221;), at a purchase price of $4.35 per Share, and (ii) 5,096,552 pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase Common Stock (the &#8220;Warrant Shares&#8221; and together with the Shares and the Pre-Funded Warrants, the &#8220;Securities&#8221;), at a purchase price of $4.34 per Pre-Funded Warrant.  The Pre-Funded Warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">holders to receive a fixed number of shares of common stock upon exercise. In addition, the Pre-Funded Warrants do not provide any guarantee of value or return.  All of the pre-funded warrants were exercised in January of 2023.</span></div><div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Common Stock</span></div><div style="margin-top:12pt;padding-right:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2023, the Company&#8217;s certificate of incorporation, as amended and restated, authorized the Company to issue 130,000,000 shares of common stock, par value of $0.0001 per share. The voting, dividend and liquidation rights of the holders of the Company&#8217;s common stock are subject to and qualified by the rights, powers and preferences of any holders of preferred stock.</span></div><div style="margin-top:12pt;padding-right:4.5pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any. Through June 30, 2023, no cash dividends had been declared or paid.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s certificate of incorporation, as amended and restated, authorizes the Company to issue 20 million shares of $0.0001 par value preferred stock, having rights and preferences to be set by the Board of Directors. No preferred shares were outstanding as of June 30, 2023.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Reserved for Future Issuance</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares reserved for future issuance at June 30, 2023 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;2021 Employee Stock Purchase Plan    </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,770,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options available for future grant:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Inducement Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 Omnibus Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,579,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common shares reserved for future issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,471,748&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704916677808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation Plans</a></td>
<td class="text">Stock-Based Compensation Plans<div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Employee Stock Purchase Plan</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2021, the Company adopted the 2021 Employee Stock Purchase Plan ("ESPP"), which was approved by stockholder vote at the 2021 Annual Meeting of Stockholders held on June 10, 2021. The ESPP provides eligible employees of the Company with an opportunity to purchase common stock of the Company through accumulated payroll deductions, which are included in other current liabilities until they are used to purchase Company shares. Eligible employees participating in the bi-annual offering period can choose to have up to the lesser of 15% of their annual base earnings or the IRS annual share purchase limit of $25,000 in aggregate market value to purchase shares of the Company&#8217;s common stock. The purchase price of the stock is the lesser of (i) 85% of the closing market price on the date of purchase and (ii) the closing market price at the beginning of the bi-annual offering period. The maximum number of shares reserved for delivery under the plan is 200,000 shares.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">       </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first enrollment period under the plan commenced on August 1, 2021 and the Company has issued 167,642  shares life-to-date under the ESPP.  The Company recognized  $37,000 and $83,000 of expense related to the plan during the three and six months ended June 30, 2023, respectively.  The Company recognized $25,000 and  $53,000 of expense related to the plan during the three and six months ended June 30, 2022, respectively.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Programs</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company&#8217;s stockholders approved the 2019 Omnibus Equity Incentive Plan (the &#8220;2019 Plan&#8221;) which was adopted by the Board of Directors (the "Board") with an effective date of June 14, 2019. The 2019 Plan allows for the grant of equity awards to employees, consultants and non-employee directors. An initial maximum of 1,500,000 shares of the Company&#8217;s common stock were available for grant under the 2019 Plan. The 2019 Plan included an evergreen provision that allowed for the annual addition of up to 4% of the Company&#8217;s fully-diluted outstanding stock, with a maximum allowable increase of 4,900,000 shares over the term of the 2019 Plan. In accordance with this provision, the shares available for grant were increased in 2020 through 2023 by a total of 4,408,871 shares. At the Company's Annual Shareholders meeting on June 28, 2023, shareholders voted to increase the allowable shares under the 2019 plan by 4,440,000 shares as well as to eliminate the evergreen provision.  The 2019 Plan is currently administered by the Board, or, at the discretion of the Board, by a committee of the Board, which determines the exercise prices, vesting schedules and other restrictions of awards under the 2019 Plan at its discretion. Options to purchase stock may not have an exercise price that is less than the fair market value of underlying shares on the date of grant, and may not have a term greater than ten years. Incentive stock options granted to employees typically vest over four years. Non-statutory options granted to employees, officers, members of the Board, advisors, and consultants of the Company typically vest over <span style="-sec-ix-hidden:f-481">three</span> or four years. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares that are expired, terminated, surrendered or canceled under the 2019 Plan without having been fully exercised will be available for future awards. </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Movements during the year </span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the six months ended June 30, 2023 and 2022, respectively, for the 2019 Plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:52.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.421%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,059,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,926)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,770,076&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.42</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,170,958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,770,076&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.42</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,170,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,184,848&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.43</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:52.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.858%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,702,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(852)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145,873)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,713,248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.86</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,713,248&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.86</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,127,085&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions used in the BSM option pricing model to determine the fair value of the employee and non-employee stock option grants relating to the 2019 Plan were as follows:</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-Free Interest Rate</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk-free rate assumption is based on U.S. Treasury instruments with maturities similar to the expected term of the stock options.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Dividend Yield</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be zero.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the Company&#8217;s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of its own stock combined with a group of comparable companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the stock-based awards.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected Term </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of stock options granted under the 2019 Plan during the six months ended June 30, 2023 and 2022 was $1.17 and $7.25, respectively. The following are the underlying assumptions used in the Black-Scholes option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six  Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.93%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.6%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.9%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.99</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense for all stock awards recognized in the accompanying unaudited condensed consolidated statements of operations is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.391%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>&#160;Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months<br/>&#160;Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,792,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,561,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,297,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,985,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,570,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,798,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,062,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,777,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,131,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2023, there was $13.9 million in total unrecognized compensation expense relating to the 2019 Plan to be recognized over a weighted average period of 2.88 years.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Equity Incentive Plans Assumed from Vital Therapies</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon completion of the Transaction with Vital Therapies, Inc. ("Vital") on April 12, 2019, Vital&#8217;s 2012 Stock Option </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plan (the &#8220;2012 Plan&#8221;), Vital&#8217;s 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;) and Vital&#8217;s 2017 Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;), were assumed by the Company. All awards granted under these plans have either been forfeited or expired.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There remain 43,311 shares available for grant under the 2014 Plan as of June 30, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, Vital&#8217;s board of directors approved the Inducement Plan, which was amended and restated in November 2017. Under the Inducement Plan 46,250 shares of Vital&#8217;s common stock were reserved to be used exclusively for non-qualified grants to individuals who were not previously employees or directors as an inducement material to a grantee's entry into employment within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No expense was recorded for the plans assumed from Vital during the three and six months ended June 30, 2023 and 2022, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704916699088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text">Related Party Transactions<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Chairman Agreement with Duane Nash</span></div><div><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 15, 2020, the compensation committee of the Board of Directors of the Company independently reviewed and approved entering into an employment agreement with the Executive Chairman of the Board, Duane Nash, MD, JD, MBA (the &#8220;Executive Chairman Agreement&#8221;) and pursuant to such approval, on April 17, 2020, the Company and Dr. Nash entered into the Executive Chairman Agreement. The Executive Chairman Agreement establishes an &#8220;at will&#8221; employment relationship. On December 28, 2022, the Company and Dr. Nash entered into Addendum No. Four, which extended the term of employment from December 31, 2022 to December 31, 2023 with a base salary of $30,250 per month (which includes the cash retainer payable for serving on the Company&#8217;s Board or for acting as the Chairman of the Board). All other terms of the Executive Chairman Agreement remain the same.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704916628320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events TBD<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704907813248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Consolidation</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation and Consolidation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles, ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG and Immunic Australia Pty Ltd.  All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions. </span></div><div style="padding-left:24.75pt"><span><br/></span></div><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunic has prepared the accompanying interim unaudited condensed consolidated financial statements in accordance with United States generally accepted accounting principles, (&#8220;US GAAP&#8221;), for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to </span></div>present fairly Immunic&#8217;s consolidated financial position, consolidated results of operations, consolidated statement of stockholders&#8217; equity and consolidated cash flows for the periods and as of the dates presented. The Company&#8217;s fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2022 was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto included on the Company's Annual Report on Form 10-K filed on February 23, 2023. The nature of Immunic&#8217;s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s consolidated financial statements. The most significant estimates in the Company&#8217;s financial statements and accompanying notes relate to recoverability of goodwill, clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation and Presentation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation and Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reporting currency is United States (&#8220;U.S.&#8221;) dollars. Immunic AG is located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.&#8217;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; assets and liabilities at reporting period-end rates;</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; income statement accounts at average exchange rates for the reporting period; and</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%">&#8226; components of equity at historical rates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#8217; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock', window );">Cash and Cash Equivalents and Investments- other</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents and Investments - other</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  Time Deposits with an original maturity greater than three months are classified as Investments - other.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents and investments - other consist of cash on hand and deposits in banks located in the U.S. of approximately $62.7&#160;million, Germany of approximately $14.4&#160;million and Australia of approximately $0.2&#160;million as of June 30, 2023. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions. The Company currently deposits its cash and cash equivalents with two large financial institutions. Cash and Cash equivalents in the U.S. are held at J.P. Morgan and as of June 30, 2023 are primarily held in a U.S. Government money market fund account earning interest at a rate of 5.0%. Cash and cash equivalents in Germany are earning interest at a rate of 1.75% to 2.75% during the period ended June 30, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments - other consists of the following as of (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"></td><td style="width:22.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time Deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9,629</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9,629</span></td></tr></table></div>The time deposit accounts in our bank in Germany matured in January and April, 2023, respectively.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurement</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#8212;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#8212;Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#8212;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">Property and EquipmentProperty and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets, which range from <span style="-sec-ix-hidden:f-303">three</span> to thirteen years.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text">Impairment of Long-Lived AssetsThe Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#8217; carrying amount. Impaired assets are then recorded at their estimated fair value.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Goodwill</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#8217;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.</span></div>Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, an unfavorable clinical trial result, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These costs primarily include external development expenses and internal personnel expenses for its development programs, vidofludimus calcium, izumerogant and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program for clinical trials in MS, UC and COVID-19.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into agreements with contract research organizations (&#8220;CROs&#8221;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#8220;MSA&#8221;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaboration Arrangements</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Arrangements</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#8220;ASU&#8221;) 2014-09 &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and ASU No. 2018-18, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.</span></div>On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#8217;s patent application related to IMU-856, for which the Company received a notice of allowance from the U.S. Patent &amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistancePolicyTextBlock', window );">Government assistance</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Government assistance</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government assistance relating to research and development performed by Immunic Australia is recorded as a component of other (income) expense. This government assistance is recognized at a rate of 43.5% of the qualified research and development expenditures which are incurred. We also receive government assistance from the German Government for reimbursement of research and development expenses up to one million Euros per year. We recognized $0.3&#160;million and $2.1&#160;million of <span style="-sec-ix-hidden:f-322"><span style="-sec-ix-hidden:f-323">other income</span></span> related to research activities performed during the three and six months ended June 30, 2023, respectively and  $0.6&#160;million and $1.4&#160;million  related to research activities performed during the three and six months ended June 30, 2022, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation&#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#8217;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#8217;s common stock, the expected volatility of the price of the Company&#8217;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#8217;s judgment. If factors change and different assumptions are used, the Company&#8217;s stock-based compensation expense could be materially different in the future.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#8217;s balance sheet. A right-of-use lease asset represents the Company&#8217;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#8217;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income (Loss)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#8217; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:18pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized.  As of June 30, 2023 and 2022, respectively, the Company maintained a full valuation allowance against the balance of deferred tax assets.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is the Company&#8217;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#8217;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2022 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Warrants</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#8220;ASC 480-10&#8221;) or ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#8217;s Own Stock (&#8220;ASC 815-40&#8221;). Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable U.S. GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.  All of the Company's 5,096,552 pre-funded warrants were exercised in January 2023.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per ShareBasic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#8217;s net loss position.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued and/or Adopted Accounting Standards</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued and/or Adopted Accounting Standards</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no recently issued accounting standards that would have a significant impact on the company's consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistancePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistancePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash And Cash Equivalents And Other Investments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704914283168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTableTextBlock', window );">Schedule of Investment</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments - other consists of the following as of (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"><tr><td style="width:1.0%"></td><td style="width:22.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.470%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.852%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time Deposits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9,629</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9,629</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:73.751%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.955%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,770,076&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,713,248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org//321/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 325<br> -Publisher FASB<br> -URI https://asc.fasb.org//325/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704914256048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Other Current Assets and Prepaid Expenses</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Assets and Prepaid Expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:74.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.840%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.255%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,608&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VAT receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian research and development tax incentive</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,875&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,361&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,257&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,490&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts Payable consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.474%"></td><td style="width:0.1%"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,348&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,749&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,700&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,281&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.484%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical and related costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,668&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,807&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued legal and audit costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,613&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,986&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Schedule of Other Current Liabilities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other Current Liabilities consist of (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.527%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.740%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:f-375"><span style="-sec-ix-hidden:f-376">Lease liabilities</span></span></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">928&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">810&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704916677808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of Operating Lease Obligation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the operating lease obligation are as follows as of June 30, 2023 (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:85.106%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.945%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">820&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PV of obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,877&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704914244928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy tables present information about each major category of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:50.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets at fair value</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,666&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,666&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:50.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.830%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement at Fair&#160;Value&#160;Measurement&#160;at&#160;December&#160;31,&#160;2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair&#160;Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level&#160;3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,521&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704914236096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock', window );">Shares Reserved for Future Issuance</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares reserved for future issuance at June 30, 2023 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;2021 Employee Stock Purchase Plan    </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,358&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,770,076&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options available for future grant:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014 Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017 Inducement Equity Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019 Omnibus Equity Incentive Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,579,753&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total common shares reserved for future issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,471,748&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704914205184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock option activity for the six months ended June 30, 2023 and 2022, respectively, for the 2019 Plan:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:52.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.307%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.421%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,791,688&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,059,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,926)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,770,076&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.42</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,170,958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of June 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,770,076&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.42</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,170,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,184,848&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.43</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span><br/></span></div><div style="margin-top:12pt;text-align:center;text-indent:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"><tr><td style="width:1.0%"></td><td style="width:52.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.858%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.561%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term&#160;(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of January 1, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,157,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.54&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,702,513&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(852)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited or expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(145,873)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding as of June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,713,248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.86</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest as of June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,713,248&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.66&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.86</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable as of June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,127,085&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions Used</a></td>
<td class="text">The following are the underlying assumptions used in the Black-Scholes option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six  Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.93%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.95%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.6%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.9%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term of options (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.99</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense for Stock Awards Recognized</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation expense for all stock awards recognized in the accompanying unaudited condensed consolidated statements of operations is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.391%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.186%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months<br/>&#160;Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Six Months<br/>&#160;Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">765,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,792,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,561,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">909,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,297,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,985,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,570,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,798,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,062,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,777,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,131,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704907809904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business and Basis of Financial Statements (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">110 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>employee </div>
<div>lease</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityNumberOfEmployees', window );">Number of employees | employee</a></td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_NumberOfDevelopmentPrograms', window );">Number of development programs | lease</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (366,551)<span></span>
</td>
<td class="num">$ (317,280)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of private placement</a></td>
<td class="nump">355,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 77,294<span></span>
</td>
<td class="nump">$ 106,745<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityNumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of persons employed by the Entity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityNumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_NumberOfDevelopmentPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Development Programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_NumberOfDevelopmentPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704908356080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>financialInstitution </div>
<div>lease</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>financialInstitution </div>
<div>lease</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 77,294,000<span></span>
</td>
<td class="nump">$ 106,745,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,294,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_NumberOfFinancialInstitutionsUsedForCashDeposit', window );">Number of financial institutions used for cash deposits | financialInstitution</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 22,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="nump">$ 54,000<span></span>
</td>
<td class="nump">$ 41,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairment losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, impairment loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_GovernmentAssistanceRate', window );">Government assistance rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceAmount', window );">Government assistance, amount</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Nonoperating Income (Expense)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nonoperating Income (Expense)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_LesseeOperatingLeasesNumberOfExistingLeases', window );">Number of existing leases | lease</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant exercised (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,096,552<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 62,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Investment interest rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_DE', window );">Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 14,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_AU', window );">Australia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term (in months)</a></td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Australia and Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Investment interest rate</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term (in months)</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Australia and Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Investment interest rate</a></td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of government assistance recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes government assistance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 832<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483507/832-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of interest on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_GovernmentAssistanceRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government Assistance Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_GovernmentAssistanceRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_LesseeOperatingLeasesNumberOfExistingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Leases, Number Of Existing Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_LesseeOperatingLeasesNumberOfExistingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_NumberOfFinancialInstitutionsUsedForCashDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Financial Institutions Used For Cash Deposit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_NumberOfFinancialInstitutionsUsedForCashDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vtl_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_AU">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_AU</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=vtl_AustraliaAndGermanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=vtl_AustraliaAndGermanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704911543824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Investments - other</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9,629<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember', window );">Time Deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsLineItems', window );"><strong>Cash and Cash Equivalents [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherShortTermInvestments', window );">Investments - other</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9,629<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704909014832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Options to purchase common stock ( in shares)</a></td>
<td class="nump">5,770,076<span></span>
</td>
<td class="nump">3,713,248<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704911705840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_PrepaidClinicalAndRelatedCostsCurrent', window );">Prepaid clinical and related costs</a></td>
<td class="nump">$ 3,812<span></span>
</td>
<td class="nump">$ 5,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivableCurrent', window );">VAT receivable</a></td>
<td class="nump">1,181<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ResearchAndDevelopmentTaxIncentiveCurrent', window );">Australian research and development tax incentive</a></td>
<td class="nump">2,875<span></span>
</td>
<td class="nump">2,361<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">1,389<span></span>
</td>
<td class="nump">1,225<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total</a></td>
<td class="nump">$ 9,257<span></span>
</td>
<td class="nump">$ 9,490<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_PrepaidClinicalAndRelatedCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Clinical And Related Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_PrepaidClinicalAndRelatedCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ResearchAndDevelopmentTaxIncentiveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Tax Incentive, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ResearchAndDevelopmentTaxIncentiveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704908814592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Accounts Payable (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ClinicalCostsPayableCurrent', window );">Clinical costs</a></td>
<td class="nump">$ 4,348<span></span>
</td>
<td class="nump">$ 3,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_LegalAndAuditCostsPayableCurrent', window );">Legal and audit costs</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Other</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Total</a></td>
<td class="nump">$ 4,700<span></span>
</td>
<td class="nump">$ 4,281<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ClinicalCostsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Clinical Costs Payable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ClinicalCostsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_LegalAndAuditCostsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal And Audit Costs Payable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_LegalAndAuditCostsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704908350528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Accrued Expenses (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_AccruedClinicalCostsCurrent', window );">Accrued clinical and related costs</a></td>
<td class="nump">$ 11,668<span></span>
</td>
<td class="nump">$ 6,807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_AccruedLegalAndAuditCostsCurrent', window );">Accrued legal and audit costs</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_AccruedCompensationCurrent', window );">Accrued compensation</a></td>
<td class="nump">716<span></span>
</td>
<td class="nump">890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 12,613<span></span>
</td>
<td class="nump">$ 7,986<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_AccruedClinicalCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_AccruedClinicalCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_AccruedCompensationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Compensation, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_AccruedCompensationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_AccruedLegalAndAuditCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Legal And Audit Costs, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_AccruedLegalAndAuditCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704914208704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Details - Schedule of Other Current Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">$ 671<span></span>
</td>
<td class="nump">$ 571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">257<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 928<span></span>
</td>
<td class="nump">$ 810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Total<span></span>
</td>
<td class="text">Total<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481573/470-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704905694672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Apr. 07, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod', window );">Lessee, operating lease, extended rent holiday period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_OperatingLeaseIncrementalBorrowingRate', window );">Incremental borrowing rate on operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_OperatingAndVariableLeasesCost', window );">Operating and variable lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 238<span></span>
</td>
<td class="nump">$ 136<span></span>
</td>
<td class="nump">$ 433<span></span>
</td>
<td class="nump">$ 266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=vtl_GrafelfingGermanyMember', window );">Grafelfing, Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=vtl_NewYorkCityMember', window );">New York City</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod', window );">Rent holiday period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal option period (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">27 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">27 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_OperatingLeaseIncrementalBorrowingRate', window );">Incremental borrowing rate on operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=vtl_PlaneggGermanyMember', window );">Planegg, Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Increase in operating lease, right-of-use asset</a></td>
<td class="nump">$ 544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Beginning of Lease, Rent Holiday Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Extension of Lease, Rent Holiday Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_OperatingAndVariableLeasesCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating And Variable Leases, Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_OperatingAndVariableLeasesCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_OperatingLeaseIncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Incremental Borrowing Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_OperatingLeaseIncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=vtl_GrafelfingGermanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=vtl_GrafelfingGermanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=vtl_NewYorkCityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=vtl_NewYorkCityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=vtl_PlaneggGermanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=vtl_PlaneggGermanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704911602896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2023</a></td>
<td class="nump">$ 362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_LesseeOperatingLeaseLiabilityPaymentsAfterDueYearFour', window );">Thereafter</a></td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">2,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Interest</a></td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">PV of obligation</a></td>
<td class="nump">$ 1,877<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_LesseeOperatingLeaseLiabilityPaymentsAfterDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee &#8203;Operating&#8203; Lease &#8203;Liability &#8203;Payments After &#8203;Due &#8203;Year &#8203;Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_LesseeOperatingLeaseLiabilityPaymentsAfterDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704908964736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">$ 62,666<span></span>
</td>
<td class="nump">$ 85,521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">62,666<span></span>
</td>
<td class="nump">85,521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">62,666<span></span>
</td>
<td class="nump">85,521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">62,666<span></span>
</td>
<td class="nump">85,521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds | Level&#160;2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds | Level&#160;3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets at fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704911526160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value - Additional Information (Detail)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentInterestRate', window );">Investment interest rate</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of interest on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 4)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704905363392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Shelf Registration Statement (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>d</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 28, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration', window );">Maximum aggregate offering price of common stock, preferred stock, warrants, debt securities, and/or units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock', window );">Commission, percent of gross proceeds from sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 39,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ShelfRegistrationStatementAmountRemaining', window );">Shelf registration statement, amount remaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_December2020ATMMember', window );">December 2020 ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration', window );">Maximum aggregate offering price of common stock, preferred stock, warrants, debt securities, and/or units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ShelfRegistrationTerminationPriorWrittenNotice', window );">Shelf registration, termination, prior written notice | d</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued</a></td>
<td class="nump">$ 10,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued (in shares) | shares</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,204,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_SharesIssuedWeightedAverageSharePricePerShare', window );">common stock at a weighted average price (in dollar per share) | $ / shares</a></td>
<td class="nump">$ 7.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForCommissions', window );">Underwriter commissions</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_December2020ATMMember', window );">December 2020 ATM | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_SaleOfStockRemainingCapacity', window );">Sale of stock, remaining capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_May2022ATMMember', window );">May 2022 ATM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration', window );">Maximum aggregate offering price of common stock, preferred stock, warrants, debt securities, and/or units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ShelfRegistrationTerminationPriorWrittenNotice', window );">Shelf registration, termination, prior written notice | d</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_May2022ATMMember', window );">May 2022 ATM | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_SaleOfStockRemainingCapacity', window );">Sale of stock, remaining capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for commissions during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Aggregate Offering Price Of Securities Under Shelf Registration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_SaleOfStockRemainingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Remaining Capacity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_SaleOfStockRemainingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_SharesIssuedWeightedAverageSharePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Issued, Weighted Average Share Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_SharesIssuedWeightedAverageSharePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ShelfRegistrationStatementAmountRemaining">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shelf Registration Statement, Amount Remaining</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ShelfRegistrationStatementAmountRemaining</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ShelfRegistrationTerminationPriorWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shelf Registration, Termination, Prior Written Notice</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ShelfRegistrationTerminationPriorWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_December2020ATMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vtl_December2020ATMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_May2022ATMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vtl_May2022ATMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704914068944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Equity Offering (Details)<br></strong></div></th>
<th class="th">
<div>Oct. 10, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Share price (in USD per share) | shares</a></td>
<td class="nump">8,696,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Shares issued in private placement transaction (in shares)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Sale of stock, price per share (in USD per share)</a></td>
<td class="nump">$ 4.35<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_PreFundedWarrantsMember', window );">Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Share price (in USD per share) | shares</a></td>
<td class="nump">5,096,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Sale of stock, price per share (in USD per share)</a></td>
<td class="nump">$ 4.34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vtl_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vtl_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704914077072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock - Common Stock (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares) | shares</a></td>
<td class="nump">130,000,000<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_NumberOfVotesPerEachShareOfCommonStock', window );">Number of votes per each share of common stock | vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock, cash dividends declared (in USD per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Common stock, cash dividends paid (in USD per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_NumberOfVotesPerEachShareOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Votes Per Each Share of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_NumberOfVotesPerEachShareOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704911635936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in USD per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704909244528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Common Stock - Shares Reserved for Future Issuance (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">10,471,748<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock options</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">5,770,076<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Outstanding stock options | 2021 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">32,358<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vtl_EmployeeStockOptionsforFutureGrantMember', window );">Common stock options available for future grant: | 2014 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">43,311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vtl_EmployeeStockOptionsforFutureGrantMember', window );">Common stock options available for future grant: | 2017 Inducement Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">46,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vtl_EmployeeStockOptionsforFutureGrantMember', window );">Common stock options available for future grant: | 2019 Omnibus Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total common shares reserved for future issuance (in shares)</a></td>
<td class="nump">4,579,753<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2021EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2021EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vtl_EmployeeStockOptionsforFutureGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vtl_EmployeeStockOptionsforFutureGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_TwoThousandFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_TwoThousandFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2017InducementEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2017InducementEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704907794464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">42 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 28, 2023</div></th>
<th class="th"><div>Aug. 01, 2021</div></th>
<th class="th"><div>Apr. 25, 2021</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period over which compensation cost will be recognized, in years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2021EmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum annual contributions per employee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Purchase price of the stock, at discount from market price at purchase date (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">167,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,000<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 83,000<span></span>
</td>
<td class="nump">$ 53,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 11 months 26 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Options granted in period, weighted-average grant date fair value (in USD per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.17<span></span>
</td>
<td class="nump">$ 7.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan | Incentive stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan | Minimum | Non-statutory options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan | Maximum | Non-statutory options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember', window );">2019 Omnibus Equity Incentive Plan, Evergreen Provision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent', window );">Additional shares authorized (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,408,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease', window );">Increase in other share (in shares)</a></td>
<td class="nump">4,440,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_TwoThousandFourteenEquityIncentivePlanMember', window );">2014 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2017InducementEquityIncentivePlanMember', window );">2017 Inducement Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other than shares newly issued, the number of additional shares issued (for example, a stock split) or canceled (for example, to correct a share issuance), during the period under the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2021EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2021EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vtl_IncentiveEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vtl_IncentiveEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vtl_NonStatutoryEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vtl_NonStatutoryEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_TwoThousandFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_TwoThousandFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2017InducementEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2017InducementEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704912605536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans - Summary of Stock Option Activity (Details) - 2019 Omnibus Equity Incentive Plan - Outstanding stock options - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">3,791,688<span></span>
</td>
<td class="nump">2,157,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">2,059,314<span></span>
</td>
<td class="nump">1,702,513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(852)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited or expired (in shares)</a></td>
<td class="num">(80,926)<span></span>
</td>
<td class="num">(145,873)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">5,770,076<span></span>
</td>
<td class="nump">3,713,248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest, Ending balance (in shares)</a></td>
<td class="nump">5,770,076<span></span>
</td>
<td class="nump">3,713,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable, Ending balance (in shares)</a></td>
<td class="nump">2,184,848<span></span>
</td>
<td class="nump">1,127,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning balance (usd per share)</a></td>
<td class="nump">$ 11.33<span></span>
</td>
<td class="nump">$ 13.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (usd per share)</a></td>
<td class="nump">1.45<span></span>
</td>
<td class="nump">9.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited or expired (usd per share)</a></td>
<td class="nump">8.25<span></span>
</td>
<td class="nump">11.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, ending balance (usd per share)</a></td>
<td class="nump">7.85<span></span>
</td>
<td class="nump">11.66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest, Weighted-Average Exercise Price, Ending balance (usd per share)</a></td>
<td class="nump">7.85<span></span>
</td>
<td class="nump">11.66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, Weighted-Average Exercise Price, Ending balance (usd per share)</a></td>
<td class="nump">$ 12.05<span></span>
</td>
<td class="nump">$ 13.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Other Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted-average remaining contractual term (in years)</a></td>
<td class="text">8 years 5 months 1 day<span></span>
</td>
<td class="text">8 years 10 months 9 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options vested and expected to vest , weighted-average remaining contractual term (in years)</a></td>
<td class="text">8 years 5 months 1 day<span></span>
</td>
<td class="text">8 years 10 months 9 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, weighted-average remaining contractual term (in years)</a></td>
<td class="text">7 years 5 months 4 days<span></span>
</td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, aggregate intrinsic value</a></td>
<td class="nump">$ 2,170,958<span></span>
</td>
<td class="nump">$ 23,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options vested and expected to vest , aggregate intrinsic value</a></td>
<td class="nump">2,170,958<span></span>
</td>
<td class="nump">23,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, aggregate intrinsic value</a></td>
<td class="nump">$ 62,614<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704917682432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember', window );">2019 Omnibus Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.93%<span></span>
</td>
<td class="nump">1.95%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">101.60%<span></span>
</td>
<td class="nump">97.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (years)</a></td>
<td class="text">5 years 11 months 26 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=vtl_A2019OmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704912562768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,777<span></span>
</td>
<td class="nump">$ 4,131<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=vtl_EmployeeMember', window );">Employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,798,000<span></span>
</td>
<td class="nump">$ 2,062,000<span></span>
</td>
<td class="nump">3,777,000<span></span>
</td>
<td class="nump">4,131,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=vtl_EmployeeMember', window );">Employees | Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">889,000<span></span>
</td>
<td class="nump">765,000<span></span>
</td>
<td class="nump">1,792,000<span></span>
</td>
<td class="nump">1,561,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=vtl_EmployeeMember', window );">Employees | General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 909,000<span></span>
</td>
<td class="nump">$ 1,297,000<span></span>
</td>
<td class="nump">$ 1,985,000<span></span>
</td>
<td class="nump">$ 2,570,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=vtl_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=vtl_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139704916704240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vtl_DuaneNashMDJDMBAMember', window );">Duane Nash, MD, JD, MBA | Forecast | Board of Directors Chairman | Executive Chairman Agreement | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_vtl_SalaryCostsMonthlyBaseSalary', window );">Monthly base salary</a></td>
<td class="nump">$ 30,250<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vtl_SalaryCostsMonthlyBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Salary Costs, Monthly Base Salary</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vtl_SalaryCostsMonthlyBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vtl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vtl_DuaneNashMDJDMBAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vtl_DuaneNashMDJDMBAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=vtl_ExecutiveChairmanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=vtl_ExecutiveChairmanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>vtl-20230630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:vtl="http://vitaltherapies.com/20230630"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="vtl-20230630.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2023-07-28</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2014-04-17</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:AustraliaAndGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:AustraliaAndGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:GrafelfingGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-07</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:NewYorkCityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:NewYorkCityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">vtl:PlaneggGermanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-01</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-28</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-28</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:May2022ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:May2022ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:May2022ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-28</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:December2020ATMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-10</startDate>
            <endDate>2022-10-10</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-10</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-10</startDate>
            <endDate>2022-10-10</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vtl:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-10</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:EmployeeStockOptionsforFutureGrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-25</startDate>
            <endDate>2021-04-25</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-25</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-01</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-28</startDate>
            <endDate>2023-06-28</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:IncentiveEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:NonStatutoryEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vtl:NonStatutoryEmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandNineteenOmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2019OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">vtl:EmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-09-30</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">vtl:A2017InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001280776</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vtl:DuaneNashMDJDMBAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">vtl:ExecutiveChairmanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-28</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="employee">
        <measure>vtl:employee</measure>
    </unit>
    <unit id="lease">
        <measure>vtl:lease</measure>
    </unit>
    <unit id="financialinstitution">
        <measure>vtl:financialInstitution</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="d">
        <measure>utr:D</measure>
    </unit>
    <unit id="vote">
        <measure>vtl:vote</measure>
    </unit>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-26">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-27">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-28">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-29">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-30">0001280776</dei:EntityCentralIndexKey>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-63" id="f-303">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-5" id="f-322">http://fasb.org/us-gaap/2023#NonoperatingIncomeExpense</us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-1" id="f-323">http://fasb.org/us-gaap/2023#NonoperatingIncomeExpense</us-gaap:GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-3" id="f-372">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-373">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-4" id="f-375">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList contextRef="c-3" id="f-376">http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-121" id="f-481">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-559">Subsequent Events TBD</us-gaap:SubsequentEventsTextBlock>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2023-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-36201</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">Immunic, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">56-2358443</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">1200 Avenue of the Americas</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-10">Suite 200</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">New York,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">10036</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">332</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">255-9818</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">IMUX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-19">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-20">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-21">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-22">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-24">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-25" unitRef="shares">44595383</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-3" id="f-31" unitRef="usd">77294000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-32" unitRef="usd">106745000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherShortTermInvestments contextRef="c-3" decimals="-3" id="f-33" unitRef="usd">0</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments contextRef="c-4" decimals="-3" id="f-34" unitRef="usd">9629000</us-gaap:OtherShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-35" unitRef="usd">9257000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-36" unitRef="usd">9490000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-37" unitRef="usd">86551000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-38" unitRef="usd">125864000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-39" unitRef="usd">290000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-40" unitRef="usd">294000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-41" unitRef="usd">1855000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-42" unitRef="usd">1552000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="-3" id="f-43" unitRef="usd">43000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-44" unitRef="usd">43000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-45" unitRef="usd">88739000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-46" unitRef="usd">127753000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-47" unitRef="usd">4700000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-48" unitRef="usd">4281000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-49" unitRef="usd">12613000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-50" unitRef="usd">7986000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-51" unitRef="usd">928000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-52" unitRef="usd">810000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-53" unitRef="usd">18241000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-54" unitRef="usd">13077000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-55" unitRef="usd">1214000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-56" unitRef="usd">992000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-57" unitRef="usd">1214000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-58" unitRef="usd">992000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-3" decimals="-3" id="f-59" unitRef="usd">19455000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-60" unitRef="usd">14069000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-61" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-62" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-63"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-64"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-65" unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-66" unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-67" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="INF" id="f-68" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c-3" decimals="INF" id="f-69" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-70" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-3" decimals="-3" id="f-71" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-4" decimals="-3" id="f-72" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-73"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-74"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-75" unitRef="shares">130000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-76" unitRef="shares">130000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-77" unitRef="shares">44488371</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="INF" id="f-78" unitRef="shares">44488371</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="INF" id="f-79" unitRef="shares">39307286</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="INF" id="f-80" unitRef="shares">39307286</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-81" unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-82" unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-3" decimals="-3" id="f-83" unitRef="usd">431849000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-4" decimals="-3" id="f-84" unitRef="usd">427925000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-3" id="f-85" unitRef="usd">3982000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-86" unitRef="usd">3035000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-87" unitRef="usd">-366551000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-88" unitRef="usd">-317280000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-89" unitRef="usd">69284000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-90" unitRef="usd">113684000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-91" unitRef="usd">88739000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-92" unitRef="usd">127753000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-5" decimals="-3" id="f-93" unitRef="usd">21172000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-6" decimals="-3" id="f-94" unitRef="usd">16538000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-95" unitRef="usd">44135000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-7" decimals="-3" id="f-96" unitRef="usd">33983000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-97" unitRef="usd">3849000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-6" decimals="-3" id="f-98" unitRef="usd">4072000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-99" unitRef="usd">8137000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-7" decimals="-3" id="f-100" unitRef="usd">8062000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-5" decimals="-3" id="f-101" unitRef="usd">25021000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-6" decimals="-3" id="f-102" unitRef="usd">20610000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-103" unitRef="usd">52272000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-7" decimals="-3" id="f-104" unitRef="usd">42045000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-105" unitRef="usd">-25021000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-6" decimals="-3" id="f-106" unitRef="usd">-20610000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-107" unitRef="usd">-52272000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-7" decimals="-3" id="f-108" unitRef="usd">-42045000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest contextRef="c-5" decimals="-3" id="f-109" unitRef="usd">968000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-6" decimals="-3" id="f-110" unitRef="usd">106000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-3" id="f-111" unitRef="usd">1768000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-7" decimals="-3" id="f-112" unitRef="usd">113000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-113" unitRef="usd">54000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-114" unitRef="usd">-1397000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-115" unitRef="usd">1233000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-7" decimals="-3" id="f-116" unitRef="usd">-777000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-117" unitRef="usd">1022000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-118" unitRef="usd">-1291000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-119" unitRef="usd">3001000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-7" decimals="-3" id="f-120" unitRef="usd">-664000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-121" unitRef="usd">-23999000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-122" unitRef="usd">-21901000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-123" unitRef="usd">-49271000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-124" unitRef="usd">-42709000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-125"
      unitRef="usdPerShare">-0.54</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-126"
      unitRef="usdPerShare">-0.54</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-127"
      unitRef="usdPerShare">-0.72</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-128"
      unitRef="usdPerShare">-0.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-129"
      unitRef="usdPerShare">-1.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-130"
      unitRef="usdPerShare">-1.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-131"
      unitRef="usdPerShare">-1.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-132"
      unitRef="usdPerShare">-1.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="0" id="f-133" unitRef="shares">44432955</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="0" id="f-134" unitRef="shares">44432955</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="0" id="f-135" unitRef="shares">30248767</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="0" id="f-136" unitRef="shares">30248767</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="0" id="f-137" unitRef="shares">44036352</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="0" id="f-138" unitRef="shares">44036352</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="0" id="f-139" unitRef="shares">28686910</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="0" id="f-140" unitRef="shares">28686910</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-141" unitRef="usd">-23999000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-142" unitRef="usd">-21901000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-143" unitRef="usd">-49271000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-144" unitRef="usd">-42709000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-5" decimals="-3" id="f-145" unitRef="usd">171000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-6" decimals="-3" id="f-146" unitRef="usd">-350000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-147" unitRef="usd">947000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-7" decimals="-3" id="f-148" unitRef="usd">-408000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-5" decimals="-3" id="f-149" unitRef="usd">-23828000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-6" decimals="-3" id="f-150" unitRef="usd">-22251000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-151" unitRef="usd">-48324000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-7" decimals="-3" id="f-152" unitRef="usd">-43117000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-8" decimals="INF" id="f-153" unitRef="shares">39307286</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-154" unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-155" unitRef="usd">427925000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-156" unitRef="usd">3035000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-157" unitRef="usd">-317280000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-158" unitRef="usd">113684000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-159" unitRef="usd">-25272000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-160" unitRef="usd">-25272000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-14" decimals="-3" id="f-161" unitRef="usd">1979000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-13" decimals="-3" id="f-162" unitRef="usd">1979000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-15" decimals="-3" id="f-163" unitRef="usd">776000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-13" decimals="-3" id="f-164" unitRef="usd">776000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-16"
      decimals="INF"
      id="f-165"
      unitRef="shares">5096552</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-14" decimals="-3" id="f-166" unitRef="usd">51000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-13" decimals="-3" id="f-167" unitRef="usd">51000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-17"
      decimals="INF"
      id="f-168"
      unitRef="shares">44403838</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-17" decimals="-3" id="f-169" unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-3" id="f-170" unitRef="usd">429955000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-171" unitRef="usd">3811000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-172" unitRef="usd">-342552000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-173" unitRef="usd">91218000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-22" decimals="-3" id="f-174" unitRef="usd">-23999000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-175" unitRef="usd">-23999000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-23" decimals="-3" id="f-176" unitRef="usd">1798000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-5" decimals="-3" id="f-177" unitRef="usd">1798000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-24" decimals="-3" id="f-178" unitRef="usd">171000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-3" id="f-179" unitRef="usd">171000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-25"
      decimals="INF"
      id="f-180"
      unitRef="shares">84533</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-23" decimals="-3" id="f-181" unitRef="usd">96000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-5" decimals="-3" id="f-182" unitRef="usd">96000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-26"
      decimals="INF"
      id="f-183"
      unitRef="shares">44488371</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-26" decimals="-3" id="f-184" unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-3" id="f-185" unitRef="usd">431849000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-3" id="f-186" unitRef="usd">3982000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-3" id="f-187" unitRef="usd">-366551000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-188" unitRef="usd">69284000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-30"
      decimals="INF"
      id="f-189"
      unitRef="shares">26335418</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-3" id="f-190" unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-191" unitRef="usd">324237000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-192" unitRef="usd">-252000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-33" decimals="-3" id="f-193" unitRef="usd">-196873000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-34" decimals="-3" id="f-194" unitRef="usd">127115000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-35" decimals="-3" id="f-195" unitRef="usd">-20808000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-36" decimals="-3" id="f-196" unitRef="usd">-20808000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-37" decimals="-3" id="f-197" unitRef="usd">2069000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-36" decimals="-3" id="f-198" unitRef="usd">2069000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-38" decimals="-3" id="f-199" unitRef="usd">-58000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-36" decimals="-3" id="f-200" unitRef="usd">-58000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-39"
      decimals="INF"
      id="f-201"
      unitRef="shares">852</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-37" decimals="-3" id="f-202" unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-36" decimals="-3" id="f-203" unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-36" decimals="-3" id="f-204" unitRef="usd">918000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-39"
      decimals="INF"
      id="f-205"
      unitRef="shares">2904113</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-37" decimals="-3" id="f-206" unitRef="usd">29638000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-36" decimals="-3" id="f-207" unitRef="usd">29638000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-40"
      decimals="INF"
      id="f-208"
      unitRef="shares">29240383</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-3" id="f-209" unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="-3" id="f-210" unitRef="usd">355949000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="-3" id="f-211" unitRef="usd">-310000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-43" decimals="-3" id="f-212" unitRef="usd">-217681000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-44" decimals="-3" id="f-213" unitRef="usd">137961000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-45" decimals="-3" id="f-214" unitRef="usd">-21901000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-215" unitRef="usd">-21901000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-46" decimals="-3" id="f-216" unitRef="usd">2062000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-6" decimals="-3" id="f-217" unitRef="usd">2062000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-47" decimals="-3" id="f-218" unitRef="usd">-350000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-6" decimals="-3" id="f-219" unitRef="usd">-350000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-48"
      decimals="INF"
      id="f-220"
      unitRef="shares">24612</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-46" decimals="-3" id="f-221" unitRef="usd">130000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-6" decimals="-3" id="f-222" unitRef="usd">130000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-6" decimals="-3" id="f-223" unitRef="usd">308000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-48"
      decimals="INF"
      id="f-224"
      unitRef="shares">1300000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-46" decimals="-3" id="f-225" unitRef="usd">9946000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-6" decimals="-3" id="f-226" unitRef="usd">9946000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c-49"
      decimals="INF"
      id="f-227"
      unitRef="shares">30564995</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-49" decimals="-3" id="f-228" unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-50" decimals="-3" id="f-229" unitRef="usd">368087000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-51" decimals="-3" id="f-230" unitRef="usd">-660000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-52" decimals="-3" id="f-231" unitRef="usd">-239582000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-53" decimals="-3" id="f-232" unitRef="usd">127848000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-233" unitRef="usd">-49271000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-234" unitRef="usd">-42709000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-235" unitRef="usd">54000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-7" decimals="-3" id="f-236" unitRef="usd">41000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="c-1" decimals="-3" id="f-237" unitRef="usd">-665000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized contextRef="c-7" decimals="-3" id="f-238" unitRef="usd">-2103000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-239" unitRef="usd">3777000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-7" decimals="-3" id="f-240" unitRef="usd">4131000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-241" unitRef="usd">-312000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-7" decimals="-3" id="f-242" unitRef="usd">-139000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-243" unitRef="usd">449000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-7" decimals="-3" id="f-244" unitRef="usd">826000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-245" unitRef="usd">4462000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-7" decimals="-3" id="f-246" unitRef="usd">-861000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-1" decimals="-3" id="f-247" unitRef="usd">63000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-7" decimals="-3" id="f-248" unitRef="usd">-114000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-249" unitRef="usd">-39489000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-7" decimals="-3" id="f-250" unitRef="usd">-36444000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfOtherInvestments contextRef="c-1" decimals="-3" id="f-251" unitRef="usd">9796000</us-gaap:ProceedsFromSaleOfOtherInvestments>
    <us-gaap:ProceedsFromSaleOfOtherInvestments contextRef="c-7" decimals="-3" id="f-252" unitRef="usd">0</us-gaap:ProceedsFromSaleOfOtherInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-253" unitRef="usd">125000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-254" unitRef="usd">40000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-255" unitRef="usd">9671000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-7" decimals="-3" id="f-256" unitRef="usd">-40000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-257" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-7" decimals="-3" id="f-258" unitRef="usd">39584000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-259" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-7" decimals="-3" id="f-260" unitRef="usd">5000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans contextRef="c-1" decimals="-3" id="f-261" unitRef="usd">96000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans contextRef="c-7" decimals="-3" id="f-262" unitRef="usd">130000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-1" decimals="-3" id="f-263" unitRef="usd">51000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="c-7" decimals="-3" id="f-264" unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-265" unitRef="usd">147000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-7" decimals="-3" id="f-266" unitRef="usd">39719000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-3" id="f-267" unitRef="usd">220000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-268" unitRef="usd">-2020000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-269" unitRef="usd">-29451000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-7" decimals="-3" id="f-270" unitRef="usd">1215000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-271" unitRef="usd">106745000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-34" decimals="-3" id="f-272" unitRef="usd">86863000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-273" unitRef="usd">77294000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-53" decimals="-3" id="f-274" unitRef="usd">88078000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-275" unitRef="usd">544000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-7" decimals="-3" id="f-276" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c-1" id="f-277">Description of Business and Basis of Financial Statements&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Immunic, Inc. ("Immunic" or the "Company") is a biotechnology company developing a clinical pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases. The Company is headquartered in New York City with its main operations in Gr&#xe4;felfing near Munich, Germany. The Company currently has approximately 75 employees.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Immunic is pursuing clinical development of orally administered, small molecule programs, each of which has unique features intended to directly address the unmet needs of patients with serious chronic inflammatory and autoimmune diseases. These include the vidofludimus calcium (IMU-838) program, which is in Phase 3 clinical development for patients with multiple sclerosis (&#x201c;MS&#x201d;) and which has shown therapeutic activity in Phase 2 clinical trials in patients suffering from relapsing-remitting MS and moderate-to-severe ulcerative colitis (&#x201c;UC&#x201d;); the IMU-856 program, which is targeted to regenerate bowel epithelium and restore intestinal barrier function, which could potentially be applicable in numerous gastrointestinal diseases, such as celiac disease, UC, Crohn&#x2019;s disease or irritable bowel syndrome with diarrhea; and the IMU-381 program, which is a next generation molecule being developed to specifically address the needs of gastrointestinal diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s business, operating results, financial condition and growth prospects are subject to significant risks and uncertainties, including the failure of its clinical trials to meet their endpoints, failure to obtain regulatory approval and needing additional funding to complete the development and commercialization of the Company's three development programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Financial Condition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immunic has no products approved for commercial sale and has not generated any revenue from product sales. It has never been profitable and has incurred operating losses in each year since inception in 2016. The Company has an accumulated deficit of approximately $366.6 million as of June 30, 2023 and $317.3 million as of December 31, 2022. Substantially all of Immunic's operating losses resulted from expenses incurred in connection with its research and development programs and from general and administrative costs associated with its operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Immunic expects to incur significant expenses and increasing operating losses for the foreseeable future as it initiates and continues the development of its product candidates and adds personnel necessary to advance its pipeline of product candidates. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Immunic expects that its operating losses will fluctuate significantly from quarter-to-quarter and year-to-year due to timing of development programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From inception through June 30, 2023, Immunic has raised net cash of approximately $355.6 million from private and public offerings of preferred and common stock. As of June 30, 2023, the Company had cash and cash equivalents of approximately $77.3 million.  With these funds, Immunic expects to be able to fund its operations beyond twelve months from the date of the issuance of the accompanying condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles, ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG and Immunic Australia Pty Ltd.  All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immunic has prepared the accompanying interim unaudited condensed consolidated financial statements in accordance with United States generally accepted accounting principles, (&#x201c;US GAAP&#x201d;), for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to &lt;/span&gt;&lt;/div&gt;present fairly Immunic&#x2019;s consolidated financial position, consolidated results of operations, consolidated statement of stockholders&#x2019; equity and consolidated cash flows for the periods and as of the dates presented. The Company&#x2019;s fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2022 was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto included on the Company's Annual Report on Form 10-K filed on February 23, 2023. The nature of Immunic&#x2019;s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <dei:EntityNumberOfEmployees
      contextRef="c-3"
      decimals="INF"
      id="f-278"
      unitRef="employee">75</dei:EntityNumberOfEmployees>
    <vtl:NumberOfDevelopmentPrograms contextRef="c-3" decimals="INF" id="f-279" unitRef="lease">3</vtl:NumberOfDevelopmentPrograms>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-5" id="f-280" unitRef="usd">-366600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-5" id="f-281" unitRef="usd">-317300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c-54" decimals="-5" id="f-282" unitRef="usd">355600000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-5" id="f-283" unitRef="usd">77300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-284">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation and Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements have been prepared in conformity with United States generally accepted accounting principles, ("U.S. GAAP") and include the accounts of Immunic and its wholly-owned subsidiaries, Immunic AG and Immunic Australia Pty Ltd.  All intercompany accounts and transactions have been eliminated in consolidation. Immunic manages its operations as a single reportable segment for the purposes of assessing performance and making operating decisions. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Immunic has prepared the accompanying interim unaudited condensed consolidated financial statements in accordance with United States generally accepted accounting principles, (&#x201c;US GAAP&#x201d;), for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the SEC. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These interim unaudited condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to &lt;/span&gt;&lt;/div&gt;present fairly Immunic&#x2019;s consolidated financial position, consolidated results of operations, consolidated statement of stockholders&#x2019; equity and consolidated cash flows for the periods and as of the dates presented. The Company&#x2019;s fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2022 was derived from audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. These condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and the notes thereto included on the Company's Annual Report on Form 10-K filed on February 23, 2023. The nature of Immunic&#x2019;s business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-285">Summary of Significant Accounting Policies&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s consolidated financial statements. The most significant estimates in the Company&#x2019;s financial statements and accompanying notes relate to recoverability of goodwill, clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation and Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s reporting currency is United States (&#x201c;U.S.&#x201d;) dollars. Immunic AG is located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.&#x2019;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; assets and liabilities at reporting period-end rates;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; income statement accounts at average exchange rates for the reporting period; and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; components of equity at historical rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#x2019; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents and Investments - other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  Time Deposits with an original maturity greater than three months are classified as Investments - other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents and investments - other consist of cash on hand and deposits in banks located in the U.S. of approximately $62.7&#160;million, Germany of approximately $14.4&#160;million and Australia of approximately $0.2&#160;million as of June 30, 2023. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions. The Company currently deposits its cash and cash equivalents with two large financial institutions. Cash and Cash equivalents in the U.S. are held at J.P. Morgan and as of June 30, 2023 are primarily held in a U.S. Government money market fund account earning interest at a rate of 5.0%. Cash and cash equivalents in Germany are earning interest at a rate of 1.75% to 2.75% during the period ended June 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments - other consists of the following as of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.665%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.665%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.852%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time Deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9,629&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9,629&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The time deposit accounts in our bank in Germany matured in January and April, 2023, respectively.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1&#x2014;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2&#x2014;Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3&#x2014;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets, which range from &lt;span style="-sec-ix-hidden:f-303"&gt;three&lt;/span&gt; to thirteen years. Depreciation expense was $22,000 and $20,000 for the three months ended June 30, 2023 and 2022, respectively. Depreciation expense was $54,000 and $41,000 for the six months ended June 30, 2023 and 2022, respectively&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#x2019; carrying amount. Impaired assets are then recorded at their estimated fair value. There were no impairment losses during the three and six months ended June 30, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:20.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#x2019;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, an unfavorable clinical trial result, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On October 20, 2022, the Company announced the outcome of a  significant interim analysis of its Phase 1b clinical trial of izumerogant (IMU-935) in patients with moderate-to-severe psoriasis that were not deemed positive progress. On October 21, 2022, the Company experienced a significant decrease in the Company's market capitalization.  The Company considered this to be a triggering event indicating that it is more likely than not that goodwill was impaired.  The Company performed an analysis of the fair value compared to the Company's book value, utilizing the Company's traded stock price (a level 1 fair value input). As a result of that analysis, the Company recorded an approximately $33.0&#160;million non-cash goodwill impairment charge in the fourth quarter of 2022, which represents a full write down of its previous goodwill balance.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;These costs primarily include external development expenses and internal personnel expenses for its development programs, vidofludimus calcium, izumerogant and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program for clinical trials in MS, UC and COVID-19.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into agreements with contract research organizations (&#x201c;CROs&#x201d;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#x201c;MSA&#x201d;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09 &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; and ASU No. 2018-18, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#x2019;s patent application related to IMU-856, for which the Company received a notice of allowance from the U.S. Patent &amp;amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Government assistance&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government assistance relating to research and development performed by Immunic Australia is recorded as a component of other (income) expense. This government assistance is recognized at a rate of 43.5% of the qualified research and development expenditures which are incurred. We also receive government assistance from the German Government for reimbursement of research and development expenses up to one million Euros per year. We recognized $0.3&#160;million and $2.1&#160;million of &lt;span style="-sec-ix-hidden:f-322"&gt;&lt;span style="-sec-ix-hidden:f-323"&gt;other income&lt;/span&gt;&lt;/span&gt; related to research activities performed during the three and six months ended June 30, 2023, respectively and  $0.6&#160;million and $1.4&#160;million  related to research activities performed during the three and six months ended June 30, 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#x2019;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#x2019;s common stock, the expected volatility of the price of the Company&#x2019;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#x2019;s judgment. If factors change and different assumptions are used, the Company&#x2019;s stock-based compensation expense could be materially different in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has three existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#x2019;s balance sheet. A right-of-use lease asset represents the Company&#x2019;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#x2019; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized.  As of June 30, 2023 and 2022, respectively, the Company maintained a full valuation allowance against the balance of deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is the Company&#x2019;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#x2019;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2022 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#x201c;ASC 480-10&#x201d;) or ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#x2019;s Own Stock (&#x201c;ASC 815-40&#x201d;). Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable U.S. GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.  All of the Company's 5,096,552 pre-funded warrants were exercised in January 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.751%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.953%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.955%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,770,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,713,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued and/or Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no recently issued accounting standards that would have a significant impact on the company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-286">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires the Company to make certain estimates and assumptions that affect the reported amounts of assets, liabilities, expenses and the disclosure of contingent assets and liabilities in the Company&#x2019;s consolidated financial statements. The most significant estimates in the Company&#x2019;s financial statements and accompanying notes relate to recoverability of goodwill, clinical trial expenses and share-based compensation. Management believes its estimates to be reasonable under the circumstances. Actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-287">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation and Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s reporting currency is United States (&#x201c;U.S.&#x201d;) dollars. Immunic AG is located in Germany with the euro being its functional currency. Immunic Australia Pty Ltd.&#x2019;s functional currency is the Australian dollar. All amounts in the financial statements where the functional currency is not the U.S. dollar are translated into U.S. dollar equivalents at exchange rates as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; assets and liabilities at reporting period-end rates;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; income statement accounts at average exchange rates for the reporting period; and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:180%"&gt;&#x2022; components of equity at historical rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains and losses from translation of the financial statements into U.S. dollars are recorded in stockholders&#x2019; equity as a component of accumulated other comprehensive income (loss). Realized and unrealized gains and losses resulting from foreign currency transactions denominated in currencies other than the functional currency are reflected as general and administrative expenses in the Consolidated Statements of Operations. Foreign currency transaction gains and losses related to long-term intercompany loans that are payable in the foreseeable future are recorded in Other Income (Expense). The Consolidated Statements of Cash Flows were prepared by using the average exchange rate in effect during the reporting period which reasonably approximates the timing of the cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <vtl:CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock contextRef="c-1" id="f-288">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents and Investments - other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.  Time Deposits with an original maturity greater than three months are classified as Investments - other.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents and investments - other consist of cash on hand and deposits in banks located in the U.S. of approximately $62.7&#160;million, Germany of approximately $14.4&#160;million and Australia of approximately $0.2&#160;million as of June 30, 2023. The Company maintains cash and cash equivalent balances denominated in Euro and U.S. dollars with major financial institutions in the U.S. and Germany in excess of the deposit limits insured by the government. Management periodically reviews the credit standing of these financial institutions. The Company currently deposits its cash and cash equivalents with two large financial institutions. Cash and Cash equivalents in the U.S. are held at J.P. Morgan and as of June 30, 2023 are primarily held in a U.S. Government money market fund account earning interest at a rate of 5.0%. Cash and cash equivalents in Germany are earning interest at a rate of 1.75% to 2.75% during the period ended June 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments - other consists of the following as of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.665%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.665%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.852%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time Deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9,629&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9,629&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The time deposit accounts in our bank in Germany matured in January and April, 2023, respectively.</vtl:CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-55" decimals="-5" id="f-289" unitRef="usd">62700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-56" decimals="-5" id="f-290" unitRef="usd">14400000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-57" decimals="-5" id="f-291" unitRef="usd">200000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <vtl:NumberOfFinancialInstitutionsUsedForCashDeposit
      contextRef="c-3"
      decimals="INF"
      id="f-292"
      unitRef="financialinstitution">2</vtl:NumberOfFinancialInstitutionsUsedForCashDeposit>
    <us-gaap:InvestmentInterestRate contextRef="c-58" decimals="3" id="f-293" unitRef="number">0.050</us-gaap:InvestmentInterestRate>
    <us-gaap:InvestmentInterestRate contextRef="c-59" decimals="4" id="f-294" unitRef="number">0.0175</us-gaap:InvestmentInterestRate>
    <us-gaap:InvestmentInterestRate contextRef="c-60" decimals="4" id="f-295" unitRef="number">0.0275</us-gaap:InvestmentInterestRate>
    <us-gaap:InvestmentTableTextBlock contextRef="c-1" id="f-296">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments - other consists of the following as of (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.970%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.665%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.665%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.848%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:3.470%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.852%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time Deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9,629&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9,629&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentTableTextBlock>
    <us-gaap:OtherShortTermInvestments contextRef="c-61" decimals="-3" id="f-297" unitRef="usd">0</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments contextRef="c-62" decimals="-3" id="f-298" unitRef="usd">9629000</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments contextRef="c-3" decimals="-3" id="f-299" unitRef="usd">0</us-gaap:OtherShortTermInvestments>
    <us-gaap:OtherShortTermInvestments contextRef="c-4" decimals="-3" id="f-300" unitRef="usd">9629000</us-gaap:OtherShortTermInvestments>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-301">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the price that would be received to sell an asset or be paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1&#x2014;Quoted prices in active markets for identical assets or liabilities. Level 1 assets consisted of money market funds for the periods presented. The Company had no Level 1 liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2&#x2014;Inputs other than observable quoted prices for the asset or liability, either directly or indirectly; these include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. The Company had no Level 2 assets or liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3&#x2014;Unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The Company had no Level 3 assets or liabilities for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of cash and cash equivalents, other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximates fair value due to the short period of time to maturity.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-302">Property and EquipmentProperty and equipment is stated at cost. Depreciation is computed using the straight-line method based on the estimated service lives of the assets, which range from &lt;span style="-sec-ix-hidden:f-303"&gt;three&lt;/span&gt; to thirteen years.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-64" id="f-304">P13Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:Depreciation contextRef="c-5" decimals="-3" id="f-305" unitRef="usd">22000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-6" decimals="-3" id="f-306" unitRef="usd">20000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-307" unitRef="usd">54000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-7" decimals="-3" id="f-308" unitRef="usd">41000</us-gaap:Depreciation>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c-1" id="f-309">Impairment of Long-Lived AssetsThe Company records impairment losses on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets&#x2019; carrying amount. Impaired assets are then recorded at their estimated fair value.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-6" decimals="INF" id="f-310" unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-1" decimals="INF" id="f-311" unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-5" decimals="INF" id="f-312" unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges contextRef="c-7" decimals="INF" id="f-313" unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="c-1" id="f-314">&lt;div style="margin-top:12pt;padding-left:20.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Business combinations are accounted for under the acquisition method. The total purchase price of an acquisition is allocated to the underlying identifiable net assets, based on their respective estimated fair values as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires management&#x2019;s judgment and often involves the use of significant estimates and assumptions, including assumptions with respect to future cash inflows and outflows, probabilities of success, discount rates, and asset lives, among other items. Assets acquired and liabilities assumed are recorded at their estimated fair values. The excess of the purchase price over the estimated fair values of the net assets acquired is recorded as goodwill.&lt;/span&gt;&lt;/div&gt;Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, an unfavorable clinical trial result, a significant adverse change in legal or business climate, industry market conditions, an adverse regulatory action, sustained decrease in stock price or unanticipated competition.</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-65" decimals="-5" id="f-315" unitRef="usd">33000000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-316">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;These costs primarily include external development expenses and internal personnel expenses for its development programs, vidofludimus calcium, izumerogant and IMU-856. Immunic has spent the majority of its research and development resources on vidofludimus calcium, the Company's lead development program for clinical trials in MS, UC and COVID-19.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist of expenses incurred in research and development activities, which include clinical trials, contract research services, certain milestone payments, salaries and related employee benefits, allocated facility costs and other outsourced services. Research and development expenses are charged to operations as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into agreements with contract research organizations (&#x201c;CROs&#x201d;) to provide clinical trial services for individual studies and projects by executing individual work orders governed by a Master Service Arrangement (&#x201c;MSA&#x201d;). The MSAs and associated work orders provide for regular recurrent payments and payments upon the completion of certain milestones. The Company regularly assesses the timing of payments against actual costs incurred to ensure a proper accrual of related expenses in the appropriate accounting period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:CollaborativeArrangementAccountingPolicy contextRef="c-1" id="f-317">&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Collaboration Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain collaboration and license agreements may include payments to or from the Company of one or more of the following: non-refundable or partially refundable upfront or license fees; development, regulatory and commercial milestone payments; payment for manufacturing supply services; partial or complete reimbursement of research and development costs; and royalties on net sales of licensed products. The Company assesses whether such contracts are within the scope of Financial Accounting Standards Board (FASB) Accounting Standards Update (&#x201c;ASU&#x201d;) 2014-09 &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201d; and ASU No. 2018-18, &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ("ASU 2018-18"). ASU 2018-18, clarifies that certain elements of collaborative arrangements could qualify as transactions with customers in the scope of ASC 606.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company entered into an option and license agreement (the "Daiichi Sankyo Agreement") with Daiichi Sankyo Co., Ltd. ("Daiichi Sankyo") which granted the Company the right to license a group of compounds, designated by the Company as IMU-856, as a potential new oral treatment option for gastrointestinal diseases such as celiac disease, inflammatory bowel disease, irritable bowel syndrome with diarrhea and other barrier function associated diseases. During the option period, the Company performed agreed upon research and development activities for which it was reimbursed by Daiichi Sankyo up to a maximum agreed-upon limit. Such reimbursement was recorded as other income. There are no additional research and development reimbursements expected under this agreement.&lt;/span&gt;&lt;/div&gt;On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#x2019;s patent application related to IMU-856, for which the Company received a notice of allowance from the U.S. Patent &amp;amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856.</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:GovernmentAssistancePolicyTextBlock contextRef="c-1" id="f-318">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Government assistance&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Government assistance relating to research and development performed by Immunic Australia is recorded as a component of other (income) expense. This government assistance is recognized at a rate of 43.5% of the qualified research and development expenditures which are incurred. We also receive government assistance from the German Government for reimbursement of research and development expenses up to one million Euros per year. We recognized $0.3&#160;million and $2.1&#160;million of &lt;span style="-sec-ix-hidden:f-322"&gt;&lt;span style="-sec-ix-hidden:f-323"&gt;other income&lt;/span&gt;&lt;/span&gt; related to research activities performed during the three and six months ended June 30, 2023, respectively and  $0.6&#160;million and $1.4&#160;million  related to research activities performed during the three and six months ended June 30, 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:GovernmentAssistancePolicyTextBlock>
    <vtl:GovernmentAssistanceRate contextRef="c-1" decimals="3" id="f-319" unitRef="number">0.435</vtl:GovernmentAssistanceRate>
    <us-gaap:GovernmentAssistanceAmount contextRef="c-5" decimals="-5" id="f-320" unitRef="usd">300000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceAmount contextRef="c-1" decimals="-5" id="f-321" unitRef="usd">2100000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceAmount contextRef="c-6" decimals="-5" id="f-324" unitRef="usd">600000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:GovernmentAssistanceAmount contextRef="c-7" decimals="-5" id="f-325" unitRef="usd">1400000</us-gaap:GovernmentAssistanceAmount>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock contextRef="c-1" id="f-326">&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative expenses consist primarily of salaries and related costs for personnel in executive, finance, business development and other support functions. Other general and administrative expenses include, but are not limited to, stock-based compensation, insurance costs, professional fees for legal, accounting and tax services, consulting, related facility costs and travel.&lt;/span&gt;&lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-327">&lt;div style="margin-top:18pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the cost of employee and non-employee services received in exchange for equity awards based on the grant-date fair value of the award recognized generally as an expense (i) on a straight-line basis over the requisite service period for those awards whose vesting is based upon a service condition, and (ii) on an accelerated method for awards whose vesting is based upon a performance condition, but only to the extent it is probable that the performance condition will be met. Stock-based compensation is (i) estimated at the date of grant based on the award&#x2019;s fair value for equity classified awards and (ii) final measurement date for liability classified awards. Forfeitures are recorded in the period in which they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of stock options using the Black-Scholes-Merton option-pricing model ("BSM"), which requires the use of estimates and subjective assumptions, including the risk-free interest rate, the fair value of the underlying common stock, the expected dividend yield of the Company&#x2019;s common stock, the expected volatility of the price of the Company&#x2019;s common stock, and the expected term of the option. These estimates involve inherent uncertainties and the application of management&#x2019;s judgment. If factors change and different assumptions are used, the Company&#x2019;s stock-based compensation expense could be materially different in the future.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-328">&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company leases office space and office equipment. The underlying lease agreements have lease terms of less than 12 months and up to 60 months. Leases with terms of 12 months or less at inception are not included in the operating lease right of use asset and operating lease liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has three existing leases for office space. At inception of a lease agreement, the Company determines whether an agreement represents a lease and at commencement each lease agreement is assessed as to classification as an operating or financing lease. The Company's leases have been classified as operating leases and an operating lease right-of-use asset and an operating lease liability have been recorded on the Company&#x2019;s balance sheet. A right-of-use lease asset represents the Company&#x2019;s right to use the underlying asset for the lease term and the lease obligation represents its commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company&#x2019;s leases do not provide an implicit rate, the Company has used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The right-of-use lease asset includes any lease payments made prior to commencement and excludes any lease incentives. The lease term used in estimating future lease payments may include options to extend when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or changes in expectations regarding the lease term. Variable lease costs such as common area costs and property taxes are expensed as incurred. Leases with an initial term of twelve months or less are not recorded on the balance sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-63" id="f-329">P12M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-64" id="f-330">P60M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <vtl:LesseeOperatingLeasesNumberOfExistingLeases contextRef="c-3" decimals="INF" id="f-331" unitRef="lease">3</vtl:LesseeOperatingLeasesNumberOfExistingLeases>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="c-1" id="f-332">&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Accumulated other comprehensive income (loss) has been reflected as a separate component of stockholders&#x2019; equity in the accompanying Consolidated Balance Sheets and consists of foreign currency translation adjustments (net of tax).&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-333">&lt;div style="margin-top:18pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to corporate income tax laws and regulations in the U.S., Germany and Australia. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment in their application.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes the asset and liability method of accounting for income taxes which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the audited consolidated financial statements. Deferred income tax assets and liabilities are determined based on the differences between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of changes in tax rates on deferred tax assets and liabilities is recognized in operations in the period that includes the enactment date. Deferred taxes are reduced by a valuation allowance when, in the opinion of management, it is more likely than not some portion or the entire deferred tax asset will not be realized.  As of June 30, 2023 and 2022, respectively, the Company maintained a full valuation allowance against the balance of deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is the Company&#x2019;s policy to provide for uncertain tax positions and the related interest and penalties based upon management&#x2019;s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.  The Company is subject to U.S. federal, New York, California, Texas, German and Australian income taxes. The Company is subject to U.S. federal or state income tax examination by tax authorities for tax returns filed for the years 2003 and forward due to the carryforward of NOLs. Tax years 2016 through 2022 are subject to audit by German and Australian tax authorities. The Company is not currently under examination by any tax jurisdictions.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:StockholdersEquityPolicyTextBlock contextRef="c-1" id="f-334">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for issued warrants either as a liability or equity in accordance with ASC 480-10, Accounting for Certain Financial Instruments with Characteristics of both Liabilities and Equity (&#x201c;ASC 480-10&#x201d;) or ASC 815-40, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company&#x2019;s Own Stock (&#x201c;ASC 815-40&#x201d;). Under ASC 480-10, warrants are considered a liability if they are mandatorily redeemable and they require settlement in cash, other assets, or a variable number of shares. If warrants do not meet liability classification under ASC 480-10, the Company considers the requirements of ASC 815-40 to determine whether the warrants should be classified as a liability or as equity. Under ASC 815-40, contracts that may require settlement for cash are liabilities, regardless of the probability of the occurrence of the triggering event. Liability-classified warrants are measured at fair value on the issuance date and at the end of each reporting period. Any change in the fair value of the warrants after the issuance date is recorded in the consolidated statements of operations as a gain or loss. If warrants do not require liability classification under ASC 815-40, in order to conclude warrants should be classified as equity, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 815-40 or other applicable U.S. GAAP standard. Equity-classified warrants are accounted for at fair value on the issuance date with no changes in fair value recognized after the issuance date.  All of the Company's 5,096,552 pre-funded warrants were exercised in January 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-66"
      decimals="INF"
      id="f-335"
      unitRef="shares">5096552</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-336">Net Loss Per ShareBasic net loss per share attributable to common stockholders is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share attributable to common stockholders is computed by dividing the net loss by the weighted-average number of common shares and, if dilutive, common stock equivalents outstanding for the period determined using the treasury-stock method. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company&#x2019;s net loss position.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-337">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potentially dilutive securities, not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive, are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:73.751%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.953%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.955%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,770,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,713,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-67" decimals="0" id="f-338" unitRef="shares">5770076</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-68" decimals="0" id="f-339" unitRef="shares">3713248</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-340">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued and/or Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no recently issued accounting standards that would have a significant impact on the company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c-1" id="f-341">Balance Sheet Details&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Current Assets and Prepaid Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Current Assets and Prepaid Expenses consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.840%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.986%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.255%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid clinical and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;VAT receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Australian research and development tax incentive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts Payable consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.046%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.474%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal and audit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.484%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued legal and audit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&lt;span style="-sec-ix-hidden:f-372"&gt;&lt;span style="-sec-ix-hidden:f-373"&gt;Other Current Liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Current Liabilities consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.527%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.752%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.912%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.740%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-375"&gt;&lt;span style="-sec-ix-hidden:f-376"&gt;Lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="c-1" id="f-342">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Current Assets and Prepaid Expenses consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.840%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.986%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.255%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid clinical and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;VAT receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Australian research and development tax incentive&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <vtl:PrepaidClinicalAndRelatedCostsCurrent contextRef="c-3" decimals="-3" id="f-343" unitRef="usd">3812000</vtl:PrepaidClinicalAndRelatedCostsCurrent>
    <vtl:PrepaidClinicalAndRelatedCostsCurrent contextRef="c-4" decimals="-3" id="f-344" unitRef="usd">5608000</vtl:PrepaidClinicalAndRelatedCostsCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent contextRef="c-3" decimals="-3" id="f-345" unitRef="usd">1181000</us-gaap:ValueAddedTaxReceivableCurrent>
    <us-gaap:ValueAddedTaxReceivableCurrent contextRef="c-4" decimals="-3" id="f-346" unitRef="usd">296000</us-gaap:ValueAddedTaxReceivableCurrent>
    <vtl:ResearchAndDevelopmentTaxIncentiveCurrent contextRef="c-3" decimals="-3" id="f-347" unitRef="usd">2875000</vtl:ResearchAndDevelopmentTaxIncentiveCurrent>
    <vtl:ResearchAndDevelopmentTaxIncentiveCurrent contextRef="c-4" decimals="-3" id="f-348" unitRef="usd">2361000</vtl:ResearchAndDevelopmentTaxIncentiveCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-349" unitRef="usd">1389000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-350" unitRef="usd">1225000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-351" unitRef="usd">9257000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-352" unitRef="usd">9490000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-353">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts Payable consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.046%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.011%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.969%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.474%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal and audit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:74.484%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued clinical and related costs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued legal and audit costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <vtl:ClinicalCostsPayableCurrent contextRef="c-3" decimals="-3" id="f-354" unitRef="usd">4348000</vtl:ClinicalCostsPayableCurrent>
    <vtl:ClinicalCostsPayableCurrent contextRef="c-4" decimals="-3" id="f-355" unitRef="usd">3749000</vtl:ClinicalCostsPayableCurrent>
    <vtl:LegalAndAuditCostsPayableCurrent contextRef="c-3" decimals="-3" id="f-356" unitRef="usd">128000</vtl:LegalAndAuditCostsPayableCurrent>
    <vtl:LegalAndAuditCostsPayableCurrent contextRef="c-4" decimals="-3" id="f-357" unitRef="usd">288000</vtl:LegalAndAuditCostsPayableCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c-3" decimals="-3" id="f-358" unitRef="usd">224000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableOtherCurrent contextRef="c-4" decimals="-3" id="f-359" unitRef="usd">244000</us-gaap:AccountsPayableOtherCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-360" unitRef="usd">4700000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-361" unitRef="usd">4281000</us-gaap:AccountsPayableCurrent>
    <vtl:AccruedClinicalCostsCurrent contextRef="c-3" decimals="-3" id="f-362" unitRef="usd">11668000</vtl:AccruedClinicalCostsCurrent>
    <vtl:AccruedClinicalCostsCurrent contextRef="c-4" decimals="-3" id="f-363" unitRef="usd">6807000</vtl:AccruedClinicalCostsCurrent>
    <vtl:AccruedLegalAndAuditCostsCurrent contextRef="c-3" decimals="-3" id="f-364" unitRef="usd">123000</vtl:AccruedLegalAndAuditCostsCurrent>
    <vtl:AccruedLegalAndAuditCostsCurrent contextRef="c-4" decimals="-3" id="f-365" unitRef="usd">169000</vtl:AccruedLegalAndAuditCostsCurrent>
    <vtl:AccruedCompensationCurrent contextRef="c-3" decimals="-3" id="f-366" unitRef="usd">716000</vtl:AccruedCompensationCurrent>
    <vtl:AccruedCompensationCurrent contextRef="c-4" decimals="-3" id="f-367" unitRef="usd">890000</vtl:AccruedCompensationCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-368" unitRef="usd">106000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-369" unitRef="usd">120000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-370" unitRef="usd">12613000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-371" unitRef="usd">7986000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="c-1" id="f-374">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other Current Liabilities consist of (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.527%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.752%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.912%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.740%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-375"&gt;&lt;span style="-sec-ix-hidden:f-376"&gt;Lease liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-377" unitRef="usd">671000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-378" unitRef="usd">571000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-379" unitRef="usd">257000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-380" unitRef="usd">239000</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-381" unitRef="usd">928000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-382" unitRef="usd">810000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-383">Commitments and Contingencies&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases certain office space under non-cancelable operating leases. The leases terminate on July 31, 2025 for the New York City office, June 30, 2025 for the Gr&#xe4;felfing, Germany office and November 30, 2028 related to the new lease of a research laboratory in Planegg, Germany. The Company formerly leased office space in Planegg-Martinsried, Germany pursuant to a modified lease that terminated on August 31, 2020. These agreements include both lease (e.g., fixed rent) and non-lease components (e.g., common-area and other maintenance costs). The non-lease components are deemed to be executory costs and are therefore excluded from the minimum lease payments used to determine the present value of the operating lease obligation and related right-of-use asset. The New York City lease was extended on December 22, 2022 for an additional 27 months resulting in the new lease termination date of July 31, 2025. The New York City lease has a renewal option, but this was not included in calculating the right of use asset and liabilities. On April 7, 2020, the Company signed a five year lease for its facility in Gr&#xe4;felfing, Germany. On March 1, 2021 and August 1, 2022 the Company added additional lease space at the Gr&#xe4;felfing, Germany office.  Renewal options were not included in calculating the right of use asset and liabilities for this facility. In February 2023, the Company leased space in Germany for a research laboratory. The leases do not have concessions, leasehold improvement incentives or other build-out clauses. Further, the leases do not contain contingent rent provisions. The New York City lease had a six month rent holiday at the beginning of the lease as well as a three month rent holiday upon the 27 month extension starting May 2023. There were net additions of $544,000 related to the addition of new laboratory space in Planegg, Germany in February 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;The leases do not provide an implicit rate and, due to the lack of a commercially salable product, the Company is generally considered unable to obtain commercial credit. Therefore, the Company estimated its incremental interest rate to be 6% for the original leases and 8% for the New York City extension and German laboratory, considering the quoted rates for the lowest investment-grade debt and the interest rates implicit in recent financing leases. Immunic used its estimated incremental borrowing rate and other information available at the lease commencement date in determining the present value of the lease payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Immunic&#x2019;s operating lease costs and variable lease costs were $238,000 and $136,000  for the three months ended June 30, 2023 and 2022, respectively and $433,000 and $266,000 for the six months ended June 30, 2023 and 2022, respectively. Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of the operating lease obligation are as follows as of June 30, 2023 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.106%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.945%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PV of obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contractual Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2023, the Company has non-cancelable contractual obligations under certain agreements related to its development programs for vidofludimus calcium and IMU-856 totaling approximately $3.4&#160;million, all of which is expected to be paid in the next twelve months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Commitments and Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Daiichi Sankyo Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 5, 2020, the Company exercised its option to obtain the exclusive worldwide right to commercialization of IMU-856. Among other things, the option exercise grants Immunic AG the rights to Daiichi Sankyo&#x2019;s patent application related to IMU-856, for which the Company received a notice of allowance from the U.S. Patent &amp;amp; Trademark Office in August 2022. In connection with the option exercise, the Company paid a one-time upfront licensing fee to Daiichi Sankyo. Under the Daiichi Sankyo Agreement, Daiichi Sankyo is also eligible to receive future development, regulatory and sales milestone payments, as well as royalties related to IMU-856. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is not currently a party to any litigation, nor is it aware of any pending or threatened litigation, that it believes would materially affect its business, operating results, financial condition or cash flows. However, its industry is characterized by frequent claims and litigation including securities litigation, claims regarding patent and other intellectual property rights and claims for product liability. As a result, in the future, the Company may be involved in various legal proceedings from time to time.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-69" id="f-384">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <vtl:LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod contextRef="c-70" id="f-385">P6M</vtl:LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod>
    <vtl:LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod contextRef="c-1" id="f-386">P3M</vtl:LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-71" id="f-387">P27M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <vtl:IncreaseDecreaseInOperatingLeaseRightOfUseAsset contextRef="c-72" decimals="-3" id="f-388" unitRef="usd">544000</vtl:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <vtl:OperatingLeaseIncrementalBorrowingRate contextRef="c-3" decimals="2" id="f-389" unitRef="number">0.06</vtl:OperatingLeaseIncrementalBorrowingRate>
    <vtl:OperatingLeaseIncrementalBorrowingRate contextRef="c-71" decimals="2" id="f-390" unitRef="number">0.08</vtl:OperatingLeaseIncrementalBorrowingRate>
    <vtl:OperatingAndVariableLeasesCost contextRef="c-5" decimals="-3" id="f-391" unitRef="usd">238000</vtl:OperatingAndVariableLeasesCost>
    <vtl:OperatingAndVariableLeasesCost contextRef="c-6" decimals="-3" id="f-392" unitRef="usd">136000</vtl:OperatingAndVariableLeasesCost>
    <vtl:OperatingAndVariableLeasesCost contextRef="c-1" decimals="-3" id="f-393" unitRef="usd">433000</vtl:OperatingAndVariableLeasesCost>
    <vtl:OperatingAndVariableLeasesCost contextRef="c-7" decimals="-3" id="f-394" unitRef="usd">266000</vtl:OperatingAndVariableLeasesCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-395">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of the operating lease obligation are as follows as of June 30, 2023 (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.106%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.945%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;PV of obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-396" unitRef="usd">362000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-3" decimals="-3" id="f-397" unitRef="usd">820000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-3" decimals="-3" id="f-398" unitRef="usd">495000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-3" decimals="-3" id="f-399" unitRef="usd">140000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-3" decimals="-3" id="f-400" unitRef="usd">144000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <vtl:LesseeOperatingLeaseLiabilityPaymentsAfterDueYearFour contextRef="c-3" decimals="-3" id="f-401" unitRef="usd">136000</vtl:LesseeOperatingLeaseLiabilityPaymentsAfterDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-3" decimals="-3" id="f-402" unitRef="usd">2097000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-3" decimals="-3" id="f-403" unitRef="usd">220000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-404" unitRef="usd">1877000</us-gaap:OperatingLeaseLiability>
    <us-gaap:ContractualObligation contextRef="c-3" decimals="-5" id="f-405" unitRef="usd">3400000</us-gaap:ContractualObligation>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-406">Fair Value&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy tables present information about each major category of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at Fair&#160;Value&#160;Measurement&#160;at&#160;December&#160;31,&#160;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between Level&#160;1, Level&#160;2 or Level&#160;3 assets during the periods presented.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the Company&#x2019;s money market funds which are included as a component of cash and cash equivalents on the consolidated balance sheet, realized gains and losses are included in interest income (expense) on the consolidated statements of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our money market fund account is held in our bank in the U.S. and was earning interest at a rate of 5.0% in a U.S. Government money market fund.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has cash balances in banks in excess of the maximum amount insured by the FDIC and other international agencies as of June 30, 2023. The Company has not historically experienced any credit losses with balances in excess of FDIC limits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of other current assets and prepaid expenses, accounts payable, accrued expenses, and other current liabilities approximate their fair values due to their short-term nature. The fair value and book value of the money market funds presented in the table above are the same.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-407">&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following fair value hierarchy tables present information about each major category of the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:50.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.830%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.098%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement at Fair&#160;Value&#160;Measurement&#160;at&#160;December&#160;31,&#160;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level&#160;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-73" decimals="-3" id="f-408" unitRef="usd">62666000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-74" decimals="-3" id="f-409" unitRef="usd">62666000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-75" decimals="-3" id="f-410" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-76" decimals="-3" id="f-411" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-77" decimals="-3" id="f-412" unitRef="usd">62666000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-78" decimals="-3" id="f-413" unitRef="usd">62666000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-79" decimals="-3" id="f-414" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-80" decimals="-3" id="f-415" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-81" decimals="-3" id="f-416" unitRef="usd">85521000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-82" decimals="-3" id="f-417" unitRef="usd">85521000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-83" decimals="-3" id="f-418" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-84" decimals="-3" id="f-419" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-85" decimals="-3" id="f-420" unitRef="usd">85521000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-86" decimals="-3" id="f-421" unitRef="usd">85521000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-87" decimals="-3" id="f-422" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-88" decimals="-3" id="f-423" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:InvestmentInterestRate contextRef="c-58" decimals="3" id="f-424" unitRef="number">0.050</us-gaap:InvestmentInterestRate>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-425">Common Stock&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shelf Registration Statement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, Immunic filed a shelf registration statement on Form S-3. The 2020 Shelf Registration Statement permits the offering, issuance and sale of up to $250.0&#160;million of common stock, preferred stock, warrants, debt securities, and/or units in one or more offerings and in any combination of the foregoing.  As of July 28, 2023, there is $75.0&#160;million remaining on this shelf registration statement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2020, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $50.0&#160;million of common stock that may be issued and sold under an at-the-market sales agreement ("December 2020 ATM") with SVB Leerink LLC (now Leerink Partners) as agent. The Company has used, and intends to continue to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The December 2020 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Leerink LLC on the terms and subject to the conditions set forth in the December 2020 ATM or (ii) termination of the December 2020 ATM as otherwise permitted thereby. The December 2020 ATM may be terminated at any time by either party upon ten days&#x2019; prior notice, or by SVB Leerink LLC at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of July 28, 2023, $8.1&#160;million in capacity remains under the December 2020 ATM.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, the Company filed a Prospectus Supplement for the offering, issuance and sale of up to a maximum aggregate offering price of $80.0&#160;million of common stock that may be issued and sold under another at-the-market sales agreement ("May 2022 ATM") with SVB Leerink LLC as agent. The Company intends to use the net proceeds from the offering to continue to fund the ongoing clinical development of its product candidates and for other general corporate purposes, including funding existing and potential new clinical programs and product candidates. The May 2022 ATM will terminate upon the earlier of (i) the issuance and sale of all of the shares through SVB Securities LLC on the terms and subject to the conditions set forth in the May 2022 ATM or (ii) termination of the May 2022 ATM as otherwise permitted thereby. The May 2022 ATM may be terminated at any time by either party upon ten days&#x2019; prior notice, or by SVB Securities LLC at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.  As of July 28, 2023, $80.0&#160;million in capacity remains under the May 2022 ATM.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;The Company has agreed to pay SVB Securities LLC a commission equal to 3.0% of the gross proceeds from the sales of common shares pursuant to both ATM's and has agreed to provide SVB Securities LLC with customary indemnification and contribution rights.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not have any ATM activity during the three or six months ended June 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the three months ended June 30, 2022, the Company raised gross proceeds of $10.3&#160;million pursuant to the December 2020 ATM through the sale of 1,300,000 shares of common stock at a weighted average price of $7.90 per share. The net proceeds from the December 2020 ATM were $10.0&#160;million after deducting underwriter commissions of $0.3&#160;million.  In the six months ended June 30, 2022, the Company raised gross proceeds of $40.9&#160;million pursuant to the December 2020 ATM through the sale of 4,204,113 shares of common stock at a weighted average price of $9.72 per share. The net proceeds from the December 2020 ATM were $39.6&#160;million after deducting underwriter commissions of $1.2&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Offerings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;$60 Million Private Placement Equity Financing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 10, 2022, Immunic entered into a Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) for a private placement (the &#x201c;Private Placement&#x201d;) with select accredited investors and certain existing investors (each, a &#x201c;Purchaser&#x201d; and collectively, the &#x201c;Purchasers&#x201d;). Pursuant to the Purchase Agreement, the Company agreed to sell to the Purchasers (i) 8,696,552 shares of the Company&#x2019;s common stock, par value $0.0001 per share (the &#x201c;Shares&#x201d;), at a purchase price of $4.35 per Share, and (ii) 5,096,552 pre-funded warrants (the &#x201c;Pre-Funded Warrants&#x201d;) to purchase Common Stock (the &#x201c;Warrant Shares&#x201d; and together with the Shares and the Pre-Funded Warrants, the &#x201c;Securities&#x201d;), at a purchase price of $4.34 per Pre-Funded Warrant.  The Pre-Funded Warrants are classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, do not embody an obligation for the Company to repurchase its shares, and permit the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;holders to receive a fixed number of shares of common stock upon exercise. In addition, the Pre-Funded Warrants do not provide any guarantee of value or return.  All of the pre-funded warrants were exercised in January of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:22.5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-right:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2023, the Company&#x2019;s certificate of incorporation, as amended and restated, authorized the Company to issue 130,000,000 shares of common stock, par value of $0.0001 per share. The voting, dividend and liquidation rights of the holders of the Company&#x2019;s common stock are subject to and qualified by the rights, powers and preferences of any holders of preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-right:4.5pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#x2019;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any. Through June 30, 2023, no cash dividends had been declared or paid.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s certificate of incorporation, as amended and restated, authorizes the Company to issue 20 million shares of $0.0001 par value preferred stock, having rights and preferences to be set by the Board of Directors. No preferred shares were outstanding as of June 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Reserved for Future Issuance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares reserved for future issuance at June 30, 2023 are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock reserved for issuance for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;2021 Employee Stock Purchase Plan    &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,770,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options available for future grant:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2014 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Inducement Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019 Omnibus Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,579,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common shares reserved for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,471,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration contextRef="c-89" decimals="-5" id="f-426" unitRef="usd">250000000</vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration>
    <vtl:ShelfRegistrationStatementAmountRemaining contextRef="c-90" decimals="-5" id="f-427" unitRef="usd">75000000</vtl:ShelfRegistrationStatementAmountRemaining>
    <vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration contextRef="c-91" decimals="-5" id="f-428" unitRef="usd">50000000</vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration>
    <vtl:ShelfRegistrationTerminationPriorWrittenNotice contextRef="c-92" decimals="INF" id="f-429" unitRef="d">10</vtl:ShelfRegistrationTerminationPriorWrittenNotice>
    <vtl:SaleOfStockRemainingCapacity contextRef="c-93" decimals="-5" id="f-430" unitRef="usd">8100000</vtl:SaleOfStockRemainingCapacity>
    <vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration contextRef="c-94" decimals="-5" id="f-431" unitRef="usd">80000000</vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration>
    <vtl:ShelfRegistrationTerminationPriorWrittenNotice contextRef="c-95" decimals="INF" id="f-432" unitRef="d">10</vtl:ShelfRegistrationTerminationPriorWrittenNotice>
    <vtl:SaleOfStockRemainingCapacity contextRef="c-96" decimals="-5" id="f-433" unitRef="usd">80000000</vtl:SaleOfStockRemainingCapacity>
    <vtl:ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock contextRef="c-1" decimals="3" id="f-434" unitRef="number">0.030</vtl:ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-97" decimals="-5" id="f-435" unitRef="usd">10300000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-97"
      decimals="INF"
      id="f-436"
      unitRef="shares">1300000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <vtl:SharesIssuedWeightedAverageSharePricePerShare
      contextRef="c-97"
      decimals="2"
      id="f-437"
      unitRef="usdPerShare">7.90</vtl:SharesIssuedWeightedAverageSharePricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-97" decimals="-5" id="f-438" unitRef="usd">10000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForCommissions contextRef="c-97" decimals="-5" id="f-439" unitRef="usd">300000</us-gaap:PaymentsForCommissions>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-98" decimals="-5" id="f-440" unitRef="usd">40900000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-98"
      decimals="INF"
      id="f-441"
      unitRef="shares">4204113</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <vtl:SharesIssuedWeightedAverageSharePricePerShare
      contextRef="c-98"
      decimals="2"
      id="f-442"
      unitRef="usdPerShare">9.72</vtl:SharesIssuedWeightedAverageSharePricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-98" decimals="-5" id="f-443" unitRef="usd">39600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForCommissions contextRef="c-98" decimals="-5" id="f-444" unitRef="usd">1200000</us-gaap:PaymentsForCommissions>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-99"
      decimals="INF"
      id="f-445"
      unitRef="shares">8696552</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-100"
      decimals="INF"
      id="f-446"
      unitRef="usdPerShare">0.0001</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SharePrice
      contextRef="c-100"
      decimals="INF"
      id="f-447"
      unitRef="usdPerShare">4.35</us-gaap:SharePrice>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-101"
      decimals="INF"
      id="f-448"
      unitRef="shares">5096552</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SharePrice
      contextRef="c-102"
      decimals="INF"
      id="f-449"
      unitRef="usdPerShare">4.34</us-gaap:SharePrice>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-450" unitRef="shares">130000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-451"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <vtl:NumberOfVotesPerEachShareOfCommonStock contextRef="c-3" decimals="INF" id="f-452" unitRef="vote">1</vtl:NumberOfVotesPerEachShareOfCommonStock>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="c-1"
      decimals="INF"
      id="f-453"
      unitRef="usdPerShare">0</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-1"
      decimals="INF"
      id="f-454"
      unitRef="usdPerShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-455" unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-456"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-457" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock contextRef="c-1" id="f-458">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares reserved for future issuance at June 30, 2023 are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:86.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.638%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock reserved for issuance for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;2021 Employee Stock Purchase Plan    &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,770,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options available for future grant:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2014 Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017 Inducement Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019 Omnibus Equity Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,579,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total common shares reserved for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,471,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-103"
      decimals="INF"
      id="f-459"
      unitRef="shares">32358</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-104"
      decimals="INF"
      id="f-460"
      unitRef="shares">5770076</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-105"
      decimals="INF"
      id="f-461"
      unitRef="shares">43311</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-106"
      decimals="INF"
      id="f-462"
      unitRef="shares">46250</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-107"
      decimals="INF"
      id="f-463"
      unitRef="shares">4579753</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c-3" decimals="INF" id="f-464" unitRef="shares">10471748</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-465">Stock-Based Compensation Plans&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2021 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 25, 2021, the Company adopted the 2021 Employee Stock Purchase Plan ("ESPP"), which was approved by stockholder vote at the 2021 Annual Meeting of Stockholders held on June 10, 2021. The ESPP provides eligible employees of the Company with an opportunity to purchase common stock of the Company through accumulated payroll deductions, which are included in other current liabilities until they are used to purchase Company shares. Eligible employees participating in the bi-annual offering period can choose to have up to the lesser of 15% of their annual base earnings or the IRS annual share purchase limit of $25,000 in aggregate market value to purchase shares of the Company&#x2019;s common stock. The purchase price of the stock is the lesser of (i) 85% of the closing market price on the date of purchase and (ii) the closing market price at the beginning of the bi-annual offering period. The maximum number of shares reserved for delivery under the plan is 200,000 shares.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;       &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The first enrollment period under the plan commenced on August 1, 2021 and the Company has issued 167,642  shares life-to-date under the ESPP.  The Company recognized  $37,000 and $83,000 of expense related to the plan during the three and six months ended June 30, 2023, respectively.  The Company recognized $25,000 and  $53,000 of expense related to the plan during the three and six months ended June 30, 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, the Company&#x2019;s stockholders approved the 2019 Omnibus Equity Incentive Plan (the &#x201c;2019 Plan&#x201d;) which was adopted by the Board of Directors (the "Board") with an effective date of June 14, 2019. The 2019 Plan allows for the grant of equity awards to employees, consultants and non-employee directors. An initial maximum of 1,500,000 shares of the Company&#x2019;s common stock were available for grant under the 2019 Plan. The 2019 Plan included an evergreen provision that allowed for the annual addition of up to 4% of the Company&#x2019;s fully-diluted outstanding stock, with a maximum allowable increase of 4,900,000 shares over the term of the 2019 Plan. In accordance with this provision, the shares available for grant were increased in 2020 through 2023 by a total of 4,408,871 shares. At the Company's Annual Shareholders meeting on June 28, 2023, shareholders voted to increase the allowable shares under the 2019 plan by 4,440,000 shares as well as to eliminate the evergreen provision.  The 2019 Plan is currently administered by the Board, or, at the discretion of the Board, by a committee of the Board, which determines the exercise prices, vesting schedules and other restrictions of awards under the 2019 Plan at its discretion. Options to purchase stock may not have an exercise price that is less than the fair market value of underlying shares on the date of grant, and may not have a term greater than ten years. Incentive stock options granted to employees typically vest over four years. Non-statutory options granted to employees, officers, members of the Board, advisors, and consultants of the Company typically vest over &lt;span style="-sec-ix-hidden:f-481"&gt;three&lt;/span&gt; or four years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares that are expired, terminated, surrendered or canceled under the 2019 Plan without having been fully exercised will be available for future awards. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Movements during the year &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for the six months ended June 30, 2023 and 2022, respectively, for the 2019 Plan:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.444%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.307%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.307%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.759%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.421%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,791,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,059,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80,926)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,770,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,170,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,770,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,170,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,184,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.43&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.020%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.561%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.561%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.858%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.561%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,157,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,702,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(145,873)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,713,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,713,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,127,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions used in the BSM option pricing model to determine the fair value of the employee and non-employee stock option grants relating to the 2019 Plan were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-Free Interest Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The risk-free rate assumption is based on U.S. Treasury instruments with maturities similar to the expected term of the stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Dividend Yield&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company has not issued any dividends and does not expect to issue dividends over the life of the options. As a result, the Company has estimated the dividend yield to be zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the Company&#x2019;s limited operating history and a lack of company specific historical and implied volatility data, the Company estimates expected volatility based on the historical volatility of its own stock combined with a group of comparable companies that are publicly traded. The historical volatility data was computed using the daily closing prices for the selected companies&#x2019; shares during the equivalent period of the calculated expected term of the stock-based awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected Term &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected term of options is estimated considering the vesting period at the grant date, the life of the option and the average length of time similar grants have remained outstanding in the past.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of stock options granted under the 2019 Plan during the six months ended June 30, 2023 and 2022 was $1.17 and $7.25, respectively. The following are the underlying assumptions used in the Black-Scholes option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six  Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.93%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.95%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.9%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of options (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense for all stock awards recognized in the accompanying unaudited condensed consolidated statements of operations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.391%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.186%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months&lt;br/&gt;&#160;Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months&lt;br/&gt;&#160;Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;765,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,792,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,561,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;909,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,297,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,985,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,570,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,798,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,062,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,777,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,131,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2023, there was $13.9 million in total unrecognized compensation expense relating to the 2019 Plan to be recognized over a weighted average period of 2.88 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Equity Incentive Plans Assumed from Vital Therapies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon completion of the Transaction with Vital Therapies, Inc. ("Vital") on April 12, 2019, Vital&#x2019;s 2012 Stock Option &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Plan (the &#x201c;2012 Plan&#x201d;), Vital&#x2019;s 2014 Equity Incentive Plan (the &#x201c;2014 Plan&#x201d;) and Vital&#x2019;s 2017 Inducement Equity Incentive Plan (the &#x201c;Inducement Plan&#x201d;), were assumed by the Company. All awards granted under these plans have either been forfeited or expired.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There remain 43,311 shares available for grant under the 2014 Plan as of June 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2017, Vital&#x2019;s board of directors approved the Inducement Plan, which was amended and restated in November 2017. Under the Inducement Plan 46,250 shares of Vital&#x2019;s common stock were reserved to be used exclusively for non-qualified grants to individuals who were not previously employees or directors as an inducement material to a grantee's entry into employment within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No expense was recorded for the plans assumed from Vital during the three and six months ended June 30, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="c-108"
      decimals="INF"
      id="f-466"
      unitRef="number">0.15</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="c-108"
      decimals="INF"
      id="f-467"
      unitRef="number">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-109"
      decimals="INF"
      id="f-468"
      unitRef="shares">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-110"
      decimals="INF"
      id="f-469"
      unitRef="shares">167642</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-111" decimals="-3" id="f-470" unitRef="usd">37000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-112" decimals="-3" id="f-471" unitRef="usd">83000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-113" decimals="-3" id="f-472" unitRef="usd">25000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-114" decimals="-3" id="f-473" unitRef="usd">53000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-115"
      decimals="INF"
      id="f-474"
      unitRef="shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <vtl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent
      contextRef="c-116"
      decimals="INF"
      id="f-475"
      unitRef="number">0.04</vtl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-116"
      decimals="INF"
      id="f-476"
      unitRef="shares">4900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="c-117"
      decimals="INF"
      id="f-477"
      unitRef="shares">4408871</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease
      contextRef="c-118"
      decimals="INF"
      id="f-478"
      unitRef="shares">4440000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-119" id="f-479">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-120" id="f-480">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-122" id="f-482">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-483">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock option activity for the six months ended June 30, 2023 and 2022, respectively, for the 2019 Plan:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.444%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.307%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.307%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.759%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.421%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,791,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,059,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80,926)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,770,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,170,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,770,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,170,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,184,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.43&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:22.5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.052%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.020%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.561%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.561%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.858%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.561%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&#160;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of January 1, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,157,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,702,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(145,873)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,713,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,713,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,127,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.00&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-123"
      decimals="INF"
      id="f-484"
      unitRef="shares">3791688</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-123"
      decimals="2"
      id="f-485"
      unitRef="usdPerShare">11.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-124"
      decimals="INF"
      id="f-486"
      unitRef="shares">2059314</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-124"
      decimals="2"
      id="f-487"
      unitRef="usdPerShare">1.45</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-124"
      decimals="INF"
      id="f-488"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-124"
      decimals="2"
      id="f-489"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c-124"
      decimals="INF"
      id="f-490"
      unitRef="shares">80926</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-124"
      decimals="2"
      id="f-491"
      unitRef="usdPerShare">8.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-125"
      decimals="INF"
      id="f-492"
      unitRef="shares">5770076</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-125"
      decimals="2"
      id="f-493"
      unitRef="usdPerShare">7.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-124" id="f-494">P8Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-125" decimals="0" id="f-495" unitRef="usd">2170958</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c-125"
      decimals="INF"
      id="f-496"
      unitRef="shares">5770076</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-125"
      decimals="2"
      id="f-497"
      unitRef="usdPerShare">7.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-124" id="f-498">P8Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-125" decimals="0" id="f-499" unitRef="usd">2170958</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-125"
      decimals="INF"
      id="f-500"
      unitRef="shares">2184848</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-125"
      decimals="2"
      id="f-501"
      unitRef="usdPerShare">12.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-124" id="f-502">P7Y5M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-125" decimals="0" id="f-503" unitRef="usd">62614</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-126"
      decimals="INF"
      id="f-504"
      unitRef="shares">2157460</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-126"
      decimals="2"
      id="f-505"
      unitRef="usdPerShare">13.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-127"
      decimals="INF"
      id="f-506"
      unitRef="shares">1702513</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-127"
      decimals="2"
      id="f-507"
      unitRef="usdPerShare">9.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-127"
      decimals="INF"
      id="f-508"
      unitRef="shares">852</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-127"
      decimals="2"
      id="f-509"
      unitRef="usdPerShare">5.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c-127"
      decimals="INF"
      id="f-510"
      unitRef="shares">145873</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-127"
      decimals="2"
      id="f-511"
      unitRef="usdPerShare">11.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-128"
      decimals="INF"
      id="f-512"
      unitRef="shares">3713248</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-128"
      decimals="2"
      id="f-513"
      unitRef="usdPerShare">11.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-127" id="f-514">P8Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-128" decimals="0" id="f-515" unitRef="usd">23870</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c-128"
      decimals="INF"
      id="f-516"
      unitRef="shares">3713248</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-128"
      decimals="2"
      id="f-517"
      unitRef="usdPerShare">11.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-127" id="f-518">P8Y10M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-128" decimals="0" id="f-519" unitRef="usd">23870</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-128"
      decimals="INF"
      id="f-520"
      unitRef="shares">1127085</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-128"
      decimals="2"
      id="f-521"
      unitRef="usdPerShare">13.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-127" id="f-522">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-128" decimals="0" id="f-523" unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="INF" id="f-524" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-129"
      decimals="2"
      id="f-525"
      unitRef="usdPerShare">1.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-130"
      decimals="2"
      id="f-526"
      unitRef="usdPerShare">7.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-527">The following are the underlying assumptions used in the Black-Scholes option pricing model to determine the fair value of stock options granted to employees and to non-employees under this stock plan:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.812%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six  Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.93%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.95%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.9%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term of options (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.99&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-129" decimals="4" id="f-528" unitRef="number">0.0393</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-130" decimals="4" id="f-529" unitRef="number">0.0195</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-129"
      decimals="INF"
      id="f-530"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-130"
      decimals="INF"
      id="f-531"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-129" decimals="3" id="f-532" unitRef="number">1.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-130" decimals="3" id="f-533" unitRef="number">0.979</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-129" id="f-534">P5Y11M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-130" id="f-535">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-536">&lt;div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation expense for all stock awards recognized in the accompanying unaudited condensed consolidated statements of operations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.391%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.115%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.408%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.186%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months&lt;br/&gt;&#160;Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Six Months&lt;br/&gt;&#160;Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;765,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,792,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,561,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;909,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,297,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,985,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,570,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,798,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,062,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,777,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,131,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ShareBasedCompensation contextRef="c-131" decimals="-3" id="f-537" unitRef="usd">889000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-132" decimals="-3" id="f-538" unitRef="usd">765000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-133" decimals="-3" id="f-539" unitRef="usd">1792000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-134" decimals="-3" id="f-540" unitRef="usd">1561000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-135" decimals="-3" id="f-541" unitRef="usd">909000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-136" decimals="-3" id="f-542" unitRef="usd">1297000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-137" decimals="-3" id="f-543" unitRef="usd">1985000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-138" decimals="-3" id="f-544" unitRef="usd">2570000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-139" decimals="-3" id="f-545" unitRef="usd">1798000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-140" decimals="-3" id="f-546" unitRef="usd">2062000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-141" decimals="-3" id="f-547" unitRef="usd">3777000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-142" decimals="-3" id="f-548" unitRef="usd">4131000000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-3" decimals="-5" id="f-549" unitRef="usd">13900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-1" id="f-550">P2Y10M17D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-143"
      decimals="INF"
      id="f-551"
      unitRef="shares">43311</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-144"
      decimals="INF"
      id="f-552"
      unitRef="shares">46250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-145" decimals="INF" id="f-553" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-146" decimals="INF" id="f-554" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-147" decimals="INF" id="f-555" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-148" decimals="INF" id="f-556" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c-1" id="f-557">Related Party Transactions&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Executive Chairman Agreement with Duane Nash&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 15, 2020, the compensation committee of the Board of Directors of the Company independently reviewed and approved entering into an employment agreement with the Executive Chairman of the Board, Duane Nash, MD, JD, MBA (the &#x201c;Executive Chairman Agreement&#x201d;) and pursuant to such approval, on April 17, 2020, the Company and Dr. Nash entered into the Executive Chairman Agreement. The Executive Chairman Agreement establishes an &#x201c;at will&#x201d; employment relationship. On December 28, 2022, the Company and Dr. Nash entered into Addendum No. Four, which extended the term of employment from December 31, 2022 to December 31, 2023 with a base salary of $30,250 per month (which includes the cash retainer payable for serving on the Company&#x2019;s Board or for acting as the Chairman of the Board). All other terms of the Executive Chairman Agreement remain the same.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <vtl:SalaryCostsMonthlyBaseSalary contextRef="c-149" decimals="0" id="f-558" unitRef="usd">30250</vtl:SalaryCostsMonthlyBaseSalary>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>60
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    (  <V U<'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  '-@-7!>DK^N\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9++
M3L,P$$5_!7F?C)/PM-)L0*Q 0J(2B)UE3UN+^"%[4-*_)S%M*@0?T*5GKL^<
MD:9502@?\27Z@)$,IHO1]BX)%59L1Q0$0%([M#*54\)-S8V/5M+TC%L(4GW*
M+4+-^358)*DE29B!15B(K&NU$BJB)!\/>*T6?/B*?89I!=BC14<)JK("ULT3
MPW[L6S@!9AAAM.FG@'HAYNJ_V-P!=DB.R2RI81C*H<FY:8<*WI^?7O.ZA7&)
MI%,X_4I&T#[@BATGOS7W#^M'UM6\;@I^6_!F77%Q>2.N[CYFUU]^)V'KM=F8
M,S8^"G8M_+F+[AM02P,$%     @ !S8#5YE<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MM99Q=KG@+.#*? #O9U+J[8WY@>*8OO\?4$L#!!0    (  <V U?DG;GQN 4
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MB:&7G8';UR7$79= A5>7=='<08EC+25*V&P[<W%X8(A7,+86IF1:??AI0L;
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MX7)AFQG<_X@T 3"_$$(_=\P-H[Y1QG\!4$L#!!0    (  <V U>>X:$*PP0
M &<4   8    >&PO=V]R:W-H965T<R]S:&5E=#0N>&ULK5AKC^(V%/TK5KJJ
M9J5A$COO*2#M -MNU6U',[O=SQEB(-HDIK&!Z;_O=9()D-Q$M.4+Y''NL<^Q
M<WWM\4$4W^6&<T5>LS27$V.CU/;>-.5RP[-(WHDMS^'-2A19I."V6)MR6_ H
M+H.RU&26Y9E9E.3&=%P^>RRF8[%3:9+SQX+(799%Q=\//!6'B4&-MP=/R7JC
M] -S.MY&:_[,U=?M8P%W9L,2)QG/92)R4O#5Q/A [Q?4TP$EXL^$'^3)-=%2
M7H3XKF\^Q1/#TCWB*5\J31'!WY[/>)IJ)NC'7S6IT;2I T^OW]@_EN)!S$LD
M^4RDWY)8;29&8)"8KZ)=JI[$X1=>"W(UWU*DLOPEAPKKVP99[J0261T,/<B2
MO/J/7FLC3@* !P]@=0!K!S@] 78=8%_:@E,'.)>VX-8!I72STEX:-X]4-!T7
MXD *C08V?5&Z7T:#7TFN)\JS*N!M G%J.A-Y#,/.8P)74J1)'"FX>5;P!_-!
M22)6Y(\M+R(]KI*,R-?G.;EY]YZ\(TE.OFS$3D9Y+,>F@MYH3G-9M_Q0M<QZ
M6K;)9Y&KC20+Z$&,Q,^'X[V!>!-<:*Q@;U8\L$'"7W?Y';&M6\(L9B/]F5T>
MSC Y_Z_UQ7]N_<P,NYD7=LEG]_#50YZO"7_=Z@DB[[$AKD@<G$0GN7NYC99\
M8D 6D[S8<V/ZXP_4LW["_+TFV?R:9(LKD9V-A-.,A#/$/GT"QJA8;@A\9I "
M]Y#;M_K+Q(:C8O)*)KU$[*>,4A_FP_[4YRZ*>JX=G*/F793C4-L]1RVZ*-L.
M [M!G4EV&\GNH.2?>0ZS+RT51S%DO40J/1OW'!-=<;FG70B<L*6Y"W*LMC'S
M+BB@MM]2C( LC^&"O4:P-RCXBU @5W2^.4RNUVF?N1:C+;T(RO*HU1+<1;F,
MM6U9=%$.LQP7E^PWDOU!R;\)*<FJ$-F;;%A=,+E^I_$1IA>#(8(1&*88@0U(
M#AK)P7!.51M>P*JY%!DG-_48OT?S:G#-O'I-LODUR197(CL;C; 9C7!P G[*
M%0=650\(-@IA9QJ$7BM-SKH8:GFM68=@_#;1 @'1GCQ*K6-U9PV*Q*?<+<DY
MNG[4;&<)P6D)1C C:H>M-#E'8)39=DLT1N;[?H_LDZ*67I)/4?&H;HJ,(FNO
MFPAJ1%E(V\J[,-NR:%LY0N9Y3H]R=E3.!I7_#GO+%%(KJI)U%NL1L\.PO5:B
M.!JV)<PQG!,ROR,5PS'?"GO$'FM4.EAX-6()K"!$;J*"W^I=8[(D-[ WT1N5
MY@4^[!5]<-HQZZX[XU%8IWK 8/2.MM<6'.;TF7$L$^EPG8B9$2?I3F_G+K3#
MN<P.%-:U X%A=J"P7CN.)20=KB&_E4<$/!Y%>R@OUIQ %LA$7LF'7>U.207U
M)51;IW.F>HN[@Y20CF.ST'7;!B$5J<6<P/<Z21+CM&S/=CLV=9$L\ (O/"EQ
MSITZUIYTN/C\-TZ=3J@AKY"2L<>K+K+/*XP3]PHI?G&OS).#DXP7Z_+$2H(!
MNUQ5>^7F:7,J]J$\"VH]?Z#W,XH\G^M3M/*@YDA?'<%]CHIUDDN2\A4T!=\/
M=+>H3K6J&R6VY;'-BU!*9.7EAD<Q+S0 WJ^$4&\WNH'F;''Z#U!+ P04
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MOW=WL/5GWFK?=O7V4%C68%M4]S^S3X>&."E V ,%Z*$ '5N '0HPHP"-'BC
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M(5="!'<+$9..L\-MAJH2<%LE>"BQ0)4)4-$$%II.JI()N%LF.'N<'282.!<
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MIR\HFX#?EU*:76 /:.=Y\A=02P,$%     @ !S8#5S_E"Z!F!@  5!H  !@
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M=$XK)XIHN(5WDL'252X:%#_(FB&Y4 1R4+9<5"1"F%@CT$CH4H*^[8;0#@I
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MD(IQ&6,5-Y/MIO3#[/!P=(@!MZH8:XSHGXFZN_F.3?QAMG\TFCU9]DEEJE[
MJ=D^+YV.Q#QB:I,=.U"#PKHVULC9,^<2\"G<%#CUB"-/\KF-!OQ#(9CV)-'W
M:IJ%I",6,?E."/ 'EIGRE #9-=">7SUEW'N+%),1O?SU&+!NU&0<(0309?.V
M:JZWG-3@,R878OSG#A?M2(7_\$$Q!HI(;9F"B@S!P$#6^+8.:"R.RC^KDK9L
M.ZS!BESG_3Z4'+XIYREX%;"7@7%P]B/K97XO&46T?6,Z>RYJA_.E#)L16COV
M &@(M/,L1&HU&\$!$#@3[1!&O:[]R:82KND=XSN/3"Q!UQR]XH7Z_DSRUE4
M*K!Q66[C=KA5XTYJFBJ-(O]\N:L0#@XV"J$M9'U/SI"935R@S6%?:NUI+L)!
M5C%..\["3G33[-M(7#ROI.$F@\&J/)G">^F' FF!.WF&>&[?T48!CL1O!-7
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MSRB>CGADXE'2$CF 5_0J<JMV.$5C*G@%R=B8PMV:AK=-;%XY5^YL54U4 <(
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MGHG5%XE%IUN*'D9YH>/J@@&[-+4#=R;HA;R$;.4M :#71R6/C[]$SP[WY14
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MDXEHUQN]1R)WGAD@),EF?:D^X$!U1M[E_-5_=0YAECA)TL39-:$S.]!@FH$
MZ 6+ X_6-?GOLS!E^%GT [W2Y:'N)Z><]<ZK+<=QINQCX5J7$)?$R?.(X9X9
M^/6Y'.\]TR9S13,._-D[>Y@S"FL4RXDREB8H02 *!&<D2AW^>B7X#NYVU95C
MTWJ0!(JHQL@W0G24G\-9$AL>,F68*WJJ&.+Q.O>0>7YDPF\2_%P(_F5$Q%';
M82S*'\=(&P/P"(;<K?9I?WGR1$;D&AVP-BELS 0=R./1XYW__X_WF3S=IJ%L
M3%SXJ$&>!!O!ACP/><EC!_ +@<PDH;A$$?2DZ4SOG;H<3-D+G7,7/:--V9E
M1+\&-S_8.*0BVA&",O9Q9^JZ<?!SRR8"??<M4;SWV,3'8 8HI"4OH7 >W"*P
M7: *EIEK/86A';Z1 A-T(S&O/L6$I0B XG24P'?(!)4*Y0<-2V4Q%R6,#TD_
MB5(HN)$\$L+A>^"V;8*D?,#8[0.9H4MF0"X2'(V!EJ0Q$O[!5BCLJVBH\([
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;*U8;6_;.!+^*X2;+;:
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MB>1P@ JW7L##65O7^!UPI&[3 C5/9]L)<A4/:7:ZP@/"$)9YG&R2@!PEE<I
M<M%W 85';.JEMZF7HS;U(QP=EOD.]EBBW P9S_]L!C*(+/;,)OCQE @?F3S/
M-^&F)7K<B"6!(X-^JB13H.,P7/DU411 J=MR)^*W38$9ZS7R!&=@NX Z4'KK
MAT:@ ?D'Z[72A6[(SJF['?)<C!6,S+7-"F/;FDX)&T9FHEWAX?1<-(-CH6P9
ME6G^Y(7]O B1'":EL0W8L@!)PA%/3#Q(6B)';&R<BH &*B0CB*"Y!?M VR8<
MM#$FW^NBF"09<!@6+\!6X[0=BM@M".$4 6%.:@6_B)%^YP45+'JAU:T8ZG
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M3 <_K>T6,72R#L?;:D !=;8]\(%\S@ V!#/B[BAC &82 " MV'*RPJPPR2N
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M;,?3*$K*1;ER@EKDUDX>B*"TU'D9"CBF]38WH3HO]D"%R018X&]2?08T#^H
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MI=:":]QK]O@V3;0""KVIBH-+/6..#*M!5!#B_&@A30E2TCN>):',^8KJ/X
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M8L+%<NV(;C?>UG$L;JSG(1N7)7_5T(4+?+ZU7*IN$QSTW\G%3U!+ P04
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M$Y93&^LI?&^J%2J0:^@K2+<5](9T8"-C:FD"N*YJ+E\1^X);-"HKJ*=@P9F
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M)-VU)9ZOOX?O2^6,-& 55+7."BIDR%19DKE4,MG=+L=>9'3=XL14+,-)0.W
MH%YCD+Y]TQM&'W;)?26R)^+[G?B^9T_VB)]2W>4[2N[\OBVWI58ES%19U;8K
MN'.F)96S@7E7:#\NB1@N+);FYR[#^J]IV"N1/3%LT!DV^*]J@0/WA3;?VN$N
M)QKZ@:=W[\(Z'8Q&430:CL/UMLB_XY)1+XG[QUU<DW^XU;!*U"O?QPWXGM-\
MD]UJ]U1,?8=\MGY*3TC3\?_0-._/%=,K3IH%+HDR.AI15KKIZ<W$JLJWQ5ME
MJ<GZ84'/(&H70/M+11VNG;@#NH<U_0U02P,$%     @ !S8#5UI[;[<" P
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MG VQ(M5^8MJ-D;6;T@MI<.:[98E?95 V .\OI31/&SOXN^]\]A=02P,$%
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MS/&Y F4=<'TII7F9V([8/H#)7U!+ P04    "  '-@-7-O\2A]@"  #1!P
M&0   'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6RME5UOVC 4AO^*E553)W7-
M!Y#0#B*U=-4V:1HJ[78Q[<(D!V+5L3/;@6Z_?L=)B/@(%1>[(;%]WN/GO)S8
MH[54SSH#,.0EYT*/G<R8XMIU=9)!3O6E+$#@RD*JG!H<JJ6K"P4TK40Y=P//
M"]V<,N'$HVINJN*1+ UG J:*Z#+/J?IS"URNQX[O;"8>V#(S=L*-1P5=P@S,
M4S%5.'+;+"G+06@F!5&P&#LW_O4DLO%5P'<&:[WU3FPE<RF?[>!S.G8\"P0<
M$F,S4'RL8 *<VT2(\;O)Z;1;6N'V^R;[?54[UC*G&B:2_V"IR<;.T"$I+&C)
MS8-<?X*FGH'-ETBNJU^R;F(]AR2E-C)OQ$B0,U$_Z4OCPY; [Q\1!(T@.%70
M:P2]JM":K"KKCAH:CY1<$V6C,9M]J;RIU%@-$_9?G!F%JPQU)KZEG(H$R*QJ
MF3LPE'%-WI,9MDM:<B!R06Z21)60DH\OV#L:-#FOX]YAW-/LCIR?O2-GA GR
MF,E24Y'JD6N0S>[@)@W';<T1'.'X4HI+TO,N2. %O0[YY'7Y'20H]RMYL"MW
MT9'6EJ"U):CR]8[D^Z:65+"_U+;:!9E(H25G*:T[3Z1DJD"#,/4$6G3/!-K(
M*"<SG 1L<Z/)SYNY-@H;]5>7'S5 OQO ?KS7NJ )C)W"[J56X,1OW_BA]Z'+
MG?^4;,>K7NM5[[7L\:8]$EQ@"5I@#5+ T0><E-ITMD.=,ZQRVJ-F%?M^& Y'
M[FJ[KL.H<.A%;= .;[_E[9_$RV'9P-(R9>8X:IUNL(UJ>W0'M",FO.KF'+2<
M@]-\E;G][JI>Z\(;'&P=^>$>WF',\,KKQ@M;O/ D/&DR4%U<X:$EWCY71TQP
MA"MJN:)7N1ZEH;R+)SKLN"#T]__(PZCH:ACN(;E;!ZZ][+Y2M61"8TLM4.9=
M1EB1JB^0>F!D49W!<VGP1*]>,[QS0=D 7%](:38#>ZRWMWC\#U!+ P04
M"  '-@-7T,KOP-,"  ""!P  &0   'AL+W=O<FMS:&5E=',O<VAE970S,BYX
M;6RM55U/VS 4_2M6AB8F=21-/_A8&PE:T#8Q45'8'M >W.2VL7#LS'9:V*_?
MM9.&%M)JD_:2V,X]Q^>>7%\/5E(]ZA3 D*>,"SWT4F/R,]_7<0H9U4<R!X%?
MYE)EU.!4+7R=*Z") V7<#X.@[V>4"2\:N+6)B@:R,)P)F"BBBRRCZOD"N%P-
MO;:W7KAEB]38!3\:Y'0!4S#W^43AS*]9$I:!T$P*HF ^],[;9Z.^C7<!WQFL
M],:8V$QF4C[:R9=DZ 56$'"(C66@^%K""#BW1"CC5\7IU5M:X.9XS7[E<L=<
M9E3#2/(?+#'IT#OQ2 )S6G!S*U>?H<JG9_EBR;5[DE45&W@D+K21605&!1D3
MY9L^53YL -K='8"P H1_"^A4@(Y+M%3FTAI30Z.!DBNB;#2RV8'SQJ$Q&R;L
M7YP:A5\9XDQT03D5,9"I*YDQ&,JX)A_)%,LE*3@0.2<W)@5%1H52( RY9G3&
M.#,,-#DL 1\0<#\=D\.##^2 ,$'N4EEH*A(]\ V*M%OY<27HHA04[A#TM1!'
MI!.T2!B$G0;X:#]\##'"VPX>;L-]M*;V)ZS]"1U?9P??C5I0P7Y36W,M,I)"
M2\X26I:@2,A$@497R@7TZHH)])-13J:X"%CO1I.'\YDV"BOV9Y,?I8!NLP![
MBL]T3F,8>KG=2RW!B]Z_:_>#3TWN_">R+:\ZM5>=?>S1->!Y(ORE/IJR+2GZ
MCL*VF&74/VX/_.5F$F]C>ALQ6]JZM;;N7FVNAIOTE+#>QEYA[_B5GH:8SFFS
MGEZMI[=7SYTTE#?IZ;W)_30\>:7G;<Q).VC6TZ_U]/?[DX/"(A8+XOYBJS[F
MSZWUR6^]E/1VI4^D9J[^'RZ?C&WP,^P;EZ+('*44C56_7\XN>T;_#"O=\#<Z
MI+V=OE&U8$(3#G,D"HZ.T5)5=OQR8F3NFN9,&FS!;ICB)0G*!N#WN91F/;%]
MN+YVHS]02P,$%     @ !S8#5UG2&_I&!0  L2<  !D   !X;"]W;W)K<VAE
M971S+W-H965T,S,N>&ULM9IM3^LV%,>_BI5=35P)FJ<^P4HE:![&Q-T0[&Z:
MIKUP&[>U2.+.=BE\^]E)2)L23"O.WM F]?D=Q_]_<]*#1QO&'\62$(F>LS07
ME]92RM6%;8O9DF18=-B*Y.J3.>,9ENJ0+VRQX@0G15"6VI[C].T,T]P:CXIS
M=WP\8FN9TIS<<23668;YRS5)V>;2<JW7$_=TL93ZA#T>K?""/!#Y?77'U9%=
M4Q*:D5Q0EB-.YI?6E7L1NT,=4(SX@Y*-V'F/]*5,&7O4!S?)I>7H&9&4S*1&
M8/7R1"8D335)S>/?"FK5.77@[OM7>E1<O+J8*19DPM(_:2*7E];00@F9XW4J
M[]GF9U)=4$_S9BP5Q5^TJ<8Z%IJMA619%:QFD-&\?,7/U4+L!"A.>X!7!7B'
M!OA5@+\?T'TGH%L%= _-T*L">H=FZ%<!_4,#!E7 H!"K7-U"F@!+/!YQMD%<
MCU8T_:;0MXA6BM!<6_%!<O4I57%R/&%91J7REA0(YPF:L%S2?$'R&24"G:&K
M)*':,SA%-WGI?.V@DX!(3%/Q50WY_A"@DR]?T1=$<_3[DJV% HF1+=7T=!)[
M5DWENIR*]\Y47/1-)5\*%.8)25KB)^9X_Z/XT!S?-\3;:EGKM?5>U_;:,P(C
M,NT@;WB*/,?SVZ[''/[+.N\@WWDW/#@\W&M;C<]ECSZ7/3:'7ZUX!SF#(MPQ
M2.'7-O<+GO\.[Y8)L>?MOV_5&'0C22;^:3-K">RV W6%N! K/".7EBH!@O G
M8HU__,'M.S^U*0T)"R!A(20L@H3%0+"&7[JU7[HF^OB6"$'(*5(EGV-M&I02
M5?!.$7F61-\>5!G.)5JRE";X!:E1E+7=<JZ-:8YU$20L@(2%YM7T45;<6=LL
M SF-& C6L$ROMDS/>)$W^8P374A5J9PRKJ*U;91["%(%<\](K>71R#_6*R7,
M=0J:?B!]&CL=IS^RGW9- )DR/"AE!)DR!H(U!._7@O>-@O]62ZH?G)XPIWB:
MDE)?-&-"MHIL9!XK<@GK[RRXYP_W)'X[QO7W- G?CNGZ_IYN+;GZ>YP8Z.(:
M<@QJ.09&.71UY^J7S5I]_]@TI8OB2;5- B/G6 D&;Y;%[SK.G@:0&<-#,D:0
M&6,@6$/682WKT"AKS/&<I'/U-3M%,5&_/_*7-DV-D&,UA80%D+ 0$A9!PF(@
M6,,CY[5'SJ&?[L\A_0()"R!A(20L@H3%0+"&7UQGV_5P/GB^UT5:JOL).J$Y
M>B&8BZ^M+0LCYUBC@-("4%H(2HM :?$':O9* 4W.V.F'N4;6KV2#_F+\$4VH
M;*TTYOBC'0%)"T!I(2@M J7%4+2F2[RM2SSHBE,1H7P#20M :2$H+0*EQ5"T
MIF^V;4C7V+4:WQ_6-3)3CO8*:/<1E!9^L%Y]0^<(="(Q%*UIC&V_T36WR)0Q
MR$;_<ET5_U\IK5$\FY0+T/YP MI=_&"&WN!]+0+0F82?F$D$.I,8BM9TQ;:E
MZ/[?/45S@J,MTM[BVV\Y@28-#TL:@2:-H6A-X;>M1=?<6[Q+<4X6YI:'&7&T
MM)"T )06@M(B4%H,16L:9=OT= ?@#Z*@_4]06@!*"T%I$2@MAJ(U?;/MJKKF
MMFI1670/A+ZI(Z>(Z_T[9VQ^ME8#L!!$MOIH^*81W>MVFW?EB7D:1]L#M)D*
M2HM :3$4K;2'O;-!*"-\4>S]$FC&UKDL-U'49^O]95?%KJJ]\Q/W(G!;SH?N
M153N'MOBR\ULWS!?T%PH:\U5*J<S4(65E_O#R@/)5L7VI"F3DF7%VR7!">%Z
M@/I\SIA\/= )ZEUZX_\ 4$L#!!0    (  <V U=GP&\ZLP(  ,P'   9
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M<,-/%;J0P.LK:^DI"-=G>/R*/U!+ P04    "  '-@-7ID:^T?8'  !640
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M!4A8B(1%()@FOUDCOYGY6KA_%NSW?=&+>R_J?Y_0C(1+A8:$N4B8AX3Y2%B
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M]NHOP_Q+\F:SZ@7U"V^2A%GY?_)6;=OKD,DRRY.H:LSW( KB];_^]^H'L=-
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M_I &+\LBE1E9\ DIV[PI7O@9\8N')CR.3=<0'J0]M0T?$C.N&P[-KY2^> Q
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M[4FK5EOM[6<'G 05<-8V2?OOSP8""1B'Z'+]T&"8&3_/V)X9SVQ'V1M?$R+
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M;U@+ZCJ^3 GC?V%3VT8!9"MC55&#R8."R^J?/=:!V $DZ2N I 8DSP#QV2N
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M&@G9I$4'LIAP<E MMBWAG&1J& ..@$J >+XCA#],Y 95'WC^'5!+ P04
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M7OWU_Z9VC6M5-D=_UOW4FW\"4$L! A0#%     @ !S8#5P=!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M"  '-@-7!>DK^N\    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    "  '-@-7F5R<(Q &  "<)P  $P
M    @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (  <V U==
M*5<,Y 4  +(?   8              " @0X(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    "  '-@-7Y)VY\;@%  #3%P  &
M    @($H#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @
M!S8#5W6%KY,  P  70H  !@              ("!%A0  'AL+W=O<FMS:&5E
M=',O<VAE970S+GAM;%!+ 0(4 Q0    (  <V U>>X:$*PP0  &<4   8
M          " @4P7  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M    "  '-@-7!60];#(#  !D"P  &               @(%%'   >&PO=V]R
M:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ !S8#5VXQ0OZL"@  %6(
M !@              ("!K1\  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+
M 0(4 Q0    (  <V U?Q,/@L>0(  -L%   8              " @8\J  !X
M;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  '-@-7/^4+H&8&
M  !4&@  &               @($^+0  >&PO=V]R:W-H965T<R]S:&5E=#@N
M>&UL4$L! A0#%     @ !S8#5Z2L@;$J"0  4Q8  !@              ("!
MVC,  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    (  <V U>]
M8V A?!T  $)8   9              " @3H]  !X;"]W;W)K<VAE971S+W-H
M965T,3 N>&UL4$L! A0#%     @ !S8#5Z3*#LV# P  GP@  !D
M     ("![5H  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  <V U>]3M[ AP,  &D(   9              "
M@0^%  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ !S8#
M5U^2[+;Y 0  H00  !D              ("!S8@  'AL+W=O<FMS:&5E=',O
M<VAE970Q-RYX;6Q02P$"% ,4    "  '-@-7'ZH0IOD<  !370  &0
M        @(']B@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0
M   (  <V U<.=0%M) ,  #,'   9              " @2VH  !X;"]W;W)K
M<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ !S8#5]+"$XZN P  M@D
M !D              ("!B*L  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q0
M2P$"% ,4    "  '-@-70K7&X)8"  "V!0  &0              @(%MKP
M>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (  <V U<;,!-Z
M]@(  &,'   9              " @3JR  !X;"]W;W)K<VAE971S+W-H965T
M,C(N>&UL4$L! A0#%     @ !S8#5^.WF>/- @  608  !D
M ("!9[4  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  '
M-@-7"4N]1D(%   !#0  &0              @(%KN   >&PO=V]R:W-H965T
M<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (  <V U>E>B%/+0,   $)   9
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M970R.2YX;6Q02P$"% ,4    "  '-@-7S^D*O+,"   ,!P  &0
M    @(%#TP  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (
M  <V U<V_Q*'V (  -$'   9              " @2W6  !X;"]W;W)K<VAE
M971S+W-H965T,S$N>&UL4$L! A0#%     @ !S8#5]#*[\#3 @  @@<  !D
M             ("!/-D  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"
M% ,4    "  '-@-76=(;^D8%  "Q)P  &0              @(%&W   >&PO
M=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (  <V U=GP&\ZLP(
M ,P'   9              " @</A  !X;"]W;W)K<VAE971S+W-H965T,S0N
M>&UL4$L! A0#%     @ !S8#5PLG+/'A P  \!8  !D              ("!
MK>0  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  '-@-7
MKI0^V4D"   (!0  &0              @('%Z   >&PO=V]R:W-H965T<R]S
M:&5E=#,V+GAM;%!+ 0(4 Q0    (  <V U>F1K[1]@<  %91   9
M      " @47K  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%
M  @ !S8#5P[&>6B^ @  B@@  !D              ("!<O,  'AL+W=O<FMS
M:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  '-@-7GO)58.H"   R"0
M&0              @(%G]@  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+
M 0(4 Q0    (  <V U=W&KV^; (  (<&   9              " @8CY  !X
M;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ !S8#5TM+$&Q6
M P  (P\  !D              ("!*_P  'AL+W=O<FMS:&5E=',O<VAE970T
M,2YX;6Q02P$"% ,4    "  '-@-7PEK48GD+  "-DP  &0
M@(&X_P  >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    (  <V
M U?5#K;8/04  &P7   9              " @6@+ 0!X;"]W;W)K<VAE971S
M+W-H965T-#,N>&UL4$L! A0#%     @ !S8#5SFEUG:* P  @ L  !D
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M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  '-@-7EXJ[',     3 @  "P
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52P4&     #8 -@"Q#@  O"<!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>149</ContextCount>
  <ElementCount>239</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>43</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Condensed Consolidated Statements of Stockholders??? Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders??? Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Condensed Consolidated Statement of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows</Role>
      <ShortName>Condensed Consolidated Statement of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Description of Business and Basis of Financial Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements</Role>
      <ShortName>Description of Business and Basis of Financial Statements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Balance Sheet Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetails</Role>
      <ShortName>Balance Sheet Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/FairValue</Role>
      <ShortName>Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Stock-Based Compensation Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlans</Role>
      <ShortName>Stock-Based Compensation Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9954701 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9954702 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9954703 - Disclosure - Balance Sheet Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetailsTables</Role>
      <ShortName>Balance Sheet Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/BalanceSheetDetails</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9954704 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/CommitmentsandContingencies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9954705 - Disclosure - Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/FairValueTables</Role>
      <ShortName>Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/FairValue</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954706 - Disclosure - Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockTables</Role>
      <ShortName>Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/CommonStock</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954707 - Disclosure - Stock-Based Compensation Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlansTables</Role>
      <ShortName>Stock-Based Compensation Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/StockBasedCompensationPlans</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954708 - Disclosure - Description of Business and Basis of Financial Statements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails</Role>
      <ShortName>Description of Business and Basis of Financial Statements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954709 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954710 - Disclosure - Summary of Significant Accounting Policies - Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954711 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954712 - Disclosure - Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail</Role>
      <ShortName>Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954713 - Disclosure - Balance Sheet Details - Schedule of Accounts Payable (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail</Role>
      <ShortName>Balance Sheet Details - Schedule of Accounts Payable (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954714 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail</Role>
      <ShortName>Balance Sheet Details - Schedule of Accrued Expenses (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954715 - Disclosure - Balance Sheet Details - Schedule of Other Current Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail</Role>
      <ShortName>Balance Sheet Details - Schedule of Other Current Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954716 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954717 - Disclosure - Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails</Role>
      <ShortName>Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954718 - Disclosure - Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954719 - Disclosure - Fair Value - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/FairValueAdditionalInformationDetail</Role>
      <ShortName>Fair Value - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954720 - Disclosure - Common Stock - Shelf Registration Statement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails</Role>
      <ShortName>Common Stock - Shelf Registration Statement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954721 - Disclosure - Common Stock - Equity Offering (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockEquityOfferingDetails</Role>
      <ShortName>Common Stock - Equity Offering (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954722 - Disclosure - Common Stock - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockCommonStockDetails</Role>
      <ShortName>Common Stock - Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954723 - Disclosure - Common Stock - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockPreferredStockDetails</Role>
      <ShortName>Common Stock - Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954724 - Disclosure - Common Stock - Shares Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails</Role>
      <ShortName>Common Stock - Shares Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954725 - Disclosure - Stock-Based Compensation Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954726 - Disclosure - Stock-Based Compensation Plans - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation Plans - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954727 - Disclosure - Stock-Based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail</Role>
      <ShortName>Stock-Based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954728 - Disclosure - Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails</Role>
      <ShortName>Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="vtl-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954729 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:PropertyPlantAndEquipmentUsefulLife, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:SubsequentEventsTextBlock -  vtl-20230630.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="vtl-20230630.htm">vtl-20230630.htm</File>
    <File>exhibit23120231.htm</File>
    <File>imux-63023xexhibit311.htm</File>
    <File>imux-63023xexhibit322.htm</File>
    <File>imux-6x3023xexhibit312.htm</File>
    <File>imux-6x30x23xexhibit321.htm</File>
    <File>vtl-20230630.xsd</File>
    <File>vtl-20230630_cal.xml</File>
    <File>vtl-20230630_def.xml</File>
    <File>vtl-20230630_lab.xml</File>
    <File>vtl-20230630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>vtl-20230630_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="484">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="31">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>66
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "vtl-20230630.htm": {
   "axisCustom": 0,
   "axisStandard": 18,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 484,
    "http://xbrl.sec.gov/dei/2023": 31
   },
   "contextCount": 149,
   "dts": {
    "calculationLink": {
     "local": [
      "vtl-20230630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "vtl-20230630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "vtl-20230630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "vtl-20230630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vtl-20230630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "vtl-20230630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 371,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2023": 9,
    "http://xbrl.sec.gov/dei/2023": 5,
    "total": 14
   },
   "keyCustom": 28,
   "keyStandard": 211,
   "memberCustom": 19,
   "memberStandard": 23,
   "nsprefix": "vtl",
   "nsuri": "http://vitaltherapies.com/20230630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://vitaltherapies.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Balance Sheet Details",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://vitaltherapies.com/role/BalanceSheetDetails",
     "shortName": "Balance Sheet Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://vitaltherapies.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Fair Value",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://vitaltherapies.com/role/FairValue",
     "shortName": "Fair Value",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Common Stock",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://vitaltherapies.com/role/CommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Stock-Based Compensation Plans",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlans",
     "shortName": "Stock-Based Compensation Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Related Party Transactions",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://vitaltherapies.com/role/RelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://vitaltherapies.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954701 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "18",
     "role": "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954702 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "19",
     "role": "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954703 - Disclosure - Balance Sheet Details (Tables)",
     "menuCat": "Tables",
     "order": "20",
     "role": "http://vitaltherapies.com/role/BalanceSheetDetailsTables",
     "shortName": "Balance Sheet Details (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954704 - Disclosure - Commitments and Contingencies (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://vitaltherapies.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954705 - Disclosure - Fair Value (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://vitaltherapies.com/role/FairValueTables",
     "shortName": "Fair Value (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954706 - Disclosure - Common Stock (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://vitaltherapies.com/role/CommonStockTables",
     "shortName": "Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954707 - Disclosure - Stock-Based Compensation Plans (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlansTables",
     "shortName": "Stock-Based Compensation Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-3",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityNumberOfEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954708 - Disclosure - Description of Business and Basis of Financial Statements (Details)",
     "menuCat": "Details",
     "order": "25",
     "role": "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails",
     "shortName": "Description of Business and Basis of Financial Statements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-3",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityNumberOfEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954709 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "26",
     "role": "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-5",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherShortTermInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954710 - Disclosure - Summary of Significant Accounting Policies - Investments (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails",
     "shortName": "Summary of Significant Accounting Policies - Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-61",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-67",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954711 - Disclosure - Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-67",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vtl:PrepaidClinicalAndRelatedCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954712 - Disclosure - Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail",
     "shortName": "Balance Sheet Details - Schedule of Other Current Assets and Prepaid Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vtl:PrepaidClinicalAndRelatedCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-3",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesIssued",
       "us-gaap:PreferredStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-3",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vtl:ClinicalCostsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954713 - Disclosure - Balance Sheet Details - Schedule of Accounts Payable (Detail)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail",
     "shortName": "Balance Sheet Details - Schedule of Accounts Payable (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vtl:ClinicalCostsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vtl:AccruedClinicalCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954714 - Disclosure - Balance Sheet Details - Schedule of Accrued Expenses (Detail)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail",
     "shortName": "Balance Sheet Details - Schedule of Accrued Expenses (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "vtl:AccruedClinicalCostsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954715 - Disclosure - Balance Sheet Details - Schedule of Other Current Liabilities (Detail)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail",
     "shortName": "Balance Sheet Details - Schedule of Other Current Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vtl:LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954716 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vtl:LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954717 - Disclosure - Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails",
     "shortName": "Commitments and Contingencies - Maturities of Operating Lease Obligation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-3",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-77",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954718 - Disclosure - Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "Fair Value - Schedule of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-77",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "vtl:CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-58",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentInterestRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954719 - Disclosure - Fair Value - Additional Information (Detail)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
     "shortName": "Fair Value - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-89",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954720 - Disclosure - Common Stock - Shelf Registration Statement (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
     "shortName": "Common Stock - Shelf Registration Statement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-89",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "vtl:MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-99",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954721 - Disclosure - Common Stock - Equity Offering (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
     "shortName": "Common Stock - Equity Offering (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-99",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-3",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954722 - Disclosure - Common Stock - Common Stock (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://vitaltherapies.com/role/CommonStockCommonStockDetails",
     "shortName": "Common Stock - Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-3",
      "decimals": "INF",
      "lang": "en-US",
      "name": "vtl:NumberOfVotesPerEachShareOfCommonStock",
      "reportCount": 1,
      "unique": true,
      "unitRef": "vote",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-5",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-5",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-3",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954723 - Disclosure - Common Stock - Preferred Stock (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://vitaltherapies.com/role/CommonStockPreferredStockDetails",
     "shortName": "Common Stock - Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-3",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954724 - Disclosure - Common Stock - Shares Reserved for Future Issuance (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
     "shortName": "Common Stock - Shares Reserved for Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "vtl:ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-3",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954725 - Disclosure - Stock-Based Compensation Plans - Additional Information (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation Plans - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-123",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954726 - Disclosure - Stock-Based Compensation Plans - Summary of Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation Plans - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-123",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954727 - Disclosure - Stock-Based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail",
     "shortName": "Stock-Based Compensation Plans - Ranges of Underlying Assumptions Used in BSM Option Pricing Model to Determine Fair Value of Stock Options Granted to Employees and Nonemployees (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-129",
      "decimals": "4",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954728 - Disclosure - Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails",
     "shortName": "Stock-Based Compensation Plans - Schedule of Stock-based Compensation Expense for Stock Awards Recognized (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-139",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-149",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "vtl:SalaryCostsMonthlyBaseSalary",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954729 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-149",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "vtl:SalaryCostsMonthlyBaseSalary",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-5",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Comprehensive Loss",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-5",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-30",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-35",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-6",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Condensed Consolidated Statements of Stockholders\u2019 Equity (Parenthetical)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical",
     "shortName": "Condensed Consolidated Statements of Stockholders\u2019 Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-6",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Condensed Consolidated Statement of Cash Flows",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows",
     "shortName": "Condensed Consolidated Statement of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Description of Business and Basis of Financial Statements",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements",
     "shortName": "Description of Business and Basis of Financial Statements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vtl-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 43,
   "tag": {
    "country_AU": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AUSTRALIA",
        "terseLabel": "Australia"
       }
      }
     },
     "localname": "AU",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_DE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GERMANY",
        "terseLabel": "Germany"
       }
      }
     },
     "localname": "DE",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityNumberOfEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of persons employed by the Entity",
        "label": "Entity Number of Employees",
        "terseLabel": "Number of employees"
       }
      }
     },
     "localname": "EntityNumberOfEmployees",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r431",
      "r498",
      "r526",
      "r575",
      "r608",
      "r609",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Board of Directors Chairman [Member]",
        "terseLabel": "Board of Directors Chairman"
       }
      }
     },
     "localname": "BoardOfDirectorsChairmanMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r136",
      "r137",
      "r199",
      "r205",
      "r334",
      "r503",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188",
      "r228",
      "r343",
      "r375",
      "r402",
      "r403",
      "r465",
      "r468",
      "r472",
      "r473",
      "r478",
      "r499",
      "r500",
      "r509",
      "r513",
      "r518",
      "r522",
      "r572",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188",
      "r228",
      "r343",
      "r375",
      "r402",
      "r403",
      "r465",
      "r468",
      "r472",
      "r473",
      "r478",
      "r499",
      "r500",
      "r509",
      "r513",
      "r518",
      "r522",
      "r572",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188",
      "r220",
      "r228",
      "r260",
      "r261",
      "r262",
      "r342",
      "r343",
      "r375",
      "r402",
      "r403",
      "r465",
      "r468",
      "r472",
      "r473",
      "r478",
      "r499",
      "r500",
      "r509",
      "r513",
      "r518",
      "r522",
      "r525",
      "r566",
      "r572",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r185",
      "r186",
      "r187",
      "r188",
      "r220",
      "r228",
      "r260",
      "r261",
      "r262",
      "r342",
      "r343",
      "r375",
      "r402",
      "r403",
      "r465",
      "r468",
      "r472",
      "r473",
      "r478",
      "r499",
      "r500",
      "r509",
      "r513",
      "r518",
      "r522",
      "r525",
      "r566",
      "r572",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r136",
      "r137",
      "r199",
      "r205",
      "r334",
      "r504",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r229",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r151",
      "r229",
      "r541",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r171",
      "r172",
      "r395",
      "r398",
      "r400",
      "r467",
      "r470",
      "r475",
      "r480",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r501",
      "r514",
      "r525",
      "r573",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r171",
      "r172",
      "r395",
      "r398",
      "r400",
      "r467",
      "r470",
      "r475",
      "r480",
      "r487",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r501",
      "r514",
      "r525",
      "r573",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r151",
      "r229",
      "r541",
      "r542",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r561",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Relationship to Entity [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r21",
      "r521"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableOtherCurrent": {
     "auth_ref": [
      "r21"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable, Other, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "AccountsPayableOtherCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r29",
      "r30",
      "r71",
      "r116",
      "r366",
      "r380",
      "r381"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r2",
      "r13",
      "r30",
      "r292",
      "r295",
      "r328",
      "r376",
      "r377",
      "r550",
      "r551",
      "r552",
      "r557",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r66",
      "r521",
      "r623"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r392",
      "r557",
      "r558",
      "r559",
      "r602",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r50",
      "r51",
      "r232"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r14",
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r264",
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Options to purchase common stock ( in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r95",
      "r112",
      "r135",
      "r163",
      "r167",
      "r169",
      "r173",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r287",
      "r289",
      "r308",
      "r362",
      "r424",
      "r521",
      "r533",
      "r570",
      "r571",
      "r612"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r108",
      "r118",
      "r135",
      "r173",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r287",
      "r289",
      "r308",
      "r521",
      "r570",
      "r571",
      "r612"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total assets at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BankTimeDepositsMember": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.",
        "label": "Bank Time Deposits [Member]",
        "terseLabel": "Time Deposits",
        "verboseLabel": "Time Deposits"
       }
      }
     },
     "localname": "BankTimeDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation and Consolidation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r58",
      "r82",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Description of Business and Basis of Financial Statements"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r32",
      "r110",
      "r502"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets",
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r32",
      "r79",
      "r132"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r1",
      "r79"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [
      "r113",
      "r114",
      "r115",
      "r162",
      "r203",
      "r204",
      "r205",
      "r207",
      "r210",
      "r215",
      "r217",
      "r384",
      "r385",
      "r386",
      "r387",
      "r513",
      "r540",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrant exercised (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for collaborative arrangements.",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "terseLabel": "Collaboration Arrangements"
       }
      }
     },
     "localname": "CollaborativeArrangementAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r25",
      "r55",
      "r363",
      "r411"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 4)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r87",
      "r182",
      "r183",
      "r488",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Total common shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Common stock, cash dividends paid (in USD per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Common stock, cash dividends declared (in USD per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r523",
      "r524",
      "r525",
      "r527",
      "r528",
      "r529",
      "r530",
      "r557",
      "r558",
      "r602",
      "r622",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in USD per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockCommonStockDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r65",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockCommonStockDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r14",
      "r65",
      "r412",
      "r430",
      "r625",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r65",
      "r365",
      "r521"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.0001 par value; 130,000,000 shares authorized and 44,488,371 and 39,307,286 shares issued and outstanding as of June 30, 2023 and December\u00a031, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r31",
      "r121",
      "r123",
      "r129",
      "r358",
      "r373"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [
      "r556"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Contractual obligation"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Maximum annual contributions per employee (as a percent)"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r7",
      "r38"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r7",
      "r165"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r230",
      "r234",
      "r265",
      "r266",
      "r268",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r130",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r152",
      "r154",
      "r156",
      "r157",
      "r158",
      "r160",
      "r299",
      "r300",
      "r359",
      "r374",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r130",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r154",
      "r156",
      "r157",
      "r158",
      "r160",
      "r299",
      "r300",
      "r359",
      "r374",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted (in USD per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r33",
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r310"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period over which compensation cost will be recognized, in years"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Outstanding stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r14",
      "r106",
      "r125",
      "r126",
      "r127",
      "r138",
      "r139",
      "r140",
      "r142",
      "r148",
      "r150",
      "r161",
      "r174",
      "r175",
      "r219",
      "r269",
      "r270",
      "r271",
      "r285",
      "r286",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r328",
      "r376",
      "r377",
      "r378",
      "r392",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [
      "r302",
      "r303",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r302",
      "r303",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r200",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r303",
      "r339",
      "r340",
      "r341",
      "r511",
      "r512",
      "r515",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r302",
      "r303",
      "r304",
      "r305",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/FairValue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r200",
      "r221",
      "r226",
      "r303",
      "r339",
      "r515",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r200",
      "r221",
      "r226",
      "r303",
      "r340",
      "r511",
      "r512",
      "r515",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r200",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r303",
      "r341",
      "r511",
      "r512",
      "r515",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level\u00a03"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r200",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r339",
      "r340",
      "r341",
      "r511",
      "r512",
      "r515",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r301",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r10",
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "auth_ref": [
      "r81",
      "r432",
      "r531",
      "r604",
      "r605",
      "r624"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction.",
        "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax",
        "negatedTerseLabel": "Unrealized foreign currency loss"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation and Presentation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r74",
      "r435"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r176",
      "r179",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r7",
      "r177",
      "r178",
      "r179",
      "r510"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill, impairment loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GovernmentAssistanceAmount": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of government assistance recognized.",
        "label": "Government Assistance, Amount",
        "terseLabel": "Government assistance, amount"
       }
      }
     },
     "localname": "GovernmentAssistanceAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GovernmentAssistancePolicyTextBlock": {
     "auth_ref": [
      "r319",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for government assistance.",
        "label": "Government Assistance [Policy Text Block]",
        "terseLabel": "Government assistance"
       }
      }
     },
     "localname": "GovernmentAssistancePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of income or comprehensive income that includes government assistance.",
        "label": "Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Government Assistance, Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "GovernmentAssistanceStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r0",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r180",
      "r181",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r181",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r124",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Other current assets and prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r75",
      "r164"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentInterestRate": {
     "auth_ref": [
      "r465",
      "r466",
      "r468",
      "r469",
      "r471",
      "r472",
      "r478",
      "r479",
      "r525",
      "r563",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of interest on investment.",
        "label": "Investment Interest Rate",
        "terseLabel": "Investment interest rate"
       }
      }
     },
     "localname": "InvestmentInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_InvestmentTableTextBlock": {
     "auth_ref": [
      "r544",
      "r545",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment.",
        "label": "Investment [Table Text Block]",
        "terseLabel": "Schedule of Investment"
       }
      }
     },
     "localname": "InvestmentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r394",
      "r396",
      "r397",
      "r399",
      "r401",
      "r464",
      "r467",
      "r470",
      "r474",
      "r475",
      "r476",
      "r477",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r394",
      "r396",
      "r397",
      "r399",
      "r401",
      "r464",
      "r467",
      "r470",
      "r474",
      "r475",
      "r476",
      "r477",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "terseLabel": "Maturities of Operating Lease Obligation"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r607"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Renewal option period (in months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term (in years)",
        "verboseLabel": "Lease term (in months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r22",
      "r135",
      "r173",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r288",
      "r289",
      "r290",
      "r308",
      "r410",
      "r507",
      "r533",
      "r570",
      "r612",
      "r613"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r70",
      "r96",
      "r368",
      "r521",
      "r555",
      "r565",
      "r603"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r24",
      "r109",
      "r135",
      "r173",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r288",
      "r289",
      "r290",
      "r308",
      "r521",
      "r570",
      "r612",
      "r613"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r20",
      "r60",
      "r61",
      "r62",
      "r63",
      "r135",
      "r173",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r288",
      "r289",
      "r290",
      "r308",
      "r570",
      "r612",
      "r613"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Long term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r189",
      "r568",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r184",
      "r185",
      "r186",
      "r189",
      "r568",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueAdditionalInformationDetail",
      "http://vitaltherapies.com/role/FairValueScheduleofFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r131"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r79",
      "r80",
      "r81"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r72",
      "r81",
      "r97",
      "r107",
      "r119",
      "r122",
      "r127",
      "r135",
      "r141",
      "r143",
      "r144",
      "r145",
      "r146",
      "r149",
      "r150",
      "r155",
      "r163",
      "r166",
      "r168",
      "r170",
      "r173",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r300",
      "r308",
      "r371",
      "r433",
      "r453",
      "r454",
      "r508",
      "r531",
      "r570"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss)",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued and/or Adopted Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of noncash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r163",
      "r166",
      "r168",
      "r170",
      "r508"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r323"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "PV of obligation"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r323"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r323"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r322"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r117",
      "r521"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r111"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r4",
      "r12",
      "r94"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r14",
      "r18",
      "r120",
      "r123",
      "r128",
      "r311",
      "r312",
      "r317",
      "r357",
      "r372",
      "r550",
      "r551"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Foreign exchange translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other current liabilities.",
        "label": "Other Current Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r23",
      "r521"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherShortTermInvestments": {
     "auth_ref": [
      "r56",
      "r361",
      "r548"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term investments classified as other.",
        "label": "Other Short-Term Investments",
        "terseLabel": "Investments - other"
       }
      }
     },
     "localname": "OtherShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherSundryLiabilitiesCurrent": {
     "auth_ref": [
      "r23",
      "r39"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.",
        "label": "Other Sundry Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherSundryLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForCommissions": {
     "auth_ref": [
      "r5"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for commissions during the current period.",
        "label": "Payments for Commissions",
        "terseLabel": "Underwriter commissions"
       }
      }
     },
     "localname": "PaymentsForCommissions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r64",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in USD per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockPreferredStockDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r64",
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockPreferredStockDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r64",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r64",
      "r412",
      "r430",
      "r625",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockPreferredStockDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r64",
      "r364",
      "r521"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 20,000,000 authorized and no shares issued or outstanding as of June 30, 2023 and December 31, 2022"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r549"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Other current assets and prepaid expenses",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail",
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r3"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from public offering of common stock through At The Market Sales Agreement, net",
        "verboseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r3"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from Issuance of Private Placement",
        "terseLabel": "Proceeds from issuance of private placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": {
     "auth_ref": [
      "r3",
      "r17"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Excluding Option Exercised",
        "terseLabel": "Proceeds from shares issued in connection with the Company's employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfOtherInvestments": {
     "auth_ref": [
      "r543"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from the sale of investments classified as other.",
        "label": "Proceeds from Sale of Other Investments",
        "terseLabel": "Sale of investments - other"
       }
      }
     },
     "localname": "ProceedsFromSaleOfOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r3",
      "r17"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r553"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from the exercise of pre-funded warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r8",
      "r360",
      "r370",
      "r521"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r8",
      "r102",
      "r105",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful life (in years)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r227",
      "r332",
      "r333",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r429",
      "r431",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party, Type [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r332",
      "r333",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [
      "r436",
      "r437",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r227",
      "r332",
      "r333",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r429",
      "r431",
      "r463",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party, Type [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r329",
      "r330",
      "r331",
      "r333",
      "r335",
      "r389",
      "r390",
      "r391",
      "r438",
      "r439",
      "r440",
      "r460",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r57",
      "r278",
      "r620"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r67",
      "r91",
      "r367",
      "r379",
      "r381",
      "r388",
      "r413",
      "r521"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets",
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r106",
      "r138",
      "r139",
      "r140",
      "r142",
      "r148",
      "r150",
      "r174",
      "r175",
      "r269",
      "r270",
      "r271",
      "r285",
      "r286",
      "r291",
      "r293",
      "r294",
      "r296",
      "r298",
      "r376",
      "r378",
      "r392",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r326",
      "r520"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right-of use asset obtained in exchange for lease obligation"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Share price (in USD per share)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "verboseLabel": "Shares issued in private placement transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Stock-based Compensation Expense for Stock Awards Recognized"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/FairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "terseLabel": "Schedule of Other Current Assets and Prepaid Expenses"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r53",
      "r54",
      "r436",
      "r437",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r231",
      "r233",
      "r235",
      "r236",
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r15",
      "r16",
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Valuation Assumptions Used"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r89",
      "r90",
      "r91",
      "r113",
      "r114",
      "r115",
      "r162",
      "r203",
      "r204",
      "r205",
      "r207",
      "r210",
      "r215",
      "r217",
      "r384",
      "r385",
      "r386",
      "r387",
      "r513",
      "r540",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r6"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementofCashFlows",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Purchase price of the stock, at discount from market price at purchase date (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "RSUs granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [
      "r231",
      "r233",
      "r235",
      "r236",
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "verboseLabel": "Shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Other Disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable, Ending balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable, Weighted-Average Exercise Price, Ending balance (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedLabel": "Forfeited or expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited or expired (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Options granted in period, weighted-average grant date fair value (in USD per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r239",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "periodStartLabel": "Outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r239",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, ending balance (usd per share)",
        "periodStartLabel": "Outstanding, beginning balance (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r255"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Options vested and expected to vest , aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Options vested and expected to vest, Ending balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options vested and expected to vest, Weighted-Average Exercise Price, Ending balance (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other than shares newly issued, the number of additional shares issued (for example, a stock split) or canceled (for example, to correct a share issuance), during the period under the plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Other Share Increase (Decrease)",
        "terseLabel": "Increase in other share (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r235",
      "r236",
      "r237",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (usd per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r230",
      "r238",
      "r257",
      "r258",
      "r259",
      "r260",
      "r263",
      "r272",
      "r273",
      "r274",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Sale of stock, price per share (in USD per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term of options (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options exercisable, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable, weighted-average remaining contractual term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, weighted-average remaining contractual term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options vested and expected to vest , weighted-average remaining contractual term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r82",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r14",
      "r28",
      "r106",
      "r125",
      "r126",
      "r127",
      "r138",
      "r139",
      "r140",
      "r142",
      "r148",
      "r150",
      "r161",
      "r174",
      "r175",
      "r219",
      "r269",
      "r270",
      "r271",
      "r285",
      "r286",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r311",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r328",
      "r376",
      "r377",
      "r378",
      "r392",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r161",
      "r344",
      "r382",
      "r393",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r412",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r431",
      "r434",
      "r435",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r455",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r161",
      "r344",
      "r382",
      "r393",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r412",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r431",
      "r434",
      "r435",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r455",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r14",
      "r27",
      "r43",
      "r91",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Shares issued from exercise of pre-funded warrants and issuance of common stock - at the market Sales Agreement net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r14",
      "r64",
      "r65",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Shares issued in connection with the Company's employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r14",
      "r64",
      "r65",
      "r91",
      "r384",
      "r455",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Stock issued (in shares)",
        "verboseLabel": "Shares issued in connection with the Company's stock option plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r64",
      "r65",
      "r91",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r14",
      "r28",
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Shares issued from exercise of pre-funded warrants and issuance of common stock - at the market Sales Agreement net of issuance costs"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r14",
      "r64",
      "r65",
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Shares issued in connection with the Company's Employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r14",
      "r64",
      "r65",
      "r91",
      "r392",
      "r455",
      "r485",
      "r532"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Shares issued",
        "verboseLabel": "Shares issued in connection with the Company's stock option plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesScheduleofPotentiallyDilutiveSecuritiesNotIncludedinCalculationofDilutedNetLossperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r65",
      "r68",
      "r69",
      "r84",
      "r414",
      "r430",
      "r456",
      "r457",
      "r521",
      "r533",
      "r555",
      "r565",
      "r603",
      "r625"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.",
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets",
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r88",
      "r134",
      "r202",
      "r204",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r216",
      "r219",
      "r297",
      "r458",
      "r461",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity.",
        "label": "Equity [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "StockholdersEquityPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r318",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r318",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r318",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r336",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Details"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TangibleAssetImpairmentCharges": {
     "auth_ref": [
      "r59",
      "r85"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.",
        "label": "Tangible Asset Impairment Charges",
        "terseLabel": "Impairment losses"
       }
      }
     },
     "localname": "TangibleAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r35",
      "r36",
      "r37",
      "r99",
      "r100",
      "r103",
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValueAddedTaxReceivableCurrent": {
     "auth_ref": [
      "r547"
     ],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Value Added Tax Receivable, Current",
        "terseLabel": "VAT receivable"
       }
      }
     },
     "localname": "ValueAddedTaxReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r153",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r152",
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://vitaltherapies.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "vtl_A2017InducementEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2017 Inducement Equity Incentive Plan [Member]",
        "label": "2017 Inducement Equity Incentive Plan [Member]",
        "terseLabel": "2017 Inducement Equity Incentive Plan"
       }
      }
     },
     "localname": "A2017InducementEquityIncentivePlanMember",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_A2019OmnibusEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2019 Omnibus Equity Incentive Plan [Member]",
        "label": "2019 Omnibus Equity Incentive Plan [Member]",
        "terseLabel": "2019 Omnibus Equity Incentive Plan"
       }
      }
     },
     "localname": "A2019OmnibusEquityIncentivePlanMember",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansRangesofUnderlyingAssumptionsUsedinBSMOptionPricingModeltoDetermineFairValueofStockOptionsGrantedtoEmployeesandNonemployeesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_A2021EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Employee Stock Purchase Plan",
        "label": "2021 Employee Stock Purchase Plan [Member]",
        "terseLabel": "2021 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "A2021EmployeeStockPurchasePlanMember",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_AccruedClinicalCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Costs, Current",
        "label": "Accrued Clinical Costs, Current",
        "terseLabel": "Accrued clinical and related costs"
       }
      }
     },
     "localname": "AccruedClinicalCostsCurrent",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_AccruedCompensationCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Compensation, Current",
        "label": "Accrued Compensation, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "AccruedCompensationCurrent",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_AccruedLegalAndAuditCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Legal And Audit Costs, Current",
        "label": "Accrued Legal And Audit Costs, Current",
        "terseLabel": "Accrued legal and audit costs"
       }
      }
     },
     "localname": "AccruedLegalAndAuditCostsCurrent",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccruedExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_AustraliaAndGermanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Australia and Germany",
        "label": "Australia and Germany [Member]",
        "terseLabel": "Australia and Germany"
       }
      }
     },
     "localname": "AustraliaAndGermanyMember",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash And Cash Equivalents And Other Investments",
        "label": "Cash And Cash Equivalents And Other Investments [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents and Investments- other"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndOtherInvestmentsPolicyTextBlock",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vtl_ClinicalCostsPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Costs Payable, Current",
        "label": "Clinical Costs Payable, Current",
        "terseLabel": "Clinical costs"
       }
      }
     },
     "localname": "ClinicalCostsPayableCurrent",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_December2020ATMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 2020 ATM",
        "label": "December 2020 ATM [Member]",
        "terseLabel": "December 2020 ATM"
       }
      }
     },
     "localname": "December2020ATMMember",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_DuaneNashMDJDMBAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Duane Nash, MD, JD, MBA",
        "label": "Duane Nash, MD, JD, MBA [Member]",
        "terseLabel": "Duane Nash, MD, JD, MBA"
       }
      }
     },
     "localname": "DuaneNashMDJDMBAMember",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_EmployeeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee [Member]",
        "label": "Employee [Member]",
        "terseLabel": "Employees"
       }
      }
     },
     "localname": "EmployeeMember",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansScheduleofStockbasedCompensationExpenseforStockAwardsRecognizedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_EmployeeStockOptionsforFutureGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Options for Future Grant [Member]",
        "label": "Employee Stock Options for Future Grant [Member]",
        "terseLabel": "Common stock options available for future grant:"
       }
      }
     },
     "localname": "EmployeeStockOptionsforFutureGrantMember",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_ExecutiveChairmanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Executive Chairman Agreement",
        "label": "Executive Chairman Agreement [Member]",
        "terseLabel": "Executive Chairman Agreement"
       }
      }
     },
     "localname": "ExecutiveChairmanAgreementMember",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_GovernmentAssistanceRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Assistance Rate",
        "label": "Government Assistance Rate",
        "terseLabel": "Government assistance rate"
       }
      }
     },
     "localname": "GovernmentAssistanceRate",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vtl_GrafelfingGermanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grafelfing, Germany",
        "label": "Grafelfing, Germany [Member]",
        "terseLabel": "Grafelfing, Germany"
       }
      }
     },
     "localname": "GrafelfingGermanyMember",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_IncentiveEmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive Employee Stock Option [Member]",
        "label": "Incentive Employee Stock Option [Member]",
        "terseLabel": "Incentive stock options"
       }
      }
     },
     "localname": "IncentiveEmployeeStockOptionMember",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset",
        "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset",
        "terseLabel": "Increase in operating lease, right-of-use asset"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_LegalAndAuditCostsPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal And Audit Costs Payable, Current",
        "label": "Legal And Audit Costs Payable, Current",
        "terseLabel": "Legal and audit costs"
       }
      }
     },
     "localname": "LegalAndAuditCostsPayableCurrent",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofAccountsPayableDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Beginning of Lease, Rent Holiday Period",
        "label": "Lessee, Operating Lease, Beginning of Lease, Rent Holiday Period",
        "terseLabel": "Rent holiday period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseBeginningOfLeaseRentHolidayPeriod",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vtl_LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Extension of Lease, Rent Holiday Period",
        "label": "Lessee, Operating Lease, Extension of Lease, Rent Holiday Period",
        "terseLabel": "Lessee, operating lease, extended rent holiday period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExtensionOfLeaseRentHolidayPeriod",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vtl_LesseeOperatingLeaseLiabilityPaymentsAfterDueYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee \u200bOperating\u200b Lease \u200bLiability \u200bPayments After \u200bDue \u200bYear \u200bFour",
        "label": "Lessee \u200bOperating\u200b Lease \u200bLiability \u200bPayments After \u200bDue \u200bYear \u200bFour",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsAfterDueYearFour",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesMaturitiesofOperatingLeaseObligationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_LesseeOperatingLeasesNumberOfExistingLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Leases, Number Of Existing Leases",
        "label": "Lessee, Operating Leases, Number Of Existing Leases",
        "terseLabel": "Number of existing leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesNumberOfExistingLeases",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vtl_MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum Aggregate Offering Price Of Securities Under Shelf Registration",
        "label": "Maximum Aggregate Offering Price Of Securities Under Shelf Registration",
        "terseLabel": "Maximum aggregate offering price of common stock, preferred stock, warrants, debt securities, and/or units"
       }
      }
     },
     "localname": "MaximumAggregateOfferingPriceOfSecuritiesUnderShelfRegistration",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_May2022ATMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "May 2022 ATM",
        "label": "May 2022 ATM [Member]",
        "terseLabel": "May 2022 ATM"
       }
      }
     },
     "localname": "May2022ATMMember",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_NewYorkCityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New York City",
        "label": "New York City [Member]",
        "terseLabel": "New York City"
       }
      }
     },
     "localname": "NewYorkCityMember",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_NonStatutoryEmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Statutory Employee Stock Option [Member]",
        "label": "Non-Statutory Employee Stock Option [Member]",
        "terseLabel": "Non-statutory options"
       }
      }
     },
     "localname": "NonStatutoryEmployeeStockOptionMember",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_NumberOfDevelopmentPrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Development Programs",
        "label": "Number Of Development Programs",
        "terseLabel": "Number of development programs"
       }
      }
     },
     "localname": "NumberOfDevelopmentPrograms",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/DescriptionofBusinessandBasisofFinancialStatementsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vtl_NumberOfFinancialInstitutionsUsedForCashDeposit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Financial Institutions Used For Cash Deposit",
        "label": "Number of Financial Institutions Used For Cash Deposit",
        "terseLabel": "Number of financial institutions used for cash deposits"
       }
      }
     },
     "localname": "NumberOfFinancialInstitutionsUsedForCashDeposit",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vtl_NumberOfVotesPerEachShareOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Votes Per Each Share of Common Stock",
        "label": "Number of Votes Per Each Share of Common Stock",
        "terseLabel": "Number of votes per each share of common stock"
       }
      }
     },
     "localname": "NumberOfVotesPerEachShareOfCommonStock",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockCommonStockDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vtl_OperatingAndVariableLeasesCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Variable Leases, Cost",
        "label": "Operating And Variable Leases, Cost",
        "terseLabel": "Operating and variable lease costs"
       }
      }
     },
     "localname": "OperatingAndVariableLeasesCost",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_OperatingLeaseIncrementalBorrowingRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Incremental Borrowing Rate",
        "label": "Operating Lease, Incremental Borrowing Rate",
        "terseLabel": "Incremental borrowing rate on operating leases"
       }
      }
     },
     "localname": "OperatingLeaseIncrementalBorrowingRate",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vtl_PlaneggGermanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Planegg, Germany",
        "label": "Planegg, Germany [Member]",
        "terseLabel": "Planegg, Germany"
       }
      }
     },
     "localname": "PlaneggGermanyMember",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_PreFundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-Funded Warrants",
        "label": "Pre-Funded Warrants [Member]",
        "terseLabel": "Pre-Funded Warrants"
       }
      }
     },
     "localname": "PreFundedWarrantsMember",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockEquityOfferingDetails",
      "http://vitaltherapies.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_PrepaidClinicalAndRelatedCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Clinical And Related Costs, Current",
        "label": "Prepaid Clinical And Related Costs, Current",
        "terseLabel": "Prepaid clinical and related costs"
       }
      }
     },
     "localname": "PrepaidClinicalAndRelatedCostsCurrent",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_ResearchAndDevelopmentTaxIncentiveCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research And Development Tax Incentive, Current",
        "label": "Research And Development Tax Incentive, Current",
        "terseLabel": "Australian research and development tax incentive"
       }
      }
     },
     "localname": "ResearchAndDevelopmentTaxIncentiveCurrent",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/BalanceSheetDetailsScheduleofOtherCurrentAssetsandPrepaidExpensesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_SalaryCostsMonthlyBaseSalary": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Salary Costs, Monthly Base Salary",
        "label": "Salary Costs, Monthly Base Salary",
        "terseLabel": "Monthly base salary"
       }
      }
     },
     "localname": "SalaryCostsMonthlyBaseSalary",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_SaleOfStockRemainingCapacity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Remaining Capacity",
        "label": "Sale Of Stock, Remaining Capacity",
        "terseLabel": "Sale of stock, remaining capacity"
       }
      }
     },
     "localname": "SaleOfStockRemainingCapacity",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]",
        "label": "Schedule Of Common Stock Reserved For Future Issuance [Table Text Block]",
        "terseLabel": "Shares Reserved for Future Issuance"
       }
      }
     },
     "localname": "ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vtl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent",
        "label": "Share-based Compensation Arrangement By Share-Based Payment Award, Additional Shares Authorized, Percent",
        "terseLabel": "Additional shares authorized (as a percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalSharesAuthorizedPercent",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vtl_SharesIssuedWeightedAverageSharePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Issued, Weighted Average Share Price Per Share",
        "label": "Shares Issued, Weighted Average Share Price Per Share",
        "terseLabel": "common stock at a weighted average price (in dollar per share)"
       }
      }
     },
     "localname": "SharesIssuedWeightedAverageSharePricePerShare",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "vtl_ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock",
        "label": "Shelf Registration Agreement, Commission, Percent Of Gross Proceeds On Sale Of Common Stock",
        "terseLabel": "Commission, percent of gross proceeds from sale of common stock"
       }
      }
     },
     "localname": "ShelfRegistrationAgreementCommissionPercentOfGrossProceedsOnSaleOfCommonStock",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vtl_ShelfRegistrationStatementAmountRemaining": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf Registration Statement, Amount Remaining",
        "label": "Shelf Registration Statement, Amount Remaining",
        "terseLabel": "Shelf registration statement, amount remaining"
       }
      }
     },
     "localname": "ShelfRegistrationStatementAmountRemaining",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vtl_ShelfRegistrationTerminationPriorWrittenNotice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shelf Registration, Termination, Prior Written Notice",
        "label": "Shelf Registration, Termination, Prior Written Notice",
        "terseLabel": "Shelf registration, termination, prior written notice"
       }
      }
     },
     "localname": "ShelfRegistrationTerminationPriorWrittenNotice",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockShelfRegistrationStatementDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vtl_TwoThousandFourteenEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Fourteen Equity Incentive Plan [Member]",
        "label": "Two Thousand Fourteen Equity Incentive Plan [Member]",
        "terseLabel": "2014 Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandFourteenEquityIncentivePlanMember",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision",
        "label": "Two Thousand Nineteen Omnibus Equity Incentive Plan, Evergreen Provision [Member]",
        "terseLabel": "2019 Omnibus Equity Incentive Plan, Evergreen Provision"
       }
      }
     },
     "localname": "TwoThousandNineteenOmnibusEquityIncentivePlanEvergreenProvisionMember",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/StockBasedCompensationPlansAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vtl_TwoThousandNineteenOmnibusEquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Nineteen Omnibus Equity Incentive Plan",
        "label": "Two Thousand Nineteen Omnibus Equity Incentive Plan [Member]",
        "terseLabel": "2019 Omnibus Equity Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandNineteenOmnibusEquityIncentivePlanMember",
     "nsuri": "http://vitaltherapies.com/20230630",
     "presentation": [
      "http://vitaltherapies.com/role/CommonStockSharesReservedforFutureIssuanceDetails",
      "http://vitaltherapies.com/role/StockBasedCompensationPlansSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "808",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//350-20/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org//718/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iv)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org//830/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "832",
   "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "832",
   "URI": "https://asc.fasb.org//1943274/2147483507/832-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org//850/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org//855/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-10",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(14))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(15))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(17))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(19))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(b)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r534": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r535": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r536": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r537": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r538": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r539": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "321",
   "URI": "https://asc.fasb.org//321/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "325",
   "URI": "https://asc.fasb.org//325/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org//210/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.5)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org//320/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org//450/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org//205/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(18))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org//235/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org//275/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org//440/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org//505/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Subparagraph": "b.",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147481160/942-230-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>67
<FILENAME>0001280776-23-000013-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001280776-23-000013-xbrl.zip
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M=+D$BGZ/9RMQM&5*"H@@_9Y)-X:C#:1PUN!C2%DO[3J.5F72+4L0)VZ %*G
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M.L.Q$ ]?>C$8N>%+NS1EQ]9C=>>PPSYN[?W%Z:M^;WQE&X<U6=E37.>YP&.
MY8YQ0P%_X"D220$H@M,3*6SAQ;U8B?#V(>Z?,V%3J6V->3[PC9;1$971*67X
MVK(SX)X1'!GA??>0%EQ-B=TBIC[4$A*] 6_W1F=T'J;V1EE\BH_"UUX5">#U
M,Q]X&[R(GO*V'+Q0OK50CH66A-AD"R1\SC^X:KU\1('A9>?K,8"?L[=DT;P
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ML?&"AG-=M"I5(G'*X?Q])E@JT7'8E;WUJK'W)1PQS/55L5W$M$L8";S9X4@
M7 J(2\.=_F<@W(XGCC<E!%;IF;^$2>2#4Q 08>(8%W8J4;  4>[LTW E 3N]
MZ3$&^B/ O'"GE9[8Z/?49D=1*N1%\\@.C[^="9;*/&!95\B_4B+D*-:>U.CK
M5>I7QBF)\SO'$L=2):7R!N>F-*$L5TPH;W!V+#L (W^*BR7K:8_?6<\[S^HL
M:V-;G;]$+A$4<8^N.O.SH=FVKA3@/LN+!@YA14P7W'-'WM1CM,R>.SV%]=SI
M]9I*:3&D,E![XJ#ER:BW:H&N[6M'RX1,/?DYSU?MEM#-IZ>6T,V'\R;G3<Z;
M<[RY0Z>M8JE7O0XPKB(U>VI94ZTX^W+VY>S+V/?@;;YZ7>Q I/?*:JW/F9<S
M[QDS;[$:WJ7^80?K;=33@(V[."-CV<$M7(+)>9CS\!GS<!$6WN88=C_&[37Z
M7;TI]\[!^:5AXD^A 9^#_UKV:_\W^@_;P<#_U$]WDUQ,]I/YD$D  WYCJ\=B
MQ"K=MB8#\B=>0(M(KGR"50BOY/.;;86C!/&9!V/XB+-'C % (PI7/[)JB:61
MKR1NHE\9U]2=AT;VWY&?+&9BO)#6P"?&KY8QA+5>&<Z;,0T:G^:V-+;=U@((
M%W>_&@U;X9 2PPSHE/H 4(XQ"<A5\L/GY,S!=NEVZ4.?QX;_ NN+,=69+!$?
M_1Z['"];U]LZA5%R6!%_.-Y4FUY:X"1V397;>F?U9;$MK;RV[K7==E??[:WK
MKW7$W@'6VE/DVJQ5%;6:K+4'E-6MR5JU=D<]!+UJ^FY/KENKWI;$[>@U__BR
MNU>V+I-PQ[%KM*U.,)_L=^$[W#4*A%LZ[C![CBG/V1$Q0!:TJ,QLZ++31O0S
M@S,[FQ2H[;?R=+@,P,$[?.]M\;2Y5K":U093 P(+A%MW+OTY+A->!\$UNS]K
MH)EF-([ @"46A10MFF PRU9.T+]\6]?>DX,P >$7,K1->W4E\CE":KN\EV<O
MC)DSZ\S2W$7M,_T[<VQ/IS\R[UCEO>8XL-6F3Y;4LH7VN$CH7(^!3M8RZSKH
MG%5IUN9D-<.-#'\J2#EF7L'DW0M.2%/$8R:DZ8V^W&TJ2J>IUJ19>DDR_8 4
M6-_ >[&]UY/K\D+K2Y,_=D@;T\5&OZQR1<Y!G(-.ONE"''3PD1XZSJ>2U::L
M:)S).).="Y,5RN)0MNW$OIW"DL'VXP.H."-=(",M)5,<+!U*5QI]2>\V>]JR
M<<@Y;6UPZ,*8K5[\5HC=-G1:*X'+5. R66M*TL%'!)>:H73X0E;8P&D(A$]\
MXVWD.)8XECB6.)8XEDZ-I6+NT5%&=>DXJDML]L3E<R<^\>T\Z&BI'/\@=-2M
M%AV=U:$_'_E6MN8KL1E6V>E-'$L<2W4()VWH)%&UD4"Z!@JJ*7;W[DK!B9*+
M#HXECJ4Z8FD_OZ'B KY7/0%_5GTR^<PW'H[C6.)8XECB6-HS)+G4QFQ%2'+'
M\5"ZWNAW*A*(Y-3#>?Q,L'288X?=>%P6Q>KP^)$.&TZ6151P\AL;^.9-Z'4^
M[FU3J:&^S[@W6#*]%"S7%<JBU.CW<G++>9"FTO3#0VEUP%*99R7K!@4M,WA&
M!\J@ SE[UXMP.'MS+'$L5>\\8V<AK%1+"!^UI"%M"'IDQ",V:,<3;XBY3]A_
MC7D=+>R!@N[(V/!_D5!X FP%PO6+3P@>0P@N_ V>L9/G32\( _S+OQW];&Q&
M;\EN;G Q>22F-OIZ3F>0A?ZK%Q&$.*IW=>.YL/4 OO,P9#^']L A3\2$6T.;
M%)VI+8N8;MO41;4I27OWJ>#QKSK8!!Q+%1$0)3MF)<F&C)3'%&J]V57V;@'%
M28X+!HXECJ4Z8NE8+EWYXENKH/@^JS*8C;TOOQN^.1(4WOIR'X])/6+K2UGL
M4::15;&I]'CCOG(HL&HIHA?9"JF('E-+:'TIBSIO?<DYZ%(YZ-"M+V4).\MV
M.DU]_[G&G,DXDU5ETX5R^M0R6U_*$C:3E43>D(\STL4QTM%:7\H2-IB5M&:W
MM\\D8,YIG-.JLNE"C';HII>RA*UE%:VI=Y?YJXIV(>]X>8Y1<WZVP;'$L<2Q
MQ+'$L50E+!7SBH[1\5*65'2(FKJXCS_$Z:C"='2,AI>RU*D6&9U]#2KO=LG+
M4CB6.)9.$T>J5S,T6>JR9FB\^+MF1,E%!\<2Q]+Q!7S=Y+M6/?E^[B<+O-,E
M#\-Q+'$L<2Q=-):*A;27"DS+[8(G]3 K=9\<.DX^G,DYEHYRWK KC^L5XO&S
M/V8HUNKR=CQQO"DA NL^,XE\\ T"PKM>;JPR[.W3ER4!.[WI,0;Z(\"\<$,6
M601'6FUVI2IYTCRZPV-P9X*E,@]9UI7SKY0(.0I5EC!E=UFA<E*J-"EQAN=8
MXEBJW-%(:5)9KII4YITT#]])\[B--&4%7.F<$=6\D>:!';;2&VG**DB+IB**
M30!2A1HN\>C:%BV;8ALAP<])K!1.()4@D--ZC:4W@9,[C;[>U-4N%TE5I3@N
MDCB!< +A!%)3E[I\E=6MGLJZK+:E?XE<(BAB:5U+V;:N% "^Y45 '*Q[Q"7W
M--TT!:+,GJ:RAD&&9J>K-G6]K,DP9:"V'GUYRJ?><^G:LQ]DZLG/>0Z?7D*W
M5+E7>K=4SIN<-R^=-SL[=#(N:*YB-ERWUQ1[&F=?SKZ<?4M-9>TL]5'>I\.K
M(C;ZW6YY'5XYBW(6Y2RZ3Q/F8KI6D1I]6=&;G=YR=BSG8<[#G(=WM)*7VC^7
MSKF83"5KS9ZZ]S2J"K O#0=_"@WX7)*CDZ9+]7\;^)\6$GC@GV0_F0^9!'#@
MLT_;K@6_72E=RM]EOJ<TLI/$370G(]T]CXA@F":K2 % "ZX7PML-'_[L"C8L
M]<4W'&%B^#1=*QR1@ !Q&I%EA[25%NZ -=5R*=H,_//0=@W7M.'!((0_T 2L
M]O; V1&F_+'C/A83DM)M:S(0V\0+:'[=E4^PJ\$K^?QF6^$H$7"9!V,I(,X>
M,09 /%&X^I%52SPVOV@+N7Z9?W&U*#]ML]-1R+ CDHZFJX;4ZVFJ.+1TF9"N
MT1UH^O]BFD?\T,A/=C Q7DAKX!/C5\L8P@:O#.?-F :-3W-P&-MNLB!9:Z/@
M6 +9:MQMC?C#077I-(M"]>[[]Y_W=S=-X>[^9K6<&!O^"VR?:@EYWL(YZ>IO
M4B%XDQ6"3ZGH0\EY8P0CX:OCO06UV]^'.Y<I_7#D1? B*_A86)0<?<T_$QVU
MO-:R5R1O)3GF[29JC<SD(35_8"6.,0G(5?+#9\L.)HXQO;)=^C[ZT.>83&(A
MVIDL9X0C#MCE6#CHO797EE$^Q*?B\8=CT=&FHF/!E&/7-+W=D:65E\7VZFOK
M7MMKRY*^TUO77^LHN[UUPUJWA,"&O(-*IA<4219*]Z1OLZ?8T*U0TL23_2Y\
MA[M& 56.;).W(+RM-(EB;LL7@\],4&.5)Y;CC%4;V;(H*V5M>&4JVID"3B["
M!A7NS+;96* [IK;9$&TS8>A[8\&;$!\\&/"&,>;Q2O/BKK:AI560*(W(=LZ9
M/,@B2\JS8R%+O1H44FPLT-ZEG<=3%%ONM'!LM@HQUBWW5NB@9-NCS+W& "A*
MHZ_J35DK8;I>C4XZ.%M4:6^%V&+;CG3[L84*;"$W-7%Y6/))V*(D"Z@&BBY3
M,2V$GN 3P+YI.X36:Z,&Q+_BSR;:3%' NER5;C!5Q2;:Q>S)0[JB51GI7\@$
M$&W'K8A=2S#&'BSM7V<U(65+6.QE(LR+P"Q8X6>'X _7KG6=@6Z>\.LT^AVU
M0HTL+KPER@$(9TF)ED,X7=":98V1K9K:K+8$_>GZ!-;P+SS[CON\FY'O$]><
M"F<U3_884G2%11DWT+^)X?J,[?/9Z_\P;!?-S!D6\KA#PVS2O0NJ>%ULA4EI
M6^>D&"D5]%UZ.%M#$O<N#SI>06QRS B+)>N)\UAWEAE9K+;F./?!A,<WNVD%
M[N^+@W0*LS$6"C4UK:PR(6Z(5Y&4-ACBY9"2*H)=WI24&IGF9Z 1:AN"NZ'C
MH8*%N%H0D#"@P1G'-@:V<]DQMC,R .A8A]A;#+-XGOAD8MB60-Y1\I#=7,C+
M$./;NI!WK@EF?4"^$/;?._>1 ?D+&1) @'7+8'WM6A0MUQ0;>2)= NN -_T_
M:Z+:UIDLCZAH"^/E(Z_*6@EG%,"[-DW8!TC>B3'%+%L>K]O5_5IFAP2VCPRT
M>92/:1#JWI3/8W,5)IL-KM9.9*,V^CWY##O/U4-@^CCCBENG!Q&8"-MO,T>O
M<,BA@R$'M5(#GKF%>K)DK.U(;)F*NB!?NQ5)3;P<6Y1%!#)A'FZ,EB=;*7 ?
MDKC:!OK'(^,JG>-QJ[1"(K00)?7 M9>6D[KJ/(25?KLKM;5.E87I_3:YJB5T
M3=Y<^'6.W%.@2 *+K!Y][]6VB/7[]"=@ U@HP<5UBHK"EBZ>T^I-M5="JGB1
M&KZZF, 739X%BA4.1)X=$?N--E5U']E_+/*\N$)/VWTE 2_TW+?0\PRR!=:8
M.-7.%L"YBG20(B5E5KC3$CRT37E(;E>W$10!L(H5? 4A@0!^&%)C_VX&X\)Z
M0,(Q*9J^=[":!^0J3%8;SCB*DM70?B=6ZU_$]_(H2LY,E:H,39V_IJAM7EDR
M0)FV(YOXZ >'4YII1/X9V1.DOPL+-.[GZB[PMC%-Y@R; $Z?/,80QGG5X;5K
MW29 SN-E!?NM+M>FG"0\Q(.,A_=#RZ0=K)7?ITD^KS.YM%#H)(YS"(.I\"&.
MBW[,=89Y8/0@_L6*>--=@H$]XDUT@G WIY_,7GV[>4BTPH1YS)!H+HDN4V%W
M3YW$(YX'BGC&G=EYQ).WMDO<PC@HP>AC$@T<VP0/<4AP<C"ZBB8=;@K+\LQ?
M0CB"7;^,A.M0P-$!WPW_%U@5&,P(A.L7G]"&UTWL$,2CCV5$'W&,,P[ZQ6G-
MZ8S9(E$BK8I1(AYY/&'D<0N2VL+.[-%C]TZO2HV*+BB6-R>TR3OQ33N@YT!,
M3'L31 5/'"SG! A!^L @>AN#VBHB@_729# /\U68I(J<_N23U!+I=,5&OTHM
MBR[5+ ZP$40@V* Z618A8-XEC"3>['"$@[&$&S9%ZS\#@8PGCC<E));&D_CD
M19@X!F_L4K)=3'MT!#]="P]2L9N^_8JEMOFM.S"@GA>PZ.+Q/#^;/V?BVLE"
M+H>X:%WW<CB,&\K'%N,HI;/&\L0GK6%$!\"\&;YON"$WF4L1SW]CT$Q,FURN
M4,"TV?N8@AO$%2:8 B)WF6"V=J^Z:A7=*WZRG'?4<)#SY'-GH]T.D[\FX%][
M4M?M@&VBEM7DL!9CV#G-[2^ZB]!<L<!RMTL#RYI45A^D(\P6/X\#Y'RBN1T.
MB4EG?Y-WDW8F%'PC)((9=RD$.J*2'_-(Z0^83/H*2-W3EKY8SML@[1D^'H:W
M,39^ #(>7&1&_/_;&?!_D"#T;3,$'Q4N@-,Z_X?,G7E<J#7ZLKRWRUH(ES6R
MV\^*. ^2/G00,BVH26@C=C&'B@OGQE9,A^2["M75(=0]8+K#+EM=\)R^[:OP
M]V*_1]B(9RVWP3"="(&;973&_(7Y50=^U9MJ3E"H>HF#W!>IC"]2;:K61'"P
MF[*T]RDN=V=*::Z^2ODTA0%YL5TW3GJ<4+K@AP$KF5(](%,6YC$)>$SL-C6U
M2KD2_#RA;)I3*D5T,C9';/8JU2#N[%V)-?*;P%]72N[#^@_U'U>]_?[/2)Q4
M29HHC;ZF-66]K'SJNGA G#$Y8RXR9J=2G(E-YGM-4>O5A3//K0J_=@NNDYN<
M7S;Z%$TF#JWE,QP!(& Z7A#Y-&<.X$!MKTR[ #"\#EE7J@ ?6%XT<$B5"TNW
M7>6Y$7OM%GQ&10II@U+!P;"E0)5#"Y@T@E_H*#G!&X0&/$>+%M(3?-" \1/>
M +:0.W!V2S7&5,\B]5^09;8- ,['--N0G? #7_LP_!D0.N7L(2:^.S<)I'_U
M,BW3D0*3ONG3/-.KT^AW<CKG[F5W;8&O>KA$G/,NBO,VG(+MQ7E;YUIKW;+;
M"1R>*\_-?N$+Y@NNQX(_A3BX#_YKV:_]W^"?Y(FQX;_8+G6;NO/*"6OLB']\
M<2RC.,:.-H9ILC)>M*I=+X2W&^#XPF)L6-F+#_[PQ/!I0FPX(F!!1ZX1679(
M$#2NA;/PZ$\TK&/@GV/7&!X,0O@#[?383L7D(FCB!<E:6T'03+S 1NEZY1/'
MP.K#SV^V%8X2_9%Y,):@XNP18P"+B,+5CU0%[KUY:&3_Q=6B[K'-3D<APXY(
M.IJN&E*OIZGBT-)E0KI&=Z#I_ROW&LE#(S_9P<1X(:V!3XQ?+6,(&[PRG#=C
M&C0^S9,CT&*\(%5FI3:+(&. Z?\V\.'1G-6>%*I+,1P*U;OOWW_>W]TTA;O[
MF]7TEF%%23X)+^:O_IZR7N@)-RE7W62YZFO*54\I5ZW<9%4V]>%G(BP^+J]U
M.S)7I,8&+/:H,W&*[4EM(;9H[Z,QO,)<=A[GC=;?HP!>$@1?2&#Z-FV'<>U:
MOQN!'3P,'WT0KVY(@Q//\)+?'=JG*+%$-68@VVY$K&NT78V.8LBBJ4KR4%%-
M4]$!>.+0U+M61QZHBMX0X"O&!,G!CT!193Z*TCQ9"PUGTB7@7_/);&Z3"_(
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M *0#Y@@E"CQ[A#T-#-^WB2\,(Y<R:?)FTXL<2YB T 6NIR0Y("A<0$VA4XI
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M"W@@5'H,(W2$D#" MP'((4(TB%4OBQD%2XHYMA02*06KL&C<-(BQ!=8@?#M
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M#?$1$3T-3S7\PCTI"Z<SN\!NL8@?Q-^DKE<<GY][T,P,]$R, MKQ(@[M!(G
M8N&>>&/$F@L?IQL;VN@UL;@S<2W:SC43?&0/K9!' \.A.B 8X>'3BL"E\ 87
M8%_V:Q**S$BY#;)M$&$Q  F61/*L('6%]$UD:Q%)&HSHB?$ [2\CL>#^$9\J
MSY2-X0)I.5N\+SG<94H"S^@)"P[B-EBNSMPAV35[\0]J_.'E1(W]7WB_PY[X
M2@8@MD$&H^N.#CQ#D$MS)3+6\-())IXETZ-L&JG"#V>(E";]Q%J(T1)(_RF%
M^@#UDV6;+*P;4U;R*/.,F9\<GZ;0 1O ?K :I*EVCBY8^DN.2;IE*J2Z*152
M/EDJI%PT%?)I%AE<<,W!=\EQRSN+;KEB2&;/4'5),D6U:YJ]84?JB);2(9+2
MDWK:HEO^%(W'2$J U,RWA=G'A>3K.^0[;E[,_.(ETNEJ ZFG*%I''2J#@4DZ
MNF+I/<U4 /UZHV"0XV= 'H:WH,$P5A7,H-8]D^#$3S:_)MWA6;@O*,J8VY+F
M$:QR09;B#*G='>N#8"ZRB1D2QB_0!RS'0B )W&*=&43C2>P^H'PT6,]S)NM0
M'*,/,TY##K2P&A2Z$Q?0T>#"W!D/U;]S71,8N;_0I GZ.+TO\X;$!%_4T)MC
M@50%C+T@G#]S2K>XXL4KE59.!0PUS@G+T#*]5[!I6.4@32GR/ M/.9H+>2GS
M$*$#]%H#@^GBV<RLMO ]=31 FS@V>8V#([,-,#V#AV:>2Z,B.+&)Z1K3]LUH
MC >C)AY(7>,QBY,J*)8#9MD8(1?P73X[/8UCLQXPT4I*:*_W<0I)(]#D0.?N
M#4UT-:?/F?#1M6O17YF'&JR,PBZ)[PHS>4%9%D-'2, C9 !"L9(-P)Z-H%MD
M1R9H:.PU@0/8;/.AE31@ M(NS0BU/,<Q_*"=#6_"DT ^220RSKJ>V; D\KTX
M?Q Y+4F=1+,V_G9[371T)D&6GZ,)G?"%]"DW7E^;AE03(1J+I%P1](:6,KN<
M_WZT2_$RE?GL[31"$<9D0S<-,B-[/7N0983SHRQH\'4(]X%/=54:?6FGH*X>
M4A>EC.[G57H&MC^C-6;NM[!U(@7%YYUS-T^_7W"M,,=VYEG/8O;P,RJM%[*(
M^<1G680(S<VM,2Q0Q7IN<FZ;Q!)"861C C55TA0 YY$S\ ?8=#&AQWDT5,%G
MU$CLN:XP)^>%!<O814/'MY@ 71>?P7.;%-K4.LRDY'GH]M/+/AF!R8-.=$RF
M'W"I']O@[V/B;'Q@'[E^\NO+XIZ849-FZ@]CK9E*QKE#*<")ESV+8C<A^[,E
M@9GKKI2Q;/LTKDQH1&E-IE<FL2RV,C/FZJQD#@'S,$O]$KZN67W>UADX 4^.
MY[ZTP) ;SQ_/.9Z1&N^P^HDQ39+\5Z53+:#X@8+E+L;-+=O5QR1HMG)/M!WM
M5QJ->T.UE9ZZ#*9"%"3YV[G"AR9],D?#BOSDUD5!%)<"I,;O-)N$P73M+"N(
M6L1I?+ ,"Q9SKE?D9K@6A=D=;0-' ;+2>.TMNONRWI45TQIV.P-%E7NRH??4
M@=X1=<,@)M%[YVOLIOV+Z0^W6;,$CZ1GP!1:C%7/0D#/E?OAR11*4AK*'<%=
M0-0.34B/>PJ.9T51L%105R^T5&6,4<[8Z:0Y_$FJ#6UF%B1^XF+B4EL0<"_"
M%T+#]>M>_(+%DS/IF/D$B@O3 8L*W&LF$W-0=1[*=&6'[3@-8VG;R5DC#7/0
M!#Q7&%%505.(8ZB#M!L8[J\YQR2UXO=,V>N<(KE,;_2[<GO5Y,PXPRPM>=UW
MB]T3;%''T25J>U7_M31E'= \\Q+WW*=VBGU*C;[8EC=M<SE]<KXD XNA0VJZ
MK$JB3([,ENRS6W3(\8$Y,Y25A1K_ /F6S8( >1%&:;UURD/X>$)LK-<CRL3D
M,)"QH8 92I09,2Y)K12\^H(A/1>9>BX<QRR0N)S0)Z\V>6,6APG/PLLP[&;-
M3(^ K%CFJG+OF6P(5\,L!L-*(DH_F?GB+A5E:5;076;E.-443%4DMUA]K*\R
M6RHDU^5&/WSSEC-0':QZ70FO>2LA"XPYC(-2&A''0L?N+^U'P)WGOQANYAQX
MH5*&&J@ !M_&8GM\$K-YXN!Y2@.H\PB2L_^+A"SA-?:D!<)*89CM#7J >M;,
MFH6OK<212V&\Q.N]+%J6&MK-%.Q=_#4<PI3"N"7/@(R3Y-O+8_[^/0/():K*
MQ,40+N7N3,_N3-UC9RHV5<GI1/#O- NGV*JZ8EFKZN#Y9NZJ,IY,[+^PXOUY
ML;E'^M ^EM2&-,9ZOOH2\ZDDL5()5;DGX!M/M!<[_A!95,R>*79$6>U:G4&/
M#,V!:!GZ0.P1U5R5V[39E9[_CFH9FM8;6JIL2:K>A34-C)YH=109OM)!@5/L
M;&LF-IXQOK+L_>O%S]PKZAGEN'R)[Y,:6NP<@:98TK]]H K;B^"[5O"QO..%
M! YQFGC"TK27JHGVXR0@5\D/GY,.C;9+=T4?^AQ_,I8#2/B+?<WQ@^QRS!.:
MWM8URA9Q+\KXPS''M.FEA<ZO[!HLN-OMK+PLMJ65UT[SVI[:*_VU2EO55E_=
M9[$=>:O7[CNWXM3C%M;,SZA><^<YFV>?41@7![FE+-(YZ!UIQMU)(3 7L=R)
M=K8=/+S%.[8>.5MMJBH4B.IN&'1 SSZ>1IX?/H,7F;$,<IJFZUJCO^R=<JR>
M *ORSE@M-C0,[.Z^WNS*^GJTUUT?KV_>?XD4MF%R72&QH9<F-CC*#XCR#4.)
MRY(IBBAN+U/F.^\?+<)6C3*QS2&.9Y8V,3L725/%L)]MY-.CRFR(F!X1L[.:
MOQ@N+<&AQUX3WW:25AH^H0W_[%?B3',*7P1!6"J<*)!";-@^/=Q:.*GPHTSJ
MQ8Q4I!K%7(JF"P,D! H*X3LQ\!P+(7 61^]T:Z]T:W9 ^[FY+-F QM.!2@A+
M<7J;5:J9A%;685])@@FV;C+V#=O0"1/#IM=H=A4FP1MI*B@])*19$""PG?D$
MK $)W["A07P$A/,N;-,&@(1!4K<VGH&>5AJVLX5#+Y'-RL-!U($<LH,1YIW2
MXLIX>R.;^-AF;,HVE!9MP((([=+,2C;>[3& C[7Y914OW@!@^QHG=TVB."L!
M4](6[XS<Y7O?1K@KNG2:2)<NB!U1T@--P\>L!>Q2/J )5I@%XF"[)1K/BU]$
M5XU%<@/Z/8OUX*0@R;RU_'#?*:CR&VZ>G85+\>RGOT8>GEQ3DHQ; M!L0$8P
M+*W6QI733-,X$1G3=&9YR&V!OE>0DLMQ))70(>Y+1Y#+U:[YE:VTB9'KI2_/
M9CZO?L.YX4F.\73'J#63\YGAB7_.(3$!3BH^4D'1%(A-7Y"VWZ;M&9+?/L=G
M_TF![O)K ^!-FJ2?1P<YU(,<O?R6&3UM\\KD76E**%8-L.^LH1=YQ0LOAW*4
MF')^YDA/5"38"QU$6]R+FH0CSTJF$<2 SA:AQ4]DE45R3C+3!6E%W9*$6(DG
MY3+Q1(OQXTRG&?!69LXTDS,JEG&3+0BA><I@&R3IV\V9!1SG3C=9CQ R=X]K
M+;QRKK DFYB<P6_2O! 5++I!268 4@+:X%33LPS,#9D!JP?>5-E@+6;H/_K8
M,R*</CI8">Y:F.;&^ESG9U<KHKQXQ&MVNIJD*CU-'X+_8W5U3=$T0Q_*W8YL
M=H;RHF^0?)+B-_W>^JKOFG)0OL.X$6#S("()B&A7A9 UB YIT]LV!NU!+]KQ
MVP-:_!'A';-R $R5Q#6U:&]5)D0%5AH;6]=)5:J% RQ>T>YW[%>2'C(G!<AQ
M;0 ;Z8Q%(7,PQ>RTEOW>&MD6 /X*245)NY]37&:2B/*IL[N4);22/'\&9!@Y
MW^PA64Z1LR)_H1&[(JJX%-L/T<_ 5A%+70;R7.@YX,9RB788*99DNCY@D_W(
M=C$:<;8M3(V2FT#$RRE_A1M5=P^XSBZL4\Q?9Z)$YQ+@<]*XZ(;P=&XA]%$2
MEC8<P.RU>PWG2I>$I0US>?=:9Z_15Z7U6 KL]^(XVDJ6GY5:O0,KTO914#WX
M7^Q@X@6&\S#\YKDOWS" 0F<FKRI@4L2E;"W-5'L]HZL.I(&D2BHQ1&78U8EN
M2)HF#TQE4<7./H\R'#_;HM\5V(</IFL/W8QQ!V6[$71SU4*L1@]<NAD XZ)
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MK/]^>Q**5_Y\GCP?-E)[6S%A).O&(MU6,K1JI\Y"DD1Z+G@6:9#]8Z@0)==
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MKO6:TO_OZRW3TS[O::839<>1*JX^*39J;:4XOCK7#I/#"IG*1^$V/8U+1J6
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M>'8Q&.YKEL1VUW$</H2&H%X%06V* .Q,4*.SB_Y1$]1#9/OA]0QYPNXBQQ9
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M>X$13J>>(PS8%?POR$L1&8 YYXX=.,!R43*&*43XT9:!R\EE@*< ]["7\+/
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M;LH9-,+G:"@'_5=5M(.]&GN-U'EVVADV4N=8:.=CF%38/+!%))U7.!'[17&
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M[TGY^'DG8^0][)!>GN'X5SR#S2?X-036&5 J:PD,K9.XX6^%25U$7))X<)@
MW2K]0]!(3-6W>V[_\.8X7&O.J!!P4^[)BK[]^/[J76$H0!009:#?]58$#K;R
MMLNCPUI&<4,XJV'FQ<LP0@GFKVC&5>3!$L@EX$<.O-=;*G*FN23Z_K-MTZ9\
M;^XMBZ.OCOCN'#N*5C30C"Z"V1 !70ZXT/NH@XRAB2R2I>%L$R9EG#JS0@V
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M*-EU22Q<4[*8I4"=G@9OLLJ _X8?R,'%2S7-+<X&6*;76WB*'!3T@X"8D^$
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M]$J)+)*N4X&W7V'3V4K89%[SEQ!UE0K0;@*G9JP\(9J-XPG)4DM5G'?VPG;
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M,'%%CT^!K6(8A(-W+*-M'ZM^EE'"Y6\4"\7?^N*6ZG1<L01QP&49&!83P(!
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M?(&ROG;O*VE9FY)6#L6.&F(@P^QO+F+?6+E-M4GY]#&^F$P-36^P>*'9N'C
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M/FG"O?@BEHR0&3?(U]M;$&PQ<ZI[+Q:F@NV],!4HY2=)7/P$95'AHP+WQ&\
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MSE'JIT^SV+\7K+LL45T/@  F@#VV\IY@E"XFPR-9T+[B@G.!?L/W!;1.HZ2
M17B1D\SA5Z1(D#@HGLS$I"JQ6!J4U/!G@IF@N%O?OJ\@E"U#";VS"I(HI"\]
M.?)7>^"N[S".(^Y/(M4U[Q5]<Z;^/MO11:OY*A ]SB1O/WM+$\B,B0<RPID%
M<"H05G*RF9(I%.C*9-W"6PC<*!)1+'S)G$/TR'FX.UYCJ2H.6.P1>P Q*E@S
M=691"*NAG]"WYZ#XAM%*.N67(:TB4AVQ9?Q+$/6AGOXGVSPR$1-@_.\P^FZ\
M0\&3QAXH?J;/6 N,7P$ G<[H9]!)I_C^0-B1\0DA.3.-7P6&X%;TGHQ3448U
MA9U_D/$+'PW[64[ACL[H0\H\(#U*PI0"[70CJ1ZE*1+(_R-R:*B^D0AZ4&OF
M."%O'L+E8]ZCTJB TX#EF+E-9\!Q ,9_ LN>"M*(8H,]>&RS<$XFK>Y&*BR1
M!',P$ (A7&+3H&AYJ2\80[1D*.Z&/VQ.Z5[4*E/&>$.F3'?T5AU(R0Z/<.C+
M#./BW6I(H>*9W^H<I)JWP-E]CB^B$(-M;R0]?KK))3MDP (#_CZ0I"- C#@4
M9[Y#[$XWT"EII:ABJ5>C'X;3.L@V1V-I$<.?YY' )!+\XM,-O74>HA=]*8 /
M @[=8?YLXCN"&X-B!3783MF6?W^GMLRZH;+ZRI!*34F25[?4>Q1DT22\!P50
M++!$P4=HJZSJ,&+-#C-DX4P3.XH\5.MD2%&MS.ZW5)7UR6(&\O0!$AC !R $
MF"V%V'%K@]X=:HLJ5#!E,@G<.:H0COK"-'Y_9QKOHG 69"8#?T5>.]@2SV'D
M4\2KP 7H"KYHC$Y%P)LR9Y@R@\O L0&Q?RP-"164_"D1303%:1FGI$T/^C:H
M&XZDP(Q&4NJH/>D&%?C$]-U\K%N.S*0:05@D+K@R,'6<AZ "/F2T1&@;%VQ*
MC<)1$V/S+?.IE VI\@C/G8JHO#GHG)%#^3+GZ#!J#[KM_[VU6O]9W)X9MK\$
MZU^*W_^EKX?6&/[1;B]^\$_RSI/.H+?X\9 YH(,^/(@.A;TJ3\>)820NT0\Z
M#V-0HMT[U+5=PXV2V^SBS0TBQ43J9Q)?4ATP,BQBNVB62RL8.+-R-,3 TB,2
MP!@%#^EWOJ:#,6<AQV3D<@ ]3A:<VZ#ANDJ;JY!/\#)X>F[_)T2-*?HNEBPI
M4SGWX?/-[U\_I*]"-VW5$3&*JJ3,.J'W-9-Z)FF8D4>/+.\1$DM8%6Y+P%X3
M5A$%!A1L9V62*W&YDJY38)>1<C74;0F@%<.?9#).0E,+4A"$J#9/RM)WE[_]
M=O7EPU<&_+I#$APPM@=/KSGF%UVX1R*]6U).E!=4!!%P*XK R#MA3[MR06D^
M(1*IH?1M2"<7>]U%FEJC9_.0XR9_* ]-<I\.I\\1VR\9=;8B(^-I7KX=#4O/
M$N8MG8<)>A46YV3($%1M=H.(P)6 ZK6,3Z"<(.U1E"TS#?AZ=KZ6 D'!M6#^
M-[W**.T-)9H7Q<O"PXH_%#?;1_^%=/KD]BHS!#C@H]1S=IK<AJ0]QC+<@U+3
MY' H(B[]-DTC1NLMU:_2, UQQ%R6!'IK.$"#4I(5_-1?1[(5[GW"X0_/P? /
M^G8XHDX&V$+V;.!N#%+WX0QF]J_8,:@W<>KG1/[F@5;/3A."=5K/Q7E5'&U"
M1@@L![ZJ5XU>9<BA>V@AAZ/7%:ZF:98],8X<"58'T4@B@U"<>('@$,.Y;MJ:
M_-&=%V$&/&5'B@3Q&;TV),_82PXD.;.+^BY75]K*$B<?#%OW'#W5#395?."+
M'RB:9N%B!AR,/3I 69]N6L97X3!G622<"N\:>DR&6"':L9227G-@EH2V3/ L
M'6:)I3!.Y/'^F-L ]P%9:V/>!3HSPXC#G/ 6*Y6]GX'K65I5?6IUQ7'H>/1C
M:;$16RJ^%CD$*L8RSP&CLB*8D:,Y#]$)F&]3+V_TMS!%GV@?.5:-.D@6(+O
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M+I-+XK"392C+9M*Z%&PC&Z<Z5CI]FYY5"AGLA?D=!U<5OU-5<A%YRA6[@WM
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MGLXI&['. 9UY_ZK6W.A /!$E.8M%%!Q053V^8VKUXJ^R80)IM26&&3(J4#.
MTTA*BU(3?4%2289" A6 I0]9G<01V7=XX]H0 ^H,7-NAC!)QHC53M8MS.%2@
M8XYMU5V!":]R1AR9?106\?A5LJTPK)=$<2*G;8;WQAS=*6I: 38%YZ&ZV#[,
MSI[D7,V4F4XH'LO& Y6;*S94'%^@H:-R.]=V'9.^%]5I,YT/KHY2_52:'ZIY
MN-/H]Q%ZJW^EF!5+G$LM(09TG9/R5^OGM//G+'FL,\,,B;ED:)G4 9Z'0"*[
M$]+V\L4MS=D&90MSI#$+>FG_D'*;AY4HWQ\/AV)G!ZH!<1*Q7P1S").Y](9@
M6=;Y)$VW@)?+O*?C0[.<5OI&8M9;$Y9?'@MZ[9@ =866.C8&XT,?RRDW&*CR
M3-+BD003J^8']!THG $G\Z#T!\M&K%20D"T](@@[^*XH)992 T617<S8<>QX
MIC)Q9H;X,_% Q2 N/;%I8BK'=;S"SE+WG50JM=EP8;(D>TH95EWD][=^.*&B
M/KE,E(W5*"SS-,I+TT>@',,?'F\,_Y 9TPFPXO75&+)3/I]/"NVW&:_*27>[
MWD1&V<U58YR;P*TN]3XRT@;+(@1>D$T"PG1\Z7OC,BKE%:U^&[O"9 $4'">0
M)K:STF<S&K=@.# ']4/46/5]^:#+GE,1&K$Q57[KAU3/AOJ[30-O5F33K\G/
M^B9'B.>6 #ZXO$=6*+V27/7+[N+,3WE/@UJ7V)L2)8!6<LNE8)ULAEU W)PR
MP*<)E4V0SS*_/!PK6WU[Q>?E4C_*F9"[$=5A\@PJCHN\./.+?B-?ZB?V6W[(
M^RUS;LL=E=7_O[TO;6Y;R<[^*RC'D\CO"]$$N-N96R7+]HPRWF+YSLVW*9!H
MBAB#  >+9.;7YRS=0 ,$*9*BQ$68JN3:)M#HY6Q]EN<<@@3Y46B"PY!%<3I%
MJ?&_@I.1\YZ#2\(OU1[=PLYDC73D%Y3&QCSQ<THAF,7BC?K#6]>+9[XS?^,%
M-&-ZZ:W<0ZGF4:_=8N]AD$Y2/-.F\L]2Y0T&C5ZSAUHOB>#_7/5AJ1 ;I!!?
M)^[B;^U6HVM;2W]N-I;_MFI8RVH,VH.MAEW]6]_NUI,]JLEVVFL-^YHHEZD7
M^ .YZ,\O6B]*"2UO[-DOPRI:*YBT4681YHY=RYK^?:*FR>DL5K>9@QS+A6=K
M&JRS)K;2][.J!7719 &Z5#DL7>KB\35QH2].9U<NJ<:FL '/AI#S-4G]1EI_
MEA@4BC34]([J/%&9[VK!2VE]81RIZA>'.JF-M7<A)Y[CWKVL*?(1=O5/1R^U
MJ]=UYN+M(I+56F$*0[GQJZ4D9%LG*,;/TL!)72\1[JM-3GGHC'[>1 CG<"XG
MBN'Q\7C5XJN.'W;PZ:^YM/"O"W?8-VL8HO>N>QW!L?48V\YCX\,<T__*AVG0
M?P>'?*K+"G/*1[O)RIO&7F79FBM?4'T;+5%?6H2C'M3:;,NT>G:UD;T-#6^P
MW(WXN/3),A_71'=,1&=US4ZK7Q-=371/N+:VV6VUCY[F<I-Y,QNCDOX.[Y#L
M_4B%?2QUHZO?NI>"([ CER?,+;\>;K8/1T+K+;/?'FQ([BM._;$$TKHWJ-,\
MI+;9W-@\K@_IB0_IS+9;"\ZE^G@.YG@Z3WTX!Z_/5<Y%$ 9B-3'53Q:?W*7#
MK=4[9$/I!]=\+CA3MS*3Y"XL]:X?HURQ.V;3MK:[,*RW$4=TV3NMDVV:7:M9
MG^SIG6S;;%LURQZO?V;+LSMU>VY70=N]KOA3&,M>U>%BDOD65Y6U0_E'0OQG
M;'!L?)G9)*7A6*ZAIW>V9'+49WN*9TM&1WVTS\3D>"8NI'5MK8,V.:2/H[*R
MLO9SJ'0)L#JV3-$YN3O321WLF67:@PT44WVH1W"HMMFR6C6W'JN'X\SJ#3;F
MR.=G:QRA>^.+2 C<8,M[@*Q&:<VPN42*A=7WEJ.<= ;@CG?GL+GES&Z9@\$&
M@F&WN[/G&V;-(36'W,\AECEH;NUEJ3FDYI"3YQ"S.>@_4P8Y<2?EQLD*)^6D
M?$V80;\MZ6BU!2SA@<+ $8;V_0W*<KSQX=QXV6YTLS8E6K?U^]"<3$2/))RT
MB%'8UGC)5A!K$G$]$F-?8,_,,^^5X1@O6XV6UC%%Z^)>U1Z$P9\U&#B<P#=J
M4-W*X927][;&-V>$CSE%8-H9(E&-?!&%L1>;,".>DE5HXK+]E*P2>AZUA>9N
M(_2QW7[-SC^R;/FT0XCE>RN6;, M3:G9Z%5.R8W2&X5PCPA@E=^!264--1 \
M3&).,WX@?$-]HEOYB04$XI5M=+2-<(KC3(3C$N"JB=^RLF]E[2H0O$]B_ =A
M<$Z(JP1";"R"$--WSVZ]Y9NC)B*[0HTB3%L(J-$,;4TB;L+(PUX%.C/$W-."
MVJ\Y/H$TCF.1((LR=[A"C@_3!D)IZ[V%-J>/16I<1BBI/Q(2,!I$F)?(!M&2
M04JSROFW]%W9]5SK,BU9M +;\.A%\#J8VVKC6 @W&_83"^'LX.X<'1I4L@'1
M=DYBV</(Z?>R2,4'<F+6>1-I1E_Y^IRS29/*K<&'#X:>"LBN1>UM:RSWQ-J[
M2#A. I)DF#*D(PQXIC1:;Y&*L*>=!'L5OT:$#B9A77/%VVP,*I5"&? :)N&H
M+A) 3]AL0FBPV%'6-R)3LKH*R$:F?GP(19MUY76KEELAG9>QRBI=58#8C9=U
M_,H@=<N+S&4']B?CAK'!RA$>J:_1/0Q4#UT/7>.[+^"[]VM\]QUC-5N=2JSF
M:^_73I":);%AA^ 3Q6Y>WHNO1FX^!7SA>K(U<G.-W%RM/)K<^7F)JJAQFX\=
M ;3&;:YQFQ]]8VO<YAJW^8!VM<9MGM6XS35N\\-206K<YJ<XU1JW>;LE'G86
M3KMM6JW.T<.9UD1W3$37:IF#_I:U3371U42W96JE:76.'Z'^Q,OF6ENB=9U&
M FP-W+SD?GB2R=Y],+UZ-2;PH1]2LUL#-Q_X(?4VO<'4)_34UM=SKFNI\9MK
M_.;'QV^^;^7/LS1TL\4?MFCIV*:];9.UPZCN?*!'I2;A8R?AMFTVVUOZFVL2
MKDGX %9M-4W;WO3>?DPD?.(N1GL_W?L._BYR$N!<-?;X?3V4R(:L08Q/\6S9
MN*K/]A3/EJV.^FR?B<WQ3/R?-?CX-I>%(Y5A+;/9W'7/IB.^.IW:\9YUN^W=
M89#7!WLP!]LRN]U=N^R.^'B/\ 3/.IT-KGRUO^-X;(^G!R,_=5?U[C?HL'GF
MK#TP[=Y3 BX?V-6S9I6:5=9WL/6:3XG>7[-*S2K'R2I=L]/=.LQP_)QRXOY,
M:S\)MP=RIZAQRE?@E%M+,')70Y=5 IVN?.4^D/*>-HT# 2FWGQBDO!J9=8\@
MY585I.NC(8C;#T,0SW#/E\WZX=#J)9#RSGY RHMD>3@@Y=TM0,J?*4IY403K
MR,E/*($K$<K/%'%72V-8R:W&]AHQ%-":LU=VP $E.BNR7;4HNEE^!+E<65CZ
M_3T*U$0:-4PZ4VY+AR'?%^6N 9'^4*1SO7%)-2;Y$N#U(D2ZKIER=8G@LDXP
M$@L+03CS.3R$6V!QEAQNU5]$!&=J?!0N$?EG)F]D&>.C%^!(FT"L=PX=8GU#
M#>&Y?W[AC3J=EAAWFJ+3&[0=J]_OM9MC=V +T76ZP][@'[WFBPJ6*Z$0/SJ_
M+0!1$>3P)^]?J>=ZR9PV_]*9(52S 78]&"0CK8[H9&"F:=5,NFB/7(9 &"AO
MCV6E*P&D_Q#&!'0F:!>T>MP4KSS.#/YX"TQ [!-.03G2RF/'9YTJWTBD)D-;
MR@GFP$>W(@!E1:) CD8O@3;-O@//1,90"#+SQQY+DVQ0X-TT0KF;%ZA)286F
MI ,<3Q(G1AXG"QC_,$NDMK6;5C?_%&RF,QJE<(.@&;IB[(T\8G-:X"\0T(GP
M44UTNYIUZ"05,-@O6U9/Z[E!O4V,]V(DID-83LM2>N Z'<:)$TA9!O\/GRNB
M<,OUL-#!3<;=TDTOW@!8S@@MAQ$M[LY+)C3.4LDG;586Z33F"C-#VO]Q',+!
MXB2R\?,\Y^56Q)'1-^XM$")H+-A0. (VIVBC@9!N @_HPM$]$+AA4CN1!B@?
MG8)/1Z4:"T$4/$Z3-")M?8=4# ("]I5&RC\*K\PBD6D3^E']13]*23**@V!R
MKN=F'4T<U]7,2B 0N"D[H%]A33Q3:3.0"0-<24>+O.#>HO+5OCGS9@)W##^X
M^#'0TFS[X T.9H6^-B0,>'&<!BY\(A+%ST\%A8^#FW,P3J:&GRF*0 A\GO9&
M/P/Q2XS2A!EYF,)FPU@&$:FXF9OX-++2R)OAHI()<";,!U<$?#6$UX:) ^^X
MV,(F3&\F-%O)0"0?Q@:2X! ('$<V]24(F!O,;,QB/;@!AHYXTX;P3XF7M1,
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MTBGE2%Q]_OV\W^G"RYBYADDZ10R^5I[*;2K@1,[=\V()YLF?'@J#4GLEU&$
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M";8;QF=4I-?.6  /ZK7/S_?D>L<@3CN-K!HERZ9Y@&_E,,[O 1(3;HT[@RR
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M#\9P["TW'%\/0W<._YDD4_^W_P-02P,$%     @ !S8#5T]L''5!#@  PHX
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M#%RD\*@4EYQ6@2G5>M%[$RVCLGE-4'$5^DVTT+8PO)E1S);2*1T@T4P$A3E
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M.-:Z-^UZBL84G0^-D8:ZN<_H^$J+RC"!\/I![B#FW8*[1N'MAIN_>&8A"!^
M!5NOO+1D0%2DMRD$IW.P)?O&4W2;2]=N%[-<Q%!]Y'2%06&<E2@H#66&UVT
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M0,J#+('L@YX6*MG2M9Y_7G]$&NN7'_X#4$L#!!0    (  <V U=)T0K*ESD
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MFI;MKE7\6+3K3K^@@=>ZQQ\ I3(=SN C3+X.([R'R;!)'R V)W-M_=./SF
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M768;+KR<,S]Z%T;#D_FHGZB-$9F6]JZ*+DK).&XYV8'4C":316V?<RDA#QX
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MPV$'N>]GA[@@,(%*0J/CG!6:*C1$XGB61 H7O8]HR?CJMQ'[!40'*VZ/>-A
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M3%T^EU;Z_39IINC,VBB8R()H&G!'"10MQS*4*Z6DA'>6,GXT==*KV?B!]R.
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MF?JRC*8E*RYNH*2B*"4K+PG P   FHP\V,X>]CH V-JY.*E(BY%K:>N0(PT
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M@ /@ 00 44 2D ,4 35 &] '3 !+P!9P MP!'^ !\ 0(!9X"<4 2D YD ?E
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M9Z3/"1<,%W67=R_GOMA^^?+E/4!QQ]3>V PP%;V*'^" ZW"P<(C?!Q!?9H$
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MUEZ.L*RPKG#7,6U_;'O :M<YU>81J?9ER5KEW'"XV>1"7/6\@;+N+O@P8:U
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M)8*6.-89PCG,<Q0ZI4H5MB1,VY\-XP:+6.@VR.0$3S#,T%]PZ;AALTGIKG+
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M9/,#/SQU0<F_-2__.3"V>#W^>P]9?L[V;S_;^0HPX1R07N Y$Z\O&_]:"X[
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M7.(A6:O.4=+D7.#4$'<B="K.\0G"(E10FT(.H!NY$?4N<_R1U'.%07XI;:R
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M(L**K"R\'U[X4\?\3AT+GH4*"/_N3 >@E*I5.(0HQ0AKXT4+_ A_>T2(93*
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MJ</5\_%H*='@W*;0 W_@)@Z1RG**;5*]_ !SI:^0.(<>M3+UB;QCR6C5\)@
MK4=P.OS;P,08; LT]F9SV1<UP^(+12$LJ/1.3@%*0;F"]I4:1].5JJ8[*QP1
MY?;;7?]<AS\%Q,3%XH,O0-G2?4RSCV19[P3/<_*3DC[,TMFL\:_R@4JD7<8Z
M/I-+O6:FT M_:0NO?K0>ZA*F#%*M1WNAVP>.XJ!MH;:@T(YP'I( @)4$__<;
MP3DYZ]Z=C? I#SKL<3T-CYV&H\G?C>4PU""/TX[<SDGA9L?EQLH%5;I'/C+/
MR,JU)<8B!@ZJMM8SX,71RVW'+(_V7"R/5E"6]"-%G_YS\?\Q8''\<NKEVM.2
MS!KQ$1CO?I/\[3027B;>'SF*Y5LQ)?6K_RJKOQ5@OLP R#"P  P"<'$6>.C?
M;,A&@(8(!_,3A)ML_6?D/T-@9>[W_O7Z*$M? .:_U.]7!%?\DO>OB?$500G\
M^-<%_T<(X-Z(N3X#NO3*4/3.SSVM2Y2N'WMWG\3O/H0\'%"6(*\[<D[X>K P
M7J:/-I[CS((F)4%!;<2E.3_SUHNX]*6S6J$];>:R!!"U&<IH7P;X12N9,G-9
MDG#U?>\),8*@.$YXD2Z5>)=#KV#JL/TTF6XRK<SYXY>,ED%?@ >X%<VOE9&E
M+ ?DV\^612*-PZ(":*)O>ZGT$M:91W,$AR1I*<1[4F_!76S<%PZOO^C>MG <
MNWY_IR7,'5;.,^1AB&Q63QSUEOECM.GG<H3]*3/*V3=H<*?>J&B/@FBH-]\<
M/0H)'C.1BQGF^73LLK)&0\/Q@G^Z1Y)]-%F.,V-4%4U8W1)-'ENU3PUO5!Z$
M^OIHS-@-6T4AA2F'( EEV4V/47:LSY=\)%M1CFU30[5/3N0"4Y.N<9OE4R9S
MES4=@3$'#84/?4<R3G!"8F@F,2<>=2ISFXH\A^IHG\3!,'H8)J6Q.:ZKDX^J
M[YZV2.,V_?P+=<L#4'$4\Q/U_#4&/F,X;$DNYM95305V9NS17&4$RUQYG&\R
M@8;4E5I,V3:*)+=QO9O*1=IUGEM9YJ?SQZL=IH5+DH^8RD6XLG.'V43G@/@3
M8U76:=6"Y%5P1_IHE>)\-E_<5>>OI=B6N10*5G9D9ZPP]*\,LE#!5>FCU4WY
M J P@F,'!1O8GP\2(EB^DK(2\R"R!4L9QCD*+#'O@,$=] _K'(.?QZ?S)Q#*
M<\A.#&=R!D<-9( WGK3 X^#DLH:X+(F!1_O2XHU&"L6,M7)R"'P*HON2[(U%
M%@(/-V9?S^G$!L@_D.C!&\=(:"TP^#AZ;[0#<:3GXV/JNT0^\7N?09S=$0DS
MIM1X76+8ZO))\-3"QL/WAIL')1;7QT<].*+5D.]>\^(E,HHAYM+CNRT/#HA/
M=/^,+>;1@A>Y6>)=)4[[T 6KG5*X(XF=!3=&Z@X-_VV9K%I3R2_ AM?5,+0W
M:I.KS,^4YJ9C4G$9379H_0*PQW;),7&TP ]B%ZB,*LO+58%E.'M:'@X$U9S?
M:3HM2E\XCK4;RFJ+)JJRZ>E[%1;6D<R#C9V_GU*!^K12-H+^ ']T_2Y1G;%Y
MPB@* YM<O-GML;%NZK0RZ?IMJL_JQNEX52CRT2;F40CP%-+\"<JJ^,JQ5=%T
MB9),2]W8=T,D'!6BKZ-$/KA-HTHCI?TN+.HXX#YIF]@4#656"(-\;/1R.)IJ
M%J[V<QN&UV=9(71U$825J7&4E[W*.[W>)))\RJPX3\5<<G$]K^4?9N'=WV(4
M04&G]8B_#T]CH,%!2Z;]!>AB0NEF:T?$H033T8#O8@W$_^*)X?&NA*X0QX.G
M3IGD1@%%],NF:F(,X/W8RNX0N1(OQX,,WMJ/M!I6ZL[J^/$9ZEOO>,OCNAFM
MQ&IQ"#>2/Y^5XW53&LEJ4H(_X!12V(28*E+G3^""&0W39!E1LP3KDFIQ[WC5
M8C!0UJ)2\.=3*RKH43@E,ZIDL\M>NZ;R,B&W7S;NV,E[H3RV1&+8/YLACJ^C
MOYU+W30WH>A=+VT^"_/!)39?2U(NX?HJ;E_ADB,\4O9=_EJ9U@G%/:\>,$3D
M"G*CIWBN*@S<9BJ2S&K1>9D:6/#OXA.Z&5%[TV3CGE9+<M!%*T49.P6E5#H$
M%BF_/^L**:_%;2,HD(T>B>M*XQPWZ]+!8XA2B(?ONPV?Q<#8LD[K%/T,>':+
M,W\L1Y0VZ;;T!-9G;^QL)X)4_N4^&LJ1-49(.7R@1 PKCA&S)+MN\-)=S3CN
M@FK4,(T"<62M G%9E1)QG)ZB.$DR2C ->66'3*.V\S,\AG'<QR[1,G>"E=L9
MBS!U3-&YLTK$5[F4KV6K,V#W,LB"XG/*U;%.J*Y6KV(:*>J[J$79R)UD6O:'
MX]C>\R"1QK$>H85<JH\GIIVBB>,,(8_X(1/4BVP0%^E??&"BG@@JW?R//M@@
M#%9ZC/_8@[(6>.-?5NL?*'PH'A@"]Q]\@(26Z\O^_Y./P,)-QW_Y4?XWVOQW
M]O@?[BUHY3_XL+(G\<!J8Y-U8OU//A$B!4MC'[:<&K=+*R_'Q?.7QE:])PW
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M,0R3J]N.5#:_54\LJQ*)*&ZZKRQ=4^T:D#Y,=0174,H&C>Y8A2J4DVL$F)/
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MG0BSM'2OV08@^?B215H#/'7X$2X.199V7)E=ENF-/ML55;L^F/+YQE[7/Y3
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MI>^/S<YY7WSQ<[P2Q(E[2$4GV3.;K503575&Q<WOV8#!V:!#U-"!V0ZPDGU
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M@U2(Q87!$#JR0-,QT6?%(":<B7<F%D+X<Y6)==2X["<2V9_#H4:??W;;G
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MP"-26&7TE OD8%*[2'NL&$H0:08RJ!5E96 4K>DMW0%A7EFB4JY8GZ%71;R
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M:F%T.NY2^VA]MGCU^V.5(R.!^D*9IN>&?APSZUEWKWCVU4Q\/> $\,D1#/*
MV.-GMHCU[OJR0V2CIV.Z"SN+GN@Y\93/Z@2EW/=K=-SF'>QV3<:D(MAE_O&#
MJD-/Q",7JYOU.EHZZK./B,R"[IYUF7^]X/L^:>7^.?MC9U\43#7LKPP84[L8
M5.@;]+'ZUMZFR::QIO/A#+WZW4=KG9GNCR;+,./Y9BXG .<EGEU:?_'C%414
M[8B!.H]A>Q5S;-U\,5&)G'//<>WB[(C$KI1F)%N_A\<??#AX;WX.\Y/3SFVO
MM[L;%'__GO'(6+/=3;E[9V^_&HI% (^;678Q]H@K JD^&$)21@9*&V+^=Y%,
MW^4,_>C^CWSB'R<E<T)9AJM_?+L_3^%NSJR,])\WA0BK5'"*!O_5A#^I P4#
MD/ !/SY;7>:?POW_-NG9)"%[XXOW)L='_W<I#80(8%""DLWUMXD-TAEZ;43E
MIR'P<2'+?,]NT1/Z_U25[,5JYT^%H__TY__8*K-1]/&+WG]-W[]659VHJM6L
M_ZM9<NRVRHG$FZ]KE/]"3K"KQ%/(!U3M3SPXZ7BEX<7B7RF6/ZL*]RG+Z/[M
M VVO'M2]/_!C?_G-NS>'G^QX)H.<N'A3B-YHE/'ES8?L:T_OB9S].Q_Y4>0S
M]8#3[AP!S4,M+L%37+UI6A+N$=$U$P]YLF4]U&\M<?H^^ LJ.Q0O/GR#N/IO
M,RSQ(Y]JF7,;?QU#_I?*HWO?^ZF)G?JWD-56)>2'#WZXV</2'>WTJZ/9&"+J
M[8K2\V5QW6.^)F@+;.8P])+2CPGWTP*^,2_>_OH#;"U[XE[KX*I*DYI>\X[F
MVV]1RH29[5W5>7&^556G-*Z6E-X]UJL]</U3YNVO$>^+]7^@!$E%UL>^&D^-
MDVB^0S[S3$'$.F2?S'CCF<</]+?/2HVEE#^^J^?6)W_K<V7?V K7/BE@T\[[
M=^)CQHB%88-SPUZ?6WOR;D>*6@;1T8DGKX8_KQ9O]BH\\WZAO$9M%T8C\H[[
M9TJ_'^^)(^,V;\HZM<CB-C_6#(>_OST8V"!QLA6GWLPR#=Z7%.IWXL")N(&-
MP=RIUC>!?L]%TR*8S>59I+,R/_C=%'=]G7W^"0]J[&0;.ACK=%*$-"J]UHQ<
M<)W!/7]\GPI=O^/J>%G4."/&5^BB2)#Y<N.<<F,JEI-^\]/E.TT"3TZ^<&L(
M>*<]9QVTM[ ]]*SJLSK=[<TOZV1Q1[L\>5V/EB1_5+E@)'C>;A*],#!><Z"W
M&?2M]6!*R-&8,?Z2E'NE'CHWT<7P6IA_6.=!@<2,NPL_G)#N/<:W('0E=ZU$
MXTYW/^GV17K3R60W"G$0,[_S,]R;%_9L[(=[X4,58N&?%E];^3/#X[\.:5JE
M%/;C3L:?J1IXKA,HS:]VHO-8ZL?=7\5>U5,/:(B_6BAT*&-2U4[E6Y>,, I]
MG;IN:6J4WOY$4^X)(!]KN+HT<V#\3' APOO*3;\]3-K(Z/S0E<"GG\0O=C-=
M/F$C6I@'W7Q"QWJ"%.[="EQ68J2XAO>/NS_V[:P]_B-,9+H$D\18=%Y)[N^M
MNEE/?IUPK[#]#KG9ZT/MO!Z/YXV DV6I99+FSC%[UBCQ+Y<O"LP=2]WD$#!_
M_^FUTS/?_;W;%WE%'V9HC>Z+.9PVKIUX CINK^GJFW #7+I=P.]S,A6;T=#Y
MZ4M]]2;'@\DT>,G-L%-?'5M==7ROK9>_'*^XB78B-3G.^16A)AM>1HY,VHR]
M%=P7F*]3HZK7IE+7T[S]H<]SO^.?3N<Y2?Y_S+QY7%/9MBYJE24V")8-H$2T
M;$!I@@J$*(A5HJ" ]"0T(5!*&T(2N@0A@F4#EB HO8"@]$U(:).0A(""@("A
M3R!9":CT@01!" JBM_:N77OO<^\Y9__>>^?MNO]DY;>^L=8<:\ZYQICC&V--
M?@\@G?&Y@R+\5,\"/: 'J&"[-1%Y%8[8O6<3UB57@O8YY\?.6S6!XO("JVD3
M*:8T,*?HB@^DDA_FI0]J# A@DA1%\)WNAN2!D$.UI4 $\7ZQ*V@SV[9\V%AC
M)7SA[6._KQOFBBB90W:KM5?PYAUD/? FB_8&1-<9Z_MF5_<1N<U4@D/CKZ%1
M=EEZZI_#OV[(84M4N_*;9<%7MX8?P;/-^N<3Z.!*IX/@I*@B\=Z_F?DOL',B
MD%\1;_9*J'+Z8J".<G!JL8BVC$^KFD>8'/LDL$Y#Z_TZG7W;9X9\WKF1#QC>
M/M&U\PIV9NB.:H_^[+#O2Y9$>P?=[4*3=^X+&D4IMU_?2?[V '.?\FV%PB_B
MR"05O&Y[H-8*62H916$GJ403V\NO71Z(Y1D4V%:O.E;C@UY;.A4#N6<7(%!C
M].V/?3_Y#3-8(G_@9.)0(,&&6^R*)8(Q!;48H]M:UN'AG)282'?:\N&IJ'FW
M@;/-=@&T",^-@03C8P$#.G23=%H?ORZJ9CBL>+7[9[!\X9[G=$6N0KJ?OTH"
M<[H?N'MK!%AM%JU\V^R%*?W)_3OS5X*Q;RY7#KG(_1K/K@F@H8).U&&LIQ&E
M:4*$WSL?"?S=_#,^4!6&\,O&4A/N.W5=$;L;H"3,ND+06;WV)1?#J#$B)J:W
MRIVUR81\O6^BAI9R=1#8O.;-W0/[CKZ</W/J1<K7#97*-X6@DJ\;ZG  0<8=
MD7"%=<9/@T#Y/B.LG/[*DK*"LCS*X,PF*6&\XDB@A%,O@)E/Y*+!][YY'0 F
M*3+ O>W0(;,8ZZ\;0):77QN2U\LB'*?KRD>G!2J#36I?E%=UK'XHRZT:5GXE
M0[%]]A5DC0=NU'U;XU!R]8EO>14/&&I5T!UU2]-A/XXI<$@:P0@@AN!YTX ]
M]B)5TD_YA9*R*V[-@3EL%B9J9\G/3H9@_?->67P76:)@][/ #,RZF$&6S\"1
MT)S&=RC"ND\5WR<>3LLJ;_EIW7T/<0S[$EZ&-2F=RT9Z9Y:G1#*>5Q^7XAF6
M_IYKD4D_ZSO%-K[P J5D:6\*V;-L,*C&8@8.9L"'Y[/%W>:/LB+V3 ;#%$34
MX<T1-65G C&?YPV76(Y!ZI2:S%;#@GR1P38=XD>'O5"?QGJW5<=;EH=N^3OI
M&Q AV3#O,[566]^TU>AN_"'48* ,G2J4:&6MY7EZX5CP=9^]5K?H#2[P-"MC
M\^7MGO>-W[[W$MS4>HI-8 R)":Q= T(EDV%Z8,++&X1A^#O*!_!XU1N!23O&
M;2VZ>J7Z< <(\P$:KMJ1TZDUJX\ELU?L(Z5J#<!%US2YZ.\3!008G\ /3 H]
M62ERC<J[VB.5PJ<17LV?"GNSQK(N<PP!JP)=IF&N<#AM[5(@J4EL/6#MZBZH
M-;6_+Q/W#2_3-P:R=/.= N\:;D\Z@8;-OAG747N_BAPRN85%4$',TFYPA)O\
MZU8".;NAZT5J8V'3W.(Q*YK1^OL09<65*-W9W.="E5MPLI)7##4JOD]+.2<B
M-;22%R/W;D[>TO#<?#S#]P89,D@>/:)U\_X1FC>575>=H>8V  Q$N)=B6\F"
MNM[,)F""K-!;!T6N)BX(!]Z)A(D;J=79,<]+APS#+UO;W]POR,2S.CM&C M'
M>O.:,G*_?4NI8 ;4E9$<?GL?M&8-<KHXIS")(T/%-WL*:$/(CLM7L<8T&4I&
MN@)I"1 81BXTX.Z)YTL\@,>1*R>(=0\_O.<Z9F^N#9_T=&B [)G=K9DM$D%C
MI/1U]+#MKZ!P++@ 6#OWUI%PTFE^H:[XDY!!%A.FLL16AN/1"7E15@NC;W&U
MHX;@K9WYRNYW.P9?_].(QEFO!-F5TGSF/;!B7DH&W@46OQ*J>^?);83X33)0
M'7YTRC U^T4[LS(K^AU]AT<U!=WVN?Z)5O4:\SK7@1R_^+:FL]@3L@J6XS9*
MY0_ $PNL&'QQT9#<K>H'IU1,5H(\[@ZZ&V=58@=PK-L/33$>5MRG]DCB_.R3
MLGG2+UT85M03N<Q3NF:]9J<:FKKJ:+)WV$VMA)U'&RG?*7\(6?3@[.LVGK_)
MBBERBMQ=P%K)"HB(>VBPC*B]KNS@X.G\+2B*$7'"]\&4VDJ3J'G6F?LBV$''
M;]=D8+GNN3=/+@4;!ZQX7OG<O3$'SXP7)W(GW.HK,=U,+.0H9*A(^8V_)IW[
MPN(97V6B&8#Y.R^W!FI4/P$EU9;::U/E0TIL\#A5DXX;6%1?B": 8OLGJ!]P
M,?]^IGJT?6==B>>.V;B) >T53O1,R3 E2L!7'66NW'$J:HM^HA)8ONF%$S5
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M+QTJ20NQNK8PJJX8">(PI[ K.$=8N97V9BFOGLFUDSIA6(K<0*L'+.\,M&Z
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M8<Q6Z!MBU,.DWMW)3FX.Q>]R [3(4,ZBLM5H01W:R=A2!QMV=A:E-"L!^*0
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M2E#Z#'.X(ZE4_Y!])JIHZ+FEJ)5%C",PV&(5?4BD?T__'IVDV1\BK6\,0W;
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M^!95AV@4-!8[<I>C0Q1=7TNIV#"./A. 4+YXFR  /=&EY?N<[-"CV- H_X&
MG5V0(7F=U2L 8TNLK8RHN+W(]??*3:.3*2Y@* ^XXK1:QAVD?5]"H?$VQ4>N
MNS+)7,5ROX^1/*Z<[4&\)MFK#1H.;^5/"$3=%?LN03'PD01<S_-5T;$VXB<
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MMV-CKYBGZ'CUH5@L[QXSLIINP;][/KLEU6T?7TK#V46>G&@:9B/7$1Y(*%H
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M!\Y3"\!FQ81T&-#3/0!0)T=CFB\7.O'. J0;YAA*(2;)]B!+==RR+&;\M-T
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M+@ ZM2S(9C\G+G^(!PLA]FGA29U4ERR.8#M\&^+3^0VQF&\4PU!Y31 67[R
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M8,%)"!(@A,E?[II[9]Z[W_O>S+MSOV_N6K46Y^RJZE.[.+OJ5W7V.=K6W.F
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MHB>V/_7?!&_[0W+!.P?$\<9.W*_/:6<Z2VC.U>)2/=A/,O[LQ)QLE>=^?&3
MKOF4Y_#G3CG"!"_=:)V,N5BL2?[:$ZLFPT(S+7#@QDU"ZNU.(C2K0C)"CY!.
M"JYNDC^J'8[EXH,_*+RU1NS1#26!&XYH9?)D(H@&WK,V2XFW5=A -9^_?7GQ
M\JW-Z!-W*KE?=81*A,CC8D.6IP'11@>A0$D2[U<+9?JC@@J);.?9!<MYN<@0
MNDP#FCYR>$4B_Z=F#X?'8FX=O#[S&/OO\RT3[K&D#/[1H\+C?IM))KP,]8G0
M&YV(JMS%Z6MAPBU5!:L.N9'ZSA]W/\](X"-?PWTUJZ)IM@M-7MXSJX]1-TJ'
M=CPNJ=+)II'>DWCA)PC=%T0LGB&).3%PZXWV<[4M6IY7P&GWIE1JU,\&=R")
M]G7I=T*9S*GV$R;5V%N>5Y<G/XUL5M:CW*E$4WHU!VO/J'VXU/Q_TU(KI%&C
MS(IQ)@(V%S1]>?DYS31889^(>>>+Z85JR&#G76K9J8\-1PDX"=Y/^?V*7MNO
M,?\?8=(U_K-8\L_&)*1[G!T"8XT@^TM,B86'>22YD)G?*(P\+?TA]!L$7G08
MO."4;T:0SOT<!6R)W!R&V%^\_2M0_NGE;QE9K Q,0&/:PI:+CU6C(@P@FD3K
MRJ8*\T@FN/9P4^\=/&&RM1J-XEJ83[EL +M5FS-R9_1G3WP@\6,H21P!2KZP
M-[&R6/IM-X457GW*8\'LS9C":#M868L3W18!%H6:O6^G:FU0N">SOBES*@_L
M3N3C28JM_L3:( %^JK%>A5U%MB9%.D7@6/;=V- @[2!9;Q,TK>-J]LP3 @8H
MS6S=&YS.T ,OE@K+#'"<,Q0>,SCB/45/&?;)%WP99C%J8QP2-T1!KB&CSQPW
M<CS:KD&$]O86RKQ#+MT5Q5XWN?YR*7"#Y19@O-[T5W-\GH/&6@,0XH"%DM/3
MZ1*C#6@JIOM4:V>(QS)64=!6^H%I<9?"2M1$G%DB1>LKV8!$_'G$+ZT,1:DD
MVA+A3U=X=6:*NB^&71YP5:FD\O_X'H5'#MB'#LU40@]\^!L,INJG):E2A0&0
MX8ED[53\L3N<A27I_)'"B92X4.KJ1WI7"66OI6D7Z%R86ND-[V<"[PY'8)K:
M0>_,_/ Q.!'SVB#0($8+SDQ#S[['#FW'?.!'K/VTIV>X[YIFV7B/FXV3;1=/
M 6FC,I>=RZWB)&G^!3G*CI&,GUQ,J(H>O9M%5RA;B/0F0?KH-VZE QDF<2(T
M5MJF&).3TY@CNK0 >5O\L2\SI#C!P5H/H!5.M-0QW>9\RVNDE!BC *EO0<R&
M6>*W )P <GY?TFE);D7;R!QGN2\&*__63=-["XAPC9\L.E:Z-G:(? SD(4&W
M(<5 @FX\6S+I6]O)=!0*)U/NG?-.)N-B+^\6?HI!N)19IZ:!S;\F[Q>JQ.6U
M\"3*-!3^B!*8:D/S[PR*;1.AF\@'QJ$7K@9"APF[T>^\?H%_/LE=+?< &7NK
M9B)=YOD'/5^B;@%K[=4O*YQ6,0&1:Z)/GB2Z,EXPN=)YYE["\T6B$E(.YY2\
MN>F,D+(%6J=?6%XKBI:/@,]0E*'U4<YQ6E4M#D[O@-@4Q6NL^0OJ"=UDA_#
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MG:R\^#84W9^T)J R]ZW4$>0B@K&[(VXP8\?%#[6LKXUC2'.R]@1K8JB:7Z)
M.2_ U," K'>N+'HYWNGN8:2?&G0^T^$)T1%:.-?V%036H#3S3&+CZ.F#31=T
M_(&C5R'VW+@@C-?TC":J-:Y<X!$X#22(W=&W+E]*:ZB49!++NIQ07"Z%BZN]
ME_H^I406-^]]7OV<$@IR_'LL%ED6!2RE5Q$8QRI*"C-SW1-OY07U4YKU?&4%
M2>2?YWN?#QYY7DC]D5E(?ML3_R7X;Y?4ZLDG,V(69^OQ5T1+;:_])+X+.7W
M.5CYV)W]G*;I8<BY^Y=_*.N=Z#_ZBO\C*_8;72P"O>O9=_1(9_7SWTO1Y[,!
M/O]>QB?\]S/ZO]-W"E^M'*AL<*TVKZ+^WWY0QA*G_=]K%1;OOO6?1=]G_VPE
M]C=I8)KJZMC1S0B QDRG3Z/Y*BA2N5SWL7VH J'U535T6S28G?AN>FEZOOS.
M["TJ="]B*]%Y<<PQE\5PY%P-OHJFEC8^==5E241-.4PMJN(UYJRC*( J69^=
MNWMYAZV[2^[=;P52,"T>%TS'-U>'YE"%@ECYWL]>"/E90'\)V3VILIFGF'TZ
M!\VAS*G$PW/"Z[F4GBP-C W*ZS@E*8W#OORQ7J'U_EC-+Y[V)DX.>JMQ.[YM
MA+6&>7TV_2E_GRSF*F'#X ^/8D5TKQI;+P:JZ;W0&P]#K( W;@%@5?/1*P7#
MY].'/Q-O 4D39Y.&-Y\6&WUO 8].G[\K)Z.E*1E"5LZ8A]M,]<LE+:B$SQG)
M!BL)/PMC_M*8.WMH]DQ> S<MZ0V_N'>PC5W0.$<!6A?B7#N^#R6-7_+/^RT9
M@*XB-Q([2=$3R/UZH6P,]AD=UZZSL,'+*.PTS&B^TN#NYSE%(KRF(_N@_FOH
MCH]8%B+>])F$8 W3")?@]Y)B(MDUB)'VFBP1WS9=RXQ/[:M8'97*]&NZ1A%,
MPSF$+1QI8T5BGG*RJ6*H-)3F']RR<_8X%>5(-[U0VYR]9K80A4N>>&\N#D='
M3-3$(U$[O&2G.KDP:W;K=-L$S1@EF4$XU+7O5A'J_[*MOJNG:?(6,%Z Z$U,
M)]\<KI,8FMSL\BR@]9?*R,"I$U-KUBL)'^#_L>XQ$*H*Y'('<&?DC):L/GM(
MHE68;7(YX;A-Z]'VT["Z8XL."$: 7/'T623T!;'@8G%.\*EZXR+^QB\9W11E
M=0OJ[=H.4;4P.-R[X1MRLBCM"+MP$(TR/,^;R[T%6*)2B&CV9)#4EANP\4X-
MM\2R^#G^"'[&)!=^GJD2EM3G"#%KIU19XEF#"N);0 77>+C(?;"NFC^3SJ]P
MBM*:]AA2JX,O%$9WM4RRLTN!L#*" /)44.Y-6'OJO"P(S>-X]UAY%VPERD35
M='HZ&Q_PC U0CT49]X YNH+7[(.F [&(BI9QO9+/+0 O_OZL-><]%-L8GG7>
M.'=LH:8WA7G$P(WJUXH_]_KUO3_B$WH@7UR=7Q[W"%B&#II'/#3+-\FTC"&=
M7@D9IQ\ZX'W&HK<E9$:OC,U\2,1+1QF9I6.1A\:4*O4BG24L)RY(S+'FZ!NR
MIC38;HVF#)QS>Z<U^;K9M>2,/_;E"1Q!<Z5%DV^&]4Q7'J'\Q3^]RFS7U]X\
M^"K3*C&RSH)HCK\O$RQ$_JXT>?#@F^S[KSOIT^T4N*<V6L3*"0\5E/B)>YD+
MGI(R.?>)HC'<W8&*MLFT<)GL5\Z3_C4/5;6@/-N;F# !7D:1>7'=B%G:YQWO
MG2@)=(]P$]8;24U%;7E#=QE)(@.7;EXX;:H" <'%:X(6"^IT2;@BH9D42L)\
M>TZ\(IFMJ;G'JE=I3VZ\#HBD@:364#*_UTZ;:]\R0MA9+:2<9)2$OF[!@54"
MD?6Z\1Z6#^%I*-9U)/[^CMFS]5]IZ$G\.-CY*].3=8*X2:MR&YVCO$W9Q7.A
MTBA^8K<&LK*AH:A91X:WAL;'L("")9+ZP^B\F>6FH.(?'9R==LR-^%BEJ>G$
MC5^#PQ3F!V=]I'-^YAZK9/$4!OD9?GO<>*3-_Q##&Y$TMGR%=!\9&PYS8B-V
M^ H28:U&'LQ3+?4J8N^\F-1XZJXW/#02NTH&+7H^?!KMO"A#B6OZS3(& QU1
M99<B]\OPJ%L NQ5K3[;"OGLJ2L407D(@%85I*.[>&A=4$9Q.VQ^>&"NXH&RK
MRB<IM V;QJ#?/<E?CQ7=*XS3QG#\F]#3E0T$\Y3@:X/[#?'1XAI;0UC43I.O
M+4<!) K 5"!-32C7>!"7A8&[2V,A>_V3*\%M.,([PJ0 /[2FO:HC".'*.K>C
M"([CORE_OA@EKLV4OOOV]1]P_:X&Y<*6RV'-\T')EFX)M.8XE;Z_WU0*1$%\
MQH:Y^;*1R\6$E0T7K7[IX='5-'G&-PD!%NO63CC$E4>"A'!E61GK->C[YH=^
M/P%7+7F!<Y6?S[#[6<RX=O$,MU[UF,L+PN6*]J@.AD%(]4L5E:,R;A5X(CV>
M8G>&FKB!>JR#&I!8FF;TE7EIH 6ODO#0>^*!B>C$E-'D$CDSUC.0#-72!-S5
M:ZT<84QT5I<%>>CFM=L$02SW#+))4/U4 RV/7-HY5MZ7ZS9B96?["L#<#N+]
M[06+LK. %C]^%)*(KR,9XHKDK[ ,&Z+/G^M,'NK@9:$Y8WE;]D<F_?T-C4[;
MKX%Z/US_[($X40!"3?E.-^QN[BSV:$L(S<3%_)\XB=XVO0<ES?^+H7^_BO^?
M<GZ<[?,.E$:R4HM W2U ]?'X:+682RWL2>4@MU&\;K!TQ!HZ?ZSZ7<151/$#
MIGS?A+$*A_X@A]F\$#*O00;"7X2E>UW;8O[P9_J'WS^XA(&!*P](KCHKWG:?
M=[;%A9>-,SP0<'$7EWEJ6%SL]YDY9_DN6T?[Z?;4)ZKQP3*)!/Q:#UFIYJ?*
MCSUWQXO>\&4G:+LS RU7D8^=OT1O;\QDJX:92/[#E3BDUR<5E74VC%Z;!S[Y
M_X;)_P EC/N6YMR5,U\KUV\!P_]\YOWCE'"4?CDBC^5M5>S,]3^MD?]2^@<J
ML9T-H+D-[JO7RO:L_3/9]2^E?TLIT6>M9EU@&Z*J)-1!I:Q 2KE-(([E3N(9
M>,,[>M9LR??3*@'S@R0+EWUOV_C@\.(7@6^>)[YWB9ZO/L_]/\Y@*")P1%-5
M.>  E@'LVY];Z4EZ5A*2&SY:;&]L'CREOFR_E&'&>>4AIST8_##[__>,N&U(
MXQ2B>=<<TAR"8Y%L3JAK$I_Q3V/=/\0#DV&-DX1=-HI![@!Z"S+\$K+S?S83
M_VL9XM.H437=%D+*YK#$6X#P BU57V"D?;OJ3Z+ ->;S?TZ;_[<SP@)'&];(
M?E!?RS\F3]D0X+&Y:S-@N$SI:_EA@_V?,X[]W\AXZ"-0PH.83;O"#@+< M:
M3P%+,1>[QC8UA9]LYI\H_[#@VEOH'GY__R".Y[)#;N,H]+SE8J_O2*[K)D7>
MU(WDIQ9+B.Q;U>\1UYYXYV_15^.W@%,LOP_]:;> 2K;UFRNC]'WG=I/E[^.O
MSXL:\9G8)SB:9[\0CX -SX79>O-)+N966V?3TIHN0*D@3Z4W\A4>,=];=>;J
M A$IEMLJL24A^ND?W!O1=WK-J&C-6D82^,"55WBH([TE*8*R%=U'.=;>1^E)
M'30D\A!X>VNI\:+[- *#5Q?#KD+&0"]*RV4_3&T_[%B!1R1/J21=XH0F):?,
M]M,!\^MK$>_5ZS!CCV\AJ=0,":Q"+RG>6#S(&?FXSO(X]#!P5SY.Z**L_^>C
MKQXOGMVU3AV?GN%PN6BI.\T>NTDLD9?DNM(]>ZLDDLW%;7!4T)R\B /']#]X
MVM+ZP$P(J+LBRN#I$/B"EXO,3<"=U=,=.+_B(;VB\4Q!NXH7IHBA5W$+,*9K
MAQL[0: KX[PIE8P(?2W2*5V5=SM:;XXY(A/U%36FK92T0I[B.J)X_:AZS?'U
M#3&3%,K!T2%DM.RA5U:3 ?.O;DP#2PPSM5E+=7G;&'4503(<ZF",BT=IIAT*
M%M%0=0.>)+4# %4;H6!(3E"J222&P2W B:JBF3]UM+50*=%P([8FB<DC,]PH
MR)E7X@O+#GS_=+&>G7M22N!\44'N)$=?87""FB>Q3+G6.HUO_&7TN9B$(=]-
MS_1^SY+267C]A\VI[^Q71M##"4SJ)/WB2@MPR!T%' O\-Y#ZYO;1D')/0D+U
MB)<%NH%-H#8#>OVY2E:XYN<-:F/R-$J08FBQ V<T(\KMAO"S);/K7:?K-FMS
M"\6 O108R_Z;J3*/WSZ+:^02P9,^HNH0/EN(=UI^"R#_[6L2/Q=G6<QZ;K3V
MO<WX901EI7T9? @]*[_<AW&HU5'?$UY)=]%;Y]@*SQ)E5E)PDT?F;#J9O)18
MC["]UCT;T0!FZXU07I<_H.B#&<.X"'Q*.)QU"=63%-3P@D(DR/W8#W@DEO0V
M4PSNV&Y*&U@3;G*F7GP5'75I5T[U;$-QJCAN"LP3MF-%8:<L?-A8ZHLI/1+0
M3]LN:&Q=:<K@K^%Q)W4<40IS-/'F!?F:'/I^O058OK_XRM&S%]G>$Y#J>+4L
M2'7>.C_/FVI3&"*[OA)*46NN2'2NL8D@U8Z1BDI(BLATZ!3#J5'B80N++7X4
MPA/>UM2-9Y.4+8*$5I!PE?AO+WL*M!;RB@E&8ZC7+CO)>+I/I6V]:U=KSR@W
M^,K^V8XOJ6*J]:JJX7E!#N'F1T[TNFR;">+9?G^#Z?PB<28H1\LEF\TO)8F$
M,+)& BN\64WK[6!@H@Y-Q+-8^_2HC^HT^DE%_21BCPAS,[0+%T13^LBD)@<=
M2T?KAGQ3AV9<EHN6/F+%?J*^WBHR@&7MC(T].70E[<SC8)6J5+AH<'[/\5W3
M8\K/EUT$%H]TJ#17S]ZUT,.AQ$HU&'[SQ*+42,*AI6;;HKUU\$?(FBV.!X=@
M<C,@>:348*#)@^6^-OR5*^T4=;%:MFM;S5#-%A1RI]()JQ'O)D.[:M(K-H/C
MS6B4)TZ;F3= G5'A2 N?/0S8S&C-M@H9I2$2[U].)P!&;XXD\>G1-2=9(DKG
M&-$/#F*M[LN+[S/,&\=\*WS/L,.L=&]K+-A@FAXE6I:NCVO5'E.4E%U2JS6@
MIM5]7:S$%*5L-:$,4G^<&S7&K87CZJG4=]Y5^%,@^<SMP[2S/WO5QM.M0L>2
MV5=O?=HR.'2XO5"*X9.D?9$K^ZLAF[O[:Z7/G=+"MZ0W],F_RN![JD-"I-0J
MU*=T#1K;&_:UG-,SG+ZW\[.*9.]BLJ0MVO 6.\)6])_BXNZ?=F2+FJ=]T[+4
M8_FIL$"K9A"EU%(!P%+6CX@AG.*HBONFWQK45C-O6JI171S]$QH""E4D-5]P
MKA$1B.,\"/?PO7IZV.K'>;>5UT7_Q:/2+C%(%E-XM@@U=8W_1>U,<I9 *Q;'
MI79I\SCJ"0^$G$ &L4BZ*E-R\,:G2U?U89E5ZSZ=W@<!3-YFXX)[GI.S]GZ.
MW3$W'SWRGQ3[9LS]"N"^E.5)*UU/N[?TFZ;T]2W!XIFJ7^]]9DOY=)W1K= Y
MFK)ZS7@+R&:,S!BQC-+W/;%K3=((,G#M /]ROGQ)=:%[FZZJ8JY5Y\X@[ 25
MMXM85BPG4??E)FDNA3Z=0Y7(O*3),*^N:Z5:WU52=O">U=72?TPYR\S43I]O
MH_45$6,#'R$/V7C7H;[ITGRH5SK3BT='&U6T9G?HT&EIE(;I\66VSTN'W-V'
M7;0]^-/'&D\N>./X]'6Y+;WZ"Z?P#IQ0]2U//U JQAN)F:-U!W>V@S0/XSVZ
MM,NQ-$ASDC-5RBR/^")"AO0-[EC@=7&@1&#QG[E-?GK'S7OV<P*[WJDV6[&3
MXF18N:$[%?;ZMZH+'WJ5_)[%]>Y',:)W%R;F<>U>>,<880""BE-0SJY/12A,
M7,6]V\S(E%R5F@M\'J@+1.#_/ E1,/EA=*=MJ><B=1$62I!Y<NA)-&57+1RD
MWQ9%H)_DR\T5=%#+YMK-P4/A;I X+7S"R\NGB _ET4>PJLGH/_7D7"LKM#ZC
MB6POW1IJAEDT+'-#33:,8)6>D_XC'_?<<3B\V"6.8=?:K1;^Z2Z6\> O((D0
M D)&/-"I?R?3AN[JX0A!.Q&_&$=[61R?%YJ*[!56T*\HW6>^H?&JR/E)2>5F
MJZF%<I)2A0_?$2&^5%5CMEL48:-BC[6[WJ_5V+E2,^K%X'@7PH\RQ',@NQ9A
M,-E9BLQU22-PV30D-VA F&O/UG#9)?DF=&AZM8O(("W>SQ)V6&?GC#VE+F<O
M:E6PW2IGK&"KE=;',6DZJJ).6$+)&ZN>=J%O:OROZF\!&I7R["QG879]<NX5
M.PLQ-95\M3H) E_6;7P IU&**19'K5NCVJR:KK(LE:6\Z]TBCY#89A[\-:[W
MV3IP5$H4>-6X*R"0K8]8A*VN."/9?NG(=AGFA0?WAM):>Y4MN1G(X\*<]%8&
MHD2;+=YQ&E)QB('''A8FO3;N-<Q"Z2/8A>_*D) R30D6;CV;K>;@1:[=#^\@
MA5** =9;.2 A)+R^3,W]78)9ANWIY?B[D!4/?FH(!Q6@'!.ABQU425]:6!C>
M'E?J$9GK/:N_O)O98FZ?"4(*'5=C8F*4CARRN_.T4:26,>2"W!O<VZ1)1D2+
MAFRU,?4,<U_P J9@7^_MI+9Y=N\9@N\<MH[3#OND)-J\12GJ.BN,FD]&3[>G
MTZAWL<;4O,J3<L\;3A! :8E1,N^*+V5RV7XJ45W,KFN+S'PR6,S1NJ&0S.H<
M1=(,YN+3:E60BAQ3N\L5FD"M1=;%99U0YL,(WMQW\=1F;:YITR)YJFBX:.%H
MI,^K['(C^%>X3;[XX0^77ZE5W&?CJ41^#D?_+)GPR _;\\;6ZA&VN!KPX8I!
M&\%J:6(VZR%-8$OF;C#']'%TNVY+<>E+;!YLXZ :PL)*9<_*,X^VK$B)M]YC
MWJGE5#QN^G0C*\X,QBW^>ZJD])/5;8^;K1V?QU4U&S"J+>FA9J?4F4:,-%<!
M"T[LJRVS971BC 9Z[*J..D.HYNB4UF7?+$/#)$!YOQ;'LZAG,S.U1"1]1NM
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M5]A=I&G3S_[*V)<89GB:/P*,G1PZ\<2$Y7TCG6XFA#P:,CB<FL(UWL\4_NP
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M)/"L:'RW0]HM;>6M3LJAAEY!!2Z*R/>J?ZXA>[1E&V);*<!UOS;;([*[^DP
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M3<**9X/QCU X#3T6'"F*H69094Z=<OCK"=PX?T+O+7'OT/]@"E]6C%>S#BS
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M2)%Y*515[PV=5O9BV39QJD:NF'GW]:*U#JMLCG6!*G8I3 :7-;6U#QAD?77
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M/KA08NL?DI;4X.&>)HKRIP&ZP&W[?"%@*K315:==8XM!\]E?8R_FV)Y;KLL
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M9FA-I DFDJ;EX8G_*KGNWIY[VUBRNNZQK:0\.4&@6(X?E] +U,5\$RU#/PJ
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MZ"XX53H,1G<HNKO*6/.)OW: W6[G3P1=7A]9O'SW=X;O[9D3S@)A)H/GW./
M<?_\8VFSPC6)'T#I!JV"P)B+=\I(7D,6-@KHW9AP\N%YQX$&%:/BEH6G0(%K
M5T%RQ^RFEAJFPQ[^&@N$A9FZ#F[#LQ]Y#T['IJ+RU[K9KTWL=:V=[\C*&256
MUAS9.J#ML;0I[P4M24;=^L#N6L&._ ZM-NB?S]OSZFK/@7O9K$J$T3+<9T$2
M6%NOX<[FBD:3;]$&INO7DI>VA1[1M]VH YZ6CK3AY7ATP8,"3*P'#]\*'5M]
M'ZQ%T!7GO/GMP1-GP] NIP8<'G)4WW*)]JJM#(\^!^+-R<1;I^D%OG(:S<<M
MB,#YACLK;)U$VY>/?Z7O9XRD#9F^^[6\EM&Z\^Z<B>.0C2WI4?^F])J9K_-W
MC.G^9U1M,+S-.".8R))RN;*,F>U PM+$+F3MG0#>.R&6$-0VVRD6&!3U]>Y8
MTU-:U2S86"7OJF@;>*LFYM:]+7@:JD&+8VJJB#=T<C*O=<G_6_VU.QDAN$?[
MNLI2*J*$UK'-+31\AN6<'*.>R-E]Z\Z,G<7)9YSWU$'Z73K1):#YYGFCVXLI
M!P+&Z$O(H'_U0["3]JM4=^[I.@V_D(O5#Y^X1AKT7 'G.&+<1C(3E(@)H!>V
MI;EQ^J4>&WX7IJ)*PKE'G%]^?.*OT);ZV2N);!K(.[&-(K9#A9G;$9KRX 6U
MPANA+0%A:W\!UOF/* Y3_BX''('!8\HLBFIN+SU,^2\?AVS]8 I0$%:VFQ,U
MKW7VG;>-N3E:/D>*#%[><L$EO7W9Q UI.NG ATT*E]CXKUEC%.Z7);L5;PRB
MZ(4%\>&V?$+WKX[2I"'8BWE"L8X^>M@[$&T^PI;DG(1.EUH:$RU^0.14V/HN
MVLI9!:L0EE@;>J?R6[FDY#2B7.Y32+.39IH:&$*Z$M?>YG\E[$I.*(UJG64%
M F3[T<3/76Q7)(R,EQ[[3</D8_KO@&"5ZM9EQX\"!)L70A*_7?8<7)#H2; Q
M/LPI#X888PCE%:V_,P(ZZ?V49>J.MA_$P4/_H+Z_%7$/&6Q.! (4$S1X\IE)
MGZS/8PVKO.I_"W537?(F+^<26B70KL>#FCPPN)9MIS$WVK-4AA)_3_LWX?1S
MR$S2P]-G 4FY.4*.,UN;V!<YN]FD;4)2W):-KJ%/"\_7CU^XNH>0;<GA'LJD
M&M#F"D,M^CV#=X:@-H>I><H'LNQ5%R\@&>AKYBNVZ4S^\VETG$_Q6Y6Z%Q)9
MT"Q)^$X@[S$G,]4G9E$=4 U;A<8]APK1X>S:(T2A*Z][7CU[EUG5O&@1\,-[
MG_!*WZQJO%6PFA"4M'@%M?-J4GYO:7B)T6Q=G P<U5Z[G JVL+(@LL-?LXN6
M>VNP"E25O\GV7MPL:F\?]90T<>0+:"E_*C^K(&':M*I2"K6WM1-3";PM*W=V
M3B?/D71JL7>QI5'EAT$'#Q:IZ#']_5TF+)-DM2XN56[: &I,JPK*G*GKM-W6
MVO=T3,_FVOY"O&'BL\!/F]P%P3UTOD<2FAD.4BIY5/A2W%$8D?HNBX7U=ERK
M<59@A-I%L"HSK7#81/S12U5FE,#;IATL<O"Y*0B+,7PO4__5E+'LE9!B" L'
M8J-5A'T(E79WU?_+22Q(N:I>363UO8%0@"'6^@/M"Z=U?3.I;'"FLJ\(V)ME
MZ$&^YCJM=E[1M""B$9TK;=8!)XS):)W_7ED<:.)M8_20W80Q581%I_S?"J<S
M EDW5>_0H0]^/>5+>8!>8D!6&=5FZ<%G_P+"8"<ROW]$O*^E+$:?^5YYWVLQ
M.GE]\KO/R<4'6T__,/1.+'RA?,SK\C9>5IT_M=/I??K-K>_.=+XRPMF/F_U@
M[B#*G_% ;W/TXY<F,.VMYRW3CL]X+=6**_^<^%VOEF<J7-'1#H=<$UWWU&WY
M]SM53-(R K:GTF(_-80S^N;>/JC).A><\WO\?>&R(^\TT#5L;@'R>1,'W=0)
M<X" *>QO;5'4M&,?>-75C'?PN-_/4<.3X1=,$C5!R7P@_^N.^@]C7EB!%^X?
MQZ<X/BLAJZJF;;LU&6:HCCRC!KKEG57)04V>DQM?-9&'Z989\GN;7' /%&Z6
M^F:NI\3RDMTM&N/C]]I\8)LWO4I*"4EFG0JSDZQA";QD>2@5)CPD/"QEW@0I
M<$YYDRIQ3&+1%+;&;*$F7DL+@#6-^EXZ833"WMS04BOM1&>-SP,).F#.*^+'
M(;>KY1$FU6PR)?.I. <?7WR7XQLR*:VJKE'71 P?9GWV(+7]G-&T[R27TA.@
M]5BGM%+CEH]>R#"9WT.HNC5M,IFOTEY%L,;_R*UM$+D_ZWU+7>B*M<(CH] O
MQ.E2D %.J=B$M?;"9-8)MFO)\O8R,V<WNY>U"Y9U]@O*4XP#=QX$_W7_#F-"
M8UQK _5TW FS;_\G_QG&G*G!.37(WZ@DQ0O6MBCD51;9MD9*//:/)8+ZXQC*
M+86$)PW,)NVX)'S:^_QO9!I^8@4-X1+/1]F5RRK->2A*E!;VM[=6>TEZ,SPF
MAP[N46OS/TM!!F,*8EHH;4/XA(1<H4+BL02QEEADC%-PFJ(_7=L)8RZ*J1>>
M"J<_TKB5R5X0F-F84I>UM&X"99'GV"5D04,2XPZ%YMHT\M'3P@9>.,2NI3I+
M*X1*VN> /X2=B4US-_%Y9L-AV+D/Y*!G :T]V@KL+%883&S8I'G"CD1]4[0:
MWLLLR1B53@/G_:T]J)#D'++:JMX"LHDJ&YM1X:E"*YF-NH1PFOM13?'+/NYF
M69S/$[-Y39]GN[9.^HS*E4L,]W&69_T6:O&45O\LL%LF(%QZOF+\HWO9:[@;
MOU9YV2LH4"$W$3[2RZUB6S1Y-'G)R2=%R_.(E?]H//[FS @<Y=42#M+7]FQE
M"!G5K>Z]W=%9'U($MS3JBFBZ+Z?]XL%'%.G55NV+@[L<89/I@M&;A2U#>:&-
MM_SR,W:ONR4.!;8'L'3WH4 *@6!D%3#2\'K^WAF$SSX8T[T]4A!@'#93;\R
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M#9,#]LY1*T81&U8+^8$R4H3( 2D-ANZIR'RKQ;*3(<HI1J&J]&]40V;PO$K
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M/>=+C'F^KUATEJJD\NU^\0OM&P(C?Y-""B5-S7P9/Z]P]?X1MP@/NYJLR@6
M5^4903!ABK?NGDSL74^G1<?EQD"'UVAOB_XGX6_4&#2Q7W8L(3R5%%6\AH@L
ML=_WM<S/>1F]]@\OW7.W&U6)_?&#+["L?#3@:.@P2>NZ&W?-I%99ED[66>^]
M%=GM/^.].ZA"367XU!VZ"\!JBD*-2AB-=:_M)&67<_T]U+[Y\R"IR,.]R$$@
M(HW(1DNT3N+G\FF-Z69%Y\B_IEY+0%M5) 1HI+- P<"3J?4%LV)E7.^>4L$N
M]SN*C:>?,[MR+/Y;I/NEYQ+@OWGS];>ME-FP\4<\90XO'.K'&?SU-<AT(),
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M??Z]2'7,;GWIU]778R5SMO5+3EI"TMEXFP4D)7($002/^4(,\*7Y]B?Z7R9
M[@?>P<\A28@IXIUN55+350?-ZZ#;?(S)KIJ'45$X@=JV/<RGE!5['NYL_Q*J
M\E)\O5OQ)C(&.8:PLB3JDB3/A]V-Y=J<B#:B=C6PU-A,>QUWZ7H'K"09(M.*
MBFR<R/%HX*(6_7K;(/>-S2Q2C9T6+&/[]AJAC7VJ>=71UICGG58O?L6J8[+V
MI.RD)L-93OVR;@ P@Z.Q!B_TW"+=-DKYA;5T% S*/-F:\MW9G76%+HYG3L>/
MW?("D&?O[E/T;\L+*:6&WUL=?#QWF22>NJ@\PH[-GJ<4<Z=<]0[<*7I3AJ="
ML^3*5\UH[.\&ML-"[6<'[$;[?4U:FRQB#,TEKQ_F>SU#V1+0S78!Q'IGS*D0
M!H9^>B 0ON]^=^=,OSWZ'O4YAKIPX%F(>RZ*N)+2?.6L_J]C*<N4W/LL, 1E
ME/16KF[<AZ;.]9388</$LMJ,%S3\-F&-S5E3\]8KJFG:B[Z,3A0S_N1IAERI
M1VV[^!R- ;WW?O.86>1),V4MCI/SYWOQ4N[K6+5XVE(*UCOV!_2IN?O9/<SU
MH]P'4$GK)?JB/^UR9,57?=5G-B2]!/,9LTT,'&IER38(9UQ1/9DYFYF.P1ZX
MDKT>&3K-Q/'PHZ(H@VGN>&3P^X7;O["_UP816;SS:FQPA')%;:W=(XE-$!#,
M=N>RT4K9MN.?[VZ_S?9:>I_,;7I!R__95HTIK>!WK<07.<1)5A3J*YH05Z3,
M2UI""5OS5MUWLC!RM.PZ-6H@B4H[PR;6$NPV2JA-+B1/(^A4X)@/OR4NJW _
M6/V<(P'7Q)ZN&T6O*0@X]26]S;:C[VA[G'?I"/NY5/6317SJM*8SO<2E].LE
M(@5O4\M4/ *7#Q*-9\ . C19^1CCB#@@LC"C *Y45*,8E#][VE?]Z/KE!)CC
M/@F!,7\)LX&".5 2/E]*-WX$1):Z:O :?_#8;R8VZ%&H4Z45EH,'=!PQE#40
M;!8CR1A/JN3X'><BK5+-$I#EEGE80^AZWN5#(2F7JOMQJB; %,_JOGUH:#5J
M_5!F=C([<XS78!XV,3\"7D;OHX7'?N^$A?;JQL@)09'X!30:L5NL3%MXE\IH
MYA&NI#[J:9'PL!>L'%W8W+IMC"QI')L4R$IG_;C97*"\,4;)MW.&WJ:AXTYO
M]!39-+H W/P1&FY>[J#^%-F>/N0+B)C\8/$' OI+X4\?XZ_4=0"!%X#3/*G?
M2=VEA9Q/@P[#&%;$>Z_^X7D8&/H(W3)F4S[GZ;OSZG6)$' %C0*>8H"W\*\[
MR+=L3.+&6DUFRU4\<"T&" @+"J7SHZ.I7&$P]Y.Q ]JC[KJJ[2 #KAGIYO&M
M=>3V49[4GV%W5(59TG0_Q]]21^KLJO&3,8\_%P#?CW\2+P ['ZZ>NWBO*9V*
M#<Z>N<V4D<@P1R0**8@$2-)&?*&5>FXD\X3]M#8K!P2S <(%Z80*?\<6K%@5
M46T-US+-Y;79-R-\""KVGRXED\"7);^UM4VQ3"GW&Z9JI<6U*@G3-7/"M137
MS!BON%?[^J:X-_1)&-:3FC,7X>@H))#8B]*\])PI@P_K6\[)&U,8181H%T8I
MLQO0](PB%KPXMNY)]T3ZQB]&FO1^C0Y(/B$+6!0(ELY&.^FM?#H6ZTR<6 W_
MR(927L1*H@FF !A=QERW [P<HJ0\JT: I4"(],J?/7@0^*).IIZWL*7R/J?O
M048Q[^(WW@5I/P1#-Q9,IIT1D9:J--U6*AD5N!D#EYA*>?$WF5-K7I%Z(@<B
M*-3YOX&_E]U9, ?2%F7L$,7CO-<, 85$\7;;B"YEATUW.TSNX]C0H.P<D$QS
M60-W3'1!"R(2\#4MC)'1^/ <A3X\TYQX*5<,,TP-<!.!VAJP@ZT/UW^+57T/
MSUT.233+VAC(7!#TK ;!6>B.X7!&;XYK'F:[Y\F&U=6?3OR*[L3-6ZJZ40:,
M#:[5C#:Z'%4?FE?[E,+=N4P&;+2MSKMC%^E^'U=@CVB#&>?;#RGL3S]6<<,L
M($3*)0?!I=^\>C.5=Y/48NB5?;Z&5]?+5K?H4SM"<I=;5W)8F.4A&DN*J8/$
MGJ,QW^>[C3N?:RH?WU="7*]98A^WT-5T4S^#M1Z'7,^HG=K_DUXPI%I^ 0CY
MIZ'FW\AQX;@>LW\?_)'O6/%?FGR&>UK\7YI]S:FC#3>$)J3>*'EE6F0K?X'#
M$>\6[&P4+953$GF@@))'ZMASSR1=YQ,Y\3LGKJT,O=VQ4P>"@XQ^1,JKX@@
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M*/[/+%G[:J&@E]C #P=F&/7W5H-^]1*7&AIBEKWQ+_.4%@*>#P9ZJU?Z6'I
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M=[XFTJ#%83(7[R06TP0/]"(HO]AFE@)'IX)3GK%BAZI/]R0GWL/=Q2;OVTE
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M'>S?OY8X> FG.%/<5L0$6T,@P1& _<O8<(.-U[*;)<6P9RXA\Z;-93GX0=L
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M7N<ZTYY.IRIVC$^*!SQ:"9D%WT%<,=K\C'XA.\T$&OX1B7#3D[MB<W-D<"^
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M<3\^SBF?5JEGYXIGJ)@*4M%<L3G^,SG?Z$YI]].F?I]KLQ)AQ3("%K7DXR5
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MM=PP6D$@Y&(]>-L 14$3&@R_TN(YK3R9VI!F$3\+QS)).8UJS.:%S?=O8H'
MX7<=.=CT&G8V.PXR-=7;/$GUY$(D4\B0D#7,&I..E2Z+IR+GO7F*)Y<WMKH$
MJ5B;F[Y8#)G'?$T$@C7VAO([7-*8S5"J_S$*+4$$@;9\#=A0_STU*_!R2.<,
M@9>4\'_*IMXF,95(6[,KWER\L4)8.L>]=:<;>AZ'1%&FU!&$FO@<]1%UM]*I
MY=J)R"X1D+&LQGC7'N-Q.AS+60$B$ROB4F-YMR,3!JLZE*MQSJ4YRUX]RS)%
M%F1+;RJLL^[E[*+.IR]/?R3/?Y?][VS[ATCF/CV(R7,((5))?9F[^"_ \[Y
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M<VZ$^#&@B%.JI"'>"DSVR+(NB?E]UXOP/+'/"]9>HR$E<P['N9M4A3V?V)_
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M42%DSJEH8;GU;?)946"'KJX[ ]A1J@4C9)$1"YO:ZG+Z!L+(HLQCY%Y^H_E
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MJ#SVXEXUO=@=5)IT"KV631$,@S! _1M3>>0<P')D*73M^)7W[F'KPFPV9>S
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M4@.>,RFQ]5;I0P2V[W>>\SR#">^WZ,A<QVC->SRT__^SV0W,0G6XABC4-F4
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M*8;%OICIFBF1@4_Z<1;8C,"B&1I5Z ^]5PK;#U#RL;&\51'M0A%1_#*FSE'
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M"8X5_9O7BNK:DY\^/?K/-*B__?^;UM'OK#V_!X27RAF]+9&O./.WD+;CX=F
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M1O!ED #?2".ZD3.E5$[UT08**K[^YOJYF@+88>S1_<(/5_ZP?PX]^O/F!4?
MK\U3Y=_8X[SJSFL':/[1!-L?9!L3Q7C+2:;W#)W''Z)!\VIVIJ@V70O2#PQ2
MS\CR+%NH!PVH9FR<9/'M5*.FN:U%3L_3*^LGL?X%[)+4%T*.*_5VY2:'C0-5
MW:@&4R]:.<R]=<%W.4T8I>[1')?Z6HPC8Q;4(4X>C7O1%GV;J4URV[*(/[()
MI@$@=_ MX]([4]VK+^6$2CZ9ULR^'SKZ0C23B0"0"C0-OZ+A/6L)S>K):M!?
M%A^^U0UF_JYY/M$D\/;\]]CWI,V!H!X6M+P 82F8_>7G9O2>C.FAC=0Z[LG6
MM6FG9)5'?F5X7'0ES\AP",P:^A? G'H[M' ZI.&)T2<W\6%[-_99GHB9N,,T
MNY#:]K1N9&7:]/&I(W.%LY6H**1K)>VC$S=>('N8B5::)@.;;Y'4(-I+J=32
M2%O8^@N0TK:858-EE4#%5>^Y ';8P$GJZPV_3NZG//20*'$P0W4@AJ)WQ[#A
MM-,2.]=_&7/YM/@*:Q.]*L^TMR@5'V.@IM80H=<LM352QRR&'6YJY%2U*U64
MP]3D 5#?6*VN3-!-97LC.Q4AY9JW)+WQ'%[.6GB%?7*IG6!(M_S'FN?_CK\X
M\PI3]*ND@_(7(%3W?=X3X4A<DV@/H(S%S@L(7H40N?BY:\V0HF 9%?CHD_&X
MCX"UR,#=7;.V1SM1+?>[']]\\,X?MNKEO!0Y'Y3C,X$5$..DD6@7BG\-8*(:
M9)"ZJ;PZ\:93_^-A25Q2H LUS+S+_%./?J>!ND9-9/K4EM.C>8>=W./!XM\5
M[W__^4]G>.V3I"NX<Q!Y^F!UO<-,A;KP]>J.NV>&]')*$^>'6TW#MBP]^\_A
MHR5FB<IP\A,TV?)U\%11#?.$AH#LD%L*DPNQ2@%"->@ ''1RNC.91.<=3- 5
M((EX:.^/7X96F"&O#L5AZ2A;@1(@9OWD/BPU@WBBIY/;V3_M'U<]ETMM%3W5
MB6L!6 G.)'Q"GKZ17B-?KS9=#^2^_UQS_>-;JI_&5O)$&A:VPK<YQ5\R<<_4
MZ'T<>TLI,O]]3&F'.%PFYYYL:W#X(2UN;1DH%EMKH!E)4/I*"=36P%;(97_G
M</==Y?U[JZ@+QG3X>H%OEXG9R9P]#M&FV$K)]Q_!<0VDR2/UV1I>FCZ[-WN4
MI]]=-N#*3.MP?W._.NO1]Q=9&[IS:M#E\EV"2F1%^]"CL$F=@W6QMQ(B("/8
M:+N2--7O;^;.:K/U;0ND@KJ@B:) <[);>?)$VV;5G6E/E1_Y;Z^@X62Y6CH7
M)AIV68>ZO/<QT^*4L?>,#/K".7BF\ P8P!3>L3?4SKNGN? @\CRP_=IYH7^P
M-&$DU']:#9' 50+:!J=Q+U>F_G*Z7J47Z?*<*T,AQ%OL@^BOV2H_OV*.!>@B
M0QCXY5EIH._S/])%W_U_9/!%JWD-/%?G,4QX*P_+_RH$-HS^'-)7G.XSEM\M
MD_;\['1W"XX:A4GVQZ7@1K,=X.BMJY5L@-I0NP+0IA:;W$*68YP'<'"T1KJ
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M7C][9KCW.%T&68/Z%9S^\4N)]FU#&@'$KAF^FGLJ,WE]]17F41QUKU6BN\T
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MDPOO>SZ[22V=14^&$WQR-%1KIEL&D^)4?O\^52%_-;@,Y[8/J(0F2+GTE:\
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MJNKA>X,\UO&S)6RQX\B1.SV@MD1*A%_G6MY/K;=1_@\R7M,WI4G4R+TM8DE
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M#=VP0!7HZ!;YD]\G"*G75LJ_Z1I+'2HI'C&$LS* WPZ__\PM&'KFROKB8=;
M(Q6QVR'C$ZHFEYP$*YGA.I>EN^T!NQ<W0]L-W/0SJJ]W= ZS 6G% R1T=[AW
M Z69@J4?T<NW>RE4JO&3ML7V:UY5/G7<3VVZ9CJ<VLX8KC]4K*%;CDR^#D6P
M+10J""]XHHFBR(^5)I<YQ9K-LOH*]7P:K"$BMAQO"4X0>>VWEJ57?#LGAALG
MSI5,RV,236302*BMP12-%P^\%3X]TKA;)._NL.3JMKE46+ QQ#@W8J-O\L6-
M6J+7BEQ#TT5AJV79E<OS F3M2P?%)H-B\@R-E+!U-7K=,(2AGJVAU"U!&4;N
M>A6VH[-#]P32Z"C(0PQ\=K709B(?%-S.=-]HR#L!BP?2QDHFVRRID>HUC4U7
MZOT769C_ #ZD&Z7^,"F.G'LA5Z&'UR&19,M= \:LV.,;D8;WPQE^A;UCN[)\
MQ_F^GA#PL9*M_,/\0JU',[@E6./#@2()M9#(>>\D$=V27<'4S^CW:?U:+[)!
MTA"@6(<!F+_TS(=8-P.+T,T=SYORHRNA;7IB5FVI(F-9C2M%EB(A?;FK;+NK
M"8+W=Z4D@N3,$;_,?"'HS6R.:1$/N!<SQEW#ND<V3W54ZO6^2H7)T4^AG3/F
M6I-6\<"<(*0M;6T_$PMYT92'"%J(4P\@2J2U->VF,3(M^X\QVJ;>KYN0A[5V
M^-OSV&RH[PD$)2[2%$*]G(X837A4%U46]78+/%[HI]XZ65MUM,O@D9 @V'%P
M8BW2UWA,E!FKC<:V)GY4H+D\J-X;)P^,@WL%$-7V8Y Y]?<JJB? >[ZHB:]U
M! (:WLI?>#"4C'2ZYU-VJ0E"!Y8L?][8O 3^3[3:_R=[G%T _BMG"W\ .O_Y
M4O__UJ[1F[_O2NEKJ_XD^EW(%%]WZ1(9J)-:J%*_L#&><C_^66N\NQQ=U<Q8
MTV6 #. B2: C5$#<K,,%WN4KR:=XNF]^@^<QG),<GTB'6]M_\[W. FT[@_S9
MB5@&(^SEBJTO$Q&<>GA*:7S!56&Z/A76LK-G" -T566LD[R8X1M=T3RY.@@$
M$4B"UT=M6?"4/V!(7-JW8/\5Z7#]Y"MV.$XV'3T"G(HMC966)ZN(%:H'!BPF
M-QB^]O:RR&M;]E@&5H.I*R-QTHIXPEBK4/ (,5;$UURF D]8>[@J2<AX6'!%
MN5QJL4+2D7$P\)8V[X.$ L25+=&>S^RZBZ8^#@8#\!XC_)3?W )"2/9F2;E#
M(-%"Q%WB5132=?+I<\;VX;;50QMWT7XF&@Z-SQ.%=+2(+#(;;=J-4C4?M[C'
M;[UWL\5OY9U,\Q!^64:=5!-)1M5TDT=6*/7&7;]M)6/C!H=O0C.'A,7I^LV\
M\=N18S#_55U]C+(CB;W>0FJ%">&;(WS#.R.T<_4;SUMS U?'Y\*X#F4-O,\]
M:"*@^&J$2EA58NU*D%&.QTKKHFF._1M-4DEI,2^QHF1!SUMGXZZ+0,:]MA^F
M">-LW":^\J;MV$*ZDL0#"A-A/0;.\ X -!3A2G,O#R;DV^3FD+;^<N=PPB9=
M)6S?<M8-:_V;_$K2FIL$'2X 21"S4S"?-I-NW'5"3V#\A^QKA%G<8V\J[C=:
MV_RE?V8TM+ZF!C7$!._F9K0SR+X_A;\6E0:6SWQ: <)*H6W1]>!6X8A+-1ZE
MX4H^+QD3]$>;O@@1@:XE.M<U7U+#GO8=B^W:C@V')S@X^+8"*-A/$#9]/U"/
MU*U-K(4T<2RCY7G$M)YNAC]5GZRT/GJ:_"4I96#%Q=)@EGK;4:<HM]WQ[#'&
MX["*WP7VG$'_+\)*$(=!5;=.%O0%AS-3\BP[R5MZ)RDX1$DV1[A"TT#Y9R9S
M&NG9$UQUL6PJTT5]49.WJ,C -)^!O4@0JZ=))AGTD*C";V50U/%T2^;I^ 6J
M9 6=4BUOTS;H4 ><.@T 4B:?RU#0T,17?+S+;Q_"O1P&,C'A]0:5,[^3:D?C
M>CW+ TG61I8YSUVJSJJ?E2YO1DI\A8M;^J3 T]<FE'.4NK$YL"1X!%ZH-%G0
M^/1_=F'\G]%Q!_SIB/)[IV;$G;_3*YA=@J.^!KVGJ5J>C?K\<&QNU>35NO^.
MKQ_1]HOZJ:K:A.S?A>&"@KL\O\RT6=-.DW]+78_O^VGXC"M#_V&DV-ND_I+&
M-UGW>S;^+P"N![_S^KO7BG=A@(\^V4W'\.HZ/$S[X-]2U?\VX*-I@GMT@3W:
MPMV,V8!TVQ&1+,!8@N;FME19[,W(KEB[/G/'[&5LQ+T?FD\Y#A]N[OYMW/+_
MA\<%'' Z>E75.-MHG>_:_2]_ROX!%*C?/\Q[&S4[-W& 6GS2?J2F:4_(K57_
M8@*6H*F-FNBT[B_+R2C;#%3@D:%C[WX0(VTL$9G$^YJQHZSR$/1V92HEZJU>
M7!$TMXEX>E.BUEU+)N0Z1T;A-^OF[8B.,2?'@F>I8N8IM<1I8:4'HD$'%1YJ
M]W]-[MS;SWHR?HM4?LA3?[3V(/SABGK_@ZJ7.)7<+5WHM!XJK<^[2$N4LRY4
MT*@RA^?[*&+#[!W:R^*\./7NKZYG-]>!,^@N6O:;/[T_'J>41O@'\@IGB'NA
M3NFY6?X 4D 2G[&LW?!ZED/MVH/YIT$-3OD[I :\ '#J8K^V\DQ>W&-JFW$D
M__CY'T NUS/KC#2%7_[ESQRO+4UOP.R%WCK=ZW!.X>US4^'WRZ87B=KO42TL
MQ@<DUH&Z_"M"M3H7.99_P554Y>N0C"=<DNBU >@]%(<02ONRWD+:?9 _!I&'
M %@*OBWR3-HX8PC-J'!,NTJ$.=_:"P^(IQH&6!8AS1XVJE3UP&SJE_,:YU<0
ML2E)4[?<@QBO2%R/(WYR=@?DLS'-1KD<2M5]0Y?/AZ6S.R=)0BWV:).8S=P^
M)Q-CM-?91+U3: _,6Z%H19<AK[@2+W\MWH4.)LB:D+'@\47=@Y_DR!2>:L-]
M*\6"Z9BO@<$#L^UP]:Z>V*<RFM$CPY<5:DQ$A015'P:'7PZTG7]4'Z"BK]KW
MR9&H)5W'G'QA+5UEG<FQ'"N720**"\Q</)P*3]\*P5>4U_U0<RAK,D]MYI_^
M>QABTU>$2#,WQFMQ KC[L!GGO7=&@]IV4V0G_$Q!;*8F"@O^WQ)N,%_"2"G"
MDNDA(S8:.D)*KT*Y7C/F@",P;>_8%C;W@I>S@]UW33ST;S:T"D$T>"N8L)Q$
M-PF+L;2Q/X"O\J,_\FX\M$:QGOC1GAD;[8)8%D7FUY=_^X2OW2QE,\$#IT!L
M5620+J4 VF0-]$@6JFB5[4![U:%+Y&VDY,=29B_Y9WGG\)]2]AET@=[N4W+@
M2[V<<5(R7HPR,_96/Q*G0U_?K7==E3">))3?O+D@ "]V_P*ZQ;XPEK 4DHR8
M_;L7SP1B9.Q+:5_V"_T1^/!^T')2/^M@'_8G2PP/J*^ T:=O%+([$5LI8/6
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M;.IB%7)O<RRJ.F4H^6(9CF.P,Z?(F@6CWD(P%E&OOBKI2\^?^MM.0+BQQKE
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M!7\0RP:MJ97,MLU\XY#PO-*S<T6@+6<T#GN/(@RUCR'JJ+5@A3@9T0O)"/C
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M*6T2$-K-%)5104VH\I"B*@T(9M-XUAI*!"0M'2W&W660Y.<0DBOXN0^8Z5+
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M$T*@A.Q-$[-@X?ZE(M.CH:8,25,DW!YM*UJ"I$I9<=<JM2C52C6@-!P  ?\
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MFY49E$([>A^<07>UD<)!.;B9U O%#L:2&S3![*4KW8UL,KDI?VHU.;XW4,Q
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M3?_W:@-^7A4%^+B[FNRW>%^#UVTU#PC:T,[+6M(#7N-L !P1"F0,7.MM5.O
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M(?.NE[...YL:5SV_HF)3Q]69-LIK*H]K!?5V:9/H_%XIXNF,:<7=S1H*A>;
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M,S6IT)#$2$%,J+$#<IX+I7Q8[;2+J5';%]L'$/4!S.(@K]_4/8.EV_SMA]#
MD[@AW,WND"K</+ZL>J#)?*:#46?T906/IW7+DSWW-*_GA3 K45D8=I=,01&S
M\-),04J$/0A*$D@0)3"6:9QRHZE&2:=-S9G.IK8R-U(%-J3MG+"B%6?/O4Y/
M]$;;[/@"UWVGTX)(Z*W.N:Y>9J_3HO3%S4[;.UUKNKYY4.N[^?+NI_7J]\V]
M=>2PY=,LI5A)L\6!Q# %1"BV6;%MDNR8H#S)4AIQ)S/^2C]3HXU*5+"3%53"
M@EI:WS*OYZ%MIXN @ W,%!VQZE#RM16)'F5?S[<[<NG75N5.R[^V/^Y_;?UG
M511*?7A4MI#\\NYGQ0I5[&O,?IL7A]_.2(($$EQ F3-D=O0RA93C#$8LIYIH
M%DOME"K?L]^ID42C '0M)UB4@KK?_?9!O9TO!L1RZ%U'*;4]\JKE!I6(NW0?
MX(,&.^'K?QH&8/>;]P,!/=*U_)" >UW<[P!;RZU^G]9&N_+?0<5F/H NKW?<
M,:[6:GZWK+:?XNG+FBT+8T;:X[C;I2S_NBB_P^+C:C$W#QQ"J+'BDB%FTTX+
MB!1+;1X!! F5":$J-9O*V&L[V562J:T'M2)@IPEHR+Z+IBYVT]MSW]EYM!PW
MI6.,P= [UK/PUUJ4^#?U )4BX+?ZST&BKWO#&FK;VUF.<??$?>$ZV3#W;M#?
MD-ZQ]=OYDBW%G"W>+0UK;[9E-[\62AJA7K'B_K5Z7!7SS8PKRC.E*10HTQ#1
M6$/*9 )Q1G"L9(J,4>UJ3'OV/34"/1C4>J< F#<T %L;*:57:R",$D!66GA8
M@[YC<]WD'A#QH4_L]F#O90=-X8&5'ACQ@94?U H,A[6[]3T@YB-9X(&Q]S+"
M.Z+78HC[MCB:,=Y1U:9!WK6)WD>T9GTJ@]+O5POS?F'+(6^>]D<-A"/%$2(P
MU3:7EV0*,D4)S&6>8$TC3+1716'7CJ>V8C3D+BV\IN3_\L\DB?-_ Y4&G<]W
MVP?"^]0W&+SCG07O*ZIOG@8Y__%%)_QQ<7NW+W6([ 1&R]&RV_O=F.J3,LW,
M;94KRWZF)_N'[>$K6]BKX>=_6P>%YG&*N98<$D(S&V6;0RZU@BG6"9*:IAEQ
M,GE#"#,U1BL7?#OARA\:XH+?7J\>V'SI>6+=:Z#<V&TL^ =FO![(>U->",@"
MT6 O44:EQA"@'=-ED#:[4>B[I5A;3^YK5?WY;GG*UI]6BX6Q,.U=B9DB/,VS
M.(410CE$#$G(\]R0J#3&GD(IP]2K0+5G_U,CRIWXX/N= G^RMZ2:.OSKWFJQ
M>H!:$4\"]1TF-\X<$/R!:7( W+WILR-Z@1C3M_=12;(C-,>\V+69'IDNSF^P
MDBQEDN8(2IU'$.DTAU22"))4Q#%G$J?8J7CA]:ZF1G#G]K*JE/@O'7)%]-F^
M_B$VK)5@-^!V8Q9TOMV4.74V*_"1E:'>@Y3=&FNK.I7-J?]V=+ -:&O&AO(?
M/^RJ,5=97>0L,0R"<J5AABF"*$T)) F1,,LE27,>)3%!LZ6Z8\8:]" 3+R&<
M)@RM)DQ3E 'GS4ZT@9+1G!\+#^()C^\?+PO 3K]&(H"1<M&THCQ&_IGS DPG
MYTPK0%YY9MI;\C^)ODVB.'^WE%M1?FL5_1K#SOP\_ZH^FH^U=O-@':68< H%
MPQ*BF*;V"%I#3J-8*!WCG#H?0;MV.C5KRXH-#G+O=C![R8$5W?WTTQG[ZT?,
M0R Z,/4Y@=FA5)(SJNZ'R4.@.](I<B"4O4Z/?>%J.39V;FJT\V)?Y9H'Q=[O
M^M_3>5U_5F_GA6"+:N5X:WY7S(2*LSA6"L:Y87&4<&ZX6]FH?(0UCG1"<J?C
MX-9>IL;8.T%!)6EM%H%25O<;.I=!;6?F8% -3,6=4/*ZFW,5A4XW<RZW.MJ]
MG*N*-6_E7'^X8TC(F8CPW1GO4[U=*%YOU7OU;?/E=[7XJGY9+3?WQ8P2AG.4
MY5"G"8>(1,+00:2A$A&)N*2<^16/Z2K(U&C#?&7(,QBDZQ"X;7+' '9@DKEP
MH^0&[/6XL:XX;DP2-C?[VO]2; T^+ ,FJ>L+8JB8DJYBC!MCTA.LDYB3ONUU
MH\9;8UK)^6)K#:Q#,M8WW\1B*Y5\:]2V;I=M989_T&_8VI:$+PPW5]GHGLXW
M</MM7LR()AG&,H,YQ@(B9BB4"Q[#7+"(T4BQC'DESQY0UJD1;%/21NYD\)L5
MUO/P=<@A=F/GB0S<P 3><<R\:7H$- ,Q^9"2CDKV(T!^O!Z,T>7(J;;+__Q5
ME?<O*^,^GJDLHT(H!#.>((A0BB")LQ2R5(A<4XIE$HV21_N,<%-;%&KIZLS8
MY5'3DS$"O4^:0HZ?XQG4"XW*]$^GRC_ ;F2#GTH-@/M+YY0^)]H?(V%T"ZC!
MLD&W]3$RW=L$2ZOM<F/7JE_*@BYEG;*/9O;=VZ@HME&S+*8ZCRB'$9.&_CD1
MD'$FH2*$9%1GDB=J%/IW$'9JR\%.-O!H);47X6SIG+K6+]L 6:M4%>:I2^I4
MSYI_?=R]7192^)X5@-F%Q?K:QUI/7#Z0@=>7P,,^_?7F];./HE*Y*H5Y _8?
ME%5[ HN0Q^"\]*+D(NH?8Y'R #W8HN73Y[ G -:I^M;,UQGC9F%"4L,TU2E$
MC"A(LXA *GB,D,*9T%Z^*U\!IK;8F*F2#^/QWT,>UM/?!<@I>OBM#N.[^(_1
M&]FUO^]^DB[]8W"ZNO)/VGF9TF<?MIMBPY;2B-I:Q3QB%&M%)<P%)A")B$-"
M%8,IC41$$BU2GLTJW\3G#5MO!K;8_:3WH8%C'89CA(;P-V;>W\V7UHD'.%N4
M]2V'+7 ?Z+/02*1QG"B8<BXAPJE9*5-&(9:,17F"(X%%_5F\6;K&A$_UH]AI
M,-(GH<H__UC?P\ [MN%&>/J;MWTH^[./Y*26W0Z!:E\W@8U<MS%[Z3V=I]1_
MC.U=MZ$(7:S.M_N0AM$L(GE*L5!0<VP#/0F#3(G4F#54DYQE$99>=\#/=S.U
M#5QY,0+RDE9$0\X0B\@LRB1.!,^AIED"4:PUI-+LEE66HQ3+Q.#-9V: ^6H\
M4)O=C0\K4-_LSY?9UP?>/DOJ1%? _<IVX(P;\-Z07YDWY IV@5:N41::*:P+
M?C3>D75M +\-T5=W=S^I]0-;/M7W2-(LC7-I;XM&]C\JE]#L& TY:$*XI#$7
MF7:]&76N@ZDQ;2WC#:BE=+^:<Q:^]LD? I2!I_TQ'AWN+)T%QOU^4E^ 1KJ+
MY/SA>-TV:E.^Y6;1V==&NT74)G3SQE#K<]VL1DN%:W5OV'#^556% ZO$QL=9
MP7&*<8:S"";&]H$HRR3D)%80LR36B<"&V[Q*@KEV/#6^>R:W8P'+?LB[V4-#
MX#DP59Z#\F:4+.N^8 6RF9R['=6*\@7CV*[R?M_?TOIIS;1::%N\Z-FBF"<8
M*<ICJ"0E$*$\AHQ&%"9Y$J>2219GV-78NM#'U/CG(&8'D^L2CM>MK@#H#,PF
M9X#I8'M=0LC=_ J U$@6F,^GY&6$78&@Q0Z[].9HIM@5T9O6V+5'.[KQYG?+
MN9X+MMS<BC).Q,8V6B:=JZ)ACB4LRG+"8(+2%")BTWEKI"!/B(I%CK%"7@EQ
MW;J=&AE^WCX\L/63C09L*  .&H"="IZ>*;=!</14!8=V:,]5.Y3@MT%L,C^8
M0GFQW#H=UZOE!<2)E\OO[<Z[QH=5E=^Q7A^5)C03!$.54PU1K 1DL4H@RT2>
M2A%E@GO='3_I86K44PE8)3'UWO@=@>>\P^L.R?!;N3T: ?/'7%4]W,;LJ/VQ
M=V#GU3NSU;KPX$#!5,65H\U]EKEWR^K^16NP!$6:&BN%0Y$A84C"T 7/!8>)
M,6;2G*%4:"??^,N(/S4&:J1A'#12)NPWT.=T;PHC.^*IX:6XF:)'#L@I!= ,
M,H9CQ=&$%7X"QZ9##XQW5,TP4G2L?<OFZ[^RQ5:]6SYN-\7/ZJM:Q+7U1A.>
MISI*8*0S!A'"QNI5B8 4\SRCQ,QXS+VJVU[N:VI+4"D;B#TKT[9@Z;8Z!$)H
M8"JW4H)2S!M0"7H#:L &,)$=, E5&K:EIW&+OUY7^:2\J\,K_FD67]DDY6O%
M7JVDFJ&,Y23+<A@IGD&4QA(:!L"0QI@J'6>(N^V$CQN>VMRWL@$K'+#2N:=/
M? 96^WSO \'0&UXW[;W2(IY3M5,FQ&<-C9;\\)SXS7R'9__=?[*]66YL0U*:
MX2P^KHH-6_R_\\?R:\*Y(EPS8F]CI!#I)()4, 5%$F><9$(AM\H?[=U,;2)6
MDH):5'N ;H4%1EK/F=F"[/5Y&@:O@6=M5ZB\IO%U)#I-ZI9F1YOBUU5K3GB'
MISO705L]J,\;MBDW"C_;X3 [@JKFWBQ20C/K5LKR7$ 480JI1CGD64:0O:*5
M9K%GU;/+O4V-#.J I+VT8"=NQV*0[5"[F>O! !R8'7I@UZ4>V75,PE4?:^EK
M[%ICU]4^4UG,X:6N18'J5JOTZ]85L5I:YT.9\#'G$5<DBR")A++YVBR+Z 0B
M)C+.,$ZR1/J5$FOI;6I44A<'. C9*1]G.\".WN!0L UM7O@BUJ'PC@,2P6KL
MM/4U<CD=![5/*^>XO!2J$NNM$.NMDHUBVC-$,IXD,8,J4\AL1Z($$J$83%2*
M8XTS*KG7<9=+IU,CD5K"W04QSS@<)YB=C9"@X UOBYRKF;J#LR'TD#52+T,T
M6&'4,UV^<#74RR!<+X':\N[(Z4_>;ZV3\X.N"H?=?F7SA:UW^7:U_LF\NYD)
MIG&JD@CJ2$<0<4TA4YQ"8K9-5&*:1JD(<:FUOZ@^LW2D:[&EH(#M) 5ZM09W
M5M8>%1*'&FA'DVL"@S<PQ09(45$I6X:?5I_ [;-/H-1X ADI',?DI5-07!-S
M6H?D/<$.EF3"M;^NANY756QL9U], ^6>C>5)II6Q8R.:QQ#A3$ F<PUC37A$
M4\UDY.E?.^YB:D;L04)@1>RT#SX#I*OAV@>>P<U4+V0ZF*27E ]F@)YT,+*Y
M>4G!4^/RXI-]"P-6J?EL!;N<8A&G.8&)S4N-!,D@YS@R_V%FTFM.F7+*4-W2
MQ]0F]W&YNSH/98^2@ <XKQ^;!0!IX"G> 9\>Q0!/$ A0"O#0Y@L5 CQ1ZG(9
MP--'_29WL=[,/JL[V^!/:F7V((_W<]/L[FA,TH2J7$"!B8:(Q )RQ&S:7ZP)
MCC3FJ=/2W=K+U"9X4T+/4[!V--MG=S",!I[??O X3VTG]=L6<=- 8P$W?SM,
M\?:V1YGD3NKMIKG;PR^3#[?<).Q#:']:KPIC!41YBKA0,"%)!%$BB;'PL88J
MH9&2.8NQ]$H'/H",DR,9*Z*2+^#O:1G'@5T]849G^EZ>_7V*2M/F98I2VPEX
M>*X/Q4L[=UHD_&/X=:Y#'#IO:%M7X0I#?%'KAP_ZU6JY63.QF24LB93($$QS
MSFWT5&J].QDDD60)98@RJ?W. :YW.CV/?BDD, O'0\GH#V7Q64]&=P!;2L4C
M8?;7!F9BD[-JR#(#.\]B*M.$J8AX%80*"_4X-TB> =VEPI\#SFX+85CT!E[7
M+I;7L!+;$XF=S,.6TSB/SX %-(XZ?/&2&><!<"F2<>'-KA'QGQ_88O'CMI@O
M35\S%LL,48U@3+DUX;6VD6L$YESCF,0D3^/<+Q3^6?M3HY$ZL+N4$>R$](U\
M?X[@==]=3UP&)@@_2#I$N)]5O$=H^_/V1HYI/ZO,:3#[^<="'*V]8AMUMUK/
M_U$:B?5U2,20BK0Q#33);5!&;JN-I @J%+-((QZ;H>]^U':NRZE-[(/$1><(
M]JLP=SF(ZPO>: =S#KCU/)9K@V*08[JS';[@L5T; .W'>*UO^GO^?YDOYP_;
MAUU.IBR/%$MBF"5(0I0+!#FC*8PYSU/"<"[=4I&?M#PUDJB%<_?I/\?INA^_
ML_8#S_):KH#7R2]JV\-5_[R]T=SS9]5HNN3//^!O?]L+*8N/]ZNEJF)Q; T
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M%E-M.($FQG0U]FLB1&8^#<9TY)5=L[6WJ7%#*1Y<:;@M5'UB=0.6RK>N;2O
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MB(W="1&/S'H@N8))0@AC7$8B]JJH[-#GU*C^(+*]EES+[)G9R %I-^8-C-_
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MPRB24=XO==K%OJ=&/Z6@W:^L^*#NMD<8",O_O[NW[7$;U]9$O\^O$# 7,]V
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M^JO[Q]UN/_&YN^#Y:%M>S>1&*_>'NX4Z_*#QY#3%FHK4VBI,,0QPQA00"J<
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M[@(>9XH#Z@((<JXT+;3&T'BO&BW]C&UUJ$5-9"UK:7"M=.7>&%C^L@W>ZZM
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M(2109JU=33 'F",!!#4$Y I!G".=%;G7%4)K+V,C^TK0I!9QLOTA<<(F]XN
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MO<M \9,CB_4^$V2>:YA+DH/4I I@9A#@DFJ $.%"$JI)%I2+^49YQD94926
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M0$%S#3!4$C"1<<!S;3_0N;%?ER ::.]O=(1@Y:RJ,KD?&A+?P@U7(/=DB7A
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M11]62ZFU6O]J17?Y39R_];WYL+*];9RWCRR=$:9%3C*%4 $09!I@D@I .5=
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M9AC)%&7*R]/V<A=CFX*EE(D3<Y+\_GJ2_)O]QPKK?]YR <GK!V"WX]/S/+T
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MG/*DW@4VN_R#KE+$_;GR$6]^;-RO8J[?+.R4V"Z@6AMJD*O;Y6+<<HX!)48
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M,82J]_Q*M."9J=>CD)&OC2&JUI<Q]J>NR^/Y9X7F,(KL(A6TOWC)>Q(^%8Y
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MMSLY].Q*[L -.9+GG\[N?\"V;2-'AMY;T-[7ZLG,@-AW8*,BI4C!0VD]P69
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MR,@32EOO^K>N+7B4J$X\QN<'S.VAE$VUUS,<)TI8VKX8AQ)B!.4T0D0N0,B
M'EVP'IO/0MU%S+CP:ZST?2'U) WT6^-YM7AWSZXYIA#PH<>V+NG;FX7G*,X+
MQM(.G"PP5DL!5&W.Z8R#D!-YB%ZGA/__+,Z3UM3EB&!LO4UL*/#RB5:0UDS[
MX!C38J\)*O^[..]@O U7G/<4Y8X]MV7GC!+GE,4@$9R/)$IG%02&I=YW+S+)
M+(W<ZQSW9<[X&0D,>XT%>HIFQH;7SDD(G(*PF(L&$H\F=R37/A^L-M=U"KTH
M,N)>$<1?:2S0DQ2[UUB@ITAY1*ALKJ,MSR:_?YHD% :M$X#$+BCA/42M+'B-
M-K':+_?!1/$*T]^_++[_>/[$+33.O[E"QM7[>AP+]"2E+8Z28 ?1W3W%,9E%
M--89$-QC;1QH(4JM(>A@D]4E%=$ZK/OK%JP=LO\TTDUWZ+JW=@8MQL"9 ELG
MWRI=VP3$R" XH8Q KTEX_[M@[4EZ?WK!VE.4T &L=M1,Q:)#SAPIWC!D>J6F
MK9P+"YD7&WTA&?K6#11?:,':D_2]7\':4X3? 83:)HQ+,8'':,EK%"3/K"-X
ME6,=#9:<C3R(TKKJ]OG/G%Y ^=LQN^UXB.A@.5S9C'=S>BI]O6E-[\D4)&4D
M)"G(%U8I0@B9@W&8N?>1:=WZH.E^2EY^.N) :.S<RP_64[_G +7!P6+^:;U(
M__ST%6?E(WZ9ULQB??)EV'Y<1^^]']^P9\-A+#4Z'WC[[Z?3]=EEAM9*[FQ)
MFT/-BCUT$+RU4)QF5FAR,F/K$X&;%!QKJ"Y:)KPO&Z'^=/9Z%E87UC]Y64HF
MKP856?^B$&)AC#:#>F)KM0JB=>7' ^2,:[*.T/MMF]-*Y!UL<Y].XVJ:IV%Y
M]BE<,K1-_B6?9#$,DO-D005JB([<5Y%M-HG+9&WK&Z [B1D7.<W4?1M&363?
M XBNR/\MG-"7GY=AOJ)55D]ZMSE$)BGTB4J#9J+.BV4"O#41,'(78K BBM9)
MC<>I&AE6;=1_&U1M=3%R^],WF#;!-"F7O?K\ZWED;266*$H!DP/9;F.( <X*
M<.G)FAONN%./N#X['SXR)AIK;]%2E"-CX==P1K2+*]IEH)6A"P->'",?/UOP
MAI:)=DID)6U1MV.Q>V%P^[GC)MH'1,!1 NQAFR&#N6FVL'[[_7HJ6+G"E44)
M1K%Z,Y2<.E^COE@YR'58E(@#>"KWD#(R= ;T4XZ5>Y_PN;AUD%%G:12)1--^
MRV("+XH")7T*(=%V'%I/&MA)S/@^R=&J?AP^!\B]/P"=&U$=G6.,%I7?#(BQ
MP4! FR!P;5RPNE@^1)QTAY#N@'.(DA^&S@$2[P V&RM\;I.O<IYHI<N:)Z"M
M',D@:Q)04 (0T99DN [-&RS=2\BX!QU#;5G'RWQT9_?/Z<GIR:LO7Y;X):Q)
M0$3"=/[EPW*:JK1J)GV3;/^]3EF[DTF=E*(2)G+MBD[DVEEO:8U$"U%P+3S/
M)=R^/+W#-SZ*C)%GXAT/@L4X&AD9?+L3\]O6[-OI?L3[1+& @=M0JS L*!$D
M&65GP0E)ACBQHCS? V9[OW#D<75- 36,E'N#SF=<GDSGFR]II2R6_T:+9(WS
MWQ9K6C:3K((-G%Q*&90!Y9.G4%9RD)R1[?>2:;_/./6GO77DB7+#@JB=O,=&
MTE4BY'(EO [?0JJM_'4I+A9C 9D,M"+(#W0R1>!:HM;1E+C77/6'WC'R:+>V
M*&DER[$Q<1OMKV@SWIC,S2B U:JB'I>)/GA?_K%<K%8?EHN$F%?OYUL97#M^
MGE#@0?&"<V""CZ!4'37B:G4RXPY=D3%I<XCQ.8:HD6>V#6N;GDU;'41]&Z+?
MK5:GF-^<;OQ$\A87>5,T\QO^L?G):N)XHG!&(NA09]QDD2#F'$$GETU)3HO8
M_(!^'\)&'N+6#(;#::-?B'WZ2D)>77&592C24^#A2IUVF$F"D0<.PK"L:0E1
M5-(\N[D792,/9WLND!VCC]'WVTKZEJ5_P^F7KVO,K[[C,GS!S8\VL>^'&NW2
M-Q,3LJU,0(E5=J@HP@W! +.>?F)-H'6TUW[ZA)>./$*M\7XYE+0[,%876_O/
M),3*8IBG6QM\#IYBW.C!QB1I72C:VZU78(T.0:K(1&2-[=2C1(T\,JVYB6JK
MA8-A1:".BU; .I]N^?-B>>56UI:; I4D3]%+[VH[N0A1B Q)![0^"I]=ZUWO
M?DKVRX&R%X2AXP7^(BJNMP6C%VG>)E76]S^R?67U'J0/4TWM?$Z>M V9:0:*
M#$;U;>J,66L<1Q*+;5WF]WS5U#%;G@G'% ]8#DH;<N&PD'W,/B/1%4MHW2/E
MI513/T7O3ZFF?HK(.W!R=I=T,I,Q,J; <U$9255 BKCQ-M"&'$-J/@7V!593
M/TG=>U=3/T7V/8#H\0I BXXG7CMQ^%0[25K::S47P%QFSN2DF6GM*K_<:NHG
MJ?_IU=1/T44'Z+KF)9R7TQ1I=,Y)@.(N@V*,0W"V0%$F!:Z],K;U)?$[1'1?
M=?TD+=\N1CE*Y".G@#XLL5YJQ_QO84E265_>;F<ZHG0:LA"E#@Q*X)PJ$)VS
MF+@UX7:/ZWN3/3L>WWT-]B%X:"7.'JS(O5&E*USZP!W8>GE%U99W/CD/M9MG
M<2AT2JW[Y!Q>TS9*&?8Q#L[Q,N\ .->7UFE%/GUS+>WY;GYMJ=&BR-D85VJ[
M*3*37-84I_5@DQ Q".:(\P'=G,?HZ[&Z[4EP>,#9::J;OG!W,XTNG6/2H($2
MI:AE>12T2@I?LW:\1"UB;CZ5?!<M/1:W-<+3X3+O(L=\=?PR42RYF"OD=;TP
M%S0GVF,!&9/RY,0Q;-XOX.KM/5:N'860P^3Z(M+'U[YLDCN^YWGM$\>/$3U,
MUEBXY#GAI-;R1* 8B-5ID0B6&:NRXAB:^XUML\8WFIK4'?/5Z?IK;3&&>1)R
MU%Z7!$8I2YZ](S8Q1#!)H0OT(Z$'#*]OD]-5UO@I>G\@J#Y*Y!WX)M=8^1"6
M[Y>;.O!M;=+EEAF+C=&* +*(6K@;/02G3*WCS:+P;&+SOE-[D#6NQS(,FIJH
M8.2DS87[_C\6:UP1 V]#^KIAXN99?PHDE5@,$%>!?/B0P5NT8+1"@<PPEO4C
M&]3^;QO7=VF E8$$VY<!>C/]/LVTQ:\N8/\&TXS^RA.;T/-0KW":ZN<9+!"X
M<E"O7%*XYP6:UK?L]Z%KW#+]84Q0&R5T#JS78?7U0YCFB0[)YR(-.%O(_0^U
M'M+5B[W9:">T]\:W/LS:AZYQ*_&?"5@'*>%%A%\?+BAK%X'=_\CV0=@>I \3
MAU$<KQP%[Z"**P0"9\&7$H#+ZCYK79L%=1V'W93<G;@@VI!U^/_:N[;FMG(<
M_;[_!56\7UZVRCU)IK+5MTIG>FJ?7+R B6H<*27)F<[^^@4E^=J^'$D\/I2G
M7]RQY38)X ,($"!@'7!'(8'22D.LH^R<E)+'Q(O@K9WHIW?4532VC_3_7%?:
MC/$='%MWJ7DT($@)5;1%0HYU'#;3'J*2$H(,,BJNR0EL7[ \9&==A67M8-5$
M$-W!:ZLLOURN5^LPS_6Y=S"T<<L%1#KT0:G:FK1>CRLN51+:(6)K3_N9+745
MN[6V4X>R_B3<H"V)'^@O+[]A+HOEN\OUY1*O:O\;]8X>M,88#:3W)VZDNN?"
M+?-H +6J21 ZZKQ6$B*YU<&4%*)H/>[@Y>J><T'.<MC,_:H#G#+%!B77JI=2
M=4(ZJ9NGX4^E[GD/N>]3][P/RSLXT<[^'9;YNEE<$E$'R0)XRVG+&!AXR1DD
M"C"Y(>OJ?.OSZ\X&^JUOWDNL]V<>'\SC#@"RL=0_A!5F,M]?<;[:B6,9YI\V
M'0%6/WR_^9W="Z,-Q3=DS_.O%V%>"_)V-7C)HA:Y1'!FT[L697U[Q*"X2 Y"
M9$XT+UP=@XZ)!W4?#JN'DOE3RK@#G+\ESVGQ'7&C^K]\O3U@2G 7O4[ <ZW\
M*YYX')&!3<EGJU,(KO4A^NAF)C:0D^-D,8;0)D[Y/4#$ZMHC_GLM-=[1)%1)
M1L94^XC1%R\3A4]>0[(N< RHTOVY#@\F_8:N-W$M;B]8&TU$'1B]*_9L3A =
M?>:\),C"!7)L:B%[]K9>R/#BO+ !6]?'W5Z_W]+O8WR_@SG<$3JN'DXD)"U1
M'+*MPX3K+7#,S$%BPGO/?22E&@D?/;A;ATOR$4@<P-:)3ZHS$A"_8PM_O5RF
MSV2 *TT[$\@M';0V5]9L5,918%UG-"F!1:!&S>R0TI0A:_4!B$/DN!B1J1.#
MY.._%Q\_+RY789[?+2Z7:\3Y]NKE_;SVBYM]NTV7=S&358W;UJ@*$]8\.8-<
M7Z4K&W(08@!8]EESVG.F$6A&8_+T%H;;]_-\F38^WA,T&<PR:;*]?E.G52>I
M, S &%?6%5O$H$%"0]>;-HW2SM*T9VX_UN;GV1RK(OSR93Z+EZO'R8N>.V&B
M F.QON&U1!YI",B,:"2%AY(-P<X!2T];\M;>]HS"\@X\WX??R["@F6.<CEY$
M"NY"L. P:A"Q:!NEHX]S8P?XQ 8_'!,I'<_S'H!SZT%.^%KSH'<SG>_N9SK/
M361"QRP@(OHZ$H639I J<JFBXR%QZT9\9#)LDST^E]T+&(_758X@I7ZK"[8*
M>_].K9KIU5G.L_I-N'@_+XOEE\TGA]<8'+I2HTJ#)H0VJC=X,UNEBT4=J[YY
M:7"]FP]X4>NA_K98K5<;^,5;%YFKZSRU$05=8@B<TY=-9V.?'1V?FANA,&L?
M?&/[<-R.&]8S''P%O!M#%(EW-0?&7:%0605%<0_SH&VPFDL3'8XX0_NXS4]K
M<E\0LT_45KR@^#MP'>[<+TKKI2TY@$V*XO:D*62G#8/E7AFCLY-\\KOXEZC#
M>$D(/'5SOX\\.L+2+M+3QL5LI(,L#45?)@:H33Z@2 Q22,S)M7X=T.W-_5Z2
M?/KF?A^V3G^O]OPELW0V2\$]I,T0!>84!-01K,'BI33.ZR&C>4[NYGXO.>Y[
M<[\/4Z<'"??/7N6$D 4KLH 5ID;VR,!O6*:]DL&;DOW0F]=G%^OJKOX(F#1F
MZRG=N;[]ALLZ/&C^ZW+Q;;:ZJ="AX)VAS0Z,0ELK= I$7VLQN @$EN#Q?D_F
MXV]A']O,-.9H)' <>E7;1%+]0//YO!CG)I M5I#0B-JY4=>GN0+(4'/K+5&6
MAYQWS9./+Y5'.M2@C<;D#LZ_0?FQC)E[G0715 R%%?2O8+B!F)7U 45)94@'
MU:;)QY?*&AUS"C9G[H2 62W7YQ]J&+JMODXL!U4$Z,(HJL@H(4H*+:33I<1B
MM>6#;O'IK]Z*KNB[F\CJSH+=%,M-$* ?SOD>X')UHHM2*##(@+;.7''> )WC
MG&)1$9R/M5I_T)";(8"9TL<Y0ECWQ7T YR86^$^S>1T\?E55(5%(,FUT_E7#
MYIRGC2L-FO/(G46+PR9&/B/R.XM.+/1#1+9HP;^I!;^=.+_;N,E>)X<>R*#5
M^JL<(-I('I&5PBAK8BJ#+G.?$_SM1:<Y()H)_F#^=7#Y>O==EDC&.&T4R)03
M*"M398$&PG#)1@DM4NM6$_L_J7R)8I$)K_(/ET@'<!KG(4SV]<Z C*?PI%*.
M!0A5PX)RTI&'[WWSEG"O_0'F7K!ZD0>8>\AXXLC[.@Y\_$&?DMID8RUXQ6MI
M&1KPR",@.J9=06;U/>_IP9C[^95>XQ/+?9"P&$TL4[=6K25?87U)O_']B8>C
M7J2<11U67SL2D6L)C@<-)@HA0U&6W7?6'NZL.F2QU_C"\D"HM1?.*1S=CS'X
MQ^LR1RZ3SZ:Z/5)JBIAS!N>B ?*KN1?,F&A:EW\=O^MI+RS[\#E?6/8=H/T-
M%MHZD3M?+V?Q\JKB<A?+G<WGE^'B]H>;+LP[5:=_UJ/FG.(ZIS61')PF!4_,
MD?]$6FX4.A%]H3"_=:5*@VUW[C(T1MIB6K%W@/2#.5[K*A>7\W4=XOY36/X+
MU]OQ.KNRD3=AC>?":..SEH#UADM)K\!%9<&&&F (&2U7O5C\ ?1T[N.,JQO=
M .64E>;N1+.S;V%V44_G=XOEIO/&N0I,9:L*.&3U173P-;E<!]E;BC^B3<BZ
M<9&>H67BR[H359:6 .EG:-DAG+C*JJ_6R\N-?_M+?1SS\7.8[YK6;!BR>C^G
M@W>VR.>!8K+B(P+C-FY?^WIKZNV5RBH&$81I_D+BA6B;. 8Y454:$T =G$%G
M%YO?P?PP@][^4?^)YU8GG;FH@Q02$BT8@=S3 &1&HO;>LE*PL5H,V]FTDRTF
M!O4(PIOX1O)@AMX\8KS?L/\JHI)8LF:209+T14DZ^!RS$B2Q0@A/[F&ZE^!Y
M\!ISO!T.@K)Y95#N2.@=6..C';['.7*N(M/6%@,LU'%+MC (.42(WFJ;<T%K
MF@\''H^<0<IB7YFR] :34]:8C1NW^>C]/"VQ7B'@]K_G:#USBFNR$J9.9A#5
MA8L2K(]%"AT2YM9=348@8Y"&N+\T9!18]*(9\7D6Q/LL>!=FR\U,FK/5ZO++
M-LBIKF0B1_,C+K_P<Z^5=RD6, ZQQCCD6FIA0+N2:H!CY/VVNVT49!1J!NF)
M?\UZ,CU(>E&7@YS0^N5W7*UG\T_;.P!^+HPKNI"?:8+?%.8&<&A9;88:Z@R>
M6&PWOM8#^Q^6O6.O62>F0,(I:\%3]N!J4N>'FJ/)+$7,P4'DFLQ";:(86%$@
MBG<A.>^,:7V3-#I1P_3EM::[^\+,*2O1@S?*_\39I\_$D;-ON R?MKWU:[;S
MFGOGJG 6$Y>UX78&%:T&KYT!'GQPO,A4.HI7#B)QF(+]E3-_>3QUH&[7Q9&X
M_#9+^#"W?E[,O]')C-M#>O5QL:XU.#>?UP9>/R_6_XOK#Y@6G^:;NQ"3BE(V
M)BBQMNP,R4(H(8,0(=L2?2K-SZK1B!FF0J\UD]X'1EZSLFR-R[O%<O>C^GO\
M7&JC+3(/+.OZW$W3R9V0(D&,6&3F*@Y[!=Z#!CU(X3"U>JU9]8[1=)(]9W^[
M_/(E++\ORJU"_[.T)E]X_7V4UK-#%AR_ ^W>9/?1B)9)6XJ,I#E<6H*C$. X
M#Y SBBRYR?+^7)>_&M'NWA&DD+3 )"$775N:N P^T2$:,BM)%I=\2JU#EK\:
MT>Z)V?$:T>XC_@Z<ICOM,BD"*M(&0>%0";5C!VU;HZGE^:JH'(+VK8."U]B(
M=B\(/-6(=A]Y=(2EW>O F&-..FSZKC)00GOP61?(S&4IM"0U;6T(>WHP?K@D
MGVY$NP];^VG0-WAX3-!&)FTY:)L$T2@+!*,C:"=L++6-ZKY#PIK.ZWFI-K5[
M2?G(>3W[L+P#,W.W$T,F9:)8CI-FU7EGFO8=F7609.W"X)CSIO4+JOU;KIQ
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M,BYH=&U02P$"% ,4    "  '-@-7",:,+$H'  #!(   &@
M@ %4#P  :6UU>"TV>#,P,C-X97AH:6)I=#,Q,BYH=&U02P$"% ,4    "  '
M-@-7U.&[<5\$  !.$@  &P              @ '6%@  :6UU>"TV>#,P>#(S
M>&5X:&EB:70S,C$N:'1M4$L! A0#%     @ !S8#5V*T#C)\# $ RQD, !
M             ( !;AL  '9T;"TR,#(S,#8S,"YH=&U02P$"% ,4    "  '
M-@-73VP<=4$.  #"C@  $               @ $8* $ =G1L+3(P,C,P-C,P
M+GAS9%!+ 0(4 Q0    (  <V U==1Z6J7A0  $J]   4              "
M 8<V 0!V=&PM,C R,S V,S!?8V%L+GAM;%!+ 0(4 Q0    (  <V U=)T0K*
MESD  '*" @ 4              "  1=+ 0!V=&PM,C R,S V,S!?9&5F+GAM
M;%!+ 0(4 Q0    (  <V U>6BU.[ZN@" -N] P 3              "  >"$
M 0!V=&PM,C R,S V,S!?9S$N:G!G4$L! A0#%     @ !S8#5ZI#M^:>J0
M9"X' !0              ( !^VT$ '9T;"TR,#(S,#8S,%]L86(N>&UL4$L!
M A0#%     @ !S8#5Z)@OD5):   (JP$ !0              ( !RQ<% '9T
H;"TR,#(S,#8S,%]P<F4N>&UL4$L%!@     ,  P )0,  $: !0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
